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In Chapters 2 and 3 Ir(I)-catalysed methodology for the asymmetric hydroarylation of terminal 
alkenes is described. Initially an extensive screen of commercially available ligands was conducted to 
render a branch-selective alkene hydroarylation protocol previously developed at Bristol 
enantioselective. This study revealed ligand related reactivity trends, which enabled Dr. Simon Grélaud 
to design and synthesise a family of chiral bisphosphite ligands that promote highly enantioselective 
alkene hydroarylation with acetanilide substrates. Alongside Dr. Simon Grélaud, the protocol was 
expanded to thiophene substrates. Subsequently, investigations were directed towards the 
enantioselective alkylation of alternative heteroaromatic substrates. Excellent yields and highly 
promising levels of enantioselectivity have been achieved for styrene hydroarylation with pyrrole and 
furan moieties. 
In Chapter 4 the scope of the Ir(I)-catalysed methodology is expanded to include 1,1-
disubstituted alkenes. Challenging all-carbon quaternary centres have been generated in excellent yields 
and studies towards an enantioselective protocol have been undertaken. The mechanistic pathway has 
been investigated through deuterium labelling experiments and natural abundance 13C KIE studies using 
the Singleton method. These results revealed a pathway unique to those previously determined at Bristol 
for Ir(I)-catalysed hydroarylation of mono-substituted alkenes. 
In Chapter 5 an Ir(I)-catalysed method is presented for the -selective C−H arylation of styrenes 
by dual C−H functionalisation. The chemistry relies upon an Ir(I)-catalyst modified with an electron-
deficient ferrocene-based bisphosphine ligand. This reaction offers a regioisomeric alternative to the 
Pd-catalysed Heck and Fujiwara-Moritani reactions. The alkenylated products are useful moieties to 
rapidly build interesting N-containing heteroaromatics. 
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2. S. Grélaud, P. Cooper, L. J. Feron and J. F. Bower; Branch-Selective and Enantioselective 
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Chapter 1 – Introduction 
1.1 − The Importance of Tertiary Benzylic Stereocentres 
The development of new C−C bond forming reactions is of the upmost importance for the 
pharmaceutical, material and agrochemical industries, due to C−C bonds being ubiquitous in organic 
molecules. The way synthetic chemists form C−C bonds has been revolutionised by the advent of 
palladium-catalysed cross-coupling reactions, such as the Suzuki-Miyaura reaction, which is routinely 
used by synthetic chemists to construct C(sp2)−C(sp2) bonds.1 However, the success of the Suzuki 
reaction has led to drug candidates becoming increasingly sp2-rich, which has been linked to declining 
success rates in the clinic.2-3 
Despite the Suzuki reaction being commonly used for the formation of C(sp2)−C(sp2) bonds, the 
construction of C(sp2)−C(sp3) bonds by this method is often problematic because of challenges 
associated with several of the mechanistic steps (Scheme 1).4-8 For example, after oxidative addition of 
Pd(0)-catalyst I into an aryl halide, Pd(II)-intermediate II is formed, followed by ligand exchange in 
the presence of a base to generate Pd(II)-intermediate III (Scheme 1). The subsequent transmetallation 
step with boronic ester IV is slow due to the highly sterically congested C(sp3)−B bond, which restricts 
the formation of Pd(II)-intermediate V. Reductive elimination from V then affords target product VI. 
However, competing -hydride elimination can occur from the alkyl Pd(II)-intermediate V, resulting in 
the formation of VII, which can either undergo hydrometallation and reductive elimination to form 
linear alkylated side-product VIII or reductive elimination to form an unfunctionalised arene and an 
alkene. 
 




Scheme 1: The mechanism of the Suzuki cross-coupling reaction for the formation of C(sp2)−C(sp3) bonds. 
A general and robust cross-coupling reaction for the formation of C(sp2)−C(sp3) bonds would 
be extremely valuable. This would allow the streamlined formation of benzylic stereocentres, which are 
privileged motifs in bioactive molecules, such as naproxen,9 an anti-inflammatory drug, tapentadol,10 
an analgesic, and sertraline,11 an anti-depressant (Scheme 2). Existing large-scale synthetic routes to 
these molecules clearly illustrate the difficulties in preparing enantiomerically pure benzylic 
stereocentres. In one example, the benzylic stereocentre in naproxen is installed by asymmetric 
hydrogenation of 1,1-disubstituted alkene 2, which in turn is prepared in three steps from aryl bromide 
1 (Scheme 2a).9 A more streamlined approach could be envisaged, whereby aryl bromide 1 could be 
directly coupled with a nucleophile to form the desired C(sp2)−C(sp3) bond. One synthesis of tapentadol 
utilises chiral auxiliary 3 in the asymmetric 1,4-conjugate addition of a Grignard reagent on to 4, which 
generates moiety 5 bearing the desired tertiary benzylic stereocentre (Scheme 2b).10, 12 The extra steps 
required for the installation and removal of chiral auxiliary 3 results in low atom economy. Another 
common method to access enantioenriched benzylic stereocentres is to resolve the enantiomers by co-
crystallisation with a second chiral molecule as is shown in the synthesis of sertraline in Scheme 2c.13,14  
 




Scheme 2: Pharmaceuticals which contain tertiary benzylic stereocentres and commercial synthetic routes to 
generate them. 
The synthetic routes to install benzylic stereocentres presented above (Scheme 2) all involve 
multiple steps, which result in purification issues and large amounts of waste. Arguably, a much more 
efficient method to access these motifs would be to establish the stereocentre via a C−C bond forming 
fragment union step. This approach would provide a more direct route to benzylic stereocentres and 
would result in a more modular design, allowing each of the coupling components to be varied. In recent 
years a number of strategies have emerged for the synthesis of benzylic stereocentres via 
stereocontrolled C(sp3)−C(sp2) bond forming reactions and an overview of the current state of the art 
will be discussed in the proceeding pages. To aid the following discussion these methods have been 
broadly categorised based on whether the newly formed benzylic stereocentre is derived from an alkyl 
nucleophile (including radical species formed in situ from alkenes, alkanes etc.) (Scheme 3a), an alkyl 
electrophile (Scheme 3b), or an sp2-centre which undergoes migratory insertion during the 
transformation (Scheme 3c). Within these broad categories the methodologies can be divided further 
based on whether the transformation is enantiospecific or enantioselective. Furthermore, these 
transformations may proceed by a traditional two-electron process (similar to the Suzuki mechanism 
shown in Scheme 1) or involve radical intermediates. However, this is often challenging to differentiate, 
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so each example will be commented on specifically. The discussion will begin with the cross-coupling 
of alkyl nucleophiles with aryl electrophiles, followed by alkyl electrophiles with aryl units. 
Hydroarylation of alkenes with organoboron reagents in the presence of external hydride sources will 
then be presented. The remainder of the introduction will focus on alkene hydroarylation reactions via 
metal-catalysed activation of Caryl−H bonds. Previous work carried out at Bristol into the formation of 
benzylic stereocentres via Ir(I)-catalysed hydroarylation of styrenes and alkenes will then provide the 
basis for the research described in this thesis. 
 
Scheme 3: The current state of the art methods to synthesise tertiary benzylic stereocentres. 
1.2 − Cross-Coupling Strategies for the Formation of Tertiary Benzylic 
Stereocentres 
For the cross-coupling reactions discussed in the following section, an important distinction to 
make is whether stereodefined alkyl components are used in a stereospecific reaction or racemic alkyl 
components are used in a stereoselective reaction. Examples of each of these possibilities are discussed 
below. These transformations can proceed via either concerted two electron transformations, as seen in 
Pd-catalysed cross-couplings, or via radical-based mechanisms. Furthermore, in some cases, such as 
those where two catalytic cycles are operative, both two electron and radical mechanisms might be 
occurring. 
1.2.1 − Cross-Coupling Reactions of Alkyl Nucleophiles 
1.2.1.1 − Enantioenriched Alkyl Nucleophiles in Cross-coupling Reactions 
Scheme 1 illustrated some of the challenges associated with developing Pd-catalysed cross-
couplings for the formation of C(sp2)−C(sp3) bonds. Most notably, slow transmetallation between alkyl-
nucleophiles and transition-metals restricts the use of typical nucleophiles in these transformations. 
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Significant efforts have been directed at overcoming these problems and one promising strategy is the 
development of chiral organoboron and organotin reagents, which balance configurational stability (to 
avoid decomposition pathways) with reactivity (to promote efficient transmetallation).15-19 Another 
challenge is to avoid unwanted -hydride elimination from alkyl Pd(II)-intermediates, such as V to VII 
(Scheme 1). This has been achieved by developing new sterically demanding ligands, which either 
restrict -hydride elimination and/or promote faster reductive elimination.4, 6-7 
By combining both of these developments, the Sigman and Biscoe groups have developed a 
highly efficient and stereospecific Suzuki cross-coupling for the formation of benzylic stereocentres 
from enantioenriched alkyl trifluoroborates 6 and aryl electrophiles (Scheme 4a).20 The reaction begins 
as in the general catalytic cycle shown in Scheme 1. Initially, oxidative insertion of the Pd(0)-catalyst 
into the aryl halide forms a Pd(II)-intermediate, which proceeds via transition state I to form 7a (92% 
yield) or II to form 7b. (90% yield), depending on the ligand present. When electron-deficient ligand 
“bis-CF3PhSPhos” is employed, transition state I is preferred and overall stereoretention is observed. 
However, when more electron-rich ligand PAd3 is utilised, transition state II is accessed and the 
benzylic stereocentre forms with overall stereoinversion. Thus, Biscoe and Sigman access both 
enantiomers of the product from a single enantiomer of the starting material by judicious choice of the 
ligand. Additionally, both of these bulky, wide bite angle ligands (bis-CF3PhSPhos and PAd3) promote 
fast reductive elimination, which minimises the formation of isomeric side-products via -hydride 
elimination. More recently, Biscoe and co-workers described a stereoretentive Pd(0)-catalysed Stille 
cross-coupling reaction of enantioenriched alkylcarbastannatranes 8 with aryl bromides to generate 
target products, such as 9a and 9b, with complete retention of stereochemistry (Scheme 4b).21-22 Here, 
the desired alkyl unit is selectively activated towards transmetallation through internal coordination of 
the nitrogen atom to the azastannatrane unit. 




Scheme 4: Ligand controlled stereospecific Pd(0)-catalysed cross-coupling reactions with stereodefined alkyl 
nucleophiles and aryl halides. 
A related approach avoids the need to preform chiral nucleophiles by forming them in situ. 
Building upon previously reported procedures,23-25 Buchwald and co-workers developed an 
enantioselective Cu(I)/Pd(0)-dual-catalysed cross-coupling of alkenes with aryl halides to generate 
benzylic stereocentres (Scheme 5).26 Initially, chiral Cu(I)−H species II is formed in situ from CuBr 
precatalyst I, (R)-DTBM-SEGPHOS and methyldiphenylsilane. A styrene then undergoes 
enantioselective hydrocupration with II to afford chiral nucleophilic species III, which transmetallates 
with Pd(II)-species IV. Finally, stereoretentive reductive elimination from V is promoted by ligated 
BrettPhos to generate 1,1-diarylalkanes, such as 10a and 10b, in excellent yields (up to 99%) and 
enantiopurities (up to 98% e.e.). This methodology is noteworthy as the chiral nucleophile forms in situ 
from an alkene, avoiding prefunctionalisation steps. 




Scheme 5: Cross-coupling reaction of aryl halides with enantioenriched alkyl nucleophiles, which are formed in 
situ under Pd(0)/Cu(I) dual catalysis. 
Transition-metal free methods for the synthesis of benzylic stereocentres have begun to emerge, 
which provide a complementary approach to the methods described above (Scheme 4 and 5).27-29 
Aggarwal and co-workers have been pioneers in this area, expanding their lithiation-borylation strategy 
to the cross-coupling of a broad range of electron-rich arenes (i.e. benzenes, furans, thiophenes, indoles 
and pyridines) and boronic esters (Scheme 6).27-29 The mechanism proceeds by the addition of an in situ 
generated aryl lithium to stereodefined alkyl boronic ester 11 to form boron-ate complex I. The electron-
rich arene is then activated by electrophilic bromination with N-bromosuccinimide to generate 
intermediate II, which undergoes a 1,2-shift of the alkyl boron substituent to generate III. Finally, 
nucleophilic attack on boron triggers elimination of bromide and re-aromatisation to the arene, affording 
tertiary and more challenging quaternary benzylic stereocentres, such as 12a and 12b, with complete 
stereoretention. Additional studies have avoided the bromination step by introducing alternate leaving 
groups with phenol, aniline and pyridine reaction partners.28, 30-32 One disadvantage of these methods is 
that the formation of stereo-defined alkyl boronic esters is often labour intensive. 




Scheme 6: Stereospecific coupling of boronic esters and arene units to generate tertiary and quaternary benzylic 
stereocentres with retention of stereochemistry. 
1.2.1.2 − Enantioselective Processes Employing Racemic Alkyl Nucleophiles 
In the examples discussed so far (Section 1.2.1.1), the stereochemistry is set in a process other 
than the C−C bond forming step. An alternative, often more step economical approach is the use of 
racemic reagents under chiral catalysed conditions, whereby the stereochemistry is determined during 
the C−C bond forming event. This approach is typically not possible via two-electron pathways 
employing alkyl nucleophiles because these processes are stereospecific. Therefore, several processes 
which proceed via configurationally unstable alkyl radicals in place of organoboron species have 
emerged. Photoredox catalysis is one method which has been used to generate alkyl radicals as 
intermediates in the formation of benzylic stereocentres. This approach uses mild conditions in 
comparison to traditional C−C bond forming cross-coupling reactions (ambient temperature, visible 
light and no strong bases) and it overcomes the slow transmetallation step often associated with 
organoboron reagents due to the highly reactive nature of the radical species. In 2014, Molander and 
co-workers merged an Ir(III)-photoredox cycle with a Ni(0)-catalytic cycle to promote an 
enantioselective cross-coupling reaction between benzylic trifluoroborates 13 and aryl bromides 
(Scheme 7).33 Trifluoroborate 13 undergoes single electron oxidation by the excited photoredox catalyst 
(PRC) to give prochiral alkyl radical V. Radical V is then intercepted by chiral L-1 ligated Ni(II)-
intermediate II to form Ni(III)-intermediate III in the enantiodetermining step. Subsequent reductive 
elimination generates desired product 14 and Ni(I)-complex IV, which is reduced back to active Ni(0)-
catalyst I by the reduced Ir(II)-PRC via SET, thus completing the photoredox catalytic cycle. Despite 
the important contribution of this method towards the enantioselective synthesis of benzylic 
stereocentres, only one such example was disclosed, which achieved 14 with moderate levels of 
enantioselectivity (50% e.e.). Molander and Primer employed a related Ni(0)/Ir(I) catalyst system to 
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generate more challenging all-carbon benzylic quaternary centres; however, extension of this to 
generate quaternary stereocentres was not discussed.34 
 
Scheme 7: Dual photoredox and Ni(0)-catalysis to generate tertiary benzylic stereocentres from aryl halides and 
racemic trifluoroborates. 
In 2016, the MacMillan and Fu groups disclosed a strategy for the enantioselective arylation of 
-amino acids 15 with aryl halides in a collaborative study using photoredox catalysis (Scheme 8).35 
PRC promoted decarboxylation of enantioenriched -amino acid 15 generates prochiral radical I. 
Stereoconvergent capture by Ni(II)-intermediate II, bearing chiral ligand L-2, followed by reductive 
elimination from ensuing Ni(II)-intermediate III affords enantioenriched benzylic amines, including 
16a and 16b, in good yields and enantiopurities. In these processes, the enantioselectivity is determined 
by the chiral ligand during the combination of alkyl radical I and chiral Ni(II)-intermediate II. This 
method is notable in the fact that it uses amino acids, which are widely available and cheap, in place of 
alkyl boronic acids. However, the scope of the reaction is limited to groups that will stabilise the 
intermediate radical (i.e. arenes and amines). 




Scheme 8: Photoredox catalysed reaction of aryl halides and amino acids to generate tertiary benzylic amines 
with high enantiopurity. 
In the previous example, an alkyl radical coupling partner is generated through photoredox 
catalysis; however, these can also be generated through other methods, including hydrogen atom 
transfer (HAT). Lu and co-workers demonstrated the enantioselective C−H arylation of alkyl benzenes 
with aryl bromides to from 1,1-diarylalkanes (Scheme 9).36 They utilised an Ir(III)-PRC in combination 
with a Ni(0)-catalyst ligated with chiral bis-imidazoyl ligand L-3 to access a SET dual-catalytic 
pathway. Oxidative addition of Ni(0)-catalyst I into the aryl bromide forms Ni(II)-intermediate II, from 
which a bromine radical is released during SET, forming Ni(II)-intermediate III. In this case, benzylic 
radical IV is formed via HAT from the alkyl benzene and 4,4'-dimethoxybenzophenone (DMPB), which 
acts a co-catalyst, in the presence of the bromine radical and a base. The resulting radical IV intercepts 
Ni(II)-species III to form Ni(III)-intermediate V, from which reductive elimination affords the 1,1-
diarylated alkane 17. The active Ni(0)-catalyst I is regenerated through SET, closing the catalytic cycle. 
This protocol provides facile access to tertiary benzylic stereocentres with high enantiopurity (e.g. 
17a−c) directly from unfunctionalised benzylic positions. The methodology tolerates electron-rich and 
-poor aryl bromides, including heteroaromatics. Additionally, various carbon substituents can be 
introduced at R2. 




Scheme 9: Photoredox catalysed C−H arylation of aryl alkanes with aryl halides to form enantioenriched 1,1-
diarylalkane species. 
The previous examples (Scheme 7−9) all employ radicals that are stabilised by adjacent 
functionality (aryl and nitrogen groups), which limits the scope of these transformations. Shenvi and 
co-workers employed a Ni(I)/Co(II) dual catalytic approach to promote the hydroarylation of terminal 
alkenes with a range of electronically diverse aryl iodides (Scheme 10).37 This method allows aliphatic 
alkenes to be used in these types of reaction, most likely as a result of the tendency of Co-species to 
trap alkyl radicals. However, an enantioselective protocol is yet to be disclosed. Initially, the Co(II)-
precatalyst is oxidised by [2,4,6-Me3PyF]BF4 to a Co(III)-species, which forms active Co(III)-hydride 
catalyst I in the presence of Ph(i-PrO)SiH2. Co(III)-hydride I then undergoes Markovnikov hydrogen 
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atom transfer to an alkene to generate alkyl Co(III)-nucleophilic species II in situ. 38 Mechanistic studies 
suggest that the alkyl Co(III)-species II is oxidised to Co(IV)-species IV via SET in the presence of 
Ni(III)-species III (formed by oxidative addition of the Ni(I)-catalyst into an aryl iodide). Homolysis 
of the Co(IV)−Calkyl bond of species IV, with resulting Ni(II)-species V, forms alkyl radical species VI, 
which is rapidly accepted by subsequent Ni(III) species V. This occurs within the solvent cage via a 
“cage-rebound” process. Ni(III)-intermediate VII then undergoes reductive elimination to form the 
cross-coupled products, such as 18a and 18b, and a Ni(I)-species, completing the catalytic cycle. 
Co(III)-species related to II have been used in Minisci-type reactions to generate racemic pyridines 
bearing quaternary centres.39 
 
Scheme 10: Synthesis of tertiary benzylic centres from aryl halides and alkenes by dual Ni(I)/Co(III) catalysis. 
1.2.2 − Cross-Coupling Reactions of Alkyl Electrophiles 
1.2.2.1 − Enantioenriched Alkyl Electrophiles in Cross-coupling Reactions 
A complementary approach to the methods outlined in Section 1.2.1 is the employment of 
enantioenriched alkyl electrophiles with aryl nucleophiles. Similarly to alkyl nucleophiles, the cross-
coupling of enantioenriched electrophiles can proceed with either retention or inversion of 
stereochemistry. One example reported in 2012 by Jarvo and co-workers described the Ni(0)-catalysed 
coupling of stereodefined benzyl ethers 19 with aryl Grignard reagents (Scheme 11).40 In this example, 
a chelating leaving group is attached to the benzyl ether, which upon chelation to magnesium activates 
the C−O bond towards stereoinvertive oxidative addition by the Ni(0)-catalyst (I). Subsequent 
transmetallation with Grignard reagents and reductive elimination forms the desired benzylic centres, 
such as 20a and 20b, with overall stereoinversion. The highly nucleophilic nature of Grignard reagents 
Chapter 1 − Introduction 
13 
 
restricts the functional group tolerance and the process is limited to bisbenzylic electrophiles, 
presumably to facilitate oxidative addition of the Ni(0)-catalyst. 
 
Scheme 11: Ni(0)-catalysed cross-coupling of Grignard reagents with enantioenriched ethers. 
Towards a more versatile protocol, Watson and co-workers disclosed the Ni(0)-catalysed cross-
coupling of benzylic ammonium triflates 21 with aryl boronic acids (Scheme 12a).41 Additional studies 
by the Watson group subjected stereodefined benzylic pivalates 22 and boronic acids to a Ni(0)-catalyst 
in the absence of a phosphorus ligand (Scheme 12b).42 Both transformations are proposed to occur by 
SN2 oxidative addition of the Ni(0)-catalyst into the C−X bond (X = N or O) of the stereodefined 
substrate, which results in the inversion of configuration that is observed.41-42 Transmetallation with the 
boronic acid, is followed by reductive elimination to afford the target products. In both protocols 1,1-
diarylalkanes, such as 23a−c, were generated in excellent yields (Scheme 12a and 12b). In these 
examples the use of a Ni(0)-catalyst suppresses -hydride elimination.43 The processes discussed in 
Scheme 12 are limited to the generation of bisbenzylic or benzylic-vinylic stereocentres.41-42 This is 
presumably due to hyperconjugation of the aryl -system with the −orbital of the C−X bond 
promoting more facile oxidative addition. Processes which start from alkyl triflates or alkyl halides 
have been reported; however, these are often limited by specific functional group requirements.44-45 
 




Scheme 12: Stereodefined electrophiles in Ni(0)-catalysed Suzuki-type cross-coupling reactions to generate 
tertiary benzylic stereocentres. 
Watson and co-workers expanded the methodology in Scheme 12 to couple sterically 
demanding enantioenriched tertiary alcohol derivatives 24 with aryl boronic acids, thereby generating 
all-carbon quaternary centres with retention of stereochemistry (Scheme 13).46 It is proposed that the 
acetate of the electrophile binds to the Ni(0)-catalyst to direct SN2’-like oxidative addition (24 to II). 
Transmetallation with boronic acid III, followed by reductive elimination from IV then affords the 1,1-
diaryl quaternary stereocentres (e.g. 25a and 25b). A Ni(0) catalyst ligated with bulky biaryl phosphine 
ligand CyJohnPhos was used to prevent undesirable -hydride elimination from IV. This transformation 
requires a naphthyl substituent, which is consistent with the proposed directed oxidative addition step. 
Despite forming a range of benzylic quaternary centres in high yields and enantiopurities, the starting 
chiral alcohols are synthesised in two steps from acetophenones, resulting in increased workload and 
waste. 
 
Scheme 13: Stereodefined electrophiles in Ni(0)-catalysed cross-coupling reactions to generate all-carbon 
quaternary stereocentres. 
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1.2.2.2 − Enantioselective Processes Employing Racemic Alkyl Electrophiles 
Similar to the processes discussed in Section 1.2.1.2 employing racemic alkyl nucleophiles, 
enantioselective processes have begun to emerge which utilise racemic alkyl electrophiles. For example, 
in 2019, Tang and co-workers reported the enantioconvergent Pd(0)-catalysed cross-coupling of aryl 
boronic acids with racemic -bromo carboxamides 26 (Scheme 14).47 Here, oxidative addition of a 
Pd(0)-catalyst into the alkyl-bromine bond (to give I) is followed by transmetallation to generate Pd(II)-
species II. Subsequent reductive elimination generates a range of electron-rich and -deficient -aryl 
carboxamides (e.g. 27a and 27b). The enolisation of the starting material is critical to achieve the high 
enantioselectivities observed. The chemistry is reliant upon bulky phosphine oxide ligand L-4, which 
prevents Pd(II)-intermediate II from undergoing a second transmetallation event and subsequent 
reductive elimination to form unwanted biaryl-species.  
 
Scheme 14: Enantioselective Pd(0)-catalysed cross-coupling of racemic -bromo carboxamides with aryl 
boronic acids to generate tertiary benzylic stereocentres. 
The enantioselective cross-coupling of racemic alkyl electrophiles with organoboranes can also 
be conducted under Ni(0)-catalysed conditions; however, these protocols proceed via a radical-based 
pathway.48 In 2010, Fu and Lundin reported the enantioselective Ni(0)-catalysed cross-coupling of 
racemic amide activated alkyl halides 28 with aryl organoboranes 29 to generate benzylic stereocentres, 
such as 30a and 30b (Scheme 15).48 This process is stereoconvergent, whereby both enantiomers of 
racemic starting material 28 are catalytically converted to a single enantiomer of product 30. This 
transformation is reliant on the amide activating group on the electrophile to stabilise the intermediate 
radical formed upon oxidative addition, limiting the scope of the reaction.  
 




Scheme 15: Enantioselective cross-coupling of racemic alkyl electrophiles and aryl organoboranes via a Ni(0)-
catalysed radical-based mechanism. 
Reductive cross-coupling of two electrophilic components via asymmetric metal catalysis is 
another strategy that has been employed to generate enantioenriched benzylic stereocentres.49-52 One 
example relevant to this thesis is the enantioselective Ni(0)-catalysed reductive cross-coupling of 
(hetero)aryl iodides with racemic benzyl chlorides 31 to generate 1,1-diarylalkanes (e.g. 32a and 32b) 
(Scheme 16).52 It is proposed that following oxidative addition of the Ni(0)-catalyst into the aryl iodide 
bond to form Ni(II)-intermediate II, II is reduced to Ni(I)-intermediate III by manganese.49 This 
facilitates stereoconvergent single electron oxidative addition of benzyl chloride 31. Subsequent 
reductive elimination from Ni(III)-species IV generates enantioenriched coupled product 32 and Ni(I)-
species V, which is reduced by manganese to active Ni(0)-catalyst I. Notably, this protocol avoids 
stereodefined electrophiles and organometallic reagents, thereby minimising the number of steps 
needed to reach the target product. All of the enantioselective examples described here employ 
electrophilic radical species, which require radical stabilising functionality (e.g. aryl and amide groups) 
and limit the generality of the approach towards the synthesis of benzylic stereocentres (Scheme 7−10, 
15). 




Scheme 16: Synthesis of 1,1-diarylalkanes via a reductive Ni(0)-catalysed cross-coupling reaction. 
In 2018, a related approach was reported by Gong and Wang and co-workers, who described 
the non-enantioselective 3-fluoropyridine ligated Ni(0)-catalysed reductive cross-coupling of aryl 
iodides with tertiary alkyl halides 33 to afford demanding all-carbon quaternary centres, such as 34a−c 
(Scheme 17).53 In this example, mechanistic experiments revealed two possible catalytic cycles; a 
radical chain mechanism or a double oxidative addition pathway. In both cases, zinc acts a reductant to 
regenerate the Ni(0)-catalyst. For some transformations, isomeric side product 35 was also observed, 
which presumably forms via a -hydride elimination/migratory insertion pathway. 
 




Scheme 17: Synthesis of all-carbon quaternary centres via a reductive Ni(0)-catalysed cross-coupling reaction. 
1.2.3 − Enantioselective Hydroarylation Reactions 
The final category of C(sp2)−C(sp3) bond forming reactions that will be outlined are those 
where the stereocentre is formed during a migratory insertion step in the catalytic cycle (I to II) (Scheme 
18). This is advantageous because it uses simple alkenes as prochiral substrates and does not require 
specific stabilising groups. Furthermore, this method is innately highly atom economical and fits the 
ideals of a green process, where a stock chemical (alkene) is coupled directly without 
prefunctionalisation.  
 
Scheme 18: Migratory insertion as a route to tertiary benzylic stereocentres. 
The hydroarylation of unfunctionalised alkenes (rather than the cross-coupling of alkyl halides), 
where the hydride comes from an external source, is a powerful method to install benzylic stereocentres. 
Here, chiral Pd(II)- and Ni(0)-catalysts can be utilised for the enantioselective cross-coupling of alkenes 
with aryl boronic esters.54-55 In 2011, Sigman and co-workers developed a moderately enantioselective 
Pd(II)-catalysed alkene hydroarylation with aryl boronic esters (Scheme 19a).54 Pd(II)-hydride II forms 
via oxidation of iso-propanol by I. Enantio-determining alkene insertion into Pd(II)-hydride II is then 
followed by transmetallation of the aryl boronic ester (III to IV) and reductive elimination (IV to V). 
Oxygen acts as an external oxidant to regenerate active Pd(II)-catalyst I from Pd(0)-species VI. The 
target bisbenzylic or benzylic-vinylic stereocentres, such as 36a and 36b, were produced in moderate 
yield (up to 53%) and with promising levels of enantioselectivity (up to 59% e.e.). Building upon 
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Sigman’s seminal work,54 Mei developed a highly enantioselective Ni(0)-catalysed protocol for the 
hydroarylation of styrenes with aryl boronic acids (Scheme 19b).55 In this example, MeOH acts as the 
hydride source and chiral bis-oxazoline ligand L-7 provides high levels of enantioselectivity (up to 96% 
e.e.) for alkene hydroarylation with both aryl and vinyl boronic acids, generating benzylic stereocentres 
in high yields (e.g. 37a and 37b). This work is a significant contribution to the field as it provides access 
to benzylic stereocentres enantioselectively, directly from feedstock alkenes. 
 
Scheme 19: Enantioselective Pd(II)- and Ni(0)-catalysed hydroarylation of styrenes with boronic acids to 
generate tertiary benzylic stereocentres. 
Sigman and co-workers developed a similar Pd(II)-catalysed methodology for the 
enantioselective construction of sterically demanding all-carbon quaternary centres from secondary 
alkyl alcohols 38a and boronic acids (Scheme 20a).56 Here, a Cu-source was added to aid reoxidation 
of the Pd(0)-catalyst to active Pd(II)-species. The mechanistic pathway begins with transmetallation of 
the aryl boronic acid, followed by migratory insertion of the alkene to generate the desired quaternary 
stereocentres. Subsequent relay -hydride elimination/migratory insertion affords the carbonyl 
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compounds bearing all-carbon stereocentres enantioselectively (e.g. 39a and 39b). Through 
modification of the chiral pyridine oxazoline ligand (L-8 to L-9), Sigman and co-workers expanded the 
enantioselective dehydrogenative Heck arylation of trisubstituted alkenes 38b to electron-rich indoles 
40 (Scheme 20b).57 Here, the C3 C−H bond of indole 40 is functionalised directly to form indoles 
bearing quaternary centres (e.g. 41a and 41b). However, this protocol is only applicable for electron-
rich arenes and multiple synthetic steps are required for the synthesis of the alkenes 38.56-57  
 
Scheme 20: Enantioselective Pd(II)-catalysed hydroarylation of styrenes with boronic acids to form all-carbon 
quaternary stereocentres. 
1.3 − Metal-Catalysed C−H Activation and Asymmetric Hydroarylation 
The methodology discussed in section 1.2 has been utilised to afford benzylic stereocentres with 
excellent levels of enantioselectivity. All of the protocols presented require prefunctionalised starting 
materials, which results in extra synthetic steps, increased workload and large amounts of waste. For 
example, stereo-defined alkyl boronic esters are often synthesised via enantioselective hydroboration 
of alkene precursors58-60 and aryl halides are frequently prepared by regioselective halogenation of aryl 
C−H bonds.61-62 An ideal strategy to generate tertiary benzylic stereocentres would directly couple an 
alkene and an aryl C−H bond via directed C−H activation (Scheme 21). This desirable approach would 
generate benzylic stereocentres in an atom and step economical manner. 





Scheme 21: Asymmetric hydroarylation of alkenes via C−H activation as an ideal approach to generate benzylic 
stereocentres.  
The ability to take ‘feedstock’ materials and directly transform them into valuable products is 
highly desirable. One approach towards the direct functionalisation of C−H bonds is the well-
established Friedel-Crafts reaction, which achieves branch-selective hydroarylation of styrenes with 
unfunctionalised arenes in the presence of an acid (Scheme 22).63-66 However, this method requires 
electron-rich arenes and suffers from poor site-selectivity (ortho vs para) as well as over alkylation. 
Additionally, enantioselective alkylation by this method is challenging. Therefore, the development of 
strategies that allow the selective activation and subsequent functionalisation of the desired C−H bond 
is key to the development of this ideal. 
 
Scheme 22: Hydroarylation of alkenes via a Friedel-Crafts reaction. 
The selective functionalisation of ‘inert’ C−H bonds (~110 kcal/mol Caryl−H bond) using metal 
catalysis has gained significant attention in recent years, owing to these more direct methods being both 
environmentally and economically attractive.67-76 Organometallic C−H activation involves the direct 
insertion of a metal complex into a C−H bond with concomitant two-electron oxidation of the metal 
centre, to generate a metal-hydride (Scheme 23).77 Functionalisation of the organometallic intermediate 
can then proceed. Additionally, alternative Caryl−H metalation pathways exist, but strictly speaking these 
are not examples of C−H activation. For example, -bond metathesis (also known as concerted 
metalation deprotonation (CMD)) between a metal-ligand bond and an aryl C−H bond proceeds through 
a concerted transition state to form a C−M bond and L−H bond (Scheme 23). Alternatively, an 
electrophilic substitution pathway (SEAr) involves an initial electrophilic interaction with the electron-
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rich arene -system and an electron-deficient metal. The [M]−L bond interacts with the C−H bond of 
the resulting intermediate to form a M−C bond, whilst also re-establishing the aromaticity.  
 
Scheme 23: The various mechanisms for transition metal catalysed activation and metallation of aryl C−H bonds. 
C−H bonds are ubiquitous in organic molecules, so selectively targeting the bond of interest 
poses a considerable challenge. One approach to selectively activate C−H bonds is the use of directing 
groups, which can coordinate to the metal catalyst and hold it in the correct position for oxidative 
addition into the desired bond. This directing group strategy has been applied in hydroarylation 
reactions to generate C(sp3)−C(sp2) bonds. The first protocol for selective ortho-alkylation of arenes 
via directed metal-catalysed C−H activation was reported in 1986 by Lewis and Smith (Scheme 24).78 
Their hydroarylation methodology utilises a Ru(0)-catalyst and a catalytic phosphorus-based directing 
group, to achieve ortho-ethylation of aryl phenols. Despite the relatively harsh conditions employed 
(177 °C, 95 psi), ortho-alkylated phenols were generated exclusively as a mixture of mono- and bis-
alkylated moieties (42a and 42b). 
 
Scheme 24: The first reported example of directed metal-catalysed ortho-alkylation of arenes. 
Following Lewis and Smiths’ pioneering work (Scheme 24), Murai and co-workers described 
a Ru(0)-catalysed protocol for ortho-alkylation of aryl ketones 43 with mono-substituted alkenes to 
generate linear hydroarylation products (Scheme 25a).79 This catalytic process is significant, as it 
employs a weakly coordinating carbonyl directing group and provides the desired products atom 
economically, with alkylation occurring with complete ortho- and linear selectivity. The protocol was 
suggested to proceed by reversible carbonyl-directed oxidative addition of the Ru(0)-catalyst into the 
ortho C−H bond of the arene to give I, followed by alkene coordination (I to II). Hydrometallation 
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(insertion of the alkene into the [Ru]−H bond) (II to III) is then followed by the first irreversible step, 
C−C bond forming reductive elimination. Evidence for a hydrometallation pathway instead of a 
carbometallation pathway (insertion of the metal into the [Ru]−C bond) was provided by DFT 
calculations.80-81 The linear selectivity is most likely a product of an equilibrium preference for linear 
intermediate III (Scheme 25a) over branched intermediate VI (Scheme 25b). The Murai methodology 
has inspired the development of other transformations promoted by metal-catalysed ortho C−H 
activation. Protocols which override the usual linear selectivity to generate branched hydroarylation 
products are of particular interest as they are atom economical ways to access privileged structures 
bearing benzylic stereocentres (Scheme 25b).82 
 
Scheme 25: An ideal approach to generate benzylic stereocentres based on Murai’s pioneering work. 
1.3.1 − Directed Branch-Selective Alkene Hydroarylation 
In 1999, Uchimaru disclosed the first example of directed branch-selective alkene 
hydroarylation (Scheme 26).83 N-Methylaniline 44 and styrene were subjected to a Ru(0)-catalyst to 
generate ortho-alkylated arene 45 in 85% yield and with complete branch selectivity. The 
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transformation is suggested to proceed via amine-directed oxidative addition of the Ru(0)-catalyst into 
the ortho C−H bond, giving 4-membered chelate I. Subsequent alkene carbometallation forms II, from 
which C−H reductive elimination generates branched product 45. In contrast to Murai’s pioneering 
work, a carbometallation pathway was proposed rather than a hydrometallation pathway, due to 
insertion of the alkene into the Ru(II)−C bond relieving the strain associated with 4-membered chelate 
I. Exemplification of this protocol was not disclosed. 
 
Scheme 26: The first example of branch-selective alkene hydroarylation. 
In 2011, Yoshikai and Gao utilised a PCy3-ligated Co(0)-catalyst to promote branch-selective 
styrene hydroarylation with 2-phenylpyridine 46, generating hydroarylation products with complete 
branch selectivity (e.g. 47 in 81% yield) (Scheme 27a).84 The active Co(0)-catalyst forms in situ by 
Grignard-promoted reduction of the Co(II)-precatalyst. The ligand was found to be crucial to the 
regioselectivity of the hydroarylation reaction, with a complete switch to linear hydroarylation product, 
such as 48, observed when using IMes.HCl as the ligand. The hydroarylation of electronically varied 
styrenes with a variety of arylpyridines proceeded to give the desired products branch-selectively and 
in good yields. However, when aliphatic alkenes were utilised only linear hydroarylation products were 
isolated. Deuterium-labelling reactions resulted in scrambling of the deuterium signals, leading to a 
Murai-type mechanism being proposed. Here, reversible pyridyl directed oxidative addition and 
insertion of the alkene into the Co(II)−H bond is followed by irreversible and regioselectivity 
determining C−C reductive elimination. Hence, this is strictly the first reported example of a branch-
selective Murai-type hydroarylation (hydrometallation is operative as opposed to carbometallation).84 
Subsequent mechanistic studies by Fu and co-workers supported the mechanism proposed 
above, with DFT calculations revealing hydrometallation as the most probable pathway (Scheme 
27b).85 These studies also gave insight into the ligand controlled regioselectivity of the reaction. It was 
proposed that both the ligand shape and the steric interactions between the ligand and the arene were 
the regiocontrol factors. For example, it was suggested that the cyclohexyl substituents on PCy3 sit away 
from the Co(II)-centre (umbrella-up) in intermediate I. However, in intermediate II, the mesityl unit of 
the IMes ligand points towards the Co(II)-centre (umbrella-down), creating a more sterically crowded 
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conformation, whereby there is an interaction between the mesityl unit of the ligand and the arene. II 
is therefore disfavoured and a less sterically crowded conformation is adopted to afford linear 
regioisomer 48. 
 
Scheme 27: Ligand-controlled regioselectivity of Co(0)-catalysed styrene hydroarylation with arylpyridines. 
1.3.2 − Recent Developments in Enantio- and Branch-Selective Alkene 
Hydroarylation 
Since this first general example (Scheme 27a), a wealth of research into the branch-selective 
hydro(hetero)arylation of a range of alkenes (styrenes, aliphatic alkenes, enol ethers, acrylates) has 
emerged82 with significant contributions made by the groups of Yoshikai,84, 86-90 Shibata,91-93 
Ackermann94-95 and Nishimura.96-101 Significantly, enantioselective protocols have begun to take 
precedence, providing atom and step economical routes to benzylic stereocentres.  
In 2012, Shibata and co-workers developed an Ir(I)-catalysed method for alkene 
hydroheteroarylation at the C2-positions of indoles (Scheme 28).92 The use of a simple N-benzoyl 
directing group, promoted the alkylation of indoles 49 with a range of styrenes to afford the desired 
products branch-selectively and in excellent yields (up to 93%). Significantly, the process was effective 
with non-1-ene, an alkyl alkene, to afford 50a; here, 20 mol% of Ir(I)-catalyst and a reaction time of 
seven days was required. Additionally, promising levels of enantioselectivity were achieved for the 
enantioselective hydroarylation of styrene (42% e.e.), when using (R)-SDP as the ligand (50b). 
Interestingly, when an N-acetyl directing group was employed alongside rac-BINAP as the ligand, 
linear hydroarylation was promoted. No studies into this switch in selectivity were disclosed. 




Scheme 28: Ir(I)-catalysed alkene hydroheteroarylation with indoles and studies towards an enantioselective 
protocol. 
Following Shibata’s initial studies towards enantioselective alkene hydroarylation with indole 
derivatives (Scheme 28), Yoshikai and Lee reported a Co(I)-catalysed enantioselective protocol 
(Scheme 29).89 They utilised an imine moiety as a transient directing group (51), which they had 
previously demonstrated to promote branch-selective hydroarylation of aryl aldehydes and ketones with 
a range of styrenes.84, 87 The active Co(I)-catalyst forms in situ from Co(acac)3, chiral phosphoramidite 
ligand L-10 and Grignard reagent. The desired alkylated indoles (e.g. 52a and 52b) were generated in 
good yields (up to 90%) and enantiopurities (up to 87% e.e.). However, unlike Shibata’s methodology, 
the hydroarylation of aliphatic alkenes was not described. 
 
Scheme 29: Co(I)-catalysed methodology for the enantioselective styrene hydroheteroarylation with indoles. 
Two years later, Ackermann and co-workers reported a chiral NHC ligated Fe(I)-catalyst that 
selectively alkylates N-protected indoles 53 bearing the same transient imine directing group as 
Yoshikai and Lee (Scheme 30a).94 The protocol was applicable for the hydroarylation of a range of 
alkenyl metallocenes and styrenes with indoles equipped with carbon-based N-protecting groups. The 
active Fe(I)-catalyst forms in situ, via reduction of the Fe(III)-precatalyst in the presence of a Grignard 
reagent. Oxidative addition of the Fe(I)-catalyst into the relevant C−H bond gives intermediate I. 
Alkene coordination and subsequent coordination of a second equivalent of indole substrate promotes 
migratory insertion of the alkene into the C−Fe bond to give intermediate II. Subsequent reductive 
elimination generates the benzylic stereocentres, such as 54a and 54b, in excellent yields and 
enantiopurities. More recently, Ackermann and co-workers detailed methodology for Co(I)-catalysed 
enantioselective hydroarylation of alkenes with indoles equipped with N-methylpyridine directing 
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groups 55, to generate benzylic stereocentres, including 56a (Scheme 30b).95 Here, one example of an 
aliphatic alkene was detailed; however, desired alkylated indole 56b was produced in moderate yield 
(37%) and enantiopurity (44% e.e.). A related protocol was reported by Meek and co-workers who 
achieved enantioselective Rh(I)-catalysed alkylation of the C3-position of indoles with 1,3-dienes.102 
However, this transformation proceeds via nucleophilic attack of indole onto an allyl-rhodium 
intermediate instead of via an aryl-Rh intermediate. 
 
Scheme 30: Methodologies for the enantioselective hydroheteroarylation of alkenes with indoles. 
In 2014, Ramana and co-workers made a substantial contribution towards utilising coupling 
partners other than styrenes for branch-selective hydroarylation reactions (Scheme 31).103 They 
employed a ketone directing group for Ru(0)-catalysed branch-selective hydroheteroarylation of 
acrylates 58 with benzofurans 57. A range of terminal and -substituted acrylates generated C3-
alkylated 2‐aroylbenzofurans in excellent yields (e.g. 59a and 59b). Interestingly, a linear selective 
protocol was developed by employing additional triphenylphosphine, omitting AgOAc and changing 
the base and solvent.103  
 




Scheme 31: Ru(0)-catalysed hydroarylation of acrylates with benzofuran substrates. 
More recently, Shibata and co-workers developed methodology for the enantioselective 
hydroarylation of acrylates 61 with a range of arenes bearing acetanilide directing groups 60 (Scheme 
32).91 They employed an Ir(I)-catalyst equipped with a commercially available chiral ligand to afford 
3,3‐disubstituted propanoates in excellent yields and enantiopurities (e.g. 62a−c). Notably, in contrast 
to Ramana’s methodology, the benzylic bond is formed to the -position of the acrylate. This 
transformation is proposed to proceed via carbonyl-directed oxidative addition and hydrometallation, 
followed by irreversible C−C reductive elimination.  
 
 
Scheme 32: Enantioselective Ir(I)-catalysed hydroarylation of acrylates with acetanilides. 
In 2015, Nishimura and Ebe demonstrated that enol ethers 63 could undergo Ir(I)-catalysed 
branch-selective hydroarylation (Scheme 33).99 A range of arenes with N-based directing groups, 
including pyridines, oxazolines and oxime ethers were employed to afford benzylic ether products, such 
as 64a−d, in good yields and with complete branch selectivity. Alkyl, aryl and cyclic enol ethers all 
underwent efficient hydroarylation; however, styrenes and alkyl alkenes were unsuitable. Notably, by 
utilising a pyridine directing group, the process was expanded to the hydroheteroarylation of an enol 
ether with a thiophene derivative to give 64d. Here, 1,5-cyclooctadiene acts as a chelating ligand, with 
no external phosphine ligand required. It is proposed that both oxidative addition and alkene migratory 
insertion occur reversibly, with reductive elimination being the first irreversible and regioselectivity 
determining step.  




Scheme 33: Pyridine-directed hydroarylation of enol ethers with (hetero)arenes under Ir(I)-catalysed conditions. 
Through modification of the Ir(I)-catalyst system with chiral diene ligand (S,S)-Me-tfb*, 
Nishimura and co-workers developed an enantioselective protocol for the hydroarylation of enol ethers 
63 (Scheme 34).96 The methodology was applicable to a range of arenes 65 bearing amide-based 
directing groups, which gave benzylic ether products 66a−d, in good yields and enantiopurities (up to 
99% e.e.). The protocol tolerates the hydroarylation of both cyclic and acyclic enol ethers with a broad 
range of substituted arenes. Additionally, the alkylation of heteroaromatics proceeded to generate the 
desired products, such as 66c and 66d, in excellent yields and enantiopurity (up to 96% e.e.). Here, the 
nitrogen atom of the amide moiety (rather than the carbonyl unit as previously seen) coordinates and 
directs the Ir(I)-catalyst. Deuterium exchange experiments showed reversible hydrometallation but 
irreversible carbometallation. This method accesses benzylic alcohols enantioselectively, via an 
alternative route to traditional protocols (Grignard addition to aldehyde). It is notable for the high 
enantioselectivity achieved; however, the process requires a directing group with an acidic N−H bond 
to successfully establish 5-membered aminoiridacycle (I to II). Additionally, enol ethers are 
electronically predisposed to undergo branch-selective hydroarylation. 




Scheme 34: Enantioselective Ir(I)-catalysed hydroarylation of enol ethers with (hetero)arenes. 
Through modification of Ir(I)-pre-catalysts with chiral bisphosphine ligands, Nishimura and 
co-workers expanded their asymmetric hydroarylation methodology. For example, they reported the 
hydroarylation of vinyl ethers 68 with arenes bearing 2-aryl-substituted azole directing groups 67, 
which generated hydroarylation products, such as 69a and 69b (Scheme 35a, (R,R)-QinoxP*).97 Long 
chain alkenyl ethers 71 were isomerised by the Ir(I)-catalyst, before undergoing enantioselective 
hydroarylation with 2-phenylpyridines 70, generating hydroarylation products, such as 72a and 72b 
(Scheme 35b, (R)-BINAP).101 Additionally, cyclic tertiary benzylic stereocentres were generated 
enantioselectively via asymmetric hydroarylation of cyclic enol ethers 74 with arenes equipped with 
ketone directing groups 73 to give products, including 75a and 75b (Scheme 35c, (R)-DM-
SEGPHOS).98 




Scheme 35: Ir(I)-catalysed enantioselective hydroarylation of various enol ethers. 
 
In addition to the above examples (Scheme 29−30, 32 and 34−35), asymmetric Murai-type 
hydroarylation reactions have also been reported with strained bicyclic alkene coupling partners.104-108 
For example, in 2013 Hartwig and co-workers demonstrated the Ir(I)-catalysed asymmetric 
hydroheteroarylation of norbornene 76 to give the target products, including 77a−c, in moderate to 
excellent yields and good levels of enantiopurity when using DTBM-SEGPHOS as the chiral ligand 
(up to 98% e.e.) (Scheme 36a).106 More recently, Li and co-workers reported the hydroarylation of 
azabenzonorbornadienes 79 with indoles bearing pyrimidyl directing groups 78 (Scheme 36b).109 They 
utilised a chiral Rh(III)-precatalyst, with Ag2SO4/AgOAc as an additive to generate the desired cyclic 
benzylic stereocentres, such as 80a and b, in excellent yields and enantiopurities. These 
methodologies are significant for the high atom economy achieved and the broad range of 
heteroaromatics applicable. Despite this, the protocols are limited to highly reactive norbornene 
derivatives as the alkene coupling partner and, because this system is symmetrical, the requirement to 
control branched vs linear selectivity is obviated. 




Scheme 36: Transition-metal catalysed enantioselective hydroheteroarylation of strained bicyclic alkenes.        
The enantioselective alkene hydroarylation processes discussed so far all rely on additional 
directing groups for ortho-selective C−H functionalisation. However, it has been demonstrated in a few 
cases that hydroarylation can occur under directing group free conditions. For example, in 1994 Jordan 
and co-workers reported that a chiral Zr(III)-catalyst promoted the hydroarylation of hex-1-ene with 2-
methylpyridine 81 to generate motif 82 bearing a benzylic stereocentre with promising levels of 
enantiopurity (58% e.e.).110-111 Building upon these seminal studies (Scheme 37a), Hou and co-workers 
developed a highly enantioselective protocol (Scheme 37b).112 They employed a Sc(III)-catalyst, which 
coordinates to the pyridine N-atom, facilitating oxidative addition into the ortho C−H bond of 83. 
Subsequent alkene coordination and migratory insertion into the [Sc]−C bond, generates the alkylated 
pyridines, including 84a−c, with excellent enantiopurity (up to 96% e.e.). This significant advance 
towards directing group free branch- and enantioselective alkene hydroarylation requires substituents 
in the ortho-position of pyridine, presumably to prevent bis-alkylation from occurring. Additionally, 
this methodology is substrate specific as the C−H activation step is dependent upon the nitrogen atom 
of pyridine coordinating to the metal catalyst.  




Scheme 37: Directing group free enantioselective alkene hydroarylation with pyridine moieties. 
Another directing group free approach was reported by Ellman and co-workers, who employed 
a Rh(I)-catalyst ligated with an electron-deficient bisphosphine ligand for the branch-selective 
hydroarylation of acrylates and acrylamides with pyridines 85 and benzimidazoles 87 (Scheme 38).113-
114 Significantly, ethyl methacrylate was applicable, affording challenging all-carbon quaternary centres, 
such as 86b and 88b. Interestingly, this method offers alternate regioselectivity vs Rh-catalysed 
conjugate addition strategies.115  
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1.4 − Versatile Methodology for Ir(I)-Catalysed Branch-Selective Alkene 
Hydroarylation  
In 2014, building upon the pivotal Ir(I)-catalysed conditions developed by Shibata (Scheme 28), 
former PhD student, Dr. Giacomo Crisenza developed a protocol for branch-selective Murai-type 
alkene hydroarylation with aryl ketones 89 and amides 90 (Scheme 39a).116 A range of weakly-
coordinating carbonyl-based directing groups (e.g. ketones and amides) were employed to direct 
oxidative addition of an Ir(I)-catalyst ligated with the wide bite angle, electron-deficient bisphosphine 
ligand, dFppb (1,4-bis(di(pentafluorophenyl)phosphino)butane) (via 5-membered chelate I). The 
desired products (e.g. 92 and 93) were produced in excellent yield and with complete branch selectivity 
for the hydroarylation of a range of styrenes and aliphatic alkenes with electron-rich and -poor 
benzamides. For substrates bearing substituents in the meta-position, the ortho-regioselectivity was a 
result of both electronic and steric effects, with high selectivity often observed (e.g. 93aa’). However, 
ortho-substituents on the arene partner were not tolerated, most likely due to a steric interactions with 
the directing group, forcing it to twist out of the plane of the arene, and hence inhibiting oxidative 
addition (II to III) (Scheme 39b).116 
 
Scheme 39: Ir(I)-catalysed hydroarylation of alkenes with benzamide derivatives. 
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Similar Ir(I)-catalysed conditions were also applicable to alkene hydroarylation with electron-
rich acetanilide substrates 60 (Scheme 40).117 Here, the mechanistic pathway proceeds via more 
challenging 6-membered chelate II. Ortho-alkylated products, such as 96, were generated in excellent 
yields and with complete branch selectivity for the hydroarylation of styrenes or aliphatic alkenes. 
Significantly, by proceeding through more flexible 6-membered chelate II, ortho-substituents on the 
anilide coupling partner were tolerated (e.g, 96da’). 
 
Scheme 40: Ir(I)-catalysed hydroarylation of alkenes with acetanilide derivatives. 
Crisenza carried out experiments to elucidate the mechanistic pathways for these processes. 
Initially, the hydroarylation of deuterated alkene deuterio-91e’ with acetanilide 60c was performed and 
deuterium incorporation was observed at both the benzylic position (0.20 D, 20% deuteration) and in 
the methyl unit (1.80 D, 60% deuteration) of product deuterio-96ce’ (Scheme 41a).116-117 The observed 
scrambling supports reversible C−H oxidative addition (I to III), and reversible alkene 
hydrometallation to generate intermediates V or VI (Scheme 41b). Reductive elimination then forms 
branched product VII or linear product VIII. Crisenza determined natural abundance 13C kinetic isotope 
effects (KIE’s) using the Singleton method (see Section 4.4) and this supported a reversible 
hydrometallation pathway, followed by irreversible C−C reductive elimination.118 This mechanistic 
pathway was also found to be operative for benzamide substrates (Scheme 39). 




Scheme 41: Proposed mechanism for the carbonyl directed Ir(I)-catalysed hydroarylation of alkenes. 
For both benzamide 90 (Scheme 39) and acetanilide 60 substrates (Scheme 40), the ligand 
dFppb was crucial for achieving the high levels of branch selectivity observed.117 Indeed, when changing 
the ligand from dFppm to dFppb in the hydroarylation of styrene 91a’ with acetanilide 60a, increased 
branch selectivity was achieved (40% to 100%) (Scheme 42). This is due to the significant change in 
the bite angle of the ligand (70º to 94º). Additionally, a corresponding increase in yield of 96aa’ was 
observed (49 to 85% yield). The wide bite angle bisphosphine ligand increases the bond angle (y), 
which in turn, positions the alkyl substituent closer to the Ir−Caryl bond. This may increase the rate of 
C−C reductive elimination. Steric destabilisation of branched intermediate I would be greater than for 
linear regioisomer II, potentially explaining the branch selectivity observed. Specifically, intermediate 
I is less favourable than intermediate II and therefore, reductive elimination from I is faster than from 
II. 




Scheme 42: The effect of the ligand bite angle on conversion and branch selectivity. 
The protocols outlined above (Scheme 39 and 40) offer a facile and atom economical approach 
to generating tertiary benzylic centres with a broad range of simple styrenes and aliphatic alkenes. The 
development of an asymmetric protocol would provide a direct and waste-free alternative to cross-
coupling reactions for the enantioselective synthesis of benzylic stereocentres. 
1.5 − Outlook and Project Aims 
Since the advent of C−H activation/hydroarylation protocols, many methods for branch-selective 
alkene hydroarylation have emerged. The processes outlined in Section 1.3 represent significant 
developments towards a comprehensive protocol for a range of arenes and alkenes (i.e. styrenes, vinyl 
ethers and acrylates), with examples of enantioselective hydroarylation beginning to emerge. Despite 
these recent developments, at the outset of this project a general protocol for the carbonyl-directed 
enantioselective hydro(hetero)arylation of nonpolarized acyclic alkenes, such as -olefins, was yet to 
be reported. The methodologies developed by Crisenza for the carbonyl-directed branch-selective 
hydroarylation of simple styrenes and aliphatic alkenes were described, and this has provided the basis 
for this research project. This atom economical strategy holds great promise for generating valuable 
benzylic stereocentres enantioselectively. Additionally, no examples currently exist which generate 
more challenging quaternary benzylic stereocentres enantioselectively via a C−H activation/alkene 
hydroarylation route.  




Scheme 43: The aims of this research project. 
The research described in this thesis is split into four chapters. Chapter 2 and 3 detail 
developments into enantioselective alkene hydroarylation and hydroheteroarylation respectively. The 
main aim of these chapters was to identify a catalytic system that would allow a general enantioselective 
approach for a wide range of aromatics and heteroaromatics and to exemplify the developed protocol. 
Chapter 4 details methodology developed for the generation of all-carbon quaternary centres 
and studies undertaken into the development of an enantioselective protocol. The main goal of this 
project was to expand the Ir(I)-catalysed methodology to include 1,1-disubstituted alkenes. The scope 
was investigated, and mechanistic experiments were carried out to elucidate the catalytic cycle. 
Finally, the aim of Chapter 5 was to design and synthesise ligands that would promote a -hydride 
elimination step rather than the usual C−C reductive elimination pathway. Using this approach 1,1-
disubstituted alkenes were generated via Ir(I)-catalysed dual C−H activation and the scope of the 
reaction was investigated. The target products are useful moieties to build a range of N-containing 
heteroaromatics. 




Chapter 2 − Branch- and Enantioselective Iridium Catalysed 
Alkene Hydroarylation 
Parts of this chapter have been adapted from a publication by Grélaud et al. 
(J. Am. Chem. Soc. 2018, 140, 9351−9356) 
2.1 − Investigating Alternative Directing Groups for Branch-Selective 
Alkene Hydroarylation 
The initial studies of this project focused on identifying a suitable directing group for an enantioselective 
alkene hydroarylation. As described in Section 1.4, Dr. Giacomo Crisenza demonstrated that weakly 
coordinating carbonyl groups, including benzamide 90a (5-membered chelate) and acetanilide 60c (6-
membered chelate), were suitable directing groups to promote Ir(I)-catalysed branch-selective alkene 
hydroarylations (Scheme 44).116-117 The resulting products, such as 93aa’ and 96ca’, were generated 
with complete regioselectivity and in excellent yields (93% of 93aa’ and 99% of 96ca’). In addition to 
the mechanistic experiments described in Section 1.4 (Scheme 41), Crisenza subjected benzamide 90a 
to [Ir(cod)2]BARF/dFppb in the absence of styrene, but in the presence of deuterium oxide, to determine 
the directing ability of the acetanilide unit (Scheme 44a). High deuterium incorporation was observed 
at both the ortho-positions of deuterio-90a (C2, and C6, 0.86 D, 86% deuteration) and at the methylene 
units of the directing group (3.28 D, 82% deuteration).116 However, in the absence of deuterium oxide, 
alkylation with styrene 91a’ occurred mono-selectively at the more hindered ortho-position C2 of 90a, 
indicating that the regioselectivity (C2 vs C6) of the hydroarylation is determined at the stage of C−C 
bond formation and not by the initial C−H activation event (see Section 1.4, Scheme 41). Additionally, 
no alkylation is observed at the directing group due to C(sp2)−C(sp3) bond formation being more facile 
than C(sp3)−C(sp3). In contrast, when acetanilide 60c was subjected to deuterium oxide under Ir(I)-
catalysed conditions,117 deuterium incorporation was observed selectively at the less hindered ortho-
position of deuterio-60c (C2, 0.92 D, 92% deuteration), showing that, in this case, oxidative addition 
is the regioselectivity determining factor (Scheme 44b). These deuterium exchange experiments 
highlight the ability of acetanilide and benzamide substrates to direct oxidative addition of an Ir(I)-
species, which provides the basis for alternative directing groups to be compared. 
 





Scheme 44: Deuterium exchange reactions with benzamide 90a and acetanilide 60c, carried out by Dr. Giacomo 
Crisenza. 
The initial aim of the studies detailed in this thesis was to identify alternative directing groups 
to benzamide and acetanilide moieties, as in 90a and 60c (Scheme 44), that would successfully direct 
Ir(I) oxidative addition, and therefore promote branch-selective alkene hydroarylation. Electronically 
differentiated directing groups were investigated, alongside alternative benzamide derivatives. Initially, 
cyclic benzamide 98, where the rotation of the directing group is inhibited, was exposed to D2O under 
the developed Ir(I)-catalysed conditions (Scheme 45a). High deuterium incorporation was observed at 
the ortho-position (0.93 D, 93% deuteration) and at the methylene group (0.30 D, 15% deuteration) of 
deuterio-98. This result suggests that the lack of rotation of the directing group does not inhibit oxidative 
addition of the Ir(I)-catalyst into the ortho C−H bond. When the reaction was carried out with styrene 
91a’, under otherwise identical Ir(I)-catalysed conditions, desired hydroarylation product 99a’ was 
generated in modest yield (11%) and with complete branch selectivity (Scheme 45b). The low yield 
indicates that there is a greater barrier to C−C reductive elimination with the rigid directing group of 
98, compared to the more freely rotating benzamide unit of 90c (93% yield, Scheme 44a). Therefore, it 
is postulated that for successful reductive elimination to occur, the directing group must be able to 
dissociate and twist out of the plane of the arene, as demonstrated in Scheme 45c. 





Scheme 45: Evaluation of cyclic benzamide 98 in the Ir(I)-catalysed hydroarylation of styrene.  
Subsequent studies focused on exploring the electronic constraints of the directing group for 
successful Ir(I)-catalysed styrene hydroarylation. Arenes, bearing a range of directing groups were 
exposed to the Ir(I)-catalysed conditions developed for benzamide derivatives (see Scheme 44a), in the 
presence of D2O instead of an alkene coupling partner. Notably, only small amounts of deuterium 
incorporation were observed in pyridine N-oxide deuterio-100, ester deuterio-101 and sulfonamide 
derivative deuterio-102 and none of the desired hydroarylation products were formed in the presence 
of styrene (Table 1). Presumably, the N-oxide of 100 competes for coordination to the Ir(I)-catalyst. 
Previously, alkyl esters underwent hydroarylation of styrene under [Ir(cod)2]BARF/dFppb conditions, 
albeit in poor yield (18%).116 Nevertheless, phenyl ester 101 failed to undergo oxidative addition, most 
likely due to cross conjugation of the O-atom with the phenyl group. Likewise, sulfonamide 102 was 
unsuccessful at directing the Ir(I)-catalyst into the ortho C−H bond; however, sulfonamides have 
previously been utilised as efficient directing groups for ortho C− activation with Rh, Pd and Co 
catalysts.119-121 Additionally, 2-pyridyl units have been employed as directing groups for Co(I)-
catalysed hydroarylation of styrenes84 and Ir(I)-catalysed hydroarylation of vinyl ethers (see Section 
1.3.2).99 High deuterium incorporation was observed in both ortho-positions when strongly 
coordinating pyridyl arene 103 was exposed to D2O under Ir(I)-catalysis (0.95 D, 95% deuteration). 
However, when 103 was exposed to styrene under Ir(I)-catalysed conditions, no conversion to the 
expected hydroarylation product was observed. Presumably, the nitrogen of pyridyl arene 103, stabilises 
the Ir(III)-chelate, preventing the directing group from dissociating to facilitate C−C reductive 




elimination. These results validate that amide and anilide-based directing groups are the most efficient 
for promoting branch-selective alkene hydroarylation, so these were selected for the development of an 
enantioselective alkene hydroarylation. 
 
Table 1: Deuterium exchange reactions with arenes 100−103 bearing alternative directing groups. a The reaction 
was conducted at 150 °C. 
2.2 − Studies Towards a Branch- and Enantioselective Alkene 
Hydroarylation Reaction 
2.2.1 − Investigating Commercially Available Chiral Ligands 
Branch-selective hydroarylation protocols are an atom economical and efficient method to 
generate benzylic stereocentres enantioselectively (see Section 1.3.2). Towards this ideal, Dr. Crisenza 
examined several commercially available chiral ligands for enantioselective Ir(I)-catalysed 
hydroarylation of styrene 91a’ with benzamide 90d. These initial studies revealed that a broad range of 
wide bite angle bisphosphine ligands afforded desired product 93da’ with high branch selectivity. 
Notably, a member of the Walphos-ligand family gave hydroarylation product 93da’ in 30% yield, with 
excellent branch selectivity (>25:1) and promising levels of enantiopurity (71:29 e.r.). Following these 
preliminary results, further ligands from the Walphos and Josiphos families were investigated and the 
key results are reported in Table 2. However, none of those examined provided an improvement in 
enantioselectivity for styrene 91a’ hydroarylation with benzamide 90d. 





Table 2: Key results for the screening of commercially available chiral ligands for enantioselective styrene 
hydroarylation with benzamide 90d. 
Alongside enantioselective styrene hydroarylation with benzamide 90d, acetanilides 60a and 
60c were also investigated. Over 50 bidentate chiral phosphine ligands were evaluated under Ir(I)-
catalysis and the selected key results are reported in Table 3. The screening showed that ligands with 
wide bite angles and bulky aryl substituents on phosphorus generated the desired branched 
hydroarylation product (96aa’ or 96ca’). However, in contrast to the reaction with benzamide 90d, none 
of the ligands tested demonstrated the efficiency and branch selectivity previously achieved with dFppb 
(Scheme 44b). In some cases, alkene side-product 104 was also observed. For example, when (S,S)-f-
binaphane was used as the ligand, none of branched product 96aa’ was isolated and instead alkenylated 
product 104aa’ was observed in 51% yield, alongside linear regioisomer 97aa’ in 39% yield. It is 
postulated that alkenylation product 104aa’ forms via an alternative -hydride elimination pathway, 
which will be discussed further in Chapter 5. Ligands including MeOBIPHEP, SEGPHOS, Josiphos 
and Kelliphite all gave 96aa’/96ca’ with promising levels of enantiopurity (67:33–76.5:23.5 e.r.), albeit 
in low yields (14–44%). Notably, Kelliphite was the only ligand that provided desired hydroarylation 
product 96ca’ with complete branch selectivity (>25:1). Despite failing to identify an efficient 
commercially available ligand that gave hydroarylation products 93da’ and, 96aa’ and 96ca’, in high 
yield and selectivity (enantio- and regio-), these studies confirmed that the enantioselective 
hydroarylation of styrenes is a feasible approach for the generation of benzylic stereocentres. 
 





Table 3: Key results for the screening of commercially available chiral ligands for the enantioselective styrene 
hydroarylation with acetanilides 60a and 60c. aThe reaction was performed at 130 °C. 
2.2.3 − Investigating Chiral Anions 
In addition to the screening of commercially available chiral ligands (Scheme Table 2 and 3), 
chiral anions were considered as an alternative strategy to render the branch-selective hydroarylation of 
styrenes asymmetric. The employment of chiral anions in asymmetric catalysis is a well-established 
method.122-124 Rather than coordinating tightly to the metal centre like ligands, chiral anions interact 
with the metal through electrostatic interactions; however, whether a chiral moiety is acting as a ligand 
or an anion can often not be unequivocally distinguished. In 2007, Toste and co-workers reported 
significant examples of the use of chiral counterions in an asymmetric metal-catalysed reaction (Scheme 
46).125 They employed achiral binuclear gold catalyst L(AuCl2)2 (where L = dppm or Ph(CH3)2P), 
alongside chiral silver binaphthol-derived phosphate (R)-Ag-106a, to promote the cyclisation of allenol 
and allenamine substrates 105, giving the hydroalkoxylation products in excellent yields (e.g. 107a−c, 
73−97%) and enantiopurity (96−98% e.e.). The enantioselectivity of this transformation improved in 
non-polar solvents, such as benzene, indicating that a strong interaction between the counterion and 




cationic centre is necessary. Additionally, the enantioselectivity of the asymmetric hydroalkoxylation 
of unactivated allenes could be improved (80% to 92% e.e.) by combining a chiral ligand and chiral 
anion to afford a ‘matched pair’ effect. 
 
Scheme 46: Toste and co-workers pioneering chiral anion strategy for asymmetric metal catalysis.  
In order to investigate the use of chiral anions in the hydroarylation of styrene with acetanilide 
60a, binaphthol silver salt (R)-Ag-106b was synthesised. Acetanilide 60a and styrene 91a’ were 
subjected to Ir(cod)Cl2, dFppb and silver cation (R)-Ag-106b in 1,4-dioxane at 80–150 °C (Scheme 47); 
however, branched hydroarylation product 96aa’ was not observed. Additionally, 60a did not afford 
target 96aa’ when the reaction was conducted in THF, 1,2-DCB or DMSO, at 120–150 °C. It was 
postulated that [Ir(cod)2]Cl2 and (R)-Ag-106b might not be forming the desired Ir(I)-precatalyst 
efficiently in situ. Consequently, [Ir(cod)]Cl2 and (R)-Ag-106b were stirred at ambient temperature in 
CH2Cl2/acetone to prepare the precatalyst prior to reaction; however, conversion to desired product 
96aa’ was not observed. 
 
Scheme 47: Ir(I)-catalysed styrene hydroarylation with acetanilide 60a in the presence of silver phosphoric acid 
salt (R)-Ag-106b.  
For the branch-selective hydroarylation of styrene to proceed, a cationic Ir(I)-species is required 
(see Section 1.4, Scheme 41). It was hypothesised that the phosphate anion of (R)-Ag-106b could be 
binding to the cationic Ir(I)-centre relatively strongly. Consequently, dissociation of (R)-106b from the 
Ir(I)-centre would be unfavourable and oxidative addition of the active Ir(I)-catalyst into the ortho C−H 
bond of acetanilide 60a might be inhibited (see Section 1.4, Scheme 41). Therefore, alternative chiral 
anions with more stable conjugate bases were investigated for asymmetric hydroarylation of styrene 
with acetanilide 60a (Table 4). In 2009, both List and co-workers,126 and Giernoth and co-workers127 
independently designed and synthesised variations of chiral disulfonimide 108b for use in asymmetric 




catalysis. Disulfonimide anion Ag-108b is reported to be more acidic and therefore, has a lower pKaH 
value than phosphoric acid salt (R)-Ag-106b (pKaH value of 1.8 vs 3.4 in DMSO).128 Styrene 
hydroarylation with acetanilide 60a was initially carried out in the presence of achiral silver anion 108a 
(pKaH value of 2.4 in DMSO) (Table 4a).129 Under the reaction conditions with [Ir(cod)Cl]2, dFppb and 
sulfonamide Ag-108a, hydroarylation product 96aa’ was generated in excellent yield (88%). Following 
this positive result, (R)-Ag-108b was synthesised and utilised in the hydroarylation reaction, but no 
conversion to desired product 96aa’ was observed. This result suggests that either (R)-108b is too acidic, 
and hence the interactions with the metal centre are too weak, or the electron-withdrawing groups (−CF3) 
on 108a are required. Consequently, chiral anions with similar pKaH values to 108a were identified; 
106c and 109 both have pKaH values of 2.4 in DMSO (Table 4b).128 Additionally, 108c and 108d with 
electron-deficient R-groups on the binaphthyl backbone of the disulfonimide were considered; however, 
this area of research was not pursued further. 
 
Table 4: Ir(I)-catalysed styrene hydroarylation with acetanilide 60a in the presence of disulfonamide anions. aSee 
reference 128; bSee reference 128. 
2.2.2 − Design and Synthesis of Chiral BINOL-Based Bisphosphite and 
Bisphosphonite Ligands 
With chiral anions unsuitable for enantioselective hydroarylation, attention moved back to the 
use of chiral ligands. During the screening of commercially available chiral ligands for asymmetric 
hydroarylation of styrene 91a’ with acetanilide 60a, some key structural requirements for high 
conversion, high branch regioselectivity and enantioselectivity were identified (Table 3). Notably, only 
Kelliphite was able to offer the same level of branch selectivity (>25:1) achieved with dFppb for 




acetanilide 60a. Based on these observations, it was envisaged that modular modification of the 
backbone and end units of dFppb and/or Kelliphite would provide a ligand that could give the high 
levels of enantioselectivity desired, whilst maintaining excellent branch selectivity (Figure 1). To this 
end, wide bite angle chiral ligands with similar structural features to both dFppb and Kelliphite were 
designed. 
 
Figure 1: Modular chiral ligand design for an enantioselective Ir(I)-catalysed alkene hydroarylation. 
Ideally, a modular chiral ligand synthesis would allow rapid evaluation of each of the structural 
components of the ligand, enabling an optimal system to be designed for a general and enantioselective 
alkene hydroarylation. This approach would allow chirality to be introduced into either the backbone 
or the end units of the ligand. Initially, BINOL-based bisphosphite ligand L-13 was targeted owing to 
the ease of synthesis and ready availability of substituted BINOL moieties (Scheme 48a). The butane 
backbone was chosen to replicate the wide bite angle of dFppb; however, other backbone lengths were 
considered to ensure that the correct bite angle was identified. Initially, for proof-of-concept, 
commercially available 1,2-bis(dichlorophosphino)ethane 111a and rac-BINOL 110 were subjected to 
triethylamine under a rigorously inert and anhydrous atmosphere (Scheme 48a). However, a complex 
mixture was formed and ligand L-13 was found to be highly susceptible to hydrolysis, inhibiting its 
isolation.130 P−O bonds have greater bond energies than P−C bonds (84 vs 62 kcal/mol) and so should 
be more stable.131 Based on this, phosphonite ligand L-14 was investigated due to its similar design 
features (Scheme 48b). The synthesis began by exposing rac-BINOL 110 to phosphorus trichloride, in 
the presence of triethylamine under inert and anhydrous conditions. Desired chlorophosphite 
intermediate 112 was generated in 58% yield in a 2.6:1 mixture with hydrolysed side-product 113. The 
mixture was then reacted with ethylene glycol and triethylamine to give desired ligand L-14 in 81% 
yield, alongside 19% of unknown impurities as measured by 31P NMR analysis. After extensive 
purification under an inert atmosphere it was found that bisphosphonite ligand L-14 was also highly 
susceptible to hydrolysis, preventing its isolation. Ligands based on the structure of Kelliphite have 
successfully been complexed with Rh(acac)(cod),132 and hence the complexation of ligand L-14 to the 
Ir(I)-precatalyst prior to the reaction was investigated. However, this approach was unsuccessful. Due, 




to other successful research avenues, which are presented in Chapter 5, this area was not explored 
further until Dr. Simon Grélaud began work on this topic (see Section 2.3). 
 
Scheme 48: Design of bisphosphite and bisphosphonite ligands L-13 and L-14. aYield measured by 31P NMR 
analysis against oxidised side-products (19%). 
2.3 − Asymmetric Hydroarylation of Alkenes with Acetanilides  
2.3.1 −  Optimisation and Scope 
Following the commercially available chiral ligand studies (Table 2 and 3), Dr. Simon Grélaud 
successfully designed and synthesised a family of chiral bisphosphite ligands based on the structure of 
Kelliphite (Figure 2). The ligands consist of a highly substituted biphenyl backbone (end units in 
Kelliphite, which are shown in red), with biphenol units bearing various R-substituents at the C4-
position. Unlike ligands L-13 and L-14 (Scheme 48), which bear an ethyl linker, bisphosphite ligands 
L-15 are relatively stable to air and moisture. This is presumably due to steric hindrance from the t-
butyl groups and stabilisation from the aromatic groups, which make the P−O bonds more resistant to 
hydrolysis.  
 





Figure 2: Bisphosphite ligands L-15 designed and synthesised by Dr. Simon Grélaud. 
Under optimised conditions (Ir(cod)2BF4/(S)-L-15a (R = t-Bu)) (Table 5), hydroarylation of 
styrene 91a’ with acetanilide 60c proceeded to generate desired product 96ca’ in excellent yield (93%) 
and enantiopurity (95:5 e.r.) and with complete branch selectivity (Table 5). The methodology tolerates 
a wide range of acetanilides; a summary is outlined in Table 5a. Substitution was tolerated in each 
position around the arene of the acetanilide (e.g. 96ca’, 96ea’ and 96ga’). The absolute stereochemistry 
of 96ea’ was determined by X-ray analysis of its (+)-CSA salt, allowing tentative stereochemical 
assignment of the other hydroarylation products. For acetanilides with two available ortho-positions, 
e.g. 60g, complete selectivity for mono-ortho-alkylation was achieved. Furthermore, C−C bond 
formation was highly selective for the less hindered ortho position of meta-substituted substrates (60c 
and 60i), which presumably reflects the steric demands of the ligand. Acetanilides bearing potentially 
sensitive groups, including bromine-substituted system 60i, which gave desired product 96ia’ in good 
yield (69%) and enantiopurity (94:6 e.r.), were tolerated and the reaction conditions also accommodated 
protic functionality e.g. 96ha’ (82% yield). Additionally, the protocol offers good scope with respect to 
the styrene component (Table 5b). Ortho- and para-substituted systems (91f’ and 91g’) participated 
efficiently to give the desired products 96jf’ and 96jg’, where no decrease in enantiopurity was observed 
(97.5:2.5 and 96:4 e.r.). Significantly, the process extended to aliphatic alkenes, as demonstrated by 
hydroarylation of hex-1-ene, which generated 96jb’ in 96% yield and 94:6 e.r. Sterically demanding 
alkene 91i’ and ester substituted alkene 91j’, generated desired products 96ji’ and 96jj’ in excellent 
yields (81 and 83%) and enantiopurity (95:5 and 91.5:8.5 e.r.). 





Table 5: Scope of the enantioselective alkene hydroarylation with acetanilide derivatives. aThe reaction was run 
at 0.025 M. 
2.3.2 − Mechanistic Studies 
Following the successful development of an enantioselective alkene hydroarylation reaction 
(Table 5), Dr. Simon Grélaud probed the mechanism by carrying out a series of deuterium labelling and 
natural abundance 13C KIE experiments (see Section 4.4). This led to the mechanistic pathway proposed 
in Scheme 49a. It is suggested that the process commences with reversible carbonyl-directed oxidative 
addition of the active Ir(I)-catalyst into the ortho C−H bond to form III, followed by reversible alkene 
hydrometallation to form V and VI respectively. A deuterium exchange experiment was conducted with 
acetanilide 60j and deuterio-91k’ to afford deuterio-96jk’ (Scheme 49b). Deuterium incorporation was 
observed at both the benzylic position (0.56 D, 56% deuteration) and the methyl group (1.43 D, 48% 
deuteration). Deuterium incorporation at the benzylic position shows that the deuterium labels are 




scrambled during the reaction, which supports reversible C−H oxidative addition and reversible alkene 
hydrometallation. In contrast to the non-enantioselective protocol with dFppb, 13C KIE experiments (see 
Section 4.4) revealed C−C bond formation occurs via carbometallation from IV, as opposed to C−C 
reductive elimination from VI. Interestingly, these experiments concluded that carbometallation was in 
fact occurring reversibly and C−H reductive elimination was the first irreversible and therefore rate 
determining step. This will be discussed further in Section 4.4. The observation that the stereocentre 
generating step is reversible is unusual. This could mean that the facial selectivity for alkene 
carbometallation is low, so that both enantiomers of VII exist in equal amounts. Subsequent C−H 
reductive elimination to the major enantiomer may then be faster than to the minor enantiomer, 
obtaining the high levels of enantioselectivity observed. Alternatively, carbometallation facial 









Scheme 49: Proposed catalytic cycle for the Ir(I)-catalysed enantioselective hydroarylation of monosubstituted 
alkenes with acetanilides. 
2.3.3 − Application to Thiophene Derivatives 
To expand the scope of the enantioselective, branch-selective alkene hydroarylation, thiophene 
substrates were synthesised in collaboration with Dr. S Grélaud. Thiophene 114a performed poorly 
under the optimised Ir(I)-catalysed conditions with bisphosphite ligand (S)-L-15a (44% yield, 26:74 
e.r.), and so redesign of the chiral ligand was necessary (Table 6). It was envisaged that a ferrocene-
based bisphosphine backbone (see Section 5.3.1) would have a wide bite angle like that of ligand (S)-
L-15a. Additionally, SPINOL moieties were investigated as the chiral unit, due to them bearing readily 
modifiable substituents. Chiral SPINOL-based ligands have previously been utilised at Bristol for 
enantioselective Narasaka–Heck cyclisations.133 Ligand (R)-L-16a was found to be effective, providing 
hydroarylation product 115aa’ in 77% yield and 97.5:2.5 e.r. with complete branch selectivity. The 




absolute stereochemistry of 115aa’ was determined by X-ray diffraction. The synthesis of ligand (R)-
L-16a will be discussed in Section 4.3.3.1 (also see experimental) 
 
Table 6: Ir(I)-catalysed enantioselective alkene hydroarylation protocol with thiophene 114a with bisphosphite 
and bisphosphonate ligands. 
With optimised conditions in hand (Table 6, entry 2), alongside Dr Simon Grélaud, the scope 
of the reaction was explored with respect to the alkene coupling partner and the thiophene substrate 
(Table 7). The reaction tolerates aliphatic alkene coupling partners, with n-butyl derivative 115ac’ 
generated in excellent yield and enantiopurity (98:2 e.r.). Furthermore, hydroheteroarylation of hex-1-
ene 91c’ with C4 and C5-substituted thiophene derivatives 114b and 114c gave desired products 115bc’ 
and 115cc’ in good yields (79% and 71%) and enantiopurity (92:8 and 96.5:3.5 e.r.). The 
hydroheteroarylation of aliphatic alkenes bearing heteroatoms 91i’ and 91j’ generated desired products 
115al’ and 115aj’ in excellent enantiopurity (92:8 and 96:4 e.r.), however, ester derivative 115aj’ was 
generated in moderate yield (30%). Additionally, complex steroid alkene 91m’ was tolerated, which 
gave product 115am’ in excellent yield and diastereoselectivity (>19:1 d.r.).  





Table 7: Scope of enantioselective alkene hydroarylation with thiophene derivatives. aThe reaction was carried 
out by S. Grélaud; b150 mol% of alkene was used; c The reaction was performed at 90 °C; d100 mol% of alkene 
was used. 
2.4 − Summary and Conclusions 
Insight into the requirements of a directing group for successful oxidative addition and 
subsequent alkene hydroarylation has been gained through deuterium exchange experiments. These 
experiments highlighted the superior directing ability of amide and anilide units, which were selected 
for the development of an enantioselective alkene hydroarylation. An extensive screen of commercially 
available chiral ligands highlighted some key structural features required for high yield, high branch 
regioselectivity and high enantioselectivity. Based on these observations, Dr. Simon Grélaud designed 
and synthesised a family of bisphosphite ligands, including ligand (S)-L-15a, which promote the highly 
enantio- and branch-selective hydroarylation of alkenes with acetanilides (Scheme 50a). Development 
of ferrocene-based bisphosphonite ligand (R)-L-16a expanded the scope of the hydroarylation reaction 
to include thiophene substrates (Scheme 50b). This work represents the first example of a general, 
enantioselective and branch-selective protocol for the hydroarylation of unactivated aliphatic alkenes, 
addressing the first aims in Section 1.5. This approach offers an alternative strategy to metal-catalysed 
cross-coupling reactions, providing access to valuable benzylic stereocentres from feedstock materials 
in an atom- and step-economical approach. 





Scheme 50: Enantioselective Ir(I)-catalysed alkene hydroarylation with acetanilides and thiophenes. 




Chapter 3 − Branch- and Enantioselective Iridium Catalysed 
Alkene Hydroheteroarylation (5-Membered Chelates) 
3.1 −  Exploring 5,6-Fused N-Heteroaromatics for the Branch-Selective 
Hydroheteroarylation of Styrene 
Having successfully expanded the enantioselective alkene hydroarylation methodology to thiophenes, 
alternative heteroaromatics were explored in earlier studies. Branch-selective alkene 
hydroheteroarylation with 5,6-fused heteroaromatics remains challenging and few enantioselective 
protocols exist (see Section 1.3.2). Those that have been reported are limited in scope to styrenes, with 
aliphatic alkenes resulting in poor enantioselectivity.89, 94-95 However, there is a demand for such 
methods, as they form benzylic stereocentres which are privileged structures in the pharmaceutical 
industry. For example, tadalafil consists of an indole framework possessing a defined benzylic 
stereocentre and is used to treat erectile dysfunction (Figure 3).134 Additionally, liphagal comprises of 
a benzofuran and inhibits cell growth enzymes.135 Therefore, a general method for the asymmetric 
hydroheteroarylation of alkenes with 5,6-fused heteroaromatics would be of great significance.  
 
Figure 3: Natural products and drug molecules featuring 5,6-fused heteroaromatics, which bear tertiary benzylic 
stereocentres. 
Having successfully expanded the scope of the enantioselective Ir(I)-catalysed alkene 
hydroarylation methodology to thiophene derivatives (see Section 2.3.2), alternative heteroaromatics 
were investigated. These studies began with indole 116, which is equipped with an N-acetyl directing 
group. Previously Shibata showed that indoles of this type are suitable substrates for Ir(I)-catalysed 
directed hydroarylation of alkenes (Ir(cod)2BARF/(R)-SDP, Scheme 28, Section 1.3.2).92 A non-
enantioselective protocol was initially pursued for proof-of-concept, whereby indole 116 was exposed 
to the previously developed Ir(cod)2OTf/dFppb system (see Section 1.4) (Table 8a).117 Under these 
conditions alkylation occurred exclusively at the C3-position, generating alkyl indole 118a’ (80% yield, 
entry 1), which is in contrast to Shibata’s methodology.92 To override the inherent reactivity of indole 
and generate C2-alkylated indole 117a’ alternative commercially available bisphosphine ligands were 
explored; however, only alkylation at C3 was observed. Additionally, when the reaction was repeated 
in the absence of a phosphorus ligand, C3-alkylated product 118a’ was generated in 90% yield (entry 
2), whereas no reaction occurred in the absence of an Ir(I)-source (entry 3). These results suggest that 




rather than oxidatively inserting into the indole C−H bond as desired, the Ir(I)-precatalyst is acting as a 
π-Lewis acid to promote a Friedel-Crafts type alkylation.136 Indole 119, with an alternative diisopropyl-
amide directing group installed at the C3-position, was investigated to develop a protocol in which 
alkylation occurs selectively at C2 (Table 8b). However, under otherwise identical Ir(I)-catalysed 
conditions, C2-alkylated product 120a’ was not observed. 
 
Table 8: Studies towards Ir(I)-catalysed alkene hydroarylation with indole derivatives.  
3.2 − Studies Towards a Branch- and Enantio-selective Hydro-
heteroarylation of Styrene with Pyrroles 
At this stage, indole derivatives were unsuitable for hydroheteroarylation of styrenes under Ir(I)-
catalysed conditions; consequently, alternative heteroaromatics were examined. 5-Membered 
heteroaromatics bearing benzylic stereocentres are also common structural features in many natural 
products and drug molecules (Figure 4). Significant examples include, duloxetine137, an antidepressant, 
and pallescensin B138, which is isolated from a marine sponge. 
 
Figure 4: Natural products and drug molecules featuring 5-membered heteroaromatics, which bear tertiary 
benzylic stereocentres. 
Enantio- and branch-selective hydroarylation of alkenes with 5-membered heteroaromatics is 
currently limited to electronically predisposed alkenes (e.g. norbornene, enol ethers, 1,3-dienes) (see 




Section 1.2.3). 96, 106, 139 A general protocol for the hydroarylation of styrenes and -olefins is yet to be 
reported. Initially, pyrrole 121a, which bears a benzoyl directing group, was subjected to the previously 
developed Ir(I)-catalysed conditions (Table 9a).92 However, alkylation occurred on both the pyrrole and 
the phenyl of the directing group. To avoid alkylating the phenyl unit, a methyl-substituent was added 
to the ortho-position of the benzoyl directing group, as in pyrrole 121b (see Scheme 39, Section 1.4). 
This time, under the hydroarylation conditions, alkylated pyrrole 122ba’ was generated selectively, 
albeit in moderate yield (26% yield). Next, pyrrole 121c, which bears a dimethylated directing group, 
was employed; however, no alkylation was observed, which further highlights the narrow constraints 
of the directing group. The additional methyl group likely forces the benzoyl directing group to twist 
out-of-plane of the pyrrole moiety (I to II), thereby preventing the directed oxidative addition step 
(Table 9b).  
 
Table 9: Ir(I)-catalysed styrene hydroarylation with benzoyl protected pyrroles. 
Considering the limitations of N-benzoyl pyrroles, investigations turned to pivaloyl protected pyrrole 
123 (Scheme 51). Pivaloyl directing groups have previously been utilised in Rh(I)-catalysed linear 
selective alkenylations of indolines.140 When N-pivaloyl pyrrole 123 and styrene 91a’ were exposed to 
the Ir(I)-catalysed conditions used above, branched alkyl pyrrole 124a’ was generated, although in poor 
yield (28%, Scheme 51). Optimisation of this transformation began by investigating over 60 
commercially available mono- and bidentate phosphine ligands; however, none of these resulted in an 
improved yield of 124a’. Notably, when (rac)-BINAP was used, linear regioisomer 125a’ was observed 
in 34% yield, alongside branched product 124a’ (27% yield), which indicates that migratory insertion 
of the alkene is not regioselective in this case (see Section 1.4, Scheme 41). Alternative Ir(I)-precatalysts 




and solvents resulted in decreased or no conversion. Additionally, no improvements were achieved by 
altering the reaction temperature, time, concentration or precatalyst and ligand loadings.  
 
Scheme 51: Styrene hydroarylation with N-pivaloyl pyrrole 123. a Yield determined by 1H NMR analysis of crude 
material against an internal standard.  
Optimisation of the hydroarylation of styrene 91a’ with pivaloyl pyrrole 123 was unsuccessful, 
therefore more electron-rich N-carbamoyl directing groups were investigated. Carbamoyl directing 
groups have successfully been utilised for the Ir(I)-catalysed hydroarylation of alkenes with arenes, 
whereby a five-membered Ir(III)-chelate is produced (see Section 1.4).116 Pyrrole 126a was reacted with 
styrene 91a’ under the standard hydroarylation conditions (Ir(I)/dFppb), but no reaction was observed 
(Scheme 52). However, when using (rac)-BINAP as the ligand, branched-product 127aa’ was 
generated in modest yield (38%), alongside alkene side-product 128aa’ (5%). It is postulated that 
alkenylation product 128aa’ forms via an alternative -hydride elimination pathway, which will be 
discussed further in Chapter 5. Following this promising result, pyrrole 126a was selected for 
optimisation studies. 
  
Scheme 52: Ir(I)-catalysed styrene hydroarylation with pyrrole 126a.  
Optimisation began by investigating the R-substituent on the directing group. Under Ir(I)-
catalysed conditions (Ir(cod)2OTf/(rac)-BINAP) N-diethylcarbamoyl pyrrole 126b did not afford target 
127ba’ (Table 10a). However, N-dicyclohexylcarbamoyl pyrrole 126c gave alkyl pyrrole 127ca’ in 
excellent yield (78% yield) and with good selectivity over alkenylation side-product 1128ca’. The 
reaction is suggested to proceed with oxidative addition of the Ir(I)-catalyst into the C2 C−H bond (to 
I), followed by alkene coordination and migratory insertion into either the Ir(III)−H bond (to generate 
II) or into the Ir(III)−C bond (giving III) (Table 10b). The increase in yield observed when changing 
the size of the R-substituent from ethyl to cyclohexyl, may be explained by a steric interaction between 
the ortho C−H bond of the pyrrole and the R-substituent on the directing group in rigid 5-membered-




iridacycle II. These steric interactions could potentially be relieved through carbometallation to form 
more flexible 7-membered iridacycle III or by C−C reductive elimination from II to generate IV. 
Consequently, the rate of carbometallation/C−C reductive elimination is enhanced for derivatives with 
larger R groups, such as in N-dicyclohexyl system 126c. 
 
Table 10: Ir(I)-catalysed styrene hydroarylation with pyrroles 126a−126c. 
Despite styrene undergoing a high yielding hydroarylation with pyrrole 126c, the requirement 
of a large directing group was undesirable (Table 10). Therefore, investigations were directed towards 
developing improved conditions that would allow more varied directing groups to be employed. N-
Diisopropylcarbamoyl pyrrole 126a was selected for further optimisation studies and the key results are 
presented in Table 11. Initially, different commercially available bisphosphine ligands were 
investigated. When the reaction was run with (R)-H8-BINAP for 48 hours at 130 °C, alkyl pyrrole 127aa’ 
was generated branch-selectively in 57% yield (entry 1). Changing the concentration had minor effect 
(entry 2−3), whilst higher precatalyst and ligand loadings were beneficial to the yield (entry 4). Optimal 
conditions were achieved when acetonitrile was employed as the solvent, which afforded 127aa’ in 74% 
yield, although with little enantioselectivity (51:49 e.r.) (entry 7). Alternate Ir(I)-sources, including 
[Ir(cod)2]BF4, [Ir(cod)2]OMe and [Ir(cod)2]BARF, all resulted in reduced conversion to 127aa’ (entry 
8−10). 





Table 11: Key optimisation results for hydroheteroarylation of styrene 91a’ with pyrrole 126a using H8-BINAP 
as the ligand. aYield determined by 1H NMR analysis of crude material against an internal standard; bIsolated 
yield. 
3.2.1 − Development of an Enantioselective Protocol 
The branch-selective styrene hydroarylation methodology developed above gives branched 
alkyl pyrrole 127aa’ in good yield (74%), albeit in poor enantiopurity (51:49 e.r.) (Table 11, entry 7). 
Under these optimised conditions, pyrroles 126b and 126c with sterically varied directing groups (Et 
and Cy) generated target products 127ba’ and 127ca’ in good to excellent yields (72% and 83%), with 
minimal enantioselectivity (up to 58:42 e.r.) (Table 12). Despite the low levels of enantioselectivity 
achieved, these results suggest that the enantioselective hydroarylation of styrenes with pyrroles is a 
viable route to generate benzylic stereocentres. Additionally, these Ir(I)-catalysed conditions allow the 
high yielding formation of alkyl pyrroles 127ba’ and 127aa’, which bear smaller R substituents. 
Expanding the scope to different heteroaromatics, including azoles 129 and 130, thiophene 131 and 
indole 132, was unsuccessful at this stage (Table 12). 





Table 12: Scope of Ir(I)-catalysed hydroheteroarylation of styrene with pyrroles using (R)-H8-BINAP as the 
ligand.  
After obtaining preliminary enantioselectivity results with (R)-H8-BINAP (Table 12), over 20 
commercially available chiral ligands were screened for Ir(I)-catalysed styrene hydroarylation with N-
diisopropylcarbamoyl pyrrole 126a. In all cases the reaction suffered from poor conversion and 
selectivity. Next, chiral ligands previously developed by Dr. Simon Grѐlaud (see Section 2.3) were 
explored and the key results are presented in Table 13. Bisphosphite ligand (S)-L-15b gave alkyl pyrrole 
127aa’ in good yield (60%) and high branch selectivity, but with poor enantiopurity (60:40 e.r.) (entry 
1). Utilising ferrocene-based bisphosphonite ligand (S)-L-16b bearing H8-BINOL moieties (entry 2), 
resulted in an improvement in both yield (78%) and enantioselectivity (77:23 e.r.); however, minor 
conversion to alkene side-product 128aa’ was also observed (see Chapter 5). Changing the H8-BINOL 
moieties to SPINOL units (entry 3, (S)-L-16a) gave hydroarylation product 127aa’ in excellent yield 
(95%), albeit in poor enantiopurity (62:38 e.r.). However, improved enantioselectivity (80.5:19.5 e.r.) 
was achieved by changing the R-groups at C4 on the SPINOL units to phenyl groups (entry 4, (S)-L-
16c). No increase in yield or enantioselectivity was obtained through further modification of the R-
groups (entry 5 and 6, (S)-L-16d and (S)-L-16e). 





Table 13: Enantioselective Ir(I)-catalysed styrene hydroarylation with pyrrole 126a. aYields were determined by 
1H NMR analysis of crude material against an internal standard 
Pyrroles 126a−d with sterically varied directing groups (R = Me vs Cy), were subjected to the 
optimised conditions using bisphosphonite ligand (R)-L-16c (Table 13, entry 4). In all cases 
hydroarylation products 127aa’−127da’ were generated in good to excellent yields (65−88%) and with 
complete selectivity over the alkenylated side-products (Table 14). N-Dimethylcarbamoyl pyrrole 
derivative 126d generated product 127da’ in moderate enantiopurity (74:26 e.r.), whereas diethyl- and 
N-diisopropylcarbamoyl pyrrole moieties 127ba’ and 127aa’ were both generated in 80.5:19.5 e.r. 
Additionally, a decrease in enantioselectivity was observed for the hydroarylation of styrene 91a’ with 
pyrrole 126c, which bears large cyclohexyl groups (75:25 e.r.). This variation in enantioselectivity 
suggests that the R-substituents on the directing group can influence the facial selectivity of alkene 
migratory insertion, therefore effecting the enantiopurity of the hydroarylation product. Further fine-
tuning of the ligand ((R)-L-16f, R = H), resulted in an increase in enantiopurity (86.5:13.5 and 88:12 
e.r.), whilst maintaining good yields for N-diethyl- and diisopropylcarbamoyl hydroarylation products 
127ba’ and 127aa’ (90% and 75% yield). Alternative carbonyl-based directing groups (121a, 121b, 
133, 123) were unsuitable under these Ir(I)-catalysed conditions ((R)-L-16c, R = Ph) (Table 14). 





Table 14: Scope of Ir(I)-catalysed enantioselective styrene hydroarylation with pyrroles 126a−d. 
3.3 − Exploring Furans for the Branch- and Enantioselective 
Hydroheteroarylation of Styrene 
Having developed conditions for the hydroarylation of styrene 91a’ with pyrrole derivatives 
126a−d (Table 14), other 5-membered heteroaromatics were explored. Furan 134a, equipped with a 
diisopropylamide directing group at the C3-position, and styrene 91a’ were exposed to Ir(I)-catalysis, 
using H8-BINAP as the ligand (Table 11, entry 7) (Scheme 53a). Alkyl furan 135aa’ was formed, albeit 
in poor selectivity over linear regioisomer 136aa’ (3:1) (Scheme 53a). It was postulated that furan 134a 
would behave similarly to benzamide 90c (see Section 4.2.2) as alkene hydroarylation with both 
substrates proceeds via a 5-membered iridacycle. Accordingly, conditions developed for alkene 
hydroarylation with benzamide 90c were employed (Ir(cod)2BARF, (rac)-L-15a, 1,4-dioxane, see 
Section 4.2.2), which provided hydroarylation product 135aa’ in 51% yield, and with complete 
branched selectivity (Scheme 53b). 





Scheme 53: Ir(I)-catalysed styrene hydroheteroarylation with furan 135a. 
With regioselective conditions for styrene hydroarylation with furan 134a in hand, studies 
towards an enantioselective alkene hydroarylation protocol began. Utilising enantiopure ligand (S)-L-
15a, under otherwise identical conditions to those above (Scheme 53b), hydroarylation product 135aa’ 
was generated with moderate enantiopurity (43.5:56.5 e.r.) (Table 15, entry 1). Ferrocene-based 
bisphosphonite ligand (R)-L-16f, with SPINOL moieties, resulted in a dramatic increase in the 
enantiopurity of 135aa’ to 84.5:15.5 e.r., whilst maintaining an acceptable yield (59%) (entry 2). 
Improvements to the yield and enantioselectivity were achieved by modifying the R-substituents at C4 
of the SPINOL units of the ligand; (R)-L-16c, where R = Ph gave 135aa’ in 59% yield and with 87:13 
e.r. (entry 3), whereas (R)-L-16a, where R = mesityl generated 135aa’ in 72% yield and 90:10 e.r. 
(entry 4). Ligands (R)-L-16g and (R)-L-16h, where R = naphthyl and bromine respectively, did not 
provide any improvement to the enantioselectivity (89.5:10.5 and 86:14 e.r.) (entry 5 and 6). 
 





Table 15: Enantioselective Ir(I)-catalysed hydroarylation of styrene 91a’ with furan 134a. aYields were 
determined by 1H NMR analysis of crude material against an internal standard.  
Further optimisation of the enantioselective styrene hydroheteroarylation with furan 134a 
commenced with ferrocene-based bisphosphonite ligand (R)-L-16a and the key results are presented in 
Table 16. Alternative Ir(I)-sources, including Ir(cod)2BF4 and Ir(cod)2PF6 gave alkyl furan 135aa’ in 
good yields (80% and 68%) but diminished enantiopurity (86:14 and 85:15 e.r.) (entry 2−3). A decrease 
in concentration was beneficial (entry 4) and lower temperature provided an increase to both the yield 
and enantiopurity (entry 6−8, 92:8 to 93:7 e.r.). Changing the solvent to either toluene or 1,2-DCB gave 
a minor improvement (entry 10−12, 94:6 vs 93.5:6.5 e.r.), whilst fine tuning of the ligand (ligand (R)-
L-16j, where R = C6F5) provided alkyl furan 135aa’ in excellent yield and an e.r. of 95:5 (entry 16). 





Table 16: Selected optimisation results for the asymmetric hydroarylation of styrene 91a’ with furan 134a. 
aIsolated yield; bYield determined by 1H NMR analysis of crude material against an internal standard. 
Having developed optimised conditions for styrene hydroheteroarylation with furan 134a 
(Table 16) the scope of the reaction was explored by investigating aliphatic alkenes (Scheme 54). 
Mesityl-substituted ligand (R)-L-16a was chosen for initial studies owing to its ease of synthesis. Under 
Ir(I)-catalysed conditions (Table 16, entry 12), hydroarylation of -methyl-but-1-ene 91d’ with furan 
134a generated alkylated product 135ad’ in good yield (75%), but with poor enantiopurity (72:28 e.r.) 
(Scheme 54). Additionally, dialkylated side-product 137ad’ was isolated in 12% yield, with alkylation 
occurring at both the C2- and C4-positions of the furan moiety. Alkylation at the C4-position does not 
occur when styrene 91a’ is utilised as the alkene coupling partner, likely due to its more sterically 
demanding phenyl group preventing a second alkylation event. Furan 134a underwent alkylation with 
4-methylpent-1-ene 91h’ to give monoalkylated product 135ah’ with a significant increase in 
enantiopurity (87:13 e.r.), alongside dialkylated product 137ah’ (3:1 selectivity). It is proposed that the 
enantiopurity of 135 is subject to the steric demands of both the alkene coupling partner and directing 
group effecting the facial selectivity (see Section 2.3.2). Studies are currently ongoing in this area, with 
investigations into optimising the enantioselectivity for furan 135ac’ underway. 





Scheme 54: Hydroheteroarylation of aliphatic alkenes with furan 134a. 
It is possible that the second alkylation event observed on furan 134a (Scheme 54) has inherent 
diastereoselectivity, and therefore could occur selectively on one enantiomer of mono-alkylated product. 
Subsequently, this could enrich/erode the enantiopurity of remaining mono-alkylated product. To 
explore this, dialkylation was suppressed by reducing the reaction time to 24 hours (Scheme 55). For 
the hydroarylation of 4-methylpent-1-ene 91h’ with furan 134a, alkyl furan 135ah’ was formed in 
excellent yield (92%), with less than 5% of dialkylated product 137ah’ observed. The enantiopurity of 
135ah’ remained similar (86:14 vs 87:13 e.r.), which suggests that there is minimal preference between 
the enantiomers of 135ah’ for the second alkylation event.  
 
Scheme 55: Hydroheteroarylation of 3-methyl-but-1-ene 91h’ with furan 134a. a Yield determined by 1H NMR 
analysis of crude material against an internal standard. 
3.3.2 − Expansion of the protocol to Alternative Furan Derivatives 
With Ir(I)-catalysed conditions in hand for alkylation of furan 134a at the C2 position, studies 
to expand the protocol to alkylate furans at the C3 position began. Furans with benzylic stereocentres 




at the C3-position are valuable building blocks in the total synthesis of natural products (Scheme 
56a). For example, in 2017 Trauner and Hao utilised 138 as an intermediate for synthesising members 
of the norditerpenoids family; caribenol A and amphilectolide.141 Initial studies began by exposing furan 
139, with an amide directing group at the C2-position, to Ir(cod)2BARF/(R)-L-16c (Table 15, entry 3) 
in the presence of styrene 91a’. Alkyl furan 140a’ was produced in moderate yield (38%), alongside 
mono-dealkylated product 141a’ in 51% yield (Scheme 56b). It was postulated that mono-dealkylated 
product 141a’ was forming via dealkylation of the directing group of hydroarylation product 140a’. 
Specifically, following oxidative addition of the Ir(I)-catalyst into the terminal C−H bond of the 
isopropyl group of 140a’, -amide elimination then occurs from I to give Ir(III)-intermediate II.142 N−H 
reductive elimination from II then affords mono-dealkylated furan 141a’ and prop-1-ene. Lower 
reaction temperatures and shorter reaction times were trialled to suppress dealkylation of the directing 
group (Scheme 56c). For example, running the reaction at 100 °C for 24 hours generated 140a’ in 
excellent yield (85%) and good enantiopurity (86.5:13.5 e.r.), and with high selectivity over dealkylated 
side-product 141a’ (>25:1).  
 
Scheme 56: Ir(I)-catalysed hydroarylation of styrene 91a’ with furan 139. a Yield determined by 1H NMR analysis 
of crude material against an internal standard. 
To probe the mechanism for the dealkylation of the diisopropyl directing group, furan 139 was 
subjected to Ir(cod)2BARF/(R)-L-16c in the absence of an alkene coupling partner (Scheme 57). 




Surprisingly, 142 was isolated in 45% yield, where the isopropyl group had migrated from the nitrogen 
of the directing group to the C3-position of the furan. It is postulated that in the absence of an alkene 
coupling partner, directed C−H oxidative addition of an Ir(I)-species is followed by -amide elimination 
to generate II.142 Subsequent N-H reductive elimination gives III and prop-1-ene. Oxidative addition 
of the Ir(I)-catalyst into the C3-position of dealkylated furan III, followed by coordination of prop-1-
ene gives IV. Finally, migratory insertion of prop-1-ene and reductive elimination affords rearranged 
product 142. This is not observed in the presence of styrene, most likely due to styrene undergoing more 
favourable coordination and migratory insertion over prop-1-ene.  
 
Scheme 57: Subjection of furan 139 to Ir(I)-catalysed conditions in the absence of styrene. 
3.4 −  Exploring Thiophenes for the Branch- and Enantioselective 
Hydroheteroarylation of Styrene 
In efforts towards a general alkene hydroarylation protocol, thiophene derivatives were also 
investigated. Under the first-generation conditions for the alkylation of pyrrole 126a (Table 11, entry 
7), thiophene 131 did not give target 143a’ (Table 17a, entry 1). Nevertheless, 143a’ was generated in 
good yield (51%), albeit in poor selectivity under Ir(I)-catalysed conditions developed for furan 134a 
(Scheme 53b) (Table 17a, entry 2). Alkylation occurred at the C2- and C4-position of the thiophene, in 
a 1.6:1 ratio (143a’:144a’). Decreasing the number of equivalents of styrene had a beneficial effect 
(entry 3). Additionally, alternative ferrocene-based bisphosphonite ligand (R)-L-16c generated 
hydroarylation product 143a’ in increased yield (79%), although in poor selectivity over C4 alkylated 
product 144a’ (entry 4). Consequently, benzothiophene 145 in which the C4-position is blocked by an 
arene, was synthesised and exposed to hydroarylation conditions (Table 17b). Alkylated product 146a’ 
was produced with complete branch-selectivity, but in modest yield (45%). 
 





Table 17: Styrene hydroheteroarylation with thiophene derivatives 131 and 145. aYield determined by 1H NMR 
analysis of crude material against an internal standard; bIsolated yield. 
3.5 − Summary and Conclusions 
Significant developments towards a general and simple method for the Ir(I)-catalysed 
hydroheteroarylation of styrenes have been made. The methodology has been expanded to include 
pyrroles, furans and benzothiophenes. Using ferrocene-based bisphosphonite ligands (R)-L-16, 
enantioenriched products bearing benzylic stereocentres were afforded in good to excellent yields, with 
promising levels of enantioselectivity (Scheme 58). The methodology has been expanded to the 
hydroarylation of aliphatic alkenes with furan derivatives, to give the desired products in good yields, 
although with limited enantiopurity. Further fine-tuning of the ligand and mechanistic studies might 
allow efficient asymmetric hydroheteroarylation of a broad range of alkenes.  





Scheme 58: Enantioselective styrene hydroheteroarylation with pyrroles and furans.  
 




Chapter 4 − Iridium-Catalysed Hydroarylation of 1,1-
Disubstituted Alkenes 
4.1 − The Importance of All-Carbon Quaternary Centres 
The development of methods that readily generate quaternary centres is of great importance to 
modern synthetic chemistry. However, these highly substituted moieties are often difficult to synthesise, 
owing to steric repulsion between the carbon substituents during bond formation. There has been a 
plethora of research into the formation of cyclic systems bearing quaternary centres, employing well-
established reactions, including the Diels-Alder reaction, Pd-catalysed alkylations and intramolecular 
Heck reactions.143-149 Conversely, acyclic systems which have quaternary centres, including benzylic 
quaternary stereocentres, are much harder to access, owing to the difficulty in controlling the greater 
degrees of freedom during bond formation.148 However, synthetic methods for the generation of 
quaternary stereocentres are highly desirable because these motifs are present in biologically active 
natural products.150 A few noteworthy examples include morphine,151 a common analgesic, 
elacomine,152 which shows antimicrobial activity, verapamil,153 used to treat high blood pressure and 
cuparene,154 derivatives of which show antifungal properties (Figure 5).155  
 
Figure 5: Natural products and drug molecules bearing quaternary benzylic stereocentres. 
Methods that generate arenes bearing all-carbon quaternary centres, particularly where a 
benzylic C−C bond is created in the stereocentre determining step, remains a challenge, with few 
examples reported.156 One approach is alkylation of enantioenriched substituted allylic electrophiles or 
racemic substrates under chiral catalysis, which forms the benzylic quaternary centres adjacent to an 
alkene (Scheme 59a).157-160 Additionally, a few cross-coupling reactions that allow the formation of 
benzylic quaternary centres remote from specific functionality (e.g. alkenes) have been reported, as 
demonstrated in Section 1.2 (Scheme 59b).46, 161 However, both of these approaches involve multiple 
steps to synthesise functionalised starting materials, resulting in significant waste. Enantioselective 
hydroarylation of simple alkenes via C−H activation of an arene would provide an environmentally 
green and step-economical route to these privileged motifs. Currently, only a few non-enantioselective 
methodologies exist to establish quaternary centres via alkene hydroarylation (see Section 1.3.2).113-114 
However, these are limited to hydroarylations of electronically favourable alkenes (acrylates and 
acrylamides) with highly specific N-containing heteroaromatics. A facile alkene hydroarylation method 




that affords challenging quaternary centres enantioselectively and in high atom economy is likely to 
have widespread application (Scheme 59c). 
 




















4.2 − Generation of All-Carbon Quaternary Centres on Benzamide 
Substrates 
4.2.1 − Reaction Discovery and Optimisation 
To expand the scope of the Ir(I)-catalysed hydroarylation methodologies developed at Bristol 
to generate benzylic quaternary centres, the hydroarylation of 1,1-disubstituted alkenes was investigated. 
Previously Dr. Crisenza explored the hydroarylation of -methylstyrene 147a’ with benzamide 90c 
under various Ir(I)-catalysed conditions with dFppb as the ligand (Table 18). However, 148ca’, bearing 
a desired quaternary centre was not observed. After the development of more efficient bisphosphite 
ligands for asymmetric hydroarylations of monosubstituted alkenes, Dr. Simon Grѐlaud found that 
when N,N-diethylbenzamide 90c and -methylstyrene 147a’ were exposed to [Ir(cod)2]BARF in the 
presence of bisphosphite binaphthyl ligand (rac)-L-15b, desired product 148ca’ was produced in 
moderate yield (51%) (Table 18). This promising initial result forms the basis for the studies outlined 
in this chapter. 
 
Table 18: Ir(I)-catalysed hydroarylation of -methylstyrene 147a’ with N,N-diethylbenzamide 90c. aReaction 
conducted by Dr. Giacomo Crisenza; bReaction conducted by Dr. Simon Grélaud  
Following the preliminary results described above (Table 18), an extensive screen of 
bisphosphite ligands previously developed at Bristol (see Section 2.3) was carried out for the 
hydroarylation of 1,1-disubstituted alkene 147a’ with benzamide 90c. Initially, ligands bearing biphenol 
units with various R-substituents at the C4-position were investigated. Chloro-substituted ligand (rac)-
L-15c resulted in an increase in yield to 69% (Scheme 60). However, under these Ir(I)-catalysed 
conditions the reaction was poorly reproducible, with yields ranging from 0–69%, which led to 
extensive re-evaluation of the reaction conditions. It was postulated that this demanding reaction might 
be sensitive to water/oxygen. To test this, the hydroarylation protocol was carried out in the presence 
of air and water, both of which resulted in inhibited conversion of 90c. Therefore, to eliminate water 
and oxygen from the reaction mixture, several modifications were trialled, including the addition of 




Na2SO4 or molecular sieves to the reaction tube, flame-drying the reaction tubes prior to use (instead of 
oven drying) and freeze-pump-thawing the solvent. Eventually, reproducibility was achieved by 
distilling the 1,4-dioxane solvent from Na/benzophenone and setting up the reaction in a glove box. The 
hydroarylation of monosubstituted alkenes previously developed at Bristol exhibited good 
reproducibility under less stringent conditions and the issue seems to be specific to benzamide substrates. 
One possibility for the need for more rigorous conditions for the hydroarylation of 1,1-disubstituted 
alkenes, is that the reaction may occur less readily owing to the steric constraints of the disubstituted 
alkene. Consequently, small amounts of water/oxygen in the reaction tube could deactivate the Ir(I)-
catalyst before hydroarylation of the alkene can occur. 
 
Scheme 60: Ir(I)-catalysed hydroarylation of -methylstyrene with N,N-diethylbenzamide 90c. a Yield determined 
by 1H NMR analysis of crude material against an internal standard. 
With reproducible conditions developed, further optimisation studies began with para-phenyl 
alkene 147b’, as it is an easily handled solid (for ease of use in glovebox) and a selection of the key 
results is given in Table 19. Under these more stringent conditions, the hydroarylation of para-phenyl 
styrene derivative 147b’ with benzamide 90c, utilising chloro-substituted ligand (rac)-L-15c (R = Cl at 
C4), proceeded to generate product 148cb’ in 55% yield after 48 hours at 120 °C (Table 19, entry 1). 
Changing the R substituent of the bisphosphite ligand to an electron-donating group (i.e. R = OMe, 
(rac)-L-15d or t-Bu, (rac)-L-15a) and increasing the reaction time to 72 hours, gave an increase in 
yield of 148cb’ from 55% to 64% and 68%, respectively (entry 1 vs 2 and 3). Conversely, the addition 
of an electron-withdrawing trifluoromethyl group at the C4-position of the ligand had a detrimental 
effect on conversion of 90c to 148cb’ (entry 4, (rac)-L-15e). When utilising ligand (rac)-L-15f (see 
experimental for synthesis), where R = H, an optimal yield of 75% was achieved (entry 5). Next, 
alternative solvents were screened (e.g. toluene, 1,2-DCB, entry 6 and 7), but none of these resulted in 
improved yield. Different Ir(I)-sources, including [Ir(cod)2]OTf and [Ir(cod)2]BF4 (entry 8 and 9), 
higher precatalyst and ligand loadings (entry 10) and higher temperatures (entry 11) all failed to increase 
the yield.   





Table 19: Selected optimisation results for the hydroarylation reaction of alkene 147b’ with N,N-
diethylbenzamide 90c. aYield determined by 1H NMR analysis of crude material against an internal standard; 
bIsolated yield; cThe reaction was performed at 130 °C; dThe reaction was run for 48 h.  
4.2.2 − Scope with Respect to the Benzamide Substrates  
With optimised conditions in hand (Table 19, entry 5), the scope with respect to N,N-
diethylbenzamide derivatives was explored (Table 20). Initially, various directing groups were 
investigated. Methyl derivative 90e, and cyclic amides 90f and 90g underwent alkylation with alkene 
147b’ under the Ir(I)-catalysed conditions to deliver quaternary products 148eb’−148gb’, albeit in 
moderate yields (31−51%). However, alternative directing groups, including more sterically demanding 
90h and ketone derivative 89b were unsuccessful (Table 20). Following these initial studies, arene 90c, 
which bears an N,N-diethylamide unit, was selected to further explore the scope of this transformation. 





Table 20: Scope of the hydroarylation reaction of 1,1-disubstituted alkene 147b’ with benzamide substrates with 
respect to the directing group. 
Having identified N,N-diethylamide as the optimal directing group, the alkene hydroarylation 
reaction was conducted with benzamides bearing both electron-rich and -poor substituents (Table 21). 
Notably, in cases where two ortho-positions are differentiated (e.g. 90d, 90k and 90l), complete 
selectivity for the less hindered ortho-position (C6 vs C2) was observed. This is in contrast to the 
selectivity observed in the hydroarylation of mono-substituted alkenes with meta-substituted substrate 
93aa’ (see Section 1.4, Scheme 39), which is most likely attributed to the steric-constraints of the newly 
formed quaternary centre.116 Methyl-substituents and electron-donating methoxy groups were well 
tolerated in both the meta- and para-positions of the benzamide unit as shown in the high yielding 
formation of 148db’, 148kb’, 148mb’, 148nb’ (52−73% yield). Hydroarylation product 148lb’, bearing 
a sensitive B(pin) group was generated in a 18% yield, demonstrating the mild nature of the reaction 
conditions. However, electron poor substituents, such as in 90p and 90q were not tolerated, along with 
para-nitro derivative 90r. Additionally, pyridine derivative 90t was unsuitable, which is presumably 
due to the basic nitrogen atom coordinating to the Ir(I)-species and preventing insertion into the desired 
ortho C−H bond. Benzamides bearing ortho-substituents, such as in of 90u−90w, and benzamide 98, 
with a cyclic directing group, both failed to undergo hydroarylation. This illustrates that the directing 
group must be able to freely rotate for hydroarylation to occur. It is likely that the ortho-substituents 
force the directing group to twist out of the plane of the arene, and therefore it is ineffective at directing 
the Ir(I)-catalyst into the ortho C−H bond of 90u−90w (Scheme 61). For this reason, bis-ortho-
functionalisation is not observed. In the case of cyclic benzamide 98, the lack of rotation may inhibit 
alkene migratory insertion/reductive elimination (see Section 2.1).  





Table 21: Scope of the hydroarylation reaction of 1,1-disubstituted alkene 147b’ with benzamide substrates with 
respect to substitution of the benzamide. aYield determined by 1H NMR analysis of crude material against an 
internal standard. 
 
Scheme 61: The effect of ortho-substituents on Ir(I) oxidative addition. 
4.2.3 − Scope with Respect to the Alkene Coupling Partner  
Next, electronically diverse styrenes with substituents in the meta- and para-position 
(147c’−147g’) were evaluated (Table 22). Para-fluoro styrene derivative 147c’ reacted with benzamide 
90c efficiently to afford fluorinated product 148cc’ in good yield (74%), but para-bromo-derivative 
147d’ gave desired product 148cd’ with lower efficiency (24% yield). Electron-donating para-
methoxy-derivative 147e’ also behaved poorly, generating desired product 148ce’ in 25% yield. 
However, meta-chloro and meta-methoxy styrenes 147f’ and 147g’ were tolerated, producing 
hydroarylation products 148cf’ and 148cg’ in 65% and 70% yield respectively. Interestingly, 
hydroarylation of aliphatic alkene 147h’ with benzamide 90c generated 148ch’ in 22 % yield, alongside 
structural isomer 148ch’’ (37% yield).  





Table 22: Scope of the hydroarylation reaction of 1,1-disubstituted alkenes with benzamide 90c. a7.5 mol% of 
Ir(cod)2BARF and ligand was used; bYield determined by 1H NMR analysis of crude material against an 
internal standard. 
The unexpected formation of isomer 148ch’’ is presumed to result from hydroarylation of 
alkene 91h’, which is likely formed by alkene isomerisation of starting alkene 147h’ under the Ir(I)-
catalysed conditions (Scheme 62b). To investigate this, regioisomeric alkene 149 was subjected to Ir(I)-
catalysis, which generated 148ch’ in 16% yield, alongside structural isomer 149ch’’ in 13% yield 
(Scheme 62a). The fact that both product isomers 148ch’ and 148ch’’ are formed from alkene 147h’ 
and 149 suggests that they are isomerising under the reaction conditions. This could occur by two 
processes; an Ir−H mediated hydrometallation/-hydride elimination mechanism, or via allylic 
oxidative C−H insertion/reductive elimination.162 For example, addition of an Ir(I)−H species across the 
alkene to give I, followed by -hydride elimination to give II, would isomerise the alkene as shown in 
Scheme 62bi. Alternatively, the alkene may migrate via oxidation of the allylic C−H bond to form η3-
allyl complex III, followed by reductive elimination to give isomerised alkene 149 (Scheme 62bii).163 
Under this process, the point of unsaturation moves along the chain until 91h’ forms and undergoes 
hydroarylation with benzamide 90c. Related processes involving alkene migration via Ir(I)-catalysed 
allylic C−H insertion have been reported.162 More highly substituted alkenes are often more 
thermodynamically stable,164 therefore 91h’ is likely the more kinetically stable isomer. Ir(I)-catalysed 
alkene isomerisation occurs in competition with alkene hydroarylation, hence isomers 148ch’ and 
148ch’’ are observed. The hydroarylation of sterically demanding alkene 147n’ was trialled to avoid 
isomerisation of the alkene (Scheme 62c). However, less than 10% conversion to alkyl quaternary 




product 148cn’ was observed. The low reactivity is most likely due to less favourable coordination of 
bulkier alkene 147n’ to the Ir(III)-intermediate and a greater energy barrier to insertion of the alkene 
into the Ir(III)−H/Ir(III)−C bond. 
 
Scheme 62: Hydroarylation of aliphatic alkenes with N,N-diethylbenzamide 90c. a Yield determined by 1H NMR 
analysis of crude material against an internal standard.  
To summarise, the development of ligand (rac)-L-15f has allowed the formation of challenging 
all-carbon quaternary centres on benzamides. The protocol tolerates substitution in the meta- and para-
position of the benzamide unit and the styrene coupling partner (e.g. OMe, halogens). Current 
limitations include substitution in the ortho-position of both coupling partners and alternative 
substituents to methyl at R2 of the styrene. These results are significant considering the challenges 
associated with hydroarylation of sterically congested 1,1-disubstituted alkenes. A bulkier alkene would 
undergo less favourable coordination to Ir(III)-intermediate I formed after oxidative addition and a 
greater energy barrier for the hydrometallation (I to II) or carbometallation step (I to III) would lead to 
a low catalyst turnover (Scheme 63).  





Scheme 63: Steric constraints in the hydroarylation of 1,1-disubstituted alkenes.  
4.3 −  Expansion of the Hydroarylation of 1,1-Disubstituted Alkenes to 
Five-Membered Heteroaromatics 
4.3.1 − Hydroarylation of 1,1-Disubstituted Alkenes with Pyrrole Substrates 
Having successfully developed methodology for 1,1-disubstituted alkene hydroarylation with 
benzamide derivatives, evaluation of five-membered heteroaromatics began. In initial studies, N-
methyl-pyrrole 150a, equipped with a diisopropyl directing group at the C3-position, was exposed to 
the optimised Ir(I)-catalysed conditions. Desired alkylated product 151aa’ was generated in excellent 
yield after just 24 hours (87% yield, Table 23). The scope of the reaction was explored with respect to 
the alkene coupling partner, whereby electron-deficient fluorinated styrene 147c’ gave 151ac’ in 77% 
yield. The -methyl substituted styrenes used so far have generated achiral molecules, so -ethylstyrene 
147j’ was investigated. When pyrrole 150a was exposed to -ethylstyrene 147j’, chiral hydroarylation 
product 151aj’ was produced in 73% yield after 16 hours. Interestingly, when exposed to 2-methyl-1-
pentene 147h’, pyrrole 150a underwent facile conversion to desired product 151ah’ (83% yield). This 
is in contrast to hydroarylation of 147a’ with N,N-diethyl benzamide 90c, which formed a mixture of 
two regioisomers (Scheme 62). The fact that none of the tertiary regioisomer is formed in this case, 
suggests that the formation of alkene regioisomer 91h’ is dependent upon the substrate (Scheme 62). 
This might suggest that the alkene isomerisation is facilitated by an Ir(III)-H species, which is formed 
via oxidative addition of the Ir(I)-catalyst into the starting material (Scheme 62). The protocol was also 
extended to more elaborate systems such as steroid-derived alkene 147o’ and ferrocene-based alkene 
147p’; however, regio-selectivity for 151ap’ is poor, with a 1.3:1 ratio between alkylation at C2 and 
C4. Next alternative substituents on the pyrrole N-atom were investigated. For example, TIPS protected 
pyrrole 151b was unsuccessful, presumably due to the larger protecting group hindering alkene 
coordination. Additionally, N−H pyrrole 151c did not provide the target product, most likely due to 
metallation of the free N−H bond. 





Table 23: Scope of the hydroarylation reaction of 1,1-disubstituted alkenes with N-methyl-pyrrole 150a. aThe 
reaction was run for 16 h; b150 mol% of alkene was used; cThe reaction was run for 72 h. 
The broad applicability of the Ir(I)-catalyst system was further demonstrated by expanding the 
scope to pyrrole derivate 126a, which bears an N-carbamoyl directing group (Scheme 64). When pyrrole 
126a was exposed to -methylstyrene 147a’, desired product 152aa’ was produced in a 72% yield. 
Unfortunately, the reaction exhibited poor reproducibility, with yields ranging from 28−72%. In some 
cases, up to 50% of di-alkylated product 153aa’ was also observed. However, distillation of the 1,4-
dioxane solvent over Na/benzophenone and distillation of -methyl styrene before use, resulted in 
reproducible results, affording product 152aa’ in good yield and selectivity over di-alkylated species 
153aa’ (72% yield, Table 24). 





Scheme 64: Ir(I)-catalysed hydroarylation of -methylstyrene with pyrrole 126a. a Yield determined by 1H NMR 
analysis of crude material against an internal standard. 
Having developed reproducible conditions, alternative alkene coupling partners (e.g. 147f’, 
147c’ and 147b’) with electronically diverse groups in the meta and para-positions were explored in 
the Ir(I)-catalysed hydroarylation with pyrrole 126a. A significant drop in yield was observed for 
hydroarylation of halogenated and biphenyl alkenes 147f’, 147c’ and 147b’ (31–53% yield), albeit with 
complete selectivity for monoalkylated product 152 in each case. When pyrrole 126a was subjected to 
2-methyl-1-pentene 147h’ under Ir(I)-catalysed conditions alkene isomerisation occurred resulting in 
structural isomers 152ah’ and 152ah’’ (2.5:1) (Table 24). This mirrors the hydroarylation of 2-methyl-
1-pentene 147h’ with benzamide 90c (Scheme 62). Next, substitution around the pyrrole was explored; 
however, phenyl-substituted pyrrole 126e was unreactive under standard catalytic conditions. 
Additionally, azoles 129 and 130 remained unfunctionalised, suggesting that the nitrogen atoms were 
potentially coordinating to the Ir(I)-catalyst and deactivating it. Pyrrole 126a was also unreactive 
towards more complex alkenes, such as ferrocene-based 147p’ and steroid 147o’. 





Table 24: Scope of the hydroarylation reaction of 1,1-disubstituted alkenes with pyrroles 126a. aThe reaction was 
run for 72 h. 
To expand the scope further, indole 132 was investigated. When exposed to -methylstyrene 
147a’ under standard hydroarylation conditions, the reaction proceeded with full conversion to give 
C3-alkylated indole 154a’, with no directed alkylation at C2 observed (155a’) (Scheme 65b). This 
indicates that a Friedel-Crafts-type reaction is occurring, whereby the Ir(I)-catalyst is acting as a -
Lewis acid. This type of reaction was previously observed for the reaction of styrene 91a’ with N-acetyl 
indole 116 (Section 3.3.1, Table 8). 
 
Scheme 65: Alkylation of indole 154 via a Friedel-Crafts type mechanism. aYield determined by 1H NMR analysis 
of crude material against an internal standard. 




4.3.2 −  Hydroarylation of 1,1-Disubstituted Alkenes with Thiophene Substrates 
Having successfully expanded the hydroarylation of 1,1-disubstituted alkenes to include 
pyrrole derivatives, other five-membered heteroaromatics, including thiophene derivative 131, were 
investigated. Under standard catalytic conditions hydroarylation of -methylstyrene 147a’ with 
thiophene 131 proceeded in excellent yield (85%), albeit in poor selectivity, with alkylation occurring 
at C2 and C4 of the thiophene, in a 1.5:1 156a’:157a’ ratio respectively (Scheme 66a). At present it is 
not understood why this selectivity issue is not observed for furan 134 and only for ferrocene-based 
alkene 147p’ with pyrrole 126a. Towards a regioselective protocol, benzothiophene 145, in which C4 
is blocked by an arene, was exposed to the Ir(I)-catalysed conditions (Scheme 66b). However, no 
conversion to 158a’ was observed. Previously the hydroarylation of styrene 91a’ with benzothiophene 
145 was successful (Section 3.4, Table 17), which further highlights the greater barrier to alkene 
migratory insertion/reductive elimination with more sterically demanding 1,1-disubstituted alkenes. 
 
Scheme 66: Hydroarylation of -methylstyrene 147a’ with thiophene derivatives 131 and 145. 
4.3.3 − Hydroarylation of 1,1-Disubstituted Alkenes with Furan Substrates 
Thiophene substrates were unselective in the hydroarylation protocol and therefore alternative 5-
membered heteroaromatics were investigated. Alongside Miss Ellie Lester, the Ir(I)-catalysed 
conditions were adapted to allow the successful alkylation of furan derivative 134a with 1,1-
disubstituted alkenes. Under the standard reaction conditions, desired product 159aa’ was produced in 
excellent yield, with no starting material remaining (90% yield, Table 25, entry 1). However, it was 
found that decreasing the number of equivalents of -methylstyrene gave comparable yields (entry 2−3), 
with 1.5 equivalents of 147a’ giving 159aa’ in 90% yield (entry 4). Lowering the temperature to 110 °C 
gave decreased conversion (entry 5) and at 100 °C the reaction did not proceed (entry 6). Combining 
the lower equivalents of alkene with a shorter reaction time of 24 hours generated desired product 159aa’ 




in a yield of 94% (entry 7). The structure of 159aa’ was confirmed by single-crystal X-ray diffraction 
of crystals grown from a concentrated CHCl3 solution. 
 
Table 25: Selected optimisation results for the hydroarylation reaction of -methylstyrene 147a’ with furan 134a. 
aYield determined by 1H NMR analysis of crude material against an internal standard. 
Having optimised the hydroarylation of -methylstyrene 147a’ with furan 134a, the scope of 
the reaction, with regards to the alkene coupling partner and directing group, was explored (Table 26). 
Styrene derivatives bearing electron-donating (OMe) and electron-withdrawing (CF3) substituents in 
the meta and para-positions proceeded efficiently, giving alkylated products 159ag’, 159aq’, 159ab’ 
and 159ae’ in excellent yields (81–94% yield). The methodology tolerates alkenes 147j’ and 147r’ with 
other carbon-based substituents (e.g. ethyl and n-propyl) in the -position, which generated chiral 
quaternary stereocentres 159aj’ and 159ar’ (75% and 77% yield). Aliphatic alkenes were also 
successfully employed, with propyl derivative 147h’ and (S)-limonene 147s’ both affording desired 
products 149ah’ (77% yield) and 149as’ (64% yield) in good yields. Variation of the directing group 
found that diethyl furan derivative 134b gave desired alkylated product 159ba’ in a 63% yield. The 
protocol also demonstrated limitations, with heteroatoms in the -position of the alkene not tolerated, 
as exemplified by bromo derivative 147i’ and silane derivative 147t’. Alkenes bearing larger groups in 
the -position, including isopropyl (147u’), presumably proved too sterically demanding for efficient 
alkene coordination and resulted in no conversion to the desired quaternary product. 




Table 26: Scope of the hydroarylation reaction of 1,1-disubstituted alkenes with furans 134a and 134b. a 
Reaction was conducted by Miss Ellie Lester; b Yield determined by 1H NMR analysis of crude material against 
an internal standard. 
The hydroarylation of -methylstyrene 147a’ with furan 139, which bears an amide directing 
group at the C2-position, gave desired product 160a’ in 43% yield, alongside dealkylated product 161a’ 
in 19% yield (Scheme 67). This dealkylation event was previously observed for the Ir(I)-catalysed 
hydroarylation of styrene 91a’ with furan 139 (see Section 3.3.2, Scheme 56b). To suppress 
dealkylation of the directing group from occurring lower reaction temperatures and shorter reaction 
times were trialled. However, all of the changes made, resulted in no conversion to 160a’.  
 





Scheme 67: Ir(I)-catalysed hydroarylation of -methylstyrene 147a’ with furan 139. 
4.3.3.1 − Development of an Enantioselective Protocol 
All-carbon quaternary stereocentres are present in many biologically active compounds (Figure 
5) and hence, the development of a step-efficient and atom economical protocol for the enantioselective 
construction of these stereocentres would be of great importance to modern chemists. Towards an 
enantioselective protocol, enantiopure bisphosphite ligand L-15f was trialled under the optimised 
conditions and gave desired hydroarylation product 159aj’ with 60:40 e.r. (Table 27, entry 1). Addition 
of a t-butyl substituent to the biphenyl moiety of the ligand at the C4-position resulted in decreased 
enantioselectivity (54.5:45.5 e.r., entry 2, (S)-L-15a), whereas switching to ferrocene-based 
bisphosphonite ligand (R)-L-16f resulted in a dramatic increase in enantioselectivity to 90:10 e.r. (entry 
3), whilst maintaining a good yield (73%). No improvements were achieved when changing the 
substituents at C4 on the SPINOL moiety of the ligand (entry 4−7).  
 
Table 27: Development of an asymmetric protocol for the hydroarylation reaction of -ethylstyrene 147j’ with 
furan 126a. a Reaction was conducted by Miss Ellie Lester; Yields were determined by 1H NMR analysis of crude 
material against an internal standard.  




SPINOL derived bisphosphonite ligands L-16 are efficient for the asymmetric 
hydroheteroarylation of 1,1-disubstituted alkenes (Table 27) and monosubstituted alkenes (see Chapter 
3), but further improvements in enantioselectivity (87:13–95:5 e.r.) are desirable. Therefore, 
optimisation of the SPINOL unit of the ligand began, with a particular focus on the addition of 
substituents onto the cyclopentyl units. Despite being privileged frameworks for the synthesis of chiral 
ligands, the current approach used to synthesise SPINOL moieties consists of 7 steps, beginning with 
the condensation of 162 with acetone to generate aldol product 163. Following hydrogenation, selective 
bromination generates 164, which cyclises upon exposure to phosphotungstic acid to form SPINOL 165. 
After removal of the methoxy units, optical resolution of racemic SPINOL 166 with (R)-menthyl 
chloroformate 167, generates enantiopure menthyl SPINOL derivative 168. Finally, removal of the 
menthyl units generates bromo-SPINOL 169, which can undergo Suzuki cross-coupling reactions with 
boronic acids to form various SPINOL derivatives. This method uses stochiometric quantities of a 
resolving agent, which makes the synthesis of libraries expensive and time-consuming (Scheme 68a).133 
Recently, interest has been placed on streamlining the synthesis of SPINOL moieties, resulting in fewer 
steps and a greater variation in the points of modification.165-168 In 2018, Ding and co-workers reported 
an alternative approach to synthesising cyclohexyl-fused SPINOL moieties in 4 steps, which 
demonstrated similar levels of reactivity and enantioselectivity to well-established SPINOL-based 
chiral ligands (Scheme 68b).167 To achieve this they developed an iridium catalysed asymmetric 
hydrogenation of α,α′-bis(arylidene)-cyclohexanone 171, followed by TiCl4 catalysed spiroannulation 
of chiral ketone 172. This method can therefore be viewed as a more rapid synthetic approach to 
SPINOL units. Efforts to replicate Ding and co-workers synthesis of cyclohexyl-SPINOL variant 174, 
commenced with condensation of 170 with cyclohexanone. 171 was then subjected to the reported 
hydrogenation conditions (H2 (50 atm), [Ir] (5 mol%)); however, no conversion to 172 was observed. 
In order to promote the hydrogenation, higher hydrogen pressures and rigorous anhydrous and inert 
conditions were trialled; however, 172 was not formed. This is possibly due to differences in the 
hydrogenation equipment employed.  





Scheme 68: Reported procedures for the synthesis of SPINOL moieties. 
In 2019, Dou and co-workers developed a three step asymmetric synthesis of 3,3’-diarylated 
SPINOL units (Scheme 69a).168 They utilised a chiral rhodium catalyst for the asymmetric 1,4-
conjugate addition of aryl boronic acids onto aldol product 175, which was followed by a BF3-promoted 
spirocyclisation of 176 to afford 3,3’-diarylated SPINOLs 177. In several cases, when converted to 
chiral ligands, the SPINOL variants demonstrated higher enantioselectivities than the traditional 
SPINOL moieties. Future work will involve investigating these substituted SPINOL units on ferrocene 
moieties as chiral ligands (as shown in ligands L-16l and L-16m) (Scheme 69b) for the enantioselective 
hydroheteroarylation of mono- and disubstituted alkenes. 





Scheme 69: Dou’s reported methodology for the synthesis of SPINOL moieties 177 and potential ligands (R)-L-
16l and (R)-L-16m. 
4.4 − Studies into the Mechanism  
At this stage, a hydroarylation protocol for 1,1-disubstituted alkenes had been successfully 
developed to afford a range of structures encompassing all-carbon quaternary centres with promising 
levels of enantiopurity. Natural abundance 13C kinetic isotope and deuterium labelling experiments were 
employed to gain greater insight into the mechanistic cycle. 
4.4.1 − Determination of 13C KIEs at Natural Abundance (Singleton Method) 
The kinetic isotope effect (KIE) can be utilised for the elucidation of reaction mechanisms. It 
exploits the singularity that heavier isotopes react at a different rate compared to their lighter isotope 
counterparts. A KIE arises from a difference in vibrational energies between the isotopes at the ground 
state energy of a system, which is known as zero-point energy (ZPE). The different mass of the two 
isotopes is the main contributing factor to the change in vibrational energies and this is demonstrated 
by applying Hook’s law (Equation 1) to a covalent bond. According to Hook’s law, vibrational energy 
(En) is dependent on the frequency of the bond undergoing the reaction (ν) (Equation 2), which is 
inversely proportional to the square root of the reduced mass (μ) (Equation 3) of the two atoms either 
side of the bond (Equations 1−3).169-173 
(1)   𝐸𝑛 = (𝑛 +
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n = principle quantum number, ℎ = Planck’s constant, 𝑐 = speed of light,  
𝑘 = force constant, 𝑚 = mass 




The isotope effect is most commonly studied for hydrogen and deuterium, because of the 
relatively large difference in mass between them, which gives large, easily measured KIE values. The 
frequency of vibration (𝑣) is inversely proportional to the reduced mass (𝜇) and hence the increase in 
mass results in a C−D bond vibrating slower than a C−H bond (Equation 2). This results in a lower 
zero-point energy for C−D bonds, which means that they have a higher activation energy. Consequently, 
a C−D bond is more stable and reacts at a slower rate than a C−H bond (Figure 6). The KIE measured 
is always proportional to the difference in the Gibbs free energy (ΔZPE).169-173 
 
Figure 6: Morse curve for the isotope effect between C−H and C−D bonds. 
The difference in the rate of reaction and hence the rate constants (k) for the isotopes allows 
the KIE to be measured through the following equation, where kL is the rate constant for the lighter 
isotope and kH the rate constant for the heavier isotope (Equation 4).  




The Morse potential curve outlined in Figure 6 is only applicable for reactions that proceed by 
a simple mechanism, whereby the bond being monitored is fully broken at the transition state, i.e. 
homolytic cleavage. For more complex mechanistic pathways where the bond is partially broken at the 
transition state, the KIE depends on other factors, including the ΔZPE at the transition state; however, 
this topic will not be discussed further in this thesis.169-173 
A KIE can be classified as either primary, or secondary. A primary KIE occurs when the 
labelled bond is broken, or formed during the first irreversible step, which is also the rate-determining 
step of the mechanistic cycle. Conversely, a secondary KIE is one in which no labelled bonds are broken 
or formed during the rate-determining step and it is always smaller than a primary KIE. Substantial 




secondary KIEs are measured when there is a change in the type of bonding, hybridisation or steric 
environment at the isotopically labelled atom. However, whether these effects arise from bonding or 
non-bonding interactions such as solvation are not always clear. Standard KIEs are measured when 
kL/kH is greater than one. Additionally, inverse KIEs are observed when kL/kH is less than one.169-173 
Heavier isotopes, including 12C/13C, 14N/15N, 16O/18O and 35Cl/37Cl have also been used to gain 
further insight into reaction mechanisms. However, the KIE of these heavier isotopes is much less 
pronounced than that for 1H/2D owing to the much smaller variation in mass, and hence the 
measurements are harder to conduct accurately.174-176 For example, there is only an 8% change in mass 
when going from carbon-12 to carbon-13. This results in a minor change in the reduced mass; only 
small primary KIEs are measured and secondary KIEs are nearly completely negligible. Experimental 
measurements for these isotopes can be carried out using competition experiments between labelled 
and non-labelled species. Both species will react in the same manner, but at different rates, resulting in 
diminishment of the faster reacting species (the species containing the lighter isotope). The 
disadvantages of using labelled species is that the results often lack accuracy owing to the smaller KIEs 
measured and it is only applicable for a restricted number of systems. Additionally, labelled species are 
often difficult to synthesise, and are cost prohibitive owing to a labelled species being required for each 
KIE of interest.  
An alternative method for measuring KIEs is to employ molecules containing isotopically 
labelled atoms in their natural abundance.177 When any reaction proceeds, the unreacted starting 
material becomes enriched in the heavier, slower reacting isotope at the site of reactivity, shown by a 
significant KIE measurement. The variation in isotope arrangement is expressed by R/R0 where R and 
R0 are the amount of the minor isotope measured in the recovered and original starting material 
respectively. This ratio depends on how far to completion the reaction goes (F) and the measured KIE 
(Equation 5). As the reaction commences towards completion (F→1), R/R0 approaches infinity, 
ensuring that the KIEs become sizeable and easily measured. The accuracy of the measured KIE 
depends upon the size of the KIE, the precision of analysis (R/R0) and the uncertainty in percentage 
conversion (F) (Equations 5−6). 








One method to measure natural abundance KIEs is to use isotope ratio mass spectrometry, 
which offers more precise results than competition experiments, particularly for 13C KIEs.178 However, 
the application requires the site of interest to degrade to a small molecule e.g. CO2, which can be 
analysable by mass spectrometry, without fractionation of the isotopes. Another analytical tool for 
measuring KIEs is the use of 2H NMR, although for heavier atoms, i.e. 13C, NMR quantitation is often 
not precise enough.  




In 1995, Singleton and Thomas pioneered a general method for the determination of KIEs at 
natural abundance with high precision using 2H and 13C NMR analysis.177 The reaction of interest was 
stopped at high conversion (>70% yield) and the unreacted starting material was isolated before analysis 
by 13C NMR. The carbon signals of interest were integrated against an internal standard (a carbon atom 
in the molecule that can be assumed not to take part in the reaction mechanism i.e. KIE = 1) or if this is 
not possible, an external standard can be added. The integrations of the carbon signals allowed the 
determination of R/R0 and subsequently the KIEs relative to the standard. 
Despite the wide applicability of the Singleton method, some criteria need to be met for it to be 
successful: 1) the reaction must be scalable and clean to allow sufficient recovery of starting material 
for 13C analysis in high purity and yield; 2) the reactant of interest must be the limiting reagent; 3) the 
reaction monitored must have an irreversible step; 4) the reaction mechanism must not alter during its 
progress. Following the initial report, the Singleton method has found application in determining a wide 
range of mechanistic pathways. In particular, the Singleton method has been instrumental in gaining a 
greater understanding of the Ir(I)-catalysed hydroarylation reactions carried out at Bristol.179-180  
4.4.2 − Possible Mechanistic Pathways for the Hydroarylation of 1,1-Disubstituted 
Alkenes 
As described in previous chapters, the mechanistic pathway for the Ir(I)-catalysed 
hydroarylation of monosubstituted alkenes appears to be independent of the arene coupling partner, and 
in fact hinges upon the ligand. Using deuterium labelling experiments and 13C natural abundance 
experiments, the non-enantioselective protocol previously developed at Bristol for the hydroarylation 
of monosubstituted alkenes was suggested to advance by reversible hydrometallation. This was 
followed by the first irreversible and rate-determining step: C−C reductive elimination (Scheme 70a).180 
Significant KIEs were measured at C2 and C3 (1.031 and 1.032) for recovered styrene 91k’ in the non-
enantioselective hydroarylation of styrene 91k’ with acetanilide 60d. The significant KIE at C2 is 
consistent with C−C reductive elimination being the first irreversible step (Scheme 70c) and is 
complementary of the results found by Singleton for Hartwig’s methodology for the Pd-catalysed 
hydroamination of vinylarenes.118, 181-183 The KIE at C3 was surprising and was attributed to the arene 
portion of the alkene potentially coordinating to the iridium at the stage of reductive elimination. 
A carbometallation pathway is less commonly anticipated for hydroarylation processes, owing 
to the higher activation energy associated with olefin migratory insertion into metal−carbon over 
metal−hydrogen bonds.184 Nevertheless, a carbometallation pathway was proposed by Dr. Grѐlaud in 
the mechanistic studies for asymmetric hydroarylation of monosubstituted styrene 91k’ with acetanilide 
60j (Scheme 70c). Surprisingly, a significant KIE was measured at C1 of recovered alkene 91k’ only 
(Scheme 70b).179 The measured KIEs led to the determination that carbometallation was reversible and 
that C−H reductive elimination was in fact the first irreversible step (Scheme 70c). 





Scheme 70: Proposed catalytic cycles for the hydroarylation of monosubstituted alkenes previously developed at 
Bristol; Standard deviations for the last digit are shown in parentheses. 
For the hydroarylation of 1,1-disubstituted alkenes, it was postulated that the reaction could 
proceed by either of the mechanisms discussed above (Scheme 70c). Additionally, a third mechanistic 
pathway could be operative in which, following oxidative addition (I to III), the alkene inserts into the 
Ir(III)−C bond irreversibly to generate iridacycle V, which then undergoes C−H reductive elimination 
to afford hydroarylation product VI (Scheme 71).184-186  





Scheme 71: Alternative carbometallation pathway possible for the hydroarylation of 1,1-disubstituted alkenes. 
Irreversible carbometallation has previously been proposed for alkene hydroarylation reactions, 
including those developed by Hartwig106 and Romana.103 In 2013, Morken and co-workers employed 
the Singleton method to investigate the mechanistic pathway of their Pt(0)-catalysed enantioselective 
diboration of monosubstituted alkenes (Scheme 72).187 They subjected allylbenzene to a Pt(0)-catalyst, 
B2(pin)2 and a chiral ligand to afford diboronated species V, which was then converted to diol 179 under 
oxidative conditions in good yield (78% yield) and enantiopurity (92% e.e.). To investigate the 
mechanistic pathway, the signals of interest in the 13C spectra of recovered allylbenzene were integrated 
against internal standard C7. Significant KIEs were measured at both olefinic carbons of recovered 
alkene 178, C1 and C2 (1.012 and 1.013), with negligible KIEs at all other positions. These KIE values 
suggest that both C1 and C2 are involved in the first irreversible step, and hence alkene insertion into 
the Pt−C bond is the rate determining and first irreversible step. The stereochemistry of the reaction is 
controlled in this step when the Pt-boron complex II adds across -system of alkene 178. This allowed 
Morken to propose the catalytic cycle in Scheme 72. Here, Pt(0)-catalyst I oxidatively adds into the 
diboron bond of B2(pin)2 and this is followed by alkene coordination and irreversible insertion into the 
Pt−B bond to give IV. C−B reductive elimination then gives V.  





Scheme 72: Morken and co-workers measured KIEs and suggested catalytic cycle for the diboration of alkenes. 
Standard deviations for the last digit are shown in parentheses. 
The work described by Singleton181, Morken187 and that previously carried out at Bristol117, 179 
provide an overview of the different mechanistic pathways that can occur for alkene difunctionalisation 
reactions and, therefore the mechanisms possible for the hydroarylation of 1,1-disubstituted alkenes. 
To decipher between possible reductive elimination and carbometallation pathways, deuterium 
exchange experiments were carried out, and natural abundance 13C kinetic isotope effects (KIEs) were 
determined for the alkene coupling partner. 
4.4.3 − Deuterium Labelling Experiments 
The mechanism for the hydroarylation of 1,1-disubstituted alkenes was first probed through the 
use of a deuterium labelled alkene. ,-Bisdeuterated alkene deuterio-147b’ was prepared via Wittig 
olefination with a deuterated Wittig reagent. Deuterio-147b’ was subjected to standard catalytic 
conditions with furan 134a (Scheme 73). 1H and 2H NMR analysis of deuterio-159ab’ identified 
deuterium incorporation in both methyl groups (1.41 D, 71% deuterium) and minor deuterium 
incorporation at the C4-position of the furan (0.21 D, 21% deuterium), indicating that the carbonyl-
group also directs into this position, albeit not preferentially over C2. Recovered alkene deuterio-147b’ 




also demonstrated a scrambling of deuterium labels, with deuterium being observed in the methyl unit 
(1.1 D, 37% deuterium). Scrambling of the deuterium labels in product deuterio-159ab’ and recovered 
deuterio-147b’ indicates that both C−H oxidative addition and alkene hydrometallation are reversible. 
 
Scheme 73: A deuterium labelling study for the hydroarylation of deuterio-147b’ with furan 134a.  
4.4.4 − Determination of 13C-KIEs for the Ir(I)-Catalysed Hydroarylation of 1,1-
Disubstituted Alkenes with Furans 
To fulfil the requirements of the Singleton method discussed in Section 4.4.1, furan derivative 
134a was chosen due to the efficiency in which the alkylation reaction proceeds. Alkene 147b’ was 
selected due to it being stable to column chromatography and non-volatile, making its recovery 
relatively facile. Another key requirement of the Singleton method is the substrate being examined must 
be the limiting reagent, hence, the reaction was repeated with one equivalent of alkene 147b’ and the 
reaction time was probed to identify when the reaction reached ~70% conversion (Table 28). 
Fortunately, only small amounts of polymerised alkene 147b’ were observed (<2%), with almost 
complete recovery of alkene 147b’ achieved. The conversion was 60% after 4 hours (entry 1) and had 
reached 70% after 6 hours (entry 3), providing optimal conditions with which to proceed. 
 
Table 28: Selected optimisation results for the hydroarylation reaction of alkene 147b’ with furan 134a for KIE 
measurements. a Conversion determined by 1H NMR analysis of crude material against an internal standard. 




With optimal conditions in hand (Table 28, entry 3), the reaction was successfully scaled from 
0.1 mmol to 2.0 mmol and was carried out in repetition for validation. Each experiment was stopped 
after 6 hours, and unreacted alkene 147b’ was recovered by FCC. Recovered alkene 147b’ was analysed 
by quantitative 13C NMR (see Section 7.6.5) and olefinic carbons C1 and C2, methyl carbon C3 and 
ipso-carbon C4 (measured with C7 for which the KIE is assumed to be 1.000, due to overlapping signals) 
were integrated. The KIE for C8 was assumed to be 1.000 and hence was selected as the internal 
standard which the other carbons were integrated against. (Scheme 74). A significant kinetic isotope 
effect was observed at C2 (1.013). Interestingly, an isotope effect was observed at C1 (1.035) and an 
inverse isotope effect was observed at C3 (0.981), with negligible KIE observed at C4/7 (~1.003). 
 
Scheme 74: 13C natural abundance KIEs measured for the hydroarylation of alkene 147b’ with furan 134a; 
Standard deviations for the last digit are shown in parentheses. 
The isotope effect observed at C1 and C3 is attributed to isomerisation of the starting alkene. 
This was corroborated by subjecting alkene 147b’ to the standard Ir(I)-catalysed conditions in the 
absence of furan 134a (Scheme 75). Alkene 147b’ was recovered and analysed by quantitative 13C 
NMR. Once again, a positive isotope effect was observed at C1, with a corresponding inverse isotope 
effect at C3, the average of which was 1.000 (Scheme 75). Large 13C-equilibrium isotope effects have 
been observed, but only at low temperature.188 Therefore, it is envisaged that isotopic depletion at C1 
occurs during the synthesis of alkene 147b’ from ketone 180. Ir(I)-catalysed alkene isomerisation then 
reverts the uneven 13C distribution between C1 and C3 back to a roughly even distribution due to the 
similar energy of 13C at C1 and C3. The isotope effects are determined by integration of recovered 
alkene vs starting alkene and, therefore this appears as a positive isotope effect at C1 and a negative 
isotope effect at C3. Ir(I)-catalysed alkene isomerisation has previously been reported.189-191 Further 
experiments carried out at Bristol have provided evidence to this effect. Alkene 147b’ was prepared by 
a process in which carbons C1 and C3 both originate from the same starting material (i.e. Grignard 
addition to an ester, followed by dehydrogenation). The relative ratio of 13C at C1:C3 was different 
compared to the alkene obtained by the Wittig preparation method. This result supports that 13C 
distribution at C1 and C3 is altered during the synthesis of alkene 147b’ from ketone 180. 





Scheme 75: 13C natural abundance IEs measured for alkene 147b’ under the standard Ir(I)-catalysed conditions; 
Standard deviations for the last digit are shown in parentheses. 
Considering the isotope effects measured at C1 and C3 due to alkene synthesis, a significant 
KIE is measured at C1 and C2 (~0.016 and 0.013 respectively), indicating that both C1 and C2 are 
involved in the first irreversible step of the mechanistic cycle. The KIE values are consistent with 
carbometallation being the first irreversible step and mirror values obtained by Morken for alkene 
diboration (Scheme 72).187, 192 The proposed mechanism differs from that suggested for hydroarylation 
of monosubstituted alkenes with dFppb and ligand (S)-L-15a (Scheme 70).  
4.4.5 − Proposed Catalytic Cycle  
The mechanistic investigations above have led to the catalytic cycle proposed in Scheme 76. 
The process commences with the in-situ formation of active Ir(I)-catalyst I. Oxidative addition of I into 
the C−H bond at C2 of furan 134a is directed by the carbonyl group to give Ir(III)-intermediate II. 
Alkene coordination to Ir(III)-intermediate II generates Ir(III)-intermediate III, from which reversible 
hydrometallation to branched and linear intermediates V and IV occurs. Hydroarylation of deuterio-
147b’ alkene with furan 134a resulted in scrambling of the deuterium signals, which is consistent with 
a reversible hydrometallation step (see Scheme 74). Next, the catalytic cycle could proceed through 
C−C reductive elimination from V. However, results from natural abundance 13C KIE experiments 
disclosed that both C1 and C2 are involved in the first irreversible step, therefore, identifying 
carbometallation from Ir(III)-complex III as the productive pathway (Scheme 76). A C−C reductive 
elimination pathway from V would have a significant KIE at the olefinic C2-position only.180 It is 
probable that styrene more readily inserts into the Ir(III)−H bond over the Ir(III)−C bond (V vs VI); 
however, the reaction proceeds through a carbometallation pathway. This is most likely due to C−C 
reductive elimination from V requiring a higher activation energy than the insertion of alkene 147b’ 
into the Ir(III)−C bond to give VI.186 





Scheme 76: Proposed catalytic cycle for the hydroarylation of 1,1-disubstituted alkenes with furan 134a. 
4.5 − Summary and Conclusions 
Through development of a second generation bisphosphite ligand, Ir(I)-catalysed hydroarylation 
of 1,1-disubstituted alkenes has been achieved, providing facile access to challenging all-carbon 
quaternary centres. The methodology has already proved extremely versatile with the Ir(I)-catalyst 
system being applicable for benzenoid, pyrrole and furan substrates. The desired products are produced 
in good to excellent yields (up to 94% yield) and overall the alkene scope is broad, considering the 
steric demands of the centre being formed. Both alkyl and aryl alkenes are applicable, but one limitation 
is that heteroatoms are not tolerated in the -position. Significantly, an asymmetric protocol has been 
demonstrated using ferrocene-based bisphosphonite ligand (R)-L-16f. For example, furan 159aj’, 
bearing a benzylic quaternary centre, was generated in good yield and enantiopurity (90:10 e.r.) 
(Scheme 77). Further fine-tuning of the ligand may provide a versatile catalyst for enantioselective 
hydroarylations of 1,1-disubstituted alkenes. 





Scheme 77: Formation of quaternary stereocentre 159aj’ in good yield and enantiopurity. 
The mechanism was probed through deuterium labelling experiments and 13C-KIE experiments 
based on the Singleton method. The results of these provide clear evidence for a catalytic cycle with a 
rate-determining step that is unique compared to Ir(I)-catalysed methodologies previously developed at 
Bristol.116-117, 179 The significant KIEs measured at both olefinic carbon centres C1 and C2 provided 
evidence that carbometallation is the first irreversible step in the catalytic cycle. 13C-KIE experiments 
also highlighted an interesting variation in the 13C labels for alkene synthesis/isomerisation, showing 
an isotope effect at terminal olefin position C1 and at methyl unit C3.




Chapter 5 − Iridium-Catalysed -Selective Arylation of Styrenes 
by Dual C−H Functionalisation 
Parts of this chapter have been adapted from a publication by Cooper et al. 
(Angew. Chem. Int. Ed. 2018, 57, 14198) 
5.1 − Reaction Discovery and Proposed Mechanism for the -Arylation of 
Styrenes  
During the studies in Section 2.2.1, which involved the screening of commercially available 
chiral ligands for asymmetric styrene hydroarylation, -arylated styrenes were observed in minor 
amounts (see Table 3). For example, when attempting to perform an enantioselective styrene 
hydroarylation with acetanilide 60a under Ir(I)-catalysis with ferrocene-based bisphosphine ligand 
(S,S)-f-binaphane, -arylated styrene 104aa’ was generated in 51% yield, alongside 39% yield of linear 
hydroarylation product 97aa’ (Scheme 78a). -Arylated styrene 104aa’ was presumed to result from 
an oxidative Heck-type reaction, a proposed mechanism for which is shown in Scheme 78b. It was 
suggested that modification of the Ir(I)-precatalyst with (S,S)-f-binaphane, promoted a carbometallative 
pathway from I to III (as supported by KIE experiments, see Section 4.4.4).179 Subsequent -hydride 
elimination from III, gives 104aa’ and Ir(III)-dihydride species IV, which may be reduced to Ir(I) active 
catalyst V by excess styrene in the reaction mixture. The alkenylation process outlined (60a to 104aa’) 
most likely requires a catalyst system that enforces access to an alkene carbometallation pathway, rather 
than a hydrometallation/reductive elimination pathway (I to II and II to 96aa’), as suggested for non-
enantioselective branch-selective styrene hydroarylation.116 Similar 1,1-disubstituted alkenes have been 
observed in small amounts in Ir(I)-catalysed C−H alkylation reactions of unactivated alkenes with 
enamide directing groups.193 
 





Scheme 78: Observation of -arylated styrene product 104aa’ and a proposed mechanism for its formation. 
aYield determined by 1H NMR analysis of crude material against an internal standard. 
5.2 − Previously Developed Methodology for C−H Arylation of Alkenes 
The dual C−H functionalisation method described above (Scheme 78a) provides a regioisomeric 
product with respect to the Heck and Fujiwara-Moritani reactions.194-195 The Heck reaction employs a 
Pd(0)-catalyst in the presence of a base to cross-couple activated alkenes with aryl halides or triflates. 
Here, arylation occurs selectively at the -position, generating linear alkenes (Scheme 79a).194, 196-198 -
Arylation is much harder to achieve, with only a few examples reported and these often require highly 
activated alkenes.199-203 The related Pd(0)-catalysed Fujiwara-Moritani reaction operates under 
oxidative conditions and often in the presence of a directing group (Scheme 79b).195, 204-215 This method 
for C−C bond formation is attractive as it achieves arylation of alkenes by dual C−H functionalisation, 
which eliminates the need to prepare aryl halide or triflate reagents. The regioselectivity of this method 
mirrors that of the Heck-reaction, giving predominantly -arylated styrenes. The above discovery 
(Scheme 78a) is therefore of potential importance, as it provides a facile method for the -arylation of 
simple styrenes, whilst circumventing the need for halogenated coupling partners (Scheme 79c). 





Scheme 79: The Heck and Fujiwara-Moritani reaction.  
In 2013, Zhou and co-workers reported a general approach for a regioselective Heck-reaction 
that achieves -arylation of styrenes with aryl triflates (Scheme 80).201-203 They utilised a Pd(0)-catalyst 
ligated with ferrocene-based bisphosphine dnpf. Here, the chemistry is reliant on the bulky naphthyl 
groups on dnpf, which sterically disfavour unwanted -selective arylation. The protocol tolerates the 
coupling of styrenes and aliphatic alkenes with a range of arenes and heteroarenes to form 1,1-
disubstituted alkenes (e.g. 182a and 182b).  
 
Scheme 80: A general regioselective Heck reaction to generate 1,1-diarylated alkenes. 
Other methods which promote the -selective arylation of styrenes utilise carboxylates as 
traceless directing groups.216-217 For example, Goossen and co-workers utilised a Pd(0)-catalyst in 
conjugation with a Cu(I)-species to promote a regioselective Heck-type reaction (Scheme 81). Styrene 
183 bearing a traceless carboxylate directing group undergoes a Heck reaction with aryl halides to afford 
intermediate I. Subsequent Cu(I)-promoted protodecarboxylation affords 1,1-disubstituted alkenes, 
such as 184a and 184b, in excellent yields. 





Scheme 81: Carboxylate groups as traceless directing groups to promote -arylation. 
The aforementioned methods involve prefunctionalised starting materials, resulting in time-
consuming synthesis and waste. An alternative approach, whereby the -selective arylation of alkenes 
is achieved by dual C−H functionalisation of the feedstock materials, offers an atom and step 
economical route to these motifs. However, to date, only a few processes that achieve -selective 
arylation of styrenes by dual C−H functionalisation have been reported.218-219 For example, in 2009, 
Zhang and co-workers reported the Pd(II)-catalysed oxidative cross-coupling of indolizine 185 with 
styrenes to afford -heteroarylated products, such as 186a and 186b, in moderate to excellent yields 
(Scheme 82a).219 Zhang found that bidentate ligand, 2,2’-bipyridine, was crucial for achieving the 
desired -arylation. The authors proposed an ionic pathway, in which, carbopalladation from II occurs 
to give III, followed by -hydride elimination to afford the -arylated styrenes selectivity. The resulting 
Pd(0)-species is oxidised to the active Pd(II)-catalyst by silver carbonate, thus completing the catalytic 
cycle. Later, Hajra and co-workers described Pd(II)-catalysed C− alkenylation of imidazopyridines 
187 (Scheme 82b).218 “Ligand-free” conditions were utilised under aerobic conditions to afford desired 
products, including 188a and 188b, in good yield, with water as the only by-product. Significantly, this 
protocol was also applicable for aliphatic alkenes. Zhang and Hajra’s related methodologies are 
noteworthy for their high levels of selectivity, atom economy and simplicity. However, these protocols 
are limited to highly specific nitrogen-containing heteroaromatics.  





Scheme 82: -Selective arylation of styrenes with N-heteroaromatics by dual C−H activation. 
A study with specific relevance to this work was reported by Hartwig and Sevov, who described 
Ir(I)-catalysed -selective arylation of aliphatic alkenes with furan derivatives (Scheme 83).220 In this 
case an Ir(I)-catalyst ligated with wide bite angle bidentate TMS-SEGPHOS was utilised alongside 
t-butylethylene 91i’ as a sacrificial hydrogen acceptor. Alkenylated furans, such as 189a were generated 
in high yields and selectivities. During evaluation of the scope, it was noted that arylation occurred 
selectively at the -position with aliphatic alkenes, but -arylation was observed with styrenes (e.g. 
190a). Similar to Zhang, Hartwig proposed that the mechanism proceeds by insertion of the alkene into 
the carbon−metal bond of II to give III, followed by -hydride elimination. Evidence for this 










Scheme 83: Hartwig and co-workers Ir(I)-catalysed olefination of furan derivatives with aliphatic and aromatic 
alkenes. 
Despite these recent advances, the development of a general method that achieves selective - 
arylation of styrenes by dual C−H functionalisation is yet to be reported and would provide a 
regioisomeric alternative to the Fujiwara-Moritani and Heck reactions. To this end, optimisation studies 
into the recently discovered transformation began (Scheme 78a). 
5.3 − Optimisation of the -Selective Arylation of Styrenes 
It was previously found that an Ir(I)-catalyst ligated with ligand (S,S)-f-binaphane provided 
significant quantities of -arylated styrene 104aa’ (51% yield), alongside linear hydroarylation product 
97aa’ (39% yield, Scheme 78a). It was postulated that the ferrocene moiety of (S,S)-f-binaphane was 
vital to promoting a -hydride elimination pathway, leading to 104aa’. Evidence to this effect was 
provided by Zhou and co-workers, who found that ferrocene-based bisphosphine ligand dnpf promoted 
-arylation of styrenes (Scheme 80).201-203 With this in mind, acetanilide 60a and styrene 91a’ were 
subjected to an Ir(I)-catalyst ligated with cheaper 1,1'-bis(diphenylphosphino) ferrocene (dppf). Under 
these conditions, -arylated styrene 104aa’ was formed in 17% yield, alongside branched 
hydroarylation side-product 96aa’ in 53% yield (Scheme 84). Unlike with (S,S)-f-binaphane, none of 
linear regioisomer 97aa’ was observed under these conditions (see Scheme 78a). 
 
Scheme 84: -Selective arylation of styrene with acetanilide 60a under Ir(I)/dppf catalysed conditions. aYield 
determined by 1H NMR analysis of crude material against an internal standard. 




Following this promising result for -arylation of styrene with acetanilide 60a, further 
optimisation studies were carried out utilising dppf and the key results are presented in Table 29. 
Initially, the effect of changing the solvent was investigated (entry 1−4); however, none of those trialled 
had a significant effect on the conversion to product 104aa’. Notably, when water was used, the reaction 
still proceeded (entry 4, 15% yield), highlighting that the Ir(I)-catalyst system is relatively stable in 
aqueous conditions. Minor improvements were observed when increasing the temperature to 130 °C 
from 120 °C (entry 1 vs entry 5−6, 17% vs 23% and 22% yield). It was proposed that -arylated product 
104aa’ forms via -hydride elimination from intermediate III, generating an Ir(III)-dihydride species, 
which is converted to the active Ir(I)-catalyst by excess styrene in the reaction mixture (Scheme 78b). 
To increase the turnover of the Ir(I)-catalyst, the number of equivalents of styrene used was increased; 
however, no improvement to the yield of -arylated product 104aa’ was observed (entry 7−8). Ketones 
readily accept hydrogen from transition metal catalysts to generate the corresponding alcohols.221-223 
Therefore the addition of various ketones (e.g. benzophenone, cyclobutanone and acetone) was 
investigated, although no increase in yield of product 104aa’ was observed. Running the reaction at 
different concentrations or reaction times, and the addition of alternative Ir(I)-sources (e.g. 
[Ir(cod)2]BARF) did not have a beneficial effect. During this evaluation, alternative conditions were 
also screened with (S,S)-f-binaphane for the conversion of 60a to 104aa’, but no improvement in yield 
or selectivity was achieved. 
 
Table 29: Selected optimisation results for the -arylation of styrene 91a’ with acetanilide 60a under Ir(I)/dppf 
catalysed conditions. aYield determined by 1H NMR analysis of crude material against an internal standard. 
The Ir(I)-catalysed -arylation of styrene using dppf as the ligand demonstrated poor efficiency 
and selectivity to hydroarylation side-product 96aa’ (Table 29). To this end, over 70 commercially 




available mono- and bidentate phosphine ligands were screened for the C−H alkenylation of acetanilide 
60a and the key results are reported in Table 30. 1,4-Bis(diphenylphosphino)butane (dppb) gave 
alkenylation product 104aa’, albeit in poor yield (13%) and selectivity to branched 96aa’ and linear 
97aa’ hydroarylation side-products (0.4:1:0.2, entry 1). However, an increase in the selectivity for 
alkenylation product 104aa’ was observed when electron-withdrawing substituents were added to the 
aryl substituents of the ligand (F, L-19a and CF3, L-19b; entry 2, 1:1:0.3 and entry 3, 1:1:0.3 vs entry 
1). In contrast to dppb derivatives, ferrocene-based bisphosphine ligands (entry 4−6) gave no linear 
regioisomer 97aa’, and alkene 104aa’ was afforded in greater selectivity to branched hydroarylation 
side-product 96aa’ (4:1 vs 1:1). 
 
Table 30: Selected results for -arylation of styrene 91a’ with acetanilide 60a under Ir(I)-catalysed conditions 
utilising commercially available ligands. aYield determined by 1H NMR analysis of crude material against an 
internal standard. 
5.3.1 − Design and Synthesis of Ferrocene-Based Bisphosphine Ligands 
An achiral commercially available ligand, which gave alkenylated product 104aa’ selectively over 
hydroarylation side-products 96aa’ and 97aa’, was not identified. However, it was noted that electron-
deficient derivatives of dppb resulted in greater selectivity for -arylation product 104aa’ over branched 
side-product 96aa’ (1:1 vs 0.4:1, Table 30, entry 1−3). Additionally, ferrocene-based bisphosphine 
ligands did not result in linear hydroarylation side-product 97aa’ (Table 30, entry 4−6). These 




observations prompted the design and synthesis of dppf derivatives with electron-deficient aryl moieties 
(Table 31). Electron deficient bisphosphine ligands L-20a−d were prepared in three steps from 
ferrocene.201 Initially, ferrocene 191 was bis-lithiated with n-butyllithium and reacted with 
bis(diethylamino)chlorophosphine 192 under an inert and anhydrous atmosphere. Intermediate 193 was 
formed upon acidification with hydrochloric acid and reaction of 193 with various Grignard reagents 
gave ligands L-20a−d. These were isolated in low yields due to challenging purification. Para-cyano- 
and -methoxy reagents 194a and 194b, and ortho-substituted arene 194c did not generate the desired 
bisphosphine ligand. 
 
Table 31: Synthesis of electron-deficient ferrocene-based bisphosphine ligands L-20a−d. 
Ferrocene-based bisphosphine ligands L-20a−d were trialled under Ir(I)-catalysed conditions 
(Table 29, entry 5) for the -arylation of styrene 91a’ with acetanilide 60a (Scheme 85). In general, 
selectivity for alkenylation product 104aa’ vs hydroarylation side-product 96aa’ increased as the aryl 
moiety of the ligand became more electron-deficient (as observed with dppb derivatives; see Table 30, 
entry 1−3). Para-trifluoromethyl ligand L-20b provided -arylation product 104aa’ in the highest yield 
(44%), albeit in poor selectivity vs 96aa’ (1.5:1). Alternatively, when utilising bis-3,5-trifluoromethyl 
ligand L-20c, 104aa’ was generated in 24% yield and with good selectivity over 96aa’ (5:1). 
Conversely, pentafluorophenyl ligand L-20d generated only branched 96aa’ (30% yield) and linear 
97aa’ hydroarylation products (27% yield). It was postulated that the highly electron-withdrawing 
nature of L-20d resulted in a switch in the mechanistic cycle from a -hydride elimination to a reductive 
elimination pathway (see Scheme 78b). Additionally, commercially available naphthyl substituted 
ligand dnpf was ineffective for C−H arylation and branched hydroarylation product 96aa’ was 
generated selectively (55% yield). Bis-3,5-trifluoromethyl ligand L-20c was chosen for further 
optimisation studies, due to the high selectivity it afforded for -arylation product 104aa’ (5:1) over 
side-product 96aa’.  





Scheme 85: -Arylation of styrene 91a’ with acetanilide 60a under Ir(I)-catalysed conditions utilising ferrocene-
based bisphosphine ligands L20a-d. aYield determined by 1H NMR analysis of crude material against an internal 
standard. 
Having identified bis-3,5-trifluoromethyl bisphosphine ligand L-20c as the most selective, 
optimisation of the -arylation of styrene 91a’ with acetanilide 60a commenced (Table 32). Conducting 
the reaction at a higher temperature and extending the reaction time to 48 h was beneficial to the yield 
of alkene 104aa’ (entry 2, 41% yield). Changing the solvent and using a greater number of equivalents 
of styrene did not improve conversion to product 104aa’ (entry 3–5). Running the reaction for longer 
(72 hours) resulted in an increase in the yield of alkenylation product 104aa’ to 60% (entry 6). 
Additionally, increasing the loading of Ir(I)-precatalyst and ligand to 7.5 mol% and decreasing the 
concentration were both beneficial to the yield of alkenylation product 104aa’ (entry 7). The proposed 
-hydride elimination step to form alkene 104aa’ results in Ir(III)-dihydride species IV (see Scheme 
78, Section 5.1). Turnover of this to the active Ir(I)-species is achieved by the reduction of excess 
styrene in the reaction mixture. This is supported by the presence of ethyl benzene 181 in the crude 
reaction mixture as observed by 1H NMR and GCMS analysis (see Scheme 78, Section 5.1). To this 
end, external oxidants were investigated, to encourage more facile hydrogen removal, and hence 
increase the conversion to alkene 104aa. Pinacolone224 had a negligible effect (entry 8); however, by 
using 200 mol% t-butylethylene , alkene 104aa’ was generated in 74% yield and with a 10:2 selectivity 
over 96aa’ (entry 9). Hartwig and co-workers, previously demonstrated that t-butylethylene was an 
effective hydrogen-scavenger for the Ir(I)-catalysed -arylation of aliphatic alkenes with furan 




derivatives (Scheme 83).220 Alternative Ir(I)-sources, including [Ir(cod)2]BF4, [Ir(cod)2]OMe and 
[Ir(cod)2]BARF, all resulted in lower or no conversion to 104aa’ (entry 10–12). Notably, when 
[Ir(cod)2]BARF or [Ir(cod)2]BF4 was utilised as the precatalyst, hydroarylation product 96aa’ was 
afforded with high selectivity over arylated product 104aa’, presumably as a result of the lower 
coordinating abilities of the BARF/BF4 counterions compared to triflate.  
 
Table 32: Selected optimisation results for the -arylation of styrene 91a’ with acetanilide 60a utilising ligand 
L-20c. aYield determined by 1H NMR analysis of crude material against an internal standard; bIsolated yield. 
5.4 − Reaction Scope 
5.4.1 −  Scope with Respect to the Directing Group 
With bis-3,5-trifluoromethyl bisphosphine ligand L-20c now providing efficient conversion of 
acetanilide 60a to alkenylation product 104aa’, the scope with respect to the directing group was 
explored (Table 33). A wide range of sterically varied anilide-based directing groups, including primary, 
secondary and tertiary alkyl groups were employed to generate desired -arylated products 
104ka’−104qa’ in good to excellent yields (57−81%), and with high selectivity over hydroarylation 
side-products 96ka’−96qa’ (4:1 to >20:1). In all cases, C−H alkenylation products 104ka’−104qa’ 
were easily separated from minor hydroarylation products 96ka’−96qa’ by FCC. Higher selectivity for 
alkenylation product 104 over hydroarylation product 96 was often observed with bulkier directing 
groups. For example, cyclohexyl anilide 60p generated -arylated product 104pa’ in excellent 
selectivity over 96pa’ (8:1 vs 5:1 for 104aa’:96aa’). This protocol is currently limited to acetanilides 
where the R-group on the directing group is carbon-based and more electron rich urea or carbamate 




directing groups are not tolerated 60r and 60s (Table 33). Additionally, cyclopropanated and 
alkenylated acetanilides 60t and 60u were not viable, potentially due to competing alkene coordination 
or Ir(I) oxidative addition into the C−H/C−C bond of the cyclopropane unit. The lack of reactivity of 
N-methyl derivative 60v could possibly be attributed to 1,3-strain occurring between the methyl group 
and the ortho- C−H bond (Figure 7). Alternatively, C−H oxidative addition of the Ir(I)-catalyst into the 
methyl group could be competitive. This could potentially hinder the formation of 6-membered 
iridacycle II and therefore inhibit formation of 104va’. Other classes of directing group were also 
examined, including ketones 89a and 89b and benzamide 90a, but in all cases no conversion to the 
target products was observed. However, the lack of directing group tolerance is not considered a major 
restriction owing to the ease of installation and removal of the N-acetyl-based groups (see Section 5.5, 













Table 33: Scope of the directing group in the -arylation of styrene with anilide substrates 60k−60q. 
  
Figure 7: Steric interaction in 6-membered iridacycle intermediate II. 
5.4.2 −  Scope with Respect to the Anilide  
Having investigated the scope of the directing group, subsequent studies revealed that the C−H 
alkenylation process tolerates diverse substitution on the arene portion of the anilide coupling partner 
(Table 34). Systems with substitution in the meta-position (e.g. 60c, 60b, 60w and 60x) underwent 
highly regioselective C−H alkenylation at the less hindered ortho-position and with good selectivity 
over hydroarylation side-products 96. Para-substituted anilides (e.g. 60y, 60z and 60aa) engaged 
efficiently; for example, the potentially labile C−Br bond of 60y remained intact (61% yield), 
maintaining the possibility for further derivatisation. Additionally, 60z with a para-ester group reacted 
selectively at the C2-position of the anilide, which highlights the greater coordinating ability of 
acetanilide functionality compared to the ester moiety. Systems with highly electron-withdrawing 




groups, such as para-trifluoromethyl derivative 104ga’, suffered from poorer yields (19%). However, 
by switching to acetanilide 60ab, bearing a more sterically demanding directing group, and substituted 
styrene 91e’ (p-Tol), 104abe’ could be generated in acceptable yield (43%) and with excellent 
selectivity over 96abe’ (>20:1). This result suggests that a more electron rich alkene promotes a -
hydride elimination pathway over C−H reductive elimination (see Scheme 78b, III to 104aa). This may 
be a result of increased hyperconjugation from the more electron-rich -system into the * orbital of 
the benzylic C−H bond, which would weaken the benzylic C−H bond and therefore promote -hydride 
elimination. Anilide 60e with a methyl in the ortho-position suffered from low selectivity (2:1) for 
alkenylation product 104ea’ over hydroarylation side-product 96ea’. Nevertheless, derivative 104ael’ 
was produced in high selectivity (<20:1). Some limitations of the process include low selectivity when 
halogens are in the meta-position of the anilide (e.g. 104ia’) and no reactivity for anilides with ortho-
substituents other than a methyl-substituent, such as in 60ah. 





Table 34: Scope of anilide substrates 60 in the -arylation of styrene 91a’. a10 mol% of Ir(cod)2OTf and ligand 
was used; bThe reaction was run for 96 h; cYield determined by 1H NMR analysis of crude material against an 
internal standard. 
To expand the scope to non-aromatic coupling partners, dihydronaphthalene 195 was exposed 
to Ir(I)-catalysed conditions (Scheme 86). No conversion to expected product 196a’ was observed, but 




alkenylation product 104fa’ was isolated. Dehydrogenative aromatisation of dihydronaphthalene 195 
was unexpected and is presumed to occur via carbonyl directed oxidative addition of the Ir(I)-catalyst 
into the C2−H bond to form I, followed by -hydride elimination to form II. -Hydride elimination 
then generates alkenylation product 104fa’ in 60% yield over the two steps. Here, dehydrogenative C−C 
bond formation is occurring in conjunction with dehydrogenative aromatisation (Scheme 86). Ir(I)-
catalysts have previously demonstrated dehydrogenative properties.225 This result suggests that this 
directing group strategy promotes Ir(I) oxidative addition into activated sp3 C−H bonds which could 
demonstrate greater significance.  
 
Scheme 86: Tandem dehydrogenation/C−H arylation of 195. 
5.4.3 −  Scope with Respect to the Alkene Coupling Partner  
Following the above studies, anilide 60o was selected to explore the scope of the alkene 
coupling partner, owing to the high selectivity for arylation product 104oa’ over 96oa’ (13:1, Table 33). 
Electronically diverse substituents were well tolerated in the para-position; for example, fluorine-
derivative 104on’ and t-Bu-derivative 104op’ were generated in excellent yields (75% and 80%) (Table 
35). However, the selectivity for arylation over hydroarylation decreased for trifluoromethyl derivative 
104oo’ (4:1 vs >20:1 for 104oe’), which suggests that highly electron-withdrawing substituents impede 
the -hydride elimination pathway (see Scheme 78b, III to 104aa’). Meta-substituted styrenes 91r’ and 
91s’ proceeded smoothly to give desired products 104or’ and 104os’ in good yields (70% and 64%). 
However, for ortho-substituted styrenes 91g’ and 91t’, arylation proceeded in poorer yields (104og’ 
and 104ot’, 50% and 29%), likely due to the more congested centre during bond formation. More 
complex benzothiophene derivative 91u’ was utilised to give alkenylation product 104ou’ in a moderate 
yield; however, other vinyl heteroaromatics 91y’−91aa’ did not afford the target alkenylation products. 
This is potentially a result of the more strongly coordinating heteroatoms ligating to the Ir(I)-centre, 
which would deactivate the Ir(I)-catalyst. Additionally, styrene 91ab’ with a methyl in the -position 




was not tolerated. With the current Ir(I)-system, the C−H alkenylation process occurs efficiently with 
styrenes only. Alkyl alkenes such as, 91c’ and 91i’ including more activated enol ether 91ac’ and allene 
197 were ineffective.  
 
Table 35: Scope of the -arylation of various styrenes with anilide substrate 60o. a10 mol% of Ir(cod)2OTf and 
ligand used; bThe reaction was run at 1.0 M; cThe reaction was run for 96 h; dYield determined by 1H NMR 
analysis of crude material against an internal standard. 




The -arylation of various alkyl alkenes with acetanilide 60o did not proceed under Ir(I)-
catalysis. However, when allyltrimethylsilane 91ad’ was utilised, desilylated -selective arylation 
product 198 was isolated in 11% yield, alongside small amounts of expected product 104oad’ (4% yield) 
(Scheme 87a). It is proposed that 198 forms via protodesilylation of 104oad’, which usually occurs 
under acidic conditions.226 Increasing the reaction time, temperature, and precatalyst and ligand 
loadings all resulted in decreased conversion to 104oad’. Towards achieving the -selective arylation 
of aliphatic alkenes selectively, triethylvinylsilane 91ae’ and dimethylphenylvinylsilane 91af’ were 
investigated (Scheme 87b). It was envisaged that protodesilylation would be prohibited, through 
removal of the -hydrogen atom; however, targets 104oae’ and 104oaf’ were not observed. 
 
Scheme 87: -Selective arylation of alkene 91ad’ with acetanilide 60o. 
5.5 −  Derivatisations of the -Arylation Products 
Anilide C−H alkenylation products 104 described in this chapter are useful moieties, especially 
in the synthesis of challenging bicyclic N-containing heteroaromatics. For example, when exposed to 
phosphorus(V) oxychloride, alkenylation products (104aa’, 104ja’, 104fa’, 104pa’ and 104qa’) 
underwent efficient cycloaromatisation to afford quinoline systems 199a−199e (Scheme 88a).227 This 
heteroaromatisation strategy offers a facile and effiecient method to afford complex polycyclic systems, 
including 199b and 199c. This methodology was also applicable to estrone derivative 60aj, which 
afforded unusual quinoline 199f in 35% yield over two steps (C−H alkenylation and cycloaromatisation) 
(Scheme 88a). When alkene 104aa’ was exposed to Selectfluor228 and iodine229 fluorinated benzoxazine 
200 and azetidine 201 were generated in 81% and 44% yield (Scheme 88b). Under acidic conditions, 
hydrolysis of 104aa’ gave aniline 202 quantitatively. This then underwent facile transformation to a 
diazonium salt , which rapidly cyclised onto the alkene moiety to form cinnoline 203 in quantitative 
yield. Additionally, upon exposure to acetophenone, dihydroquinoline 204, which comprises a 
tetrasubstituted stereocentre, was formed in excellent yield (97%) (Scheme 88b). 





Scheme 88: Derivatisations of C−H alkenylation products 104. 
5.6 − Ir(I)-Catalysed -Arylation of Styrenes with Pyrrole Derivatives 
Having successfully developed methodology for the -selective arylation of styrenes with 
acetanilides, studies to expand the methodology to include more varied substrates began. To this end, 
several viable heteroaromatic coupling partners were exposed to the Ir(I)-catalysed conditions with 
styrene. When pyrrole 126a was subjected to optimised conditions (Table 32, entry 9) no reaction 
occurred. However, when pyrrole 126a was exposed to alternative (S,S)-f-binaphane ligand (see Section 
2.2.3, Table 3), under the conditions developed for styrene hydroarylation with pyrrole 126a (Section 
3.2.1, Table 11), C−H alkenylation product 128aa’ was generated in 74% yield and with high selectivity 
over branched side-product 127aa’ (Table 36). This result indicates that ligand choice can manipulate 
the delicate balance between reductive elimination and -hydride elimination pathways (see Scheme 
78b). A brief scope study of this protocol was conducted (Table 36). Notably, decreasing the size of the 
directing group (126b vs 126c) resulted in an improvement in selectivity for arylation product 128ba’ 




over hydroarylation side-product 127ba’, albeit in diminished yield (29%). This suggests that when 
utilising (S,S)-f-binaphane as the ligand, C−H reductive elimination is more facile with sterically 
demanding substituents on the directing group (see Scheme 78b, III to 104aa’). The procedure tolerates 
electronically diverse styrenes with substitution in the para- and meta-positions, affording products 
128ap’, 128an’, 128ak’ and 128as’ in moderate to good yields (25–72%). Aliphatic alkenes were less 
efficient; however, unlike acetanilide derivatives, alkenylated pyrrole 128ac’ was generated in a low 
yield (14% by 1H NMR analysis of crude material). For pyrrole 126e, which is arylated at C3, C−H 
alkenylation occurred with complete selectivity for the less hindered position (C5 over C2), giving 
128ea’ in a 50% yield. N-Methyl-pyrrole 150, equipped with a directing group at C3, gave alkenylation 
product 205a’ in 59% yield, although it was generated with poor regioselectivity, with alkenylation 
occurring in both the C2- and C4-positions (1:1.7). All other heteroaromatics trialled (e.g. 126f, 150b, 
150c, 134a, 131 and 145) were unreactive under the Ir(I)-catalysed conditions. 
 
Table 36: Extension of the C−H alkenylation process to pyrrole substrates. aThe reaction was run for 48 h; bYield 
determined by 1H NMR analysis of crude material against an internal standard. 




5.7 − Studies into the Mechanism  
Methodology for Ir(I)-catalysed -arylation of styrenes has been developed. To gain insight into 
the mechanistic cycle and to potentially develop a more versatile protocol, hydroarylation product VII 
was subjected to the C−H alkenylation conditions to monitor if dehydrogenation of VII occurred to 
generate product VIII. No conversion to alkene VIII was observed (Scheme 89a), supporting the 
proposal that VIII is generated via a carbometallation pathway (IV to VI to VII, rather than by 
dehydrogenation of VII). To evaluate the proposed mechanism further, the arylation of deuterio-91k’ 
with acetanilide 60aa was conducted (Scheme 89b). 1H- and 2H NMR analysis of deuterio-104aak’ 
disclosed deuterium incorporation at the terminal position of the alkene (0.88 D, 44% deuteration) and 
the remaining ortho-position (0.30 D, 30% deuteration). This result is consistent with reversible 
migratory insertion of deuterio-91k’ into the ortho Ir(I)−H bond (IV to V). Subsequent -hydride or -
deuteride elimination from V then occurs, where the latter forms an Ir−D species which in turn can 
undergo reversible oxidative addition into 60aa and deuterio-91k’. Additionally, deuterium 
incorporation was observed at the methyl of the directing group (0.57 D, 19% deuteration), suggesting 
that Ir(I) can also promote enol tautomerisation. Deuterium incorporation in both ortho-positions of 
deuterio-60aa (0.52 D, 26% deuteration) and the -position of alkene deuterio-91k’ (0.43 D, 43% 
deuteration) also support reversible hydrometallation. Accordingly, with this ligand system, branched 
hydroarylation side-product VII, forms by C−C reductive elimination from V or C−H reductive 
elimination from VI. 





Scheme 89: Proposed mechanistic cycle and deuterium labelling study. 
5.8 − Summary and Conclusions 
The design and synthesis of ferrocene-based bisphosphine ligand L-20c allowed efficient -
arylation of styrenes via dual C−H functionalisation. This protocol offers a regioselective alternative to 
the classical Pd(II)-catalysed Fujiwara-Moritani reaction and tolerates a wide range of electronically 
diverse acetanilides and styrene coupling partners (Scheme 90a). The -arylation products are 
synthetically useful and can undergo facile transformation to a range of diverse and interesting N-
containing heteroaromatics (Scheme 90b). By employing an alternative ferrocene-based bisphosphine 
ligand (S,S)-f-binaphane, the protocol was extended to pyrrole derivatives (Scheme 90c). 





Scheme 90: -Arylation of styrenes with acetanilide and pyrrole derivatives. 
Evidence gained through 13C KIE’s demonstrated that a carbometallative pathway was possible 
under Ir(I) catalysed conditions (see Section 4.4). It is proposed that ferrocene-based bisphosphine 
ligand L-20c promotes a carbometallation pathway, followed by -hydride elimination. This is in 
contrast to the reductive elimination pathways proposed for alkene hydroarylation (see Section 4.4). 
Deuterium labelling experiments support reversible C−H oxidative addition and hydrometallation (see 
Scheme 89a) and these results are in line with the original mechanism outlined in Scheme 78b. The 
properties associated with ferrocene-based bisphosphine ligands that promote -hydride elimination 
after carbometallation are currently not fully understood. Further studies are required to gain greater 
insight into the mechanism and to expand the scope of the methodology. 




Chapter 6 − Overall Summary and Conclusions 
The research presented in this thesis has contributed to the development of a ligand-enabled, highly 
enantioselective protocol for branch-selective alkene hydroarylation with acetanilide substrates. An 
extensive screen of commercially available chiral ligands led to a cationic Ir(I)-complex modified with 
bisphosphite ligand (S)-L-15a, as designed by Dr. Simon Grélaud. The Ir(I)/(S)-L-15a system was 
applicable to the hydroarylation of a range of aryl and alkyl substituted alkenes to afford tertiary 
benzylic stereocentres in excellent yields and enantiopurity (Scheme 91a). Development of ferrocene-
based bisphosphonite ligand (R)-L-16a expanded the scope of the hydroarylation reaction to thiophene 
substrates (Scheme 91b). These protocols provide an alternative to traditional cross-coupling reactions 
by circumventing the need for prefunctionalised starting materials. Therefore, an atom and step 
economical approach has been achieved. This work represents the first general and highly 
enantioselective protocol for branch-selective hydroarylation of unactivated aliphatic alkenes.  
Additionally, in Chapter 3, the Ir(I)/(R)-L-16d−f catalysed enantioselective branch-selective 
hydroheteroarylation methodology was expanded to other heteroaromatics (pyrroles, furans), to achieve 
tertiary benzylic stereocentres in excellent yields and with promising levels of enantioselectivity (up to 
95:5 e.r.) (Scheme 91b). Investigations into a chiral ligand which would provide a general protocol for 
enantioselective branch-selective hydroheteroarylation is currently ongoing at Bristol.  
Subsequent studies focused on expanding the Ir(I)/L-15a catalysed methodology to the 
hydroarylation of 1,1-disubstituted alkenes to access highly challenging benzylic all-carbon quaternary 
centres. This strategy allows the hydroarylation of a range of 1,1-disubstituted alkenes with aryl and 
heteroaromatic coupling partners. Studies towards an enantioselective protocol are ongoing; good 
enantioselectivity has been achieved for styrene hydroarylation with a furan substrate using ligand (R)-
L-16f (90:10 e.r.) (Scheme 91c). Deuterium labelling experiments and natural abundance 13C-KIE 
experiments employing the Singleton method have provided evidence for a catalytic cycle in which 
carbometallation is the first irreversible and therefore turnover determining step. This contrasts both the 
non-enantioselective and enantioselective Ir(I)-catalysed hydroarylations of mono-substituted alkenes 
reported at Bristol. A general protocol to access sterically demanding all-carbon quaternary centres via 
hydroarylation of unactivated alkenes is yet to be reported. 
Additionally, the synthesis of ferrocene-based electron-deficient bisphosphine ligand L-20c 
provided access to -arylated styrenes via a dual C−H functionalisation pathway (Scheme 91d). A 
carbometallative pathway, followed by -hydride elimination was invoked to explain the -arylated 
products obtained. This contrasts with the reductive elimination pathways proposed for alkene 
hydroarylation. This protocol is suitable for the hydroarylation of diverse styrenes with a range of 
substituted acetanilides. The products are synthetically useful as demonstrated by their rapid 
transformation to interesting N-containing heteroaromatics. Through re-evaluation of the ligand, this 




protocol was expanded to include pyrrole coupling partners. This strategy offers a regioselective 
alternative to the classical Pd-catalysed Heck and Fujiwara-Moritani reactions to provide challenging 
-arylated styrenes. The properties associated with ferrocene-based bisphosphine ligands that promote 
a -hydride elimination pathway are currently not fully understood. Further studies are required to gain 
greater insight into the mechanism and to expand the scope of the methodology.  
 
Scheme 91: Enantioselective hydroarylation of mono-substituted alkenes and 1,1-difunctionalised alkenes with a 
range of arenes and heteroaromatics and -arylation of styrenes by dual C−H functionalisation 
In summary, the judicious design and synthesis of several bisphosphine ligands has led to Ir(I)-
catalysed methodology for the enantio- and branch-selective alkylation and branch-selective 
alkenylation of a range of aryl and heteroaromatic substrates. The design of new bisphosphine ligands 




has provided access to mechanistic pathways and synthetic products in a step and atom economical 
manner, providing an alternative method to often labour-intensive established cross-coupling reactions.  




Chapter 7 − Experimental 
7.1 − General Experimental Details 
All materials for which a synthetic route is not described or referenced were purchased from 
commercial sources (Acros, Sigma, Alfa Aesar, Fluorochem, Strem and TCI). All reagents requiring 
purification were purified using standard laboratory techniques according to methods published by 
Perrin, Armarego, and Perrin (Pergamon Press, 1966). Catalytic reactions were carried out in Young-
type re-sealable tubes. Liquid styrene derivatives were distilled using a Hickman distilling head before 
use. All other commercially available alkenes were used as received without any further purification. 
Anhydrous solvents were obtained by distillation using standard procedures or by passage through 
drying columns supplied by Anhydrous Engineering Ltd. Anhydrous 1,4-dioxane was purchased as 
anhydrous grade and stored over activated 4Å molecular sieves prior to use. All reactions were 
performed using dry solvents unless stated otherwise. Et3N was distilled over CaH2 and stored over 
activated 4Å molecular sieves under nitrogen. The removal of the solvents in vacuo was achieved 
employing rotary evaporators connected with diaphragm pumps (15 mmHg) or, for high-boiling 
solvents, oil pumps (0.1 mmHg). Materials were then dried on a high-vacuum line prior to analysis. 
Reactions requiring anhydrous conditions were performed under a nitrogen atmosphere, using Schlenk 
techniques and flame/oven-dried equipment. In particular, catalytic reactions were carried out in oven 
dried (minimum 2 hours) or flame dried Young-type re-sealable tubes. Flash column chromatography 
(FCC) was performed using silica gel (Aldrich 40−63 µm, 230−400 mesh). Ligands were purified by 
chromatography on deactivated silica gel (stirred overnight with 10% w/w of Et3N). Thin layer 
chromatography was performed using aluminium backed 60 F254 silica plates. Visualisation was 
achieved by UV fluorescence or a basic KMnO4 solution and heat. Proton nuclear magnetic resonance 
spectra (NMR) were recorded on a JEOL ECS 400, Varian 400-MR, Varian VNMR 500a, Varian 
VNMR 500b or Bruker Advance III HD 500 Cryo. 1H NMR spectra were recorded at 400 MHz or 500 
MHz as stated. 13C NMR spectra were recorded at 100 MHz or 125 MHz as stated. In particular, 13C 
NMR analyses for the determination of KIEs (Singleton method, Chapter 4) were performed using the 
Bruker 500 Cryo instrument exclusively. Chemical shifts (δ) are given in parts per million (ppm). Peaks 
are described as singlets (s), doublets (d), triplets (t), quartets (q), septets (sept), multiplets (m) and 
broad (br.). Coupling constants (J) are quoted to the nearest 0.5 Hz. All assignments of NMR spectra 
were based on 2D NMR data (DEPT135, COSY, HSQC and HMBC and nOe experiments). Where 
compounds were isolated as a mixture of isomers (e.g. rotamers), they are referred as A and B. In situ 
yields were determined by employing 1,3,5-trimethoxybenzene as an internal standard. Mass spectra 
were recorded using a Brüker Daltonics FT-ICR-MS Apex 4e 7.0T FT-MS (ESI+ mode), Shimadzu 
GCMS QP2010+ (EI+ mode), a Bruker Ultraflex II (MALDI), Thermo Scientific Orbitrap Elite (APCI 
mode) and a Waters Synapt G2S (Nanospray). Infrared spectra were recorded on a Perkin Elmer 




Spectrum Two FTIR spectrometer as thin films or solids compressed on a diamond plate. Melting points 
were determined using Reichert melting point apparatus and are uncorrected. Optical rotations were 
measured using a ADP440+ polarimeter at the concentration and temperature stated. Enantiomeric 
excess was determined using an Agilent 1290 Infinity chiral SFC as stated for each compound. 
 
7.2 − General Procedures 
General procedure A: for deuterium exchange experiments 
An oven-dried re-sealable tube, fitted with a magnetic stirrer, was charged with substrate (0.143 mmol, 
100 mol%), [Ir(cod)2]BARF (5 mol%) and dFppb (5.61 mg, 5 mol%). The tube was fitted with a rubber 
septum and purged with nitrogen. Deuterium oxide (77 𝜇 L, 3000 mol%) in 1,4-dioxane (1.5 M 
concentration with respect to substrate) was added and the tube was fitted with a Young’s tap. The 
reaction mixture was then heated to 100−150 °C for 24 h, before being cooled to ambient temperature 
and concentrated in vacuo. Purification of the residue by FCC afforded the corresponding deuterio 
compound. 
General Procedure B: for the synthesis of silver salts 
To a round-bottom flask charged with the relevant substrate (100 mol%) and THF (0.05 M) under 
nitrogen was added Ag2O (50 mol%) and the solution was stirred at ambient temperature overnight. 
The solution was concentrated in vacuo to afford the product. The silver salts were used without further 
purification. 
General Procedure C: for the hydroarylation of styrenes with benzamide and acetanilide 
substrates 
To An oven-dried re-sealable tube, fitted with a magnetic stirrer, was charged with substrate (100 mol%), 
[Ir] (5.0 mol%) and ligand (5.0 mol%). The tube was fitted with a rubber septum and purged with 
nitrogen. Styrene (450 mol%) and anhydrous 1,4-dioxane (1.5 M concentration with respect to substrate) 
were added and the tube was fitted with a Young’s tap. The reaction mixture was then heated at 
100−130 °C for 24 h, before being cooled to ambient temperature and concentrated in vacuo. 
Purification of the residues by FCC afforded the title compounds. 
General Procedure D: for the asymmetric hydroheteroarylation of alkenes with thiophenes 
A flame-dried tube, fitted with a magnetic stirrer, was charged with thiophene substrate (0.1 mmol), 
[Ir(cod)2]OTF (5.0 mol%) and (R)-L-16a (5.0 mol%). The tube was fitted with a rubber septum and 
purged with nitrogen. Styrene derivative (120 mol%) in anhydrous 1,4-dioxane (0.5 M concentration 
with respect to substrate) was added. The tube was fitted with a Young’s tap and heated to 90−100 °C 
for 24 h before being cooled to ambient temperature and concentrated in vacuo. Purification of the 
residues by FCC afforded the pure products. 




General Procedure E: for the protection of pyrroles 
The title compounds was prepared following a literature procedure.230 A round-bottomed flask was 
charged with 4-dimethylaminopyridine (10 mol%), suspended in CH2Cl2 (1.85 M with respect to the 
acetyl chloride), under nitrogen. Pyrrole (135 mol%) and triethylamine (100 mol%) were added 
dropwise. The solution was stirred at ambient temperature for 15 minutes, followed by dropwise 
addition of the acetyl chloride derivative (100 mol%). The resulting solution was stirred overnight. The 
reaction mixture was dissolved in diethyl ether and washed with saturated aq. NaHSO4 solution, aq. 
NaHCO3 and water, before being dried over Na2SO4, filtered and concentrated in vacuo. Purification of 
the residue by FCC afforded the title compounds. 
General Procedure F: for the carbamoyl protection of N-heteroaromatics 
The title compounds were prepared following a modified literature procedure.231 A flame-dried round-
bottom flask was charged with NaH (60% in mineral oil, 120 mol%), suspended in THF (1.2 M) under 
nitrogen. The suspension was cooled to 0 °C and a solution of pyrrole or indole (100 mol%) in THF 
(0.9 M) was added dropwise over 10 minutes. The solution was stirred at 0 °C for 1 h, followed by 
dropwise addition of acetyl chloride derivative (110 mol%) in THF (0.8 M) over 10 minutes. The 
solution was then warmed to ambient temperature and stirred overnight. The reaction was quenched by 
the addition of saturated aq. NH4Cl solution and extracted with CH2Cl2. The organic extracts were 
combined, washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. Purification of 
the residue by FCC afforded the title compounds. 
General Procedure G: for the carbamoyl protection of other heteroaromatics 
The title compounds were prepared following a modified literature procedure.232A flame-dried round-
bottom flask was charged with N,N-diisopropyl carbamoyl chloride (461 mg, 2.82 mmol) and toluene 
(1.5 mL), under nitrogen. A solution of substrate (2.56 mmol), toluene (1.0 mL) and triethylamine 
(0.428 mL, 3.07 mmol) were added dropwise over 10 minutes. The resulting solution was heated to 85 
°C and stirred for 6 h. The solution was warmed to ambient temperature before being quenched with 
aq. HCl solution (5 M, 3.0 mL). The organic phase was separated, dried over Na2SO4 and concentrated 
in vacuo. Purification of the residue by FCC or recrystallisation afforded the title compounds. 
General Procedure H: for the carbamoyl protection of heteroaromatics from acids 
The title compounds were prepared following a modified literature procedure.233 An oven-dried flask 
was charged with the corresponding acid (7.80 mmol) and DMF (2 drops) in CH2Cl2 (15 mL) under 
nitrogen and the solution was cooled to 0 °C. Oxalyl chloride (0.739 mL, 8.74 mmol) was added 
dropwise over 5 minutes and the resulting solution was stirred for 2 h at 0 °C. The solvent was removed 
in vacuo, before the residue was dissolved in CH2Cl2 (15 mL), purged with nitrogen and cooled to 0 °C. 
Diisopropylamine (2.19 mL, 15.6 mmol) was added dropwise over 5 minutes, before the solution was 
warmed to ambient temperature and stirred overnight. The reaction mixture was quenched with aq. HCl 




(1 M, 20 mL) and extracted with CH2Cl2 (3 × 20 mL). The organic extracts were combined, washed 
with saturated aq. NaOH (10 mL) and brine (5 mL), dried over Na2SO4 and concentrated in vacuo. 
Purification of the residue by FCC afforded the title compounds. 
General Procedure I: for the hydroarylation of styrene with heteroaromatics 
A flame-dried tube, fitted with a magnetic stirrer, was charged with substrate (0.143 mmol), 
[Ir(cod)2]OTf (5.0 mol%) and dFppb (5.0 mol%). The tube was fitted with a rubber septum and purged 
with nitrogen. Styrene derivative (450 mol%) in anhydrous 1,4-dioxane (1.5 M concentration with 
respect to substrate) was added and the tube was fitted with a Young’s tap. The reaction mixture was 
then heated to 120 °C for 24 h before being cooled to ambient temperature and concentrated in vacuo. 
Purification of the residues by FCC afforded the title compounds. 
General Procedure J: for the asymmetric hydroarylation of pyrroles 
A flame-dried tube, fitted with a magnetic stirrer, was charged with substrate (0.143 mmol), 
[Ir(cod)2]OTf (7.5 mol%) and (R)-L-16c or (R)-L-16f (7.5 mol%). The tube was fitted with a rubber 
septum and purged with nitrogen. Styrene derivative (450 mol%) in anhydrous MeCN (1.5 M 
concentration with respect to substrate) was added and the tube was fitted with a Young’s tap. The 
reaction mixture was then heated to 130 °C for 48 h before being cooled to ambient temperature and 
concentrated in vacuo. Purification of the residues by FCC afforded the title compounds. 
General Procedure K: for the asymmetric hydroarylation of furans 
A flame-dried tube, fitted with a magnetic stirrer, was charged with substrate (0.1 mmol), 
[Ir(cod)2]BARF (5.0 mol%) and (R)-L-16a or (R)-L-16d (5.0 mol%). The tube was fitted with a rubber 
septum and purged with nitrogen. Alkene derivative (400 mol%) in anhydrous 1,2-DCB (0.5 M 
concentration with respect to substrate) was added and the tube was fitted with a Young’s tap. The 
reaction mixture was then heated to 90 °C for 48 h before being cooled to ambient temperature and 
concentrated in vacuo. Purification of the residues by FCC afforded the title compounds. 
General Procedure L: for the asymmetric hydroarylation of alternative furans 
A flame-dried tube, fitted with a magnetic stirrer, was charged with 139 (0.143 mmol), [Ir(cod)2]BARF 
(5.0 mol%) and (R)-L-16c (5.0 mol%). The tube was fitted with a rubber septum and purged with 
nitrogen. Styrene (400 mol%) in anhydrous 1,4-dioxane (1.0 M concentration with respect to substrate) 
was added and the tube was fitted with a Young’s tap. The reaction mixture was then heated to 
100−120 °C for 24−48 h before being cooled to ambient temperature and concentrated in vacuo. 
Purification of the residues by FCC afforded the title compounds. 
 
 




General Procedure M: for the preparation of -methyl styrene substrates 
To a flame-dried flask was added methyltriphenylphosphonium bromide (120 mol%) in anhydrous THF 
(0.5 M) under nitrogen and the solution was cooled to 0 °C. Potassium tert-butoxide (120 mol%) was 
added portion-wise and the resulting solution was stirred at 0 °C for 1–2 h. The relative ketone was 
added dropwise and after stirring for 20 mins at 0 °C the solution was warmed to ambient temperature 
and stirred overnight. The solution was filtered with hexane and concentrated in vacuo to provide the 
crude product. Purification by FCC afforded the pure styrene. 
General Procedure N: for the preparation of amide substrates from acyl chlorides 
To a flame-dried flask was added acyl chloride (100 mol%) in dry CH2Cl2 (0.5 M) under nitrogen. The 
solution was cooled to 0 °C, before the dropwise addition of diethylamine (400 mol%). The reaction 
was warmed to ambient temperature and stirred overnight. The solution was washed with aq. HCl (2 M, 
2 × 10 mL) and aq. NaHCO3 (2 × 10 mL), dried over Na2SO4 and concentrated in vacuo to provide the 
crude product. Purification of the residue by FCC afforded the pure amide. 
General Procedure O: for the preparation of amide substrates from carboxylic acids 
To a flame dried Schlenk tube was added carboxylic acid (100 mol%) in dry CH2Cl2 (0.8 M), under 
nitrogen. Thionyl chloride (240 mol%) was added and the tube was sealed and heated to reflux for 1 h. 
The resulting solution was cooled to ambient temperature and concentrated in vacuo. The residue was 
dissolved in dry CH2Cl2 (0.5 M) and cooled to 0 °C, before the dropwise addition of diethylamine (400 
mol%). The reaction was warmed to ambient temperature and stirred overnight. The solution was 
washed with aq. HCl (2 M, 2 × 10 mL), aq. NaHCO3 (2 × 10 mL), dried over Na2SO4 and concentrated 
in vacuo to provide the crude product. Purification of the residue by FCC afforded the pure amide. 
General Procedure P: for the formation of quaternary centres on benzamide substrates 
A flame-dried tube, fitted with a magnetic stirrer, was charged with substrate (0.1 mmol), 
[Ir(cod)2]BARF (5.0 mol%) and (rac)-L-15f (5.0 mol%). The tube was taken into a glove box where 
styrene (400 mol%) and anhydrous 1,4-dioxane (1.0 M concentration with respect to substrate) was 
added. The tube was fitted with a Young’s tap and removed from the glove box. The reaction mixture 
was then heated to 120 °C for 72 h before being cooled to ambient temperature and concentrated in 
vacuo. Purification of the residues by FCC afforded the pure products. 
General Procedure Q: for the formation of quaternary centres on 5-membered heteroaromatics 
A flame-dried tube, fitted with a magnetic stirrer, was charged with substrate (0.1 mmol), 
[Ir(cod)2]BARF (5.0 mol%) and (rac)-L-15a (5.0 mol%). The tube was fitted with a rubber septum and 
purged with nitrogen. Styrene derivative (150−400 mol%) in anhydrous 1,4-dioxane (1.0 M 
concentration with respect to substrate) was added. The tube was fitted with a Young’s tap and the 
reaction mixture was heated to 120 °C for 16−48 h before being cooled to ambient temperature and 
concentrated in vacuo. Purification of the residues by FCC afforded the pure products. 




General Procedure R: for the preparation of ligands L-20a–L-20d 
An oven-dried multi-neck flask fitted with a condenser was charged with Mg turnings (500 mol%) and 
purged with nitrogen. One iodine bead was added, and the solids were suspended in dry Et2O (4.50 
mL/mmol of Mg). To activate the magnesium, the solution was heated to reflux with a heatgun. Once 
cooled to ambient temperature, the fluorinated aryl bromide (600 mol%) was added via syringe and the 
solution was heated at reflux for 1 h. The solution was cooled to ambient temperature, before 1,1’-
bis(dichlorophosphino)ferrocene (100 mol%) dissolved in dry Et2O (6.00 mL/mmol of 1,1’-
bis(dichlorophosphino)ferrocene) was added dropwise. The solution was stirred overnight. Unreacted 
Grignard reagent was quenched by the addition of water (15 mL/mmol). The resulting solution was 
extracted with CH2Cl2 (3 × 25 mL/mmol). The organic extracts were combined, dried over Na2SO4 and 
concentrated in vacuo. The resulting oil was dissolved in CH2Cl2 and filtered through Celite® to afford 
the crude product as an orange oil. Purification by FCC (hexane/EtOAc 0−5%) followed by 
recrystallisation with cyclohexane afforded the title compounds. 
General Procedure S: for the preparation of alkene substrates 
The title compounds were prepared following a modified literature procedure.234 A resealable tube was 
charged with the corresponding bromo-reagent (2.40 mmol), vinyl boronic acid pinacol ester (0.448 
mL, 2.64 mmol), Pd(OAc)2 (21.6 mg, 0.096 mmol), SPhos (78.8 mg, 0.192 mmol) and K3PO4 (1.53 g, 
7.21 mmol). The tube was purged with nitrogen before the addition of 1,4-dioxane (9.60 mL) and water 
(0.216 mL). The reaction tube was sealed and heated to 80 °C for 2 h. The resulting solution was filtered 
through celite® with EtOAc, before washing with H2O (20 mL) and brine (20 mL). The organic extracts 
were combined, dried over Na2SO4, filtered and concentrated in vacuo. Purification of the residues by 
FCC afforded the title compounds. 
General Procedure T: for the preparation of acetanilide substrates 
The title compounds were synthesised following a modified literature procedure.235 To an ice-cooled 
solution of aniline (100 mol%), EtOAc (0.6 M with respect to substrate), and triethylamine (105 mol%), 
was added acid chloride (105 mol%) dropwise. The reaction was warmed to ambient temperature and 
stirred overnight. The resulting mixture was dissolved in EtOAc, before being washed with water and 
brine, dried over Na2SO4 and concentrated in vacuo. Purification of the residue by FCC or 
recrystallisation afforded pure acetanilide. 
General Procedure U: for the branch-selective -arylation of styrenes with acetanilide 
substrates 
An oven-dried re-sealable tube, fitted with a magnetic stirrer, was charged with substrate (100 mol%), 
[Ir(cod)2]OTf (7.5−10 mol%) and L-20c (7.5−10 mol%). The tube was fitted with a rubber septum and 
purged with nitrogen. Styrene derivative (450 mol%) and t-butylethylene (200 mol%) in anhydrous 1,4-
dioxane (0.5−1.0 M concentration with respect to substrate) were added and the tube was fitted with a 




Young’s tap. The reaction mixture was then heated at 130 °C for 72−96 h, before being cooled to 
ambient temperature and concentrated in vacuo. Purification of the residues by FCC afforded the title 
compounds. The alkenylation and hydroarylation products were easily separated by FCC. In some cases 
a second column was performed to remove an impurity associated with degradation of the ligand. 
General Procedure V: for the synthesis of quinolines  
The title compounds were prepared by a modified literature procedure.227 A 3-necked, oven-dried flask, 
fitted with a condensor was charged with the corresponding alkene (100 mol%) and purged with 
nitrogen. MeCN (0.03 M with respect to alkene) and POCl3 (1000 mol%) were added and the solution 
was heated at reflux and stirred overnight. The reaction was cooled to ambient temperature and diluted 
with water (2.0 mL). Aq. 1 M NaOH solution was added until pH 8 was reached and the resulting 
solution was extracted with EtOAc (3 × 5 mL). The organic extracts were combined, dried over Na2SO4 
and concentrated in vacuo. Purification of the residues by FCC afforded the title compounds. 
General Procedure W: for branch-selective Heck-like reaction on pyrrole substrates 
An oven-dried re-sealable tube, fitted with a magnetic stirrer, was charged with pyrrole substrate (0.1 
mmol), [Ir(cod)2]OTf (7.5−10 mol%) and (S,S)-f-Binaphane (7.5−10 mol%). The tube was fitted with 
a rubber septum and purged with nitrogen. Styrene derivative (400 mol%) in anhydrous MeCN (1.5 M 
concentration with respect to substrate) was added and the tube was fitted with a Young’s tap. The 
reaction mixture was then heated at 130 °C for 48−72 h, before being cooled to ambient temperature 















7.3 – Synthesis of Ir(I)-complexes 
NaBARF 
To a flame dried 3-neck round-bottom flask fitted with a condenser and dropping-funnel was added 
NaBF4 (1.50 g, 13.7 mmol), Mg (2.20 g, 88.8 mmol), 1 iodine crystal and Et2O (320 mL) under nitrogen. 
The solution was heated to reflux with a heat gun for 1 minute. The mixture was warmed to ambient 
temperature and 3,5-trifluoromethylbromobenzene (13.2 mL, 76.5 mmol) in Et2O (100 mL) was added 
dropwise and then heated at reflux for 30 minutes. The reaction mixture was cooled to ambient 
temperature and aq. Na2CO3 (0.7 M, 430 mL) was added slowly. The resulting solution was stirred for 
an additional 30 minutes. The mixture was then filtered, and the filtrate was extracted with Et2O (2 × 
200 mL). The organic extracts were combined, dried over Na2SO4 and concentrated in vacuo to afford 
the title compound (12.6 g, quantitative) as a light brown powder. 1H NMR (400 MHz, Acetone-d6): δ 
7.88 – 7.76 (8H, m), 7.68 (4H, s). The material was used in the next reaction without further purification. 
Bis(cyclooctadiene)iridium(I) tetrakis(3,5-bis(trifluoromethyl)phenyl) borate ([Ir(cod)2]BARF) 
The title compound was prepared following a literature procedure.116 To a solution of chloro(1,5-
cyclooctadiene)iridium (I) dimer (110 mg, 0.163 mmol) and NaBARF (300 mg, 0.339 mmol) in CH2Cl2 
(5 mL) was added 1,5-cyclooctadiene (0.375 mL, 3.06 mmol). The reaction mixture was stirred at 
ambient temperature for 2 hours and then filtered through Celite®. The solution was concentrated in 
vacuo and the residue was dried under vacuum (0.01 mmHg) to afford the title compound (406 mg, 
94%) as a black solid. 1H NMR (400 MHz, CDCl3): δ 7.70 (8H, s), 7.54 (4H, s), 4.99 (8H, s), 2.40 (8H, 
m), 2.25 (8H, m); 19F NMR (377 MHz, CDCl3): -62.2; 13C NMR (101 MHz, CDCl3): 161.8 (1:1:1:1 
pattern, 1 JB-C = 50.0 Hz), 134.9, 129.1 (qq, 2 JF-C = 32.0 Hz,4JF-C = 5.5 Hz), 124.7 (q, 1JF-C = 272.5 Hz), 
117.7, 101.2, 30.5; 19F NMR (377 MHz, CDCl3): -62.2. The spectroscopic proprieties for this compound 
were consistent with the data available in the literature.116 
Ir(cod)2OTF was synthesised by Dr. Giacomo Crisenza. [Ir(cod)2]BF6 and [Ir(cod)2]PF6 were 












7.4 − Experimental Procedures and Data for the Studies in Chapter 2 
7.4.1 − Substrate Synthesis 
60a, 60c, 90d, 91a, 101 and 103 were purchased from commercial sources (Sigma) 
2-Ethyl-3,4-dihydroisoquinolin-1(2H)-one (98) 
 
The title compound was prepared following a literature procedure.236 To a stirred suspension of NaH 
(60% in mineral oil, 377 mg, 9.43 mmol) in dry DMF (1.30 mL) was added a solution of 3,4-
dihydroisoquinolin-1-(2H)-one (555 mg, 3.77 mmol) in dry DMF (3.80 mL) dropwise, followed by 
iodoethane (0.600 mL, 7.55 mmol). The resulting mixture was heated to 80 °C and stirred for 1 h. The 
reaction was cooled to 0 °C and quenched with water (10 mL), followed by extraction with diethyl ether 
(3 × 10 mL). The organic extracts were combined, washed with water (10 mL), brine (10 mL), dried 
over Na2SO4 and concentrated in vacuo. Purification of the residue by FCC (hexane/EtOAc 40%) 
afforded the title compound (565 mg, 85%) as a yellow oil. vmax/cm
-1: 2974 (m), 2929 (m), 1639 
(m), 1481 (s); 1H NMR (400 MHz, CDCl3): δ 8.08 (1H, dd, J = 7.5, 1.5 Hz, C5-H), 7.40 (1H, ddd, J = 
7.5, 1.5, 1.5 Hz, C7-H), 7.33 (1H, ddd, J = 7.5, 1.5, 1.5 Hz, C6-H), 7.16 (1H, d, J = 7.5 Hz, C8-H), 3.63 
(2H, q, J = 7.5 Hz, C2-H2), 3.55 (2H, t, J = 6.5 Hz, C11-H2), 2.99 (2H, t, J = 6.5 Hz, C10-H2). 1.22 (3H 
t, J = 7.5 Hz, C1-H3); 13C NMR (101 MHz, CDCl3): δ 164.2 (C3), 138.1 (C9), 131.6 (C7), 129.9 (C4), 
128.3 (C5), 127.1 (C6), 126.9 (C8), 45.6 (C11), 42.3 (C2), 28.4 (C10), 12.9 (C1); HRMS: (ESI+) 
calculated for C11H14NO 176.1070. Found [M+H]+ 176.1074. 
3-(N,N-Diethylcarbamoyl)pyridine 1-oxide (100) 
 
The title compound was prepared following a literature procedure.237 A flame-dried round-bottom flask 
was charged with N,N-diethylnicotinamide (0.377 mL, 2.24 mmol) and purged with nitrogen. MeCN 
(4 mL) and urea hydrogen peroxide (444 mg, 4.70 mmol) were added, followed by the dropwise 
addition of trifluoroacetic anhydride (0.623 mL, 4.48 mmol) at 0 °C. The reaction mixture was warmed 
to ambient temperature and stirred for 4.5 hours. The reaction was quenched by the addition of saturated 
aq. sodium thiosulfate solution (4 mL) which resulted in the formation of a yellow precipitate. Aq. HCl 
solution (0.5 M, 8 mL) was then added to the stirred solution, which was then extracted with CH2Cl2 (4 
× 20 mL). The organic extracts were combined, washed with saturated aq. NaHCO3, dried over Na2SO4, 
filtered and concentrated in vacuo. Purification of the residue by FCC (EtOAc/MeOH 20%) afforded 




the title compound (255 mg, 59%) as a yellow powder. vmax/cm-1: 2875 (m), 1633 (s), 1434 (m), 1295 
(m), 1254 (m), 1014 (m); 1H NMR (400 MHz, CDCl3): δ 8.22 − 8.20 (2H, m), 7.31 (1H, m), 7.24 (1H, 
ddd, J = 8.0, 1.0, 1,0 Hz), 3.53 (2H, m), 3.27 (2H, m), 1.30 − 1.10 (6H, m); 13C NMR (126 MHz, CDCl3): 
δ 165.6, 139.6, 137.29, 136.4, 126.2, 123.6, 43.5, 39.9, 14.5, 12.9; m.p. 55−57 °C (CDCl3) (Lit.238 62–
63 °C, EtOAc). The spectroscopic proprieties for this compound were consistent with the data available 
in the literature.239  
N,N-Diethyl-4-methylbenzenesulfonamide (102) 
 
The title compounds were prepared following a literature procedure.240 A flame-dried round-bottom 
flask was charged with p-toluene sulfonyl chloride (1.00 g, 5.25 mmol) and purged with nitrogen. 
CH2Cl2 (15 mL) and trimethylamine (1.5 mL, 10.5 mmol) were added and the solution was cooled to 0 
℃. HNEt2 (1.10 mL, 10.5 mmol) was added dropwise with vigorous stirring. The solution was stirred 
at 0 ℃ for 1 h before being warmed to ambient temperature and stirred over night. The reaction was 
quenched by the addition of aq. HCl solution (2 M, 12 mL). The organic layer was separated, washed 
with aq. saturated NaHCO3 solution (30 mL), dried over Na2SO4, filtered and concentrated in vacuo. 
Purification of the residue by recrystallisation (hexane/EtOAc) afforded the title compound (0.70 g, 
59%) as colourless needles. 1H NMR (400 MHz, CDCl3): δ 7.68 (2H, d, J = 8.0 Hz), 7.27 (2H, d, J = 
8.0 Hz), 3.21 (4H, q, J = 7.0 Hz), 2.40 (3H, s), 1.11 (6H, t, J = 7.0 Hz); 13C NMR (101 MHz, CDCl3): 
δ 143.0, 137.5, 129.7, 127.1, 42.1, 21.6, 14.3, m.p. 57−58 °C (CDCl3) (Lit.241 55–57 °C, no 
recrystallisation solvent specified). The spectroscopic proprieties of this compound were consistent 
with the data available in the literature.242 
N-(Thiophen-3-yl)isobutyramide (114a) 
 
To a resealable tube was added isobutyramide (448 mg, 5.15 mmol), CuI (82.0 mg, 0.430 mmol) and 
K2CO3 (2.55 g 18.45 mmol) under nitrogen. 1,4-Dioxane (12 mL) was added followed by 3-
bromothiophene (402 µL, 4.29 mmol) and diamine ligand (68.0 µL, 0.430 mmol). The tube was sealed 
and heated at 110 °C for 18 h. After cooling to ambient temperature, the reaction mixture was filtered 
through a pad of Celite® and concentrated in vacuo. Purification of the residue by FCC (hexane/EtOAc 
30%) afforded the title compound (648 mg, 89%) as a colourless solid. vmax/cm-1: 3285 (s), 3099 (m), 
2970 (s), 1657 (s), 1537 (s); 1H NMR (400 MHz, CDCl3): δ 7.58 (1H, ddd, J = 3.0, 1.5, 1.5 Hz, C7-H), 




7.54 (1H, s, N-H), 7.21 (1H, ddd, J = 5.0, 3.0, 1.5 Hz, C6-H), 6.99 (1H, ddd, J = 5.0, 1.5, 1.5 Hz, C5-
H), 2.50 (1H, heptd, J = 7.0, 1.5 Hz, C2-H), 1.25 (6H, m, C1-H3); 13C NMR (101 MHz, CDCl3): δ 174.6 
(C3), 135.8 (C4), 124.6 (C6), 121.1 (C5), 110.2 (C7), 36.3 (C2), 19.8 (C1); HRMS: (ESI+) calculated 
for C8H12NOS 170.0634. Found [M+H]+ 170.0631. m.p. 137–139 °C. 
 





General procedure A: The reaction was run at 100 °C. Purification of the residue by FCC 
(hexane/EtOAc 70%) afforded deuterio-98 as white crystals. 1H NMR (400 MHz, CDCl3): δ 8.11 – 
8.03 (0.07H, m, C10-H), 7.39 (1H, t, J = 7.5 Hz, C8-H), 7.32 (1H, d, J = 7.5 Hz, C9-H), 7.15 (1H, dd, 
J = 7.5, 1.5 Hz, C7-H), 3.62 (1.70H, q, J = 7.0 Hz, C2-H2), 3.54 (2H, t, J = 6.5 Hz, C4-H2), 2.98 (2H, 
t, J = 6.5 Hz, C5-H2), 1.21 (3H, t, J = 7.0 Hz, C1-H3); 2H NMR (61 MHz, CHCl3): δ 8.32 – 7.88 (0.93D, 
m, C10-H), 3.79 – 3.41 (0.30D, m, C2-H2). Deuterium incorporation was calculated by integration of 
both 1H NMR and 2D NMR signals. 
deuterio-100 
 
General Procedure A: The reaction was run at 120 °C. Purification of the residue by FCC 
(hexane/EtOAc 0−15%) afforded deuterio-100 as a yellow powder. 1H NMR (400 MHz, CDCl3): δ 
8.22-8.20 (2H, m), 7.31 (1H, m), 7.24 (1H, dt, J = 8.0, 1.0 Hz), 3.53 (2H, d, J = 8.0 Hz), 3.27 (2H, d, J 
= 8.0 Hz), 1.30 − 1.10 (6H, m). No deuterium incorporation was observed by 1H or 2D NMR analysis. 
deuterio-101 
 
General Procedure A: The reaction was run at 150 °C. Purification of the residue by FCC 
(hexane/EtOAc 30%) afforded deuterio-101 as a colourless oil. 1H NMR (400 MHz, CDCl3): δ 8.27 – 
8.18 (1.8H, m), 7.65 (1H, m), 7.57 – 7.48 (2H, m), 7.48 – 7.40 (2H, m), 7.30 (1H, m), 7.25 – 7.16 (2H, 
m); 2H NMR (500 MHz, CHCl3): δ 8.25 (0.2D, s). Deuterium incorporation was calculated by 
integration of both 1H and 2D NMR signals. 






General Procedure A: The reaction was run at 100 °C. Purification of the residue by FCC 
(hexane/EtOAc 50%) afforded deuterio-102 as colourless needles. 1H NMR (400 MHz, CDCl3): δ 7.67 
(1.90H, d, J = 8.0 Hz), 7.27 (2H, d, J = 8.0 Hz), 3.20 (4H, q, J = 7.0 Hz), 2.40 (3H, s), 1.10 (6H, t, J = 
7.0 Hz); 2H NMR (500 MHz, CHCl3): δ 7.70 (0.10D, s). Deuterium incorporation was calculated by 
integration of both 1H and 2D NMR signals. 
deuterio-103 
 
General Procedure A: The reaction was run at 120 °C. Purification of the residue by FCC 
(hexane/EtOAc 30%) afforded deuterio-103 as a yellow liquid. 1H NMR (400 MHz, CDCl3): δ 8.70 
(1H, ddd, J = 5.0, 2.0, 2.0 Hz,), 8.00 (0.10H, m), 7.79 – 7.69 (2H, m), 7.51 – 7.45 (2H, m), 7.42 (1H, 
m), 7.23 (1H, ddd, J = 7.0, 5.0, 2.0 Hz); 2H NMR (500 MHz, CHCl3): δ 8.01 (1.90D, s). Deuterium 
incorporation was calculated by integration of 1H NMR signals. 
 
7.4.3 − Chiral Anions Synthesis 
 (((4R)-4-Oxidodinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin-4-yl)oxy)silver ((R)-Ag-106b) 
 
General Procedure B: The reaction was carried out with (R)-(−)-1,1′-Binaphthyl-2,2′-diyl 
hydrogenphosphate (1.10 g, 3.19 mmol). The title compound (1.01 g, 69%) was afforded as an off-
white solid. 1H NMR (400 MHz, DMSO-d6): δ 8.05 (2H, d, J = 9.0 Hz), 8.02 (2H d, J = 8.0 Hz), 7.47 
– 7.41 (4H, m), 7.30 (2H, ddd, J = 8.0, 7.0, 1.5 Hz), 7.22 (2H, d, J = 9.0 Hz); 13C NMR (101 MHz, 
DMSO-d6): δ 149.9 (d, J = 9.5 Hz), 131.9, 130.4, 129.9, 128.4, 126.1, 126.0, 124.5, 122.4, 121.7; 31P 
NMR (162 MHz, DMSO-D6): δ 6.56; m.p 261−263 °C (Et2O) (Lit.243 261 °C, decaline). The 
spectroscopic proprieties of this compound were consistent with the data available in the literature.243  
 






General Procedure B: The reaction was carried out with trifluoromethanesulfonimide (100 mg, 0.356 
mmol). The title compound (53.3 mg, 38%) was afforded as a black residue; 13C NMR (101 MHz, 
CD3CN): δ 117.4; 19F NMR (377 MHz, CD3CN): δ -80.11. The spectroscopic proprieties of this 
compound were consistent with the data available in the literature.244-245 
(3,3,5,5-Tetraoxido-4H-dinaphtho[2,1-d:1',2'-f][1,3,2]dithiazepin-4-yl)silver ((R)-Ag-108b) 
 
General Procedure B: The reaction was carried out with (R)-1,1'-binaphthyl-2-2’-disulfonimide (50.0 
mg, 0.126 mmol) . The title compound (55.5 mg, 88%) was afforded as a silver solid. vmax/cm-1: 3073 
(m), 2284 (m), 1584 (m), 1294 (s); 1H NMR (400 MHz, CD3CN): δ 8.17 – 8.04 (6H, m, ArCH), 7.58 
(2H, ddd, J = 8.0, 7.0, 1.0 Hz, ArCH), 7.30 (2H, ddd, J = 8.0, 7.0, 1.0 Hz, ArCH), 7.15 (2H, ddd, J = 
8.0, 1.0, 1.0 Hz, ArCH); 13C NMR (101 MHz, CD3CN): δ 140.7, 135.5, 134.3, 133.1, 130.0, 129.5, 
128.7, 128.4, 127.9, 123.9; HRMS: (ESI-) calculated for C20H12NO4S2 394.0213. Found [M]- 394.0210; 
m.p. 287−290 °C (CD3CN). 
 
7.4.4 − Ligand Synthesis 
Commercial ligands were purchased from Strem or Sigma 
DFppb was synthesised by Dr. Giacomo Crisenza 
4-Chlorodinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepine  
   
An oven-dried Schlenk tube fitted with a magnetic stirrer was charged with (R)-1,1’-bi(2-napthol) (2.00 
g, 6.99 mmol). The tube was fitted with a rubber septum and purged with nitrogen. The solid was 
dissolved in dry and degassed toluene (40 mL) and the resulting solution was cooled to –78 °C. Distilled 
PCl3 (0.671 mL, 7.69 mmol) and distilled trimethylamine (1.94 mL, 14.0 mmol) were added dropwise 




to the stirred solution. The resulting mixture was warmed to ambient temperature and stirred overnight. 
The resulting slurry was filtered through an oven-dried glass-fibre filter paper cannula and the salts 
were washed with dry and degassed toluene (3 × 10 mL). The solvent was removed under reduced 
pressure and the crude solid was washed with hexane (3 × 5 mL), filtered and dried under vacuum to 
furnish the title compound (1.43 g, 58%, 0.7:0.3 mixture of 112:113) as an off-white powder. Note: an 
inert atmosphere was maintained at all times; 31P NMR (CDCl3, 162 MHz): 178.9 (112), 14.4 (113). 
The phosphorus NMR data of these compounds were consistent with the data available in the 
literature.246-247 The mixture was used in the next stage of the reaction without further purification. 
1,2-Bis(dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin-4-yloxy)ethane (L-14) 
 
To an oven dried Schlenk tube was added 112/113 (250 mg, 0.510 mmol of 112). The tube was fitted 
with a rubber septum and purged with nitrogen. Dry Et2O (29 mL, freeze-pump-thawed) and ethylene 
glycol (14 µL, 0.260 mmol) was added. To the stirred solution was added distilled NEt3 (0.160 mL, 
1.12 mmol) dropwise at 0 °C. The solution was warmed to ambient temperature and stirred overnight. 
The resulting precipitate was collected by filtration through an oven dried sinter under nitrogen and 
washed with dry Et2O (2 × 5 mL). The solvent was removed in vacuo. Analysis by 31P NMR revealed 
the title product, alongside unassigned impurities. 31P NMR (CDCl3, 162 MHz): 141.5. The phosphorus 
NMR data of the title compound is consistent with the data available in the literature. Note: an inert 
atmosphere was maintained at all times; Purification of the crude product was unsuccessful.248 
4,4'-Dibromo-7,7'-dimethoxy-2,2',3,3'-tetrahydro-1,1'-spirobi[indene] (165) 
 
The title compound was synthesised following a literature procedure.133 A solution of 1,5-bis(2-bromo-
5-methoxyphenyl)pentan-3-one 164133 (5.73 g, 12.57 mmol) and phosphotungstic acid hydrate (5.44 g, 
1.89 mmol) in toluene (75 mL) was heated at 140 °C under Dean-Stark conditions overnight. The 
resulting mixture was filtered through celite® with CHCl3 and concentrated in vacuo. Purification of the 
reside by FCC (hexane/EtOAc 5%) afforded the title compound (6.05 g, 64%) as an off-white solid. 1H 
NMR (400 MHz, CDCl3): δ 7.37 – 7.16 (2H, m), 6.52 (2H, d, J = 8.5 Hz), 3.52 (6H, s), 3.06 (2H, ddd, 




J = 16.0, 9.0, 3.5 Hz), 3.00 – 2.85 (2H, m), 2.37 – 2.26 (2H, m), 2.16 (2H, ddd, J = 12.5, 9.0, 3.5 Hz); 
13C NMR (101 MHz, CDCl3): δ 155.8, 145.0, 138.2, 130.5, 111.0, 110.7, 62.1, 55.5, 38.1, 33.3; m.p. 
155–157 °C (CDCl3) (Lit.133 160–163 °C, no recrystallisation solvent specified). The spectroscopic 
proprieties of this compound were consistent with the data available in the literature.133  
4,4'-Dibromo-2,2',3,3'-tetrahydro-1,1'-spirobi[indene]-7,7'-diol (166) 
 
The title compound was synthesised following a literature procedure.133 To a solution of 4,4'-dibromo-
7,7'-dimethoxy-2,2',3,3'-tetrahydro-1,1'-spirobi[indene] (13.3 g, 30.3 mmol) in CH2Cl2 (120 mL) under 
nitrogen was added BBr3 (73.0 mL, 72.7 mmol, 1 M in CH2Cl2) dropwise at -78 °C. The mixture was 
warmed to ambient temperature and stirred overnight. The mixture was then diluted with CH2Cl2 (145 
mL), cooled to 0 °C and quenched by the slow addition of saturated aq. NaHCO3 (290 mL). The organic 
layer was collected, washed with brine (120 mL), dried over Na2SO4 and concentrated in vacuo to give 
crude 4,4'-dibromo-2,2',3,3'-tetrahydro-1,1'-spirobi[indene]-7,7'-diol (11.4 g, 92%) as a colourless foam. 
This material was used in the next step without further purification. 1H NMR (400 MHz, CDCl3): δ 7.30 
(2H, d, J = 8.5 Hz), 6.75 – 6.48 (2H, m), 4.53 (2H, s), 3.13 – 2.87 (4H, m), 2.46 – 2.13 (4H, m). 13C 
NMR (101 MHz, CDCl3): δ 152.1, 145.6, 132.7, 132.4, 116.7, 111.2, 77.5, 77.2, 76.8, 60.5, 36.9, 32.9; 
m.p. 153–155 °C (hexane) (Lit.249 148–149 °C, hexane). The spectroscopic proprieties of this compound 
were consistent with the data available in the literature.249 
 (R)-4,4'-Dibromo-2,2',3,3'-tetrahydro-1,1'-spirobi[indene]-7,7'-diyl bis((1S,2R,5S)-2-isopropyl-
5- methylcyclohexyl) bis(carbonate) ((R)-168) 
 
The title compound was synthesised following a literature procedure.133 To a solution of NaOH (4.88 
g, 122 mmol) in H2O (82 mL) was added 4,4'-dibromo-2,2',3,3'-tetrahydro1,1'-spirobi[indene]-7,7'-diol 
(11.4 g, 27.8 mmol) and a solution of tetrabutylammonium bromide (4.13 g, 12.8 mmol) in CHCl3 (82 
mL). (1R)-(−)-menthyl chloroformate (17.9 mL, 83.4 mmol) was added dropwise at 0 °C. The reaction 
mixture was warmed to ambient temperature and stirred for 20 minutes, before the phases were 
separated and the aqueous layer was extracted with CH2Cl2 (2 × 50 mL). The organic phases were 




combined, washed with brine (50 mL), dried over Na2SO4, filtered and concentrated in vacuo. 
Purification of the residue by recrystallisation (hexane, hot) afforded the title compound (6.97 g, 36%) 
as a colourless solid. vmax/cm-1: 2954 (m), 2869 (m), 1754 (s), 1462 (s); 1H NMR (400 MHz, CDCl3): δ 
7.36 (2H, d, J = 8.5 Hz, C3-H), 6.93 (2H, d, J = 8.5 Hz, C2-H), 4.33 (2H, ddd, J = 11.0, 11.0, 5.0 Hz, 
C11-H), 3.16 – 2.88 (4H, m, C8-H2), 2.38 – 2.15 (4H, m, C7-H2), 1.94 – 1.81 (2H, m, CH2), 1.67 – 1.60 
(6H, m, CH, CH2), 1.47 – 1.33 (2H, m, C12-H), 1.31 – 1.21 (2H, m, CH), 1.03 – 0.76 (18H, m, C18-
H3, CH2), 0.68 (6H, d, J = 7.0 Hz, C19-H3); 13C NMR (101 MHz, CDCl3): δ 152.5 (C10), 146.9 (C1), 
145.5 (C5), 140.3 (C6), 131.3 (C3), 122.2 (C2), 116.4 (C4), 79.2 (C11), 61.8 C9), 46.7 (CH), 40.4 
(CH2), 37.9 (C7), 34.2 (CH2), 33.0 (C8), 31.4 (C12), 25.8 (CH2), 23.3 (CH2), 22.2 (C18), 20.9 (C18), 
16.3 (C19); HRMS (Nanospray) calculated for C39H51O679Br2 773.2052 Found [M+H]+ 773.2074; m.p. 
101–102 °C (CH2Cl2); [α]24D = + 9.1 (c = 0.52, CH2Cl2). 
(R)-4,4'-Dimesityl-2,2',3,3'-tetrahydro-1,1'-spirobi[indene]-7,7'-diol  
 
To a round-bottom flask fitted with a condenser was added (R)-4,4'-dibromo-2,2',3,3'-tetrahydro-1,1'-
spirobi[indene]-7,7'-diyl bis((1S,2R,5S)-2-isopropyl-5- methylcyclohexyl) bis(carbonate) (2.33 g, 3.00 
mmol), MesB(OH)2 (1.71 g, 10.5 mmol), Pd(PPh3)4 (208 mg, 0.180 mmol), Na2CO3 (1.27 g, 12.0 mmol), 
DME (20 mL), H2O (8 mL) and EtOH (4 mL). The solution was heated at 100 °C for 16 h. The reaction 
mixture was cooled to ambient temperature and filtered through a pad of Celite® with CH2Cl2 and 
concentrated in vacuo. The residue was filtered through a pad of silica (hexane/EtOAc 20%) and 
concentrated in vacuo. The crude product was dissolved in THF/H2O/EtOH (1:1:1, 90 mL) and KOH 
(3.00 g, 53.0 mmol) was added. The solution was heated at reflux for 1 h, before the being concentrated 
in vacuo. The mixture was acidified to pH=1 with aq. HCl (2 M) and extracted with Et2O (3 × 50 mL). 
The organic extracts were combined, washed with brine, dried over Na2SO4 and concentrated in vacuo. 
Purification of the reside by FCC (toluene/EtOAc 2%) afforded the desired products (523 mg, 36%) as 
a colourless solid. vmax/cm-1: 3502 (m), 2938 (m), 2856 (m), 1472 (s), 1276 (s); 1H NMR (400 MHz, 
CDCl3): δ 6.95 (4H, s, C12-H), 6.93 (2H, d, J = 8.0 Hz, C3-H), 6.78 (2H, d, J = 8.0 Hz, C2-H), 4.67 
(2H, br. s, OH) 2.75 – 2.61 (2H, m, C7-H2), 2.62 – 2.50 (2H, m, C7-H2), 2.34 (6H, s, C15-H3), 2.31 – 
2.23 (4H, m, C8-H2), 1.99 (12H, br. s, C14-H3); 13C NMR (126 MHz, CDCl3): δ 152.0 (C1), 144.0 (C6), 
137.1 (ArC), 136.7 (ArC), 136.4 (ArC), 136.0 (ArC), 130.9 (C4), 130.7 (ArC), 130.7 (C3), 128.2 (C12), 
115.1 (C2), 58.5 (C9), 37.7 (C8), 30.7 (C7), 21.2 (C15), 20.6 (C14), 20.5 (C14); HRMS: (MALDI) 




calculated for C35H36O2Na 511.2608. Found [M+Na]+ 511.2617; m.p. 260 °C degradation (toluene); 





The title compound was prepared following a literature procedure.201 Ferrocene (1.86 g, 10.0 mmol) 
was added to a round-bottomed Schlenk flask, purged with nitrogen and dissolved in dry and 
deoxygenated hexane (47 mL). Distilled tetramethylethylenediamine (3.15 mL, 21.0 mmol) was added 
dropwise to the stirred solution over 10 minutes at ambient temperature, followed by n-BuLi (1.60 M 
in hexanes, 13.8 mL, 22.0 mmol). The solution was stirred for 22 h, before the resulting suspension was 
cooled to -78 °C in an acetone/dry ice bath. N,N-Bis(diethylamino)chlorophosphine (4.40 mL, 21.0 
mmol) dissolved in dry and deoxygenated THF (14 mL) was added dropwise to the stirred suspension. 
Once the addition had finished, the mixture was warmed to ambient temperature and stirred for 4 days. 
The reaction mixture was then cooled to -78 °C in an acetone/dry ice bath and treated with a solution 
of HCl in diethyl ether (2.00 M, 80.0 mL, 160 mmol). The solution was warmed to ambient temperature 
and stirred overnight. The resulting salts were filtered off through an oven-dried sinter funnel under a 
flow of nitrogen. The salts were washed with dry hexane (7 × 10 mL) and the filtrate was collected and 
concentrated in vacuo, affording the product (3.28 g, 85%) as an orange powder. Note: an inert 
atmosphere was maintained at all times and the compound was stored in a glovebox. 1H NMR (400 
MHz, CDCl3): δ 4.75 − 4.62 (8H, m); 31P NMR (162 MHz, CDCl3): δ 163.3. The title compound was 
used without further purification. The spectroscopic properties for this compound were consistent with 
the data available in the literature.201  
(R)-L-16a 
 
To a Schlenk tube was added (R)-4,4'-Dimesityl-2,2',3,3'-tetrahydro-1,1'-spirobi[indene]-7,7'-diol (1.20 
g, 2.46 mmol), ferrocene 193 (476 mg, 1.23 mmol), DMAP (30.0 mg, 0.246 mmol) and THF/CH2Cl2 
(2:1, 36 mL) under nitrogen. The solution was cooled to 0 °C and NEt3 (0.823 mL, 5.90 mmol) was 




added dropwise. The solution was warmed to ambient temperature and stirred overnight. The mixture 
was filtered through a pad of Celite® with Et2O and concentrated in vacuo. Purification of the residue 
by FCC (hexane/EtOAc 3%, SiO2 deactivated with 10% of Et3N) to afford the title ligand (1.09 g, 73%) 
as an orange solid. vmax/cm-1: 2946 (m), 2855 (m), 1468 (m), 1219 (m); 1H NMR (500 MHz, CDCl3): δ 
7.10 (2H, d, J = 8.0 Hz, ArCH), 6.98 (2H, d, J = 8.0 Hz, ArCH), 6.88 – 6.85 (4H, m, C14-H), 6.93 − 
6.88 (4H, m, C15-H), 6.53 (2H, d, J = 8.0 Hz, ArCH), 6.13 (2H, d, J = 8.0 Hz, ArCH), 4.68 − 4.63 (2H, 
m, ferrocene), 4.61 − 4.56 (2H, m, ferrocene), 4.36 − 4.31 (2H, m, ferrocene), 3.87 − 3.80 (2H, m, 
ferrocene), 2.71 − 2.57 (4H, m, C9-H2), 2.42 − 2.25 (16H, m, C9-H2, C18-H3), 2.16 − 2.07 (4H, m, C10-
H2), 2.05 − 1.89 (28H, m, C10-H2, C17-H3); 13C NMR (126 MHz, CDCl3): δ 148.7 (ArC), 145.1 (t, J = 
4.9 Hz, C4), 143.6 (ArC), 143.0 (ArC), 142.5 (ArC), 140.8 (ArC), 137.4 (ArC), 137.2 (ArC), 136.7 
(ArC), 136.5 (ArC), 136.2 (ArC), 136.2 (ArC), 136.0 (ArC), 135.5 (ArC), 134.3 (ArC), 133.4 (ArC), 
129.4 (ArCH), 128.2 (ArCH), 128.1 (ArCH), 128.0 (ArCH), 128.0 (ArCH), 122.9 (ArCH), 121.1 
(ArCH), 73.2 (ferrocene), 72.8 (ferrocene), 72.7 (t, J = 4.2 Hz, C1), 71.8 (ferrocene), 71.0 (ferrocene), 
59.7 (C11), 38.3 (C10), 37.8 (C10), 30.2 (C9), 29.7 (C9), 21.2 (C18), 21.2 (C18), 20.7 (C17), 20.7 
(C17), 20.3 (C17); 31P NMR (162 MHz, CDCl3): δ 158.8; HRMS: (Nanospray) calculated for 
C80H76FeO4P2Na [M+Na]+ 1241.4463. Found 1241.4426. 
 
7.4.5 − Hydroarylation Reactions 
2-Ethyl-8-(1-phenylethyl)-3,4-dihydroisoquinolin-1(2H)-one (99a’) 
 
General procedure C: The reaction was carried out with [Ir(cod)2]BARF (5 mol%) and dFppb (5 
mol%). The reaction mixture was heated at 100 °C for 24 h. Purification of the residue by FCC 
(hexane/EtOAc 50−60%) afforded the title compound (4.36 mg, 11%) as a colourless oil. vmax/cm-1: 
2961 (m), 2928 (s) 1639 (s), 1597 (m), 1478 (s); 1H NMR (500 MHz, CDCl3): δ 7.30 – 7.25 (4H, m, 
C15-H, C16-H), 7.24 – 7.20 (1H, m, C8-H), 7.16 – 7.09 (2H, m, C9-H, C17-H), 6.97 (1H, ddd, J = 7.5, 
1.0, 1.0 Hz, C7-H), 5.81 (1H, q, J = 7.0 Hz, C12-H), 3.62 (2H, q, J = 7.0 Hz, C2-H2), 3.54 – 3.41 (2H, 
m, C4-H2), 3.00 – 2.82 (2H, m, C5-H2), 1.63 (3H, d, J = 7.0 Hz, C13-H3), 1.20 (1H, t, J = 7.0 Hz, C1-
H3); 13C NMR (126 MHz, CDCl3): δ 164.5 (C3), 149.5 (C10), 147.2 (C14), 139.5 (C6), 130.7 (C8), 
128.3 (C17), 128.2 (C15), 128.1 (C16), 127.9 (C11), 125.6 (C9), 124.8 (C17), 45.6 (C4), 42.4 (C2), 
38.9 (C12), 30.4 (C5), 22.2 (C13), 13.3 (C1); HRMS: (ESI+) calculated for C19H21NONa 302.1515. 
Found [M+Na]+ 302.1520. 
 






General procedure C: The reaction was carried out with [Ir(cod)2]BARF (5 mol%) and Walphos (SL-
J005-1) (5 mol%). The reaction mixture was heated at 100 °C for 24 h. Purification of the residue by 
FCC (hexane/EtOAc %) afforded the title compound (19.1 mg, 45%, 0.7:0.3 mixture of rotamers 
A:B, >25:1 branched:linear, 71:29 e.r.) as a colourless oil. 1H NMR (CDCl3, 400 MHz): δ 7.39 − 7.03 
(7H, m, A+B), 6.97 – 6.90 (1H, m, A+B), 4.37 (0.7 H, q, J = 7.0 Hz, A), 4.21 (0.3H, q, J = 7.0 Hz, B), 
3.78 (0.3 H, dq, J = 14.0, 7.0 Hz, B), 3.61 (0.7 H, dq, J = 14.0, 7.0 Hz, A), 3.39 (0.3H, dq, J = 14.0, 7.0 
Hz B), 3.34 – 3.10 (1.3H, m, 2A + B), 2.70 (0.7H, dq, J = 14.0, 7.0 Hz, A), 2.35 (0.7H, dq, J = 14.0, 7.0 
Hz, A), 2.30 (2.1H, s, A), 2.29 (0.9H, s, B) 1.60 (3H, d, J = 7.0 Hz, A+B), 1.28 (0.9H, dd, J = 7.0, 7.0 
Hz, B), 1.16 (2.1H, dd, J = 7.0, 7.0 Hz, A), 1.10 (0.9H, dd, J = 7.0, 7.0 Hz, B), 0.83 (2.1H, dd, J = 7.0, 
7.0 Hz, A); 13C NMR (CDCl3, 100 MHz): δ 171.0 (A), 171.0 (B), 146.2 (A), 145.3 (B), 140.4 (B), 139.1 
(A), 137.3 (A), 137.2 (B)135.7 (B), 135.6 (B), 130.5 (B), 129.9 (A), 129.5 (A), 128.4 (B), 127.9 (A), 
127.8 (A), 127.7 (B), 127.3 (A), 126.2 (A), 126.1 (A), 126.0 (B), 43.1 (B), 42.6 (A), 40.8 (A), 40.2 (B), 
38.8 (B), 38.7 (A), 22.9 (A), 21.2 (B), 21.2 (B), 21.0 (A), 14.2 (B), 13.6 (A), 13.0 (B), 12.9 (A). The 
spectroscopic proprieties were consistent with the data available in literature.116 
SFC Conditions: (DAICEL CHIRALPAK-IC column (25 cm), CO2:MeOH 99:1 – 98:2, over 20 mins, 
5 mL/min, 140 bars, 60 °C). Retention times: 22.3 minutes (minor), 27.1 minutes (major), e.r. = 71:29. 
N-(2-(1-Phenylethyl)phenyl)acetamide (96aa’) 
 
General Procedure C: The reaction was carried out with [Ir(cod)2]OTf (5 mol%) and (R)-DM-
SEGPHOS (5.17 mg, 5 mol%). The reaction mixture was heated at 130 °C for 24 h. Purification of the 
residue by FCC (toluene/EtOAc 10%−30%) afforded the title compound (7.2 mg, 21%, 9:1 mixture of 
rotamers A:B, 3.5:1 branched:linear, 76.5:23.5 e.r.) as a colourless oil. 1H NMR (400 MHz, CDCl3): δ 
7.70 (0.9H, d, J = 7.5 Hz, A), 7.43 (0.9H, d, J = 7.5 Hz, A), 7.47 – 6.88 (7.2H, m, A+B), 6.72 (1H, s, 
A+B), 4.36- 4.23 (0.1H, m, B), 4.16 (0.9H, q, J = 7.0 Hz, A), 1.94 (2.7H, s, A), 1.63 (3.3H, d, J = 7.0 
Hz, A+B);13C NMR (101 MHz, CDCl3): δ 168.6, 145.4, 136.6, 135.4, 129.3, 127.4, 127.3, 127.3, 126.9, 
125.6, 125.0, 41.0, 24.1, 21.8. The spectroscopic proprieties of this compound were consistent with the 
data available in the literature.117 




Characteristic signals for the linear regioisomer 97aa’: 1H NMR (400 MHz, CDCl3): δ 2.95 − 2.81 
(4H, m), 1.94 (3H, s). 
SFC Conditions: (DAICEL CHIRALPAK-IC column (25 cm), CO2:MeOH 99:1 – 97:3, 1% every 15 




General procedure C: The reaction was carried out with [Ir(cod)2]OTf (5 mol%) and (S,S)-BDPP (5 
mol%). The reaction mixture was heated at 120 °C for 24 h. Purification of the residue by FCC 
(toluene/EtOAc 10−%) afforded the title compound (25.8 mg, 71%, 0.9:0.1 mixture of rotamers A:B, 
1:1 branched:linear, 62.5:37.5 e.r.) as a colourless solid. 1H NMR (CDCl3, 400 MHz): δ 7.53 (0.9H, s, 
A), 7.42 − 7.10 (6.2H, m, A+B), 7.04 (1H, d, J = 8.0 Hz, A), 6.73 (1H, br. s, A+B), 4.30 − 4.20 (0.1H, 
m, B), 4.13 (0.9H, q, J = 7.0 Hz, A), 2.34 (3H, s, A+B), 1.94 (2.7H, s, A), 1.75 (0.3H, s, B), 1.61 (3H, d, 
J = 7.0 Hz, A+B); 13C NMR (101 MHz, CDCl3, major rotamer signals only): δ 168.3, 145.7, 137.1, 
135.1, 133.7, 129.2, 127.3, 127.3, 126.9, 126.4, 125.6, 40.7, 24.3, 21.9, 21.3; m.p. 116−118 °C 
(hexane/CH2Cl2), (Lit. 117–119 °C, hexane/CH2Cl2). The spectroscopic proprieties of this compound 
were consistent with the data available in the literature.117 
Characteristic signals for the linear regioisomer 97ca’: 1H NMR (400 MHz, CDCl3): δ 2.92 − 2.79 
(4H, m), 2.31 (3H, s), 1.94 (3H, s). 
SFC Conditions: (DAICEL CHIRALPAK-IC column (25 cm), CO2:MeOH 99:1 – 97:3, 1% every 15 
mins, 2 mL/min, 140 bars, 40 °C). Retention times: 43.7 minutes (minor), 46.2 minutes (major), e.r. = 
63:38. 










4-(3-Isobutyramidothiophen-2-yl)pentyl 4-methylbenzenesulfonate (115al’) 
 
General Procedure D: The reaction was run at 90 °C. Purification of the residue by FCC 
(hexane/EtOAc 30−40%) afforded the title compound (33.9 mg, 82% , 92:8 e.r.) as a yellow oil. vmax/cm-
1: 3276 (m), 2965 (m), 1658 (s), 1354 (s), 1174 (s); 1H NMR (400 MHz, CDCl3): δ 7.75 (2H, d, J = 8.5 
Hz, C14-H), 7.34 (2H, d, J = 8.5 Hz, C15-H), 7.29 – 7.23 (1H, m, C5-H), 7.11 (1H, s, N-H), 7.08 (1H, 
d, J = 5.5 Hz, C6-H), 4.04 – 3.95 (2H, m, C12-H2), 3.02 (1H, p, J = 7.0 Hz, C8-H), 2.54 – 2.50 (1H, m, 
C2-H), 2.45 (1H, s, C17-H3), 1.74 – 1.53 (4H, m, C10-H2, C11-H2), 1.31 – 1.11 (9H, m, C1-H3, C9-H3); 
13C NMR (126 MHz, CDCl3): δ 175.5 (C3), 145.0 (C16), 137.5 (C7), 132.9 (C13), 131.0 (C4), 130.0 
(C15) 127.9 (C14), 124.9 (C5), 121.2 (C6), 70.6 (C12), 35.9 (C2), 34.8 (C10), 31.7 (C8), 26.6 (C11), 
23.0 (C9), 21.8 (C17), 19.9 (C1); HRMS: (ESI+) calculated for C20H28NO4S2 410.1454. Found [M+H]+ 
410.1453; [α]22D = - 17.3 (c = 0.20, CH2Cl2). 
SFC Conditions: (DAICEL CHIRALPAK-IE column (25 cm), CO2:MeOH 85:15, 2 mL/min, 140 bars, 
60 °C). Retention times: 13.8 minutes (minor), 15.0 minutes (major), e.r. = 92:8. 
Methyl 4-(3-isobutyramidothiophen-2-yl)pentanoate (115aj’) 
 
General Procedure D: The reaction was run at 100 °C. Purification of the residue by FCC 
(hexane/EtOAc 30−40%) afforded the title compound (8.40 mg, 30%, 96:4 e.r.) as a colourless oil. 
vmax/cm-1: 3289 (m), 2966 (m), 1734 (s), 1659 (s); 1H NMR (400 MHz, CDCl3): δ 8.26 (1H, s, N-H), 
7.55 (1H, d, J = 5.5 Hz, C5-H), 7.09 (1H, d, J = 5.5 Hz, C6-H), 3.72 (3H, s, C13-H3), 3.12 (1H, h, J = 
7.0 Hz, C8-H), 2.66 (1H, hept, J = 7.0 Hz, C2-H), 2.41 (1H, ddd, J = 16.0, 8.0, 4.5 Hz, C11-H2), 2.23 
(1H, ddd, J = 16.0, 8.0, 4.5 Hz, C11-H2), 1.90 – 1.74 (2H, m, C10-H2), 1.33 (3H, d, J = 7.0 Hz, C9-H3), 
1.25 (6H, d, J = 7.0 Hz, C1-H3); 13C NMR (101 MHz, CDCl3): δ 175.5 (C3, C12), 134.3 (C7), 132.3 
(C4), 124.3 (C5), 121.1 (C6), 52.1 (C13), 35.9 (C2), 34.7 (C10), 31.4 (C11), 30.9 (C8), 22.0 (C9), 19.9 




(C1), 19.8 (C1); HRMS: (ESI+) calculated for C14H22NO3S 284.1315. Found [M+H]+ 284.1316; [α]25D 
= + 21.5 (c = 0.20, CH2Cl2). 
SFC Conditions: (DAICEL CHIRALPAK-IB column (25 cm), CO2:MeOH 99:1 to 96:4 over 20 






























7.5 − Experimental Procedures and Data for the Studies in Chapter 3                         
7.5.1 − Substrate Synthesis 
116 was purchased from commercial sources (Sigma). 
91c’, 91d’ and 91h’ were purchased from commercial sources (Sigma, Acros). 
N,N-Diethyl-1-methyl-1H-indole-3-carboxamide (119) 
 
The title compound was prepared following a literature procedure.250 A 50 mL round-bottomed flask 
was charged with N,N-diethyl-1-methyl-1H-indole-3-carboxamide (175 mg, 1.00 mmol), CH2Cl2 (20 
mL) and DMF (50 𝜇L) under nitrogen. Oxalyl chloride (0.254 mL, 3.00 mmol) was added dropwise to 
the stirred solution over ten minutes and the resulting mixture was stirred at ambient temperature for 
1.5 hours, before being heated to reflux for 1 hour. The reaction was cooled to ambient temperature, 
before being concentrated in vacuo. The residue was taken up in CH2Cl2 (20 mL) and cooled to 0 ℃, 
before diethylamine (0.310 mL, 3.00 mmol) was added dropwise. The resulting solution was warmed 
to ambient temperature and stirred overnight. The reaction mixture was washed with aq. HCl solution 
(1 M, 10 mL) and the organic extract was dried over Na2SO4, filtered and concentrated in vacuo. 
Purification of the residue by FCC (CH2Cl2/MeOH 10%) afforded the title compound (182 mg, 79%) 
as an orange oil; vmax/cm-1: 2970 (m), 2932 (m), 1603 (s), 1532 (s), 1243 (s), 1100 (s); 1H NMR (400 
MHz, CDCl3): δ 7.76 (1H, ddd, J = 8.0, 1.0, 1.0 Hz, C6-H), 7.32 (1H, ddd, J = 8.0 Hz, 1.0, 1.0 Hz, C9-
H), 7.30 (1H, s, C11-H), 7.27 (1H, m, C8-H), 7.19 (1H, ddd, J = 8.0, 7.0, 1.0 Hz, C7-H), 3.80 (3H, s, 
C12-H3), 3.58 (4H, q, J = 7.0 Hz, C2-H2), 1.22 (6H, t, J = 7.0 Hz, C1-H3); 13C NMR (101 MHz, CDCl3): 
δ 166.9 (C3), 136.5 (C10), 129.5 (C11), 126.8 (C5), 122.5 (C8), 121.0 (C7), 120.7 (C6), 111.4 (C4), 
109.6 (C9), 41.4 (C2), 33.2 (C12), 14.0 (C1); HRMS: (ESI+) calculated for C14H18N2ONa 253.1311. 
Found [M+Na]+ 253.1316.  
1-Benzoyl-1H-pyrrole (121a) 
 
General Procedure E: The reaction was carried out with benzoyl chloride (0.860 mL, 7.40 mmol). 
Purification of the residue by FCC (hexane/EtOAc 10%) afforded the title compound (927 mg, 73%) 
as an orange oil. 1H NMR (400 MHz, CDCl3): δ 7.77 – 7.73 (2H, m), 7.60 (1H, m), 7.54 – 7.47 (2H, 




m), 7.31 – 7.27 (2H, m), 6.35 (2H, dd, J = 2.5, 2.0 Hz); 13C NMR (101 MHz, CDCl3): δ 167.8, 133.4, 
132.4, 129.6, 128.6, 121.4, 113.3. The spectroscopic proprieties for this compound were consistent with 
the data available in the literature.251 
 (1H-Pyrrol-1-yl)(𝝈-tolyl)methanone (121b) 
  
General Procedure E: The reaction was carried out with 𝜎-toluoylchloride (0.480 mL, 3.70 mmol). 
Purification of the residue by FCC (toluene) afforded the title compound (380 mg, 55%) as a colourless 
oil. vmax/cm-1: 1699 (s), 1465 (s), 1399 (m), 1324 (s), 1309 (s); 1H NMR (400 MHz, CDCl3): δ 7.42 (1H, 
ddd, J = 7.5, 1.5, 1.5 Hz, C3-H), 7.38 (1H, dd, J = 7.5, 1.5 Hz, C2-H), 7.30 (2H, m, C4-H, C5-H), 7.17 
– 7.12 (2H, m, C9-H), 6.35 – 6.28 (2H, m, C10-H), 2.34 (3H, s, C7-H3); 13C NMR (101 MHz, CDCl3): 
δ 168.3 (C8), 136.6 (C1), 133.8 (C6), 131.0 (C4), 130.9 (C3), 127.9 (C2), 125.6 (C5), 120.8 (C9), 113.6 
(C10), 19.5 (C7); HRMS: (ESI+) calculated for C12H11NONa 208.0733. Found [M+Na]+ 208.0736.  
(2,6-Dimethylphenyl)(1H-pyrrol-1-yl)methanone (121c) 
  
General Procedure E: The reaction was carried out with 2,6-dimethylbenzoyl chloride (224 mg, 1.33 
mmol). Purification of the residue by FCC (hexane/EtOAc 20%) afforded the title compound (175 mg, 
73%) as colourless needles. 1H NMR (400 MHz, CDCl3): δ 7.67 (1H, br. s), 7.27 (1H, t, J = 7.5 Hz), 
7.09 (2H, d, J = 7.5 Hz), 6.48 (1H, br. s), 6.39 (1H, br. s), 6.22 (1H, br. s), 2.21 (6H, s); 13C NMR (101 
MHz, CDCl3): δ 168.8, 134.9, 134.7, 129.9, 127.7, 121.2, 118.6, 114.1, 113.8, 19.3; m.p. 61−63 °C 
(CDCl3) (Lit.252 59 °C, no recrystallisation solvent specified). The spectroscopic properties of this 
compound were consistent with the data available in the literature.252  
1-(t-Butylcarbonyl)pyrrole (123) 
 
 General Procedure E: The reaction was carried out with trimethylacetyl chloride (0.911 mL, 7.40 
mmol). Purification of the residue by FCC (hexane/EtOAc 5−10%) afforded the title compound (667 
mg, 60%) as a colourless liquid. vmax/cm-1: 2981 (m), 2936 (m), 1702 (s), 1460 (s); 1H NMR (400 MHz, 




CDCl3): δ 7.46 – 7.42 (2H, m, C4-H), 6.30 – 6.22 (2H, m, C5-H), 1.46 (9H, s, C1-H3); 13C NMR (101 
MHz, CDCl3): δ 176.0 (C3), 120.7 (C4), 112.0 (C5), 40.8 (C2), 28.7 (C1); HRMS: (APCI) calculated 
for C9H13NO 152.1070. Found [M+H]+ 152.1069. 
N,N-Diisopropyl-1H-pyrrole-1-carboxamide (126a) 
  
General Procedure F: The reaction was carried out with diisopropylcarbamic chloride (2.26 g, 0.139 
mol). Purification of the residue by FCC (hexane/EtOAc 20%) afforded the title compound (2.46 g, 
quantitative) as colourless needles. vmax/cm-1: 2971 (m), 2934 (m), 1679 (s), 1430 (s), 1332 (s), 1318 
(s); 1H NMR (400 MHz, CDCl3): δ 7.00 – 6.95 (2H, m, C4-H), 6.24 – 6.19 (2H, m, C5-H), 3.83 (2H, 
hept, J = 6.5 Hz, C2-H), 1.37 (12H, d, J = 6.5 Hz, C1-H); 13C NMR (101 MHz, CDCl3): δ 152.8 (C3), 
120.2 (C4), 110.1 (C5), 48.7 (C2), 21.2 (C1); HRMS: (ESI+) calculated for C11H19N2O 195.1492. Found 
[M+H]+ 195.1492; m.p. 73−75 °C (CDCl3). 
N,N-Diethyl-1H-pyrrole-1-carboxamide (126b) 
 
General Procedure F: The reaction was carried out with diethylcarbamic chloride (0.415 mL, 3.28 
mmol). Purification of the residue by FCC (hexane/EtOAc 30%) afforded the title compound (480 mg, 
97%) as a colourless oil. vmax/cm-1: 2979 (m), 2940 (m), 1675 (s), 1421 (s), 1288 (s); 1H NMR (400 MHz, 
CDCl3): δ 7.02 (2H, dd, J = 2.5, 2.5 Hz, C4-H), 6.23 (2H, dd, J = 2.5, 2.5 Hz, C5-H), 3.44 (4H, q, J = 
7.0 Hz, C2-H2), 1.24 (6H, t, J = 7.0 Hz, C1-H3); 13C NMR (101 MHz, CDCl3): δ 154.4 (C3), 120.4 (C4), 




The title compound was prepared following a literature procedure.253 To a solution of triphosgene (451 
mg, 1.52 mmol) in dry toluene (5 mL) under nitrogen, was added dicyclohexylamine (1.00 mL, 5.02 
mmol) at -5 °C over 5 minutes. After stirring for 1 h the solution warmed to ambient temperature and 




stirred for 24 h. The solids were removed by filtration and washed with toluene (3 ×10 mL). The filtrate 
was concentrated in vacuo to afford the title compound (775 mg, 70%) as a colourless solid which was 




General Procedure F: The reaction was carried out with dicyclohexylcarbamic chloride (400 mg, 1.49 
mmol). Purification of the residue by FCC (hexane/EtOAc 10−20%) afforded the title compound (346 
mg, 85%) as a colourless solid. vmax/cm-1: 2929 (m), 2853 (m), 1676 (s) 1424 (s); 1H NMR (400 MHz, 
CDCl3): δ 7.13 – 6.64 (2H, m, C6-H), 6.59 – 5.94 (2H, m, C7-H), 3.39 – 3.26 (2H, m, C1-H), 2.08 – 
1.93 (4H, m, Cy), 1.86 – 1.57 (10H, m, Cy), 1.36 – 1.06 (6H, m, Cy); 13C NMR (101 MHz, CDCl3): δ 
153.0 (C5), 120.2 (C6), 110.1 (C7), 58.2 (C1), 31.3 (C2), 26.2 (C3), 25.4 (C4); HRMS: (ESI+) 
calculated for C17H27N2O 275.2118. Found [M+H]+ 275.2119; m.p. 96−98 °C (CDCl3). 
N,N-Dimethyl-1H-pyrrole-1-carboxamide (126d) 
 
General Procedure F: The reaction was carried out with dimethylcarbamic chloride (1.51 mL, 16.4 
mmol). Purification of the residue by FCC (hexane/EtOAc 30%) afforded the title compound (1.92 g, 
93%) as colourless needles. 1H NMR (400 MHz, CDCl3): δ 7.04 (2H, dd, J = 3.0, 2.0 Hz), 6.22 (2H, 
dd, J = 3.0, 2.0 Hz), 3.09 (6H, s); 13C NMR (101 MHz, CDCl3): δ 154.9, 120.7, 110.6, 38.7; m.p. 56–
57 °C (CDCl3) (Lit.254 70–72 °C, no recrystallisation solvent specified). The spectroscopic properties 




General procedure G: The reaction was carried out with pyrazole. Purification of the residue by FCC 
(hexane/EtOAc 10%) afforded the title compound (490 mg, 98%) as a colourless oil. vmax/cm
-1: 2974 
(m), 1686 (s), 1438 (s), 1343 (s); 1H NMR (400 MHz, CDCl3): δ 8.03 (1H, dd, J = 3.0, 1.5 Hz, C6-H), 
7.63 – 7.56 (1H, m, C4-H), 6.33 (1H, dd, J = 3.0, 1.5 Hz, C5-H), 4.21 – 4.02 (2H, m, C2-H), 1.38 (12H, 




d, J = 7.0 Hz, C1-H3); 13C NMR (101 MHz, CDCl3): δ 150.7 (C3), 141.1 (C4), 131.4 (C6), 106.7 (C5), 
48.9 (C2), 20.8 (C1); HRMS: (ESI+) calculated for C10H17N3ONa 218.1264. Found [M+Na]+ 218.1265. 
N,N-Diisopropyl-1H-imidazole-1-carboxamide (130)  
  
General procedure G: The reaction was carried out with imidazole. Purification of the residue by 
recrystallisation (hexane/EtOAc 10%) afforded the title compound (409 mg, 82%) as colourless crystals. 
vmax/cm-1: 3115 (m), 2974 (m), 1678 (s) 1433 (s); 1H NMR (400 MHz, CDCl3): δ 7.83 – 7.71 (1H, m, 
C6-H), 7.18 – 7.11 (1H, m, C5-H), 7.08 – 7.03 (1H, m, C4-H), 3.75 (2H, hept, J = 7.0 Hz, C2-H), 1.36 
(12H, d, J = 7.0 Hz, C1-H3); 13C NMR (101 MHz, CDCl3): δ 149.7 (C3), 136.4 (C6), 129.5 (C4), 117.7 
(C5), 49.1 (C2), 20.9 (C1); HRMS: (ESI+) calculated for C10H18N3O 196.1444. Found [M+H]+ 196.1444; 




General Procedure H: The reaction was carried out with 3-thiophene-carboxylic acid. Purification of 
the residue by FCC (hexane/EtOAc 50%) afforded the title compound (497 mg, 30%) as a colourless 
solid. vmax/cm-1: 3086 (m), 2967 (m) 1623 (s), 1441 (s), 1319 (s); 1H NMR (400 MHz, CDCl3): δ 7.41 – 
7.36 (1H, m, C7-H), 7.34 – 7.28 (1H, m, C6-H), 7.13 (1H, dd, J = 5.0, 1.5 Hz, C5-H), 3.82 (2H, ap. br. 
s, C2-H), 1.50 – 1.18 (12H, m, C1-H3); 13C NMR (101 MHz, CDCl3): δ 166.6 (C3), 139.3 (C4), 126.6 
(C5), 125.7 (C6), 124.2 (C7), 45.6 (C2), 21.0 (C1); HRMS: (ESI+) calculated for C11H17NOSNa 
234.0923. Found [M+Na]+ 234.0923; m.p. 77−79 °C (hexane/EtOAc). 
N,N-Diisopropyl-1H-indole-1-carboxamide (132) 
 
General Procedure E: The reaction was carried out with diisopropylcarbamic chloride (768 mg, 4.70 
mmol). Purification of the residue by recrystallisation (hexane/EtOAc) afforded the title compound (851 
mg, 82% yield) as colourless needles. vmax/cm-1: 2971 (m), 2939 (m) 1677 (s), 1428 (s),  1H NMR (400 
MHz, CDCl3): δ 7.69 – 7.65 (1H, m, C10-H), 7.62 – 7.58 (1H, m, C7-H), 7.31 – 7.23 (1H, m, C9-H), 
7.21 – 7.14 (2H, m, C4-H, C8-H), 6.57 (1H, dd, J = 3.5, 1.0 Hz, C5-H), 3.80 (2H, hept, J = 6.5 Hz, C2-
H), 1.40 (12H, d, J = 6.5 Hz, C1-H3); 13C NMR (101 MHz, CDCl3): δ 152.8 (C3), 136.0 (C11), 129.0 




(C6), 125.4 (C4), 123.3 (C9), 121.4 (C8), 120.9 (C7), 112.9 (C10), 104.8 (C5), 48.7 (C2), 21.3 (C1); 
HRMS: (ESI+) calculated for C15H21N2O 245.1648. Found [M+H]+ 245.1640; m.p. 84−86 °C 
(hexane/EtOAc). 
Benzyl 1H-pyrrole-1-carboxylate (133) 
 
General Procedure E: The reaction was carried out with benzoyl chloroformate (1.40 mL, 10.0 mmol). 
Purification of the residue by FCC (hexane/EtOAc 30%) afforded the title compound (158 mg, 8%) as 
a colourless oil. 1H NMR (400 MHz, CDCl3): δ 7.46 – 7.34 (5H, m), 7.30 (2H, dd, J = 3.0, 2.0 Hz), 
6.25 (2H, dd, J = 3.0, 2.0 Hz,), 5.38 (2H, s); 13C NMR (101 MHz, CDCl3): δ 150.5, 135.0, 128.9, 128.9, 
128.6, 120.3, 112.7, 69.0. The spectroscopic properties of this compound were consistent with the data 
available in the literature.255  
N,N-Diisopropylfuran-3-carboxamide (134a) 
 
General Procedure H: The reaction was carried out with 3-furoic acid. Purification of the residue by 
FCC (hexane/EtOAc 30−50%) afforded the title compound (1.10 g, 72%) as an off-white solid. vmax/cm-
1: 2971 (m), 2932 (m), 1618 (s), 1437 (s); 1H NMR (400 MHz, CDCl3): δ 7.64 – 7.59 (1H, m, C7), 7.42 
– 7.33 (1H, m, C6), 6.54 – 6.46 (1H, m, C5), 4.35 – 3.33 (2H, m, C2), 1.34 (12H, s, C1); 13C NMR (101 
MHz, CDCl3): δ 164.4 (C3), 142.7 (C6), 142.1 (C7), 123.5 (C4), 109.9 (C5), 47.5 (C2), 21.0 (C1); 
HRMS: (ESI+) calculated for C11H18NO2 196.1332. Found [M+H]+ 196.1338; m.p. 43−45 °C 
(hexane/EtOAc) (Lit.256 44−45 °C, hexane). 
N,N-Diisopropylfuran-2-carboxamide (139) 
 
General Procedure H: The reaction was carried out with 2-furoic acid. Purification of the residue by 
FCC (hexane/EtOAc 30) afforded the title compound (1.27 g, 84%) as a colourless oil. 1H NMR (400 
MHz, CDCl3): δ 7.46 – 7.34 (1H, m), 6.82 (1H, d, J = 3.5 Hz), 6.43 (1H, dd, J = 3.5, 2.0 Hz), 4.37 – 
3.55 (2H, m), 1.56 – 1.13 (12H, m); 13C NMR (101 MHz, CDCl3): δ 160.4, 149.7, 143.0, 114.1, 111.0, 
48.2, 21.0. The spectroscopic properties for this compound were consistent with the data available in 
the literature.257 
 






General Procedure H: The reaction was carried out with 1-benzothiophene-3-carboxylic acid. 
Purification of the residue by FCC (hexane/EtOAc 10−50%) afforded the title compound (1.50 g, 74%) 
as colourless cubes. vmax/cm-1: 2993 (m), 2963 (m), 1622 (s), 1440 (s); 1H NMR (400 MHz, CDCl3): δ 
7.89 – 7.82 (1H, m, C10-H), 7.80 – 7.73 (1H, m, C7-H), 7.43 – 7.34 (3H, m, C5-H, C8-H, C9-H), 3.84 
– 3.67 (2H, m, C2-H), 1.82 – 1.17 (12H, m, C1-H3); 13C NMR (101 MHz, CDCl3): δ 166.1 (C3), 139.8 
(C11), 137.4 (C6), 134.6 (C4), 125.0 (ArCH), 124.8 (ArCH), 123.0 (ArCH), 122.9 (C7), 122.6 (C10), 
50.1 (C2), 47.2 (C2), 21.1 (C1); HRMS: (ESI+) calculated for C15H19NOS 262.1260. Found [M+H]+ 
262.1256; m.p. 162–164 °C (CDCl3). 
 
7.5.1 − Hydroarylation Reactions 
1-(3-(1-Phenylethyl)-1H-indol-1-yl)ethan-1-one (118a’) 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
General procedure I: The reaction was carried out in the absence of a ligand. Purification of the residue 
by FCC (hexane/EtOAc 30%) afforded the title compound (34.0 mg, 90%, 0.8:0.2 mixture of rotamers 
A:B) as a yellow oil. vmax/cm-1: 2966 (m), 1681 (s), 1450 (s), 1360 (s), 1213 (m); 1H NMR (400 MHz, 
CDCl3): δ 8.41 (1H, s, C9-H, A+B), 7.34 – 7.09 (9H, m, ArC-H, A+B), 4.30 (0.8H, q, J = 7.0 Hz, C11-
H, A), 4.28-4.20 (0.2H, m, C11-H, B) 2.64 (2.4H, s, C1-H3, A), 2.61 (0.6H, s, C1-H3, B) 1.71 (2.4H, d, 
J = 7.0 Hz, C12-H, A), 1.68 (0.6H, d, J = 7.0 Hz, C12-H, B); 13C NMR (101 MHz, CDCl3, major 
rotamer signals only): δ 168.6 (C2), 145.1 (C13), 136.4 (C10), 130.2 (C5), 128.7 (C15), 127.6 (C4), 
127.5 (C14), 126.6 (C8), 125.3 (C16), 123.5 (C7), 121.8 (C3), 120.0 (C6), 116.7 (C9), 36.9 (C11), 24.2 
(C1), 22.0 (C12); HRMS: (EI) calculated for C18H17NO 263.1310. Found [M] 263.1344. Selective 
irradiation of signals for C11-H of rotamer A in a 1D gradient nOe experiment revealed a negative 











General procedure I: Purification of the residue by FCC (toluene) afforded the title product (10.8 mg, 
26%) as a colourless oil. vmax/cm-1: 3027 (m), 2929 (m), 1708 (s), 1492 (m), 1319 (s); 1H NMR (500 
MHz, CDCl3): δ 7.32 (1H, m, C6-H), 7.27 – 7.20 (2H, m, C17-H), 7.19 – 7.11 (6H, m, C4-H, C5-H, 
C8-H, C16-H, C18-H), 6.52 (1H, dd, J = 3.5, 1.5 Hz, C9-H), 6.33 (1H, ddd, J = 3.5, 1.5, 1.5 Hz, C11-
H), 6.12 (1H, dd, J = 3.5, 1.5 Hz, C10-H), 4.97 (1H, q, J = 7.0 Hz, C13-H), 1.98 (3H, s, C8-H3), 1.60 
(3H, d, J = 7.0 Hz, C14-H3); 13C NMR (126 MHz, CDCl3): δ 169.8 C1), 146.0 (C15), 140.7 (C12), 
136.3 (C2), 135.2 (C7), 130.7 (C5), 130.6 (C6), 128.3 (C17), 127.9 (C4), 127.7 (C16), 126.1 (C3), 
125.6 (C18), 123.7 (C9), 112.6 (C11), 110.8 (C10), 38.6 (C13), 22.6 (C14), 19.2 (C8); HRMS: (ESI+) 
calculated for C20H19NONa 312.1359. Found [M+Na]+ 312.1357. 
2,2-Dimethyl-1-(2-(1-phenylethyl)-1H-pyrrol-1-yl)propan-1-one (124a’) 
 
 General procedure I: Purification of the residue by FCC (toluene) afforded the title product (3.00 mg, 
8%) as a colourless oil. vmax/cm-1: 3027 (m), 2971 (m), 1711 (s), 1286 (s), 1214 (m); 1H NMR (500 MHz, 
CDCl3): δ 7.21 (2H, t, J = 7.5 Hz, C12-H), 7.14 (1H, ddd, J = 4.5, 3.0, 1.5 Hz, C4-H), 7.12 (1H, m, 
C13-H), 7.06 – 7.01 (2H, m, C11-H), 6.27 – 6.22 (1H, m, C6-H), 6.16 (1H, m, C5-H), 4.72 (1H, q, J = 
7.0 Hz, C8-H), 1.53 (3H, d, J = 7.0 Hz, C9-H3), 1.10 (9H, s, C1-H3); 13C NMR (126 MHz, CDCl3): δ 
179.4 (C3), 146.5 (C10), 140.6 (C7), 128.2 (C12), 127.7 (C11), 126.0 (C13), 120.8 (C4), 110.2 (C6), 
109.4 (C5), 41.8 (C2), 38.4 (C8), 28.6 (C1), 22.4 (C9); HRMS: (ESI+) calculated for C17H21NONa 
278.1515. Found [M+Na]+ 278.1509. 
Characteristic signals for the linear regioisomer 125a’: 1H NMR (400 MHz, CDCl3): δ 6.28 – 6.23 
(1H, m), 6.03 – 5.96 (1H, m), 3.20 – 3.13 (2H, m), 2.94 – 2.85 (2H, m), 1.46 (9H, s); 13C NMR (101 










General Procedure J: The reaction was carried out with (R)-L-16f (R = H) at 120 °C. Purification of 
the residue by FCC (hexane/EtOAc 0−3%) afforded the title compound (32.2 mg, 75%, 88:12 e.r.) as a 
colourless oil. vmax/cm-1: 2969 (m), 2931 (m), 1681 (s), 1432 (s), 1329 (s); 1H NMR (500 MHz, DMSO-
d6, 100 °C): δ 7.27 – 7.21 (2H, m, C12-H), 7.16 (1H, m, C13-H), 7.14 – 7.10 (2H, m, C11-H), 6.71 (1H, 
br. s, C4-H), 6.15 – 6.11 (1H, m, C6-H), 6.09 (1H, m, C5-H), 4.36 (1H, q, J = 7.5 Hz, C8-H), 3.42 – 
3.33 (2H, m, C2-H), 1.51 (3H, d, J = 7.5 Hz, C9-H3), 1.21 (6H, d, J = 7.0 Hz, C1-H3), 0.90 (6H, ap. s, 
C1-H3); 13C NMR (126 MHz, DMSO-d6, 100 °C): δ 151.6 (C3), 145.7 (C10), 137.3 (C7), 128.4 (C12), 
127.3 (C11), 126.1 (C13), 119.3 (C4), 107.8 (C5), 106.7 (C6), 36.2 (C8), 22.05 (C9), 19.5 (C1); HRMS: 
(ESI+) calculated for C19H26N2ONa 321.1937. Found [M+Na]+ 321.1939; [α]25D = - 0.7 (c = 0.31, 
CHCl3). 
SFC Conditions: (DAICEL CHIRALPAK-IE column (25 cm), CO2:IPA 95:5, 3 mL/min, 150 bars, 
25 °C). Retention times: 10.2 minutes (minor), 11.5 minutes (major), e.r. = 88:12. 
Note C2 is not observed by 13C NMR analysis  
N,N-Diethyl-2-(1-phenylethyl)-1H-pyrrole-1-carboxamide (127ba’) 
 
General Procedure J: The reaction was carried out with (R)-L-16f (R = H) at 120 °C. Purification of 
the residue by FCC (hexane/EtOAc 0−10%) afforded the title compound (34.9 mg, 90%, 86.5:13.5 e.r.) 
as a colourless oil. vmax/cm-1: 3026 (m), 2971 (m), 1681 (s) 1421 (s), 1286 (s); 1H NMR (400 MHz, 
CDCl3): δ 7.24 – 7.16 (2H, m, C12-H), 7.16 – 7.06 (3H, m, C11-H, C13-H), 6.67 – 6.59 (1H, m, C4-
H), 6.24 – 6.18 (1H, m, C6-H), 6.15 – 6.11 (1H, m, C5-H), 4.46 (1H q, J = 7.5 Hz, C8-H), 3.12 – 2.69 
(4H, m, C2-H2), 1.56 (3H, d, J = 7.5 Hz, C9-H3), 0.88 (6H t, J = 7.0 Hz, C1-H3); 13C NMR (101 MHz, 
CDCl3): δ 154.3 (C3), 146.1 (C10), 138.4 (C7), 128.3 (C12), 127.8 (C11), 126.2 (C13), 119.7 (C4), 
108.2 (C5), 107.6 (C6), 41.5 (C2), 37.2 (C8), 21.9 (C9), 12.7 (C1); HRMS: (ESI+) calculated for 
C17H23N2O 271.1805. Found [M+H]+ 271.1813; [α]25D = - 9.3 (c = 0.40, CHCl3). 
SFC Conditions: (DAICEL CHIRALPAK-IE column (25 cm), CO2:IPA 95:5, 3 mL/min, 150 bars, 
25 °C). Retention times: 10.2 minutes (minor), 11.5 minutes (major), e.r. = 87:13. 
 








General Procedure J: The reaction was carried out with (R)-L-16c (R = Ph) at 130 °C. Purification of 
the residue by FCC (hexane/Et2O 7.5%) afforded the title compound (47.1 mg, 87%, 75:25 e.r.) as an 
orange oil. vmax/cm-1: 2927 (m), 2854 (m), 1679 (s) 1426 (s), 1309 (s); 1H NMR (400 MHz, CDCl3): δ 
7.24 – 7.17 (2H, m, C14-H), 7.16 – 7.07 (3H, m, C13-H, C15-H), 6.62 – 6.56 (1H, m, C6-H), 6.25 – 
6.19 (1H, m, C7-H), 6.14 – 6.09 (1H, m, C8-H), 4.50 (1H, q, J = 7.0 Hz, C10-H), 2.88 – 2.67 (2H, m, 
C1-H), 2.50 – 2.14 (2H, m, Cy), 1.93 – 0.59 (18H, m, Cy), 1.53 (3H, d, J = 7.0 Hz, C11-H3); 13C NMR 
(101 MHz, CDCl3): δ 153.0 (C5), 146.6 (C12), 138.4 (C9), 128.4 (C14), 127.8 (C13), 126.1 (C15), 
119.2 (C6), 108.0 (C8), 107.2 (C7), 59.7 (C1), 56.3 (C1), 37.0 (C10), 31.2 (Cy), 30.4 (Cy), 29.8 (Cy), 
29.0 (Cy), 26.4 (Cy), 26.2 (Cy), 25.9 (Cy), 25.6 (Cy), 25.3 (Cy), 22.2 (C11); HRMS: (ESI+) calculated 
for C25H34N2NaO 401.2563. Found [M+Na]+ 401.2571; [α]25D = - 4.3 (c = 0.50, CHCl3). 
SFC Conditions: (DAICEL CHIRALPAK-IE column (25 cm), CO2:IPA 80:20, 2 mL/min, 150 bars, 
25 °C). Retention times: 10.0 minutes (major), 10.7 minutes (minor), e.r. = 75:25. 
N,N-Dimethyl-2-(1-phenylethyl)-1H-pyrrole-1-carboxamide (127da’) 
 
General Procedure J: The reaction was carried out with (R)-L-16c (R = Ph) at 130 °C. Purification of 
the residue by FCC (hexane/EtOAc 0−10%) afforded the title compound (23.3 mg, 65%, 74:26 e.r.) as 
colourless plates. vmax/cm
-1: 2971 (m), 2935 (m), 1682 (s), 1423 (s), 1286 (s); 1H NMR (400 MHz, 
CDCl3): δ 7.26 – 7.21 (2H, m, C11-H), 7.18 – 7.09 (3H, m, C10-H, C12-H), 6.62 (1H, dd, J = 3.0, 1.5 
Hz, C3-H), 6.22 – 6.15 (1H, m, C5-H), 6.15 – 6.11 (1H, m, C4-H), 4.39 (1H, q, J = 7.0 Hz, C7-H), 2.49 
(6H, br. s, C1-H3), 1.58 (3H, d, J = 7.0 Hz, C8-H3); 13C NMR (101 MHz, CDCl3): δ 155.0 (C2), 145.9 
(C9), 138.3 (C6), 128.2 (C11), 127.8 (C10), 126.3 (C12), 119.8 (C3), 108.5 (C4), 107.1 (C5), 37.5 (C1), 
37.2 (C7), 21.3 (C8); HRMS: (ESI+) calculated for C15H18N2ONa 265.1311. Found [M+H]+ 265.1315; 
m.p. 94–96 °C (CDCl3); [α]24D = - 8.0 (c = 0.19, CHCl3). 
SFC Conditions: (DAICEL CHIRALPAK-IE column (25 cm), CO2:IPA 95:5, 3 mL/min, 150 bars, 
25 °C). Retention times: 10.8 minutes (minor), 11.3 minutes (major), e.r. = 74:26. 




Note: for alkenylation products see Section 7.7 
N,N-Diisopropyl-2-(1-phenylethyl)furan-3-carboxamide (135aa’) 
 
General Procedure K: The reaction was carried out with (R)-L-16d (R = C6H5). Purification of the 
residue by FCC (hexane/EtOAc 10−15%) afforded the title compound (24.4 mg, 82%, 95:5 e.r.) as a 
yellow oil. vmax/cm-1: 2269 (m), 1938 (m), 1623 (s), 1440 (s); 1H NMR (400 MHz, CDCl3): δ 7.28 – 
7.26 (4H, m, C11-H, C12-H), 7.25 (1H, d, J = 2.0 Hz, C6-H), 7.20 – 7.14 (1H, m, C13-H), 6.24 (1H, d, 
J = 2.0 Hz, C5-H), 4.40 (1H, q, J = 7.5 Hz, C8-H), 4.04 – 3.73 (1H, m, C2-H), 3.62 – 3.19 (1H, m, C2-
H), 1.64 (3H, d, J = 7.5 Hz, C9-H3), 1.55 – 1.31 (6H, m, C1-H3), 1.20 – 0.75 (6H, m, C1-H3); 13C NMR 
(101 MHz, CDCl3): δ 165.7 (C3), 157.1 (C7), 144.2 (C10), 140.3 (C6), 128.6 (C12), 127.5 (C11), 126.5 
(C13), 117.8 (C4), 109.3 (C5), 46.0 (C2), 38.0 (C8), 20.7 (C1), 19.5 (C9); HRMS: (ESI+) calculated for 
C19H26NO2 300.1958. Found [M+H]+ 300.1957; [α]25D = + 6.3 (c = 0.50, CHCl3). 
SFC Conditions: (DAICEL CHIRALPAK-IE column (25 cm), CO2:MeOH 92.5:7.5, 2 mL/min, 140 
bars, 60 °C). Retention times: 7.1 minutes (major), 7.7 minutes (minor), e.r. = 95:5. 
General Procedure J: The reaction was carried out with H8-BINAP. Characteristic peaks for linear 
regioisomer 136aa’: 1H NMR (500 MHz, DMSO-d6) δ 6.40 (d, J = 1.9 Hz, 1H), 2.94 – 2.83 (m, 4H). 
N,N-Diisopropyl-2-(3-methylbutan-2-yl)furan-3-carboxamide (135ad’) 
 
General Procedure K: The reaction was carried out with (R)-L-16a (R = Mesityl). Purification of the 
residue by FCC (hexane/EtOAc 5−10%) afforded the title compound (20.0 mg, 75%, 72:28 e.r.) as a 
yellow oil. vmax/cm-1: 2964 (m), 2931 (m), 1624 (s), 1438 (s); 1H NMR (400 MHz, CDCl3): δ 7.23 (1H, 
d, J = 2.0 Hz, C6-H), 6.23 (1H, d, J = 2.0 Hz, C5-H), 4.20 – 3.36 (2H, m, C2-H), 2.83 – 2.73 (1H, m, 
C8-H), 1.94 – 1.80 (1H, m, C10-H), 1.68 – 1.01 (12H, m, C1-H3), 1.23 (3H, d, J = 7.0 Hz, C9-H), 0.92 
(3H, d, J = 6.5 Hz, C11-H3), 0.79 (3H, d, J = 6.5 Hz, C11-H3); 13C NMR (101 MHz, CDCl3): δ 166.0 
(C3), 159.0 (C7), 139.8 (C6), 117.9 (C4), 108.9 (C5), 50.2 (C2), 46.2 (C2), 38.9 (C8), 33.1 (C10), 21.1 
(C1), 20.9 (C11), 20.6 (C11), 16.5 (C9); HRMS: (ESI+) calculated for C16H28NO2 266.2115. Found 
[M+H]+ 266.2118; [α]25D = - 26.3 (c = 0.20, CHCl3). 




SFC Conditions: (DAICEL CHIRALPAK-IE column (25 cm), CO2:MeOH 88:2, 2 mL/min, 140 bars, 
60 °C). Retention times: 15.0 minutes (major), 16.5 minutes (minor), e.r. = 72:28 
N,N-Diisopropyl-2,4-bis(3-methylbutan-2-yl)furan-3-carboxamide (137ad’) 
 
General Procedure K: The reaction was carried out with (R)-L-16a (R = Mesityl). Purification of the 
residue by FCC (hexane/EtOAc 5−10%) afforded the title compound (4.00 mg, 12%, 0.6:0.4 mixture 
of rotamers A:B) as a colourless oil. vmax/cm-1: 2960 (m), 2927 (m), 1632 (s), 1439 (s); 1H NMR (400 
MHz, CDCl3): δ 7.03 – 6.97 (1H, m, C6-H, A+B), 4.06 (0.4H, p, J = 6.5 Hz, C2-H, B), 3.96 (0.6H, p, J 
= 6.5 Hz, C2-H, A), 3.43 (1H, p, J = 6.5 Hz, C2-H, A+B), 2.59 – 2.46 (0.6H, m, C8-H, A), 2.46 – 2.30 
(1.4H m, C8-H, A, C12-H, A+B), 2.04 – 1.70 (1H, m, aliphatic C-H, A+B), 1.57 – 1.44 (6H, m, aliphatic 
C-H), 1.28 – 1.12 (7H, m, aliphatic C-H), 1.12 – 1.05 (5H, m, aliphatic C-H), 1.00 – 0.84 (6H, m, 
aliphatic C-H), 0.84 – 0.71 (6H, m, aliphatic C-H); HRMS: (ESI+) calculated for C21H37NO2Na 
358.2717. Found [M+Na]+ 358.2710. 
Note: Due to complex rotamers, 137ad’ was characterised through comparison to 137ac’. 
N,N-Diisopropyl-2-(4-methylpentan-2-yl)furan-3-carboxamide (135ah’) 
 
General Procedure K: The reaction was carried out with (R)-L-16a (R = Mesityl). Purification of the 
residue by FCC (hexane/EtOAc 5−10%) afforded the title compound (21.3 mg, 76%, 87:13 e.r.) as a 
yellow oil. vmax/cm-1: 2951 (m), 2931 (m), 1623 (s), 1438 (s); 1H NMR (400 MHz, CDCl3): δ 7.22 (1H, 
d, J = 2.0 Hz, C6-H), 6.22 (1H, d, J = 2.0 Hz, C5-H), 4.25 – 3.29 (2H, m, C2-H), 3.20 – 3.05 (1H, m, 
C8-H), 1.73 – 1.57 (2H, m, C10-H2), 1.57 – 0.98 (13H m, C1-H3, C11-H), 1.23 (3H, d, J = 7.0 Hz, C9-
H3), 0.86 (3H, d, J = 6.5 Hz, C12-H3), 0.82 (3H, d, J = 6.5 Hz, C12-H3); 13C NMR (101 MHz, CDCl3): 
δ 165.9 (C3), 159.3 (C7), 139.8 (C6), 117.4 (C4), 109.0 (C5), 45.0 (C10), 30.3 (C8), 26.1 (C11), 23.0 
(C12), 22.6 (C12), 21.0 (C1), 19.8 (C9); HRMS: (ESI+) calculated for C17H29NO2Na 302.2091. Found 
[M+Na]+ 302.2094; [α]25D = - 24.6 (c = 0.20, CHCl3); 
SFC Conditions: (DAICEL CHIRALPAK-IE column (25 cm), CO2:IPA 95:5, 2 mL/min, 140 bars, 
60 °C). Retention times: 9.0 minutes (major), 9.8 minutes (minor), e.r. = 87:13. 
Note C2 is not observed by 13C NMR analysis  
 






General Procedure K: The reaction was carried out with (R)-L-16a (R = Mesityl). Purification of the 
residue by FCC (hexane/EtOAc 5−10%) afforded the title compound (9.00 mg, 24%, 0.7:0.3 mixture 
of rotamers A:B) as a colourless oil. a colourless oil. vmax/cm-1: 2958 (m), 2928 (m), 1633 (s), 1439 (s); 
1H NMR (400 MHz, CDCl3): δ 6.94 (0.3H, s, C6-H, B), 7.01 (0.7H, d, J = 4.5 Hz, C6-H, A), 4.17 – 3.89 
(1H, m, C2-H, A+B), 3.53 – 3.37 (1H, m, C2-H, A+B), 2.83 – 2.73 (0.3H, m, C8-H, B) 2.73 – 2.65 
(0.7H, m, C8-H, A), 2.64 – 2.39 (1H, m, C14-H, A+B), 1.71 – 1.43 (10H, m, aliphatic C-H), 1.21 – 1.05 
(14H, m, aliphatic C-H), 0.97 – 0.78 (12H, m, aliphatic C-H); HRMS: (ESI+) calculated for 
C23H41NO2Na 386.3030. Found [M+Na]+ 386.3040. 
Note: Due to complex rotamers, 137ah’ was characterised through comparison to 137ac’. 
2-(Hexan-2-yl)-N,N-diisopropylfuran-3-carboxamide (135ac’) 
  
General Procedure K: The reaction was carried out with (R)-L-16a (R = Mesityl). Purification of the 
residue by FCC (hexane/EtOAc 5−10%) afforded the title compound (20.5 mg, 73%) as a colourless 
oil. vmax/cm-1: 2962 (m), 2929 (m), 1625 (s), 1438 (s); 1H NMR (400 MHz, CDCl3): δ 7.22 (1H, d, J = 
2.0 Hz, C6-H), 6.22 (1H, d, J = 2.0 Hz, C5-H), 4.17 – 3.88 (1H, m, C2-H), 3.61 – 3.25 (1H, m, C2-H), 
3.05 – 2.95 (1H, m, C8-H), 1.75 – 1.59 (1H, m, C10-H), 1.58 – 1.47 (1H, m, C10-H), 1.46 – 1.05 (16H, 
m, C1-H3, C11-H2, C12-H2), 1.24 (3H, d, J = 7.0 Hz, C9-H3), 0.84 (3H, t, J = 7.0 Hz, C13-H3); 13C 
NMR (101 MHz, CDCl3): δ 166.0 (C3), 159.1 (C7), 139.8 (C6), 117.4 (C4), 109.0 (C5), 50.2 (C2), 46.1 
(C2), 35.5 (C10), 32.5 (C8), 29.9 (C11), 22.8 (C12), 21.0 (C1), 19.4 (C9), 14.2 (C13); HRMS: (ESI+) 











General Procedure K: The reaction was carried out with (R)-L-16a (R = Mesityl). Purification of the 
residue by FCC (hexane/EtOAc 5-10%) afforded the title compound (2.5 mg, 9%) as a colourless oil. 
vmax/cm-1: 2961 (m), 2928 (m), 1632 (s), 1438 (s); 1H NMR (400 MHz,CDCl3): δ 7.00 (1H, s, C6-H), 
4.10 – 3.93 (1H, m, C2-H), 3.54 – 3.35 (1H, m, C2-H), 2.79 – 2.63 (1H, m, C8-H), 2.62 – 2.42 (1H, m, 
C14-H), 1.72 – 1.58 (2H, m, Chexane-H), 1.55 – 1.46 (6H, m, Chexane-H), 1.37 – 1.07 (22H, m, 
Chexane-H, C1-H3), 0.99 – 0.74 (6H, m, C13-H3, C9-H3); 13C NMR (126 MHz, CDCl3): δ 166.1 (C3), 
166.0 (C3), 166.0 (C3), 165.9 (C3), 156.5 (C7), 156.3 (C7), 155.4 (C7), 155.1 (C7), 136.0 (C6), 135.9 
(C6), 135.7 (C6), 135.5 (C6), 130.5 (C4), 130.4 (C4), 130.3 (C4), 130.3 (C4), 118.2 (C5), 118.0 (C5), 
117.9 (C5), 117.7 (C5), 50.6 (C2), 45.8 (C2), 37.8 (Chexane), 37.2 (Chexane), 36.7 (Chexane), 36.2 
(Chexane), 35.9 (Chexane), 35.8 (Chexane), 35.0 (Chexane), 34.8 (Chexane), 33.0 (C8), 32.6 (C8), 
33.0 (Chexane), 32.6 (Chexane), 30.2 (Chexane), 30.0 (Chexane), 29.9 (Chexane), 29.9 (Chexane), 
29.8 (Chexane), 29.7 (C14), 29.6 (C14), 23.0 (C1), 22.9 (C1), 22.6 (C1), 22.6 (C1), 21.6 (C1), 21.4 
(C1), 20.9 (Chexane), 20.7 (Chexane), 20.7 (Chexane), 20.5 (Chexane), 20.4 (Chexane), 20.3 
(Chexane), 19.6 (Chexane), 19.5 (Chexane), 18.9 (Chexane), 18.7 (Chexane), 14.3 (C9/13), 14.2 
(C9/13), 14.1 (C9/13); HRMS: (ESI+) calculated for C23H41NO2Na 386.3030. Found [M+Na]+ 386.2027. 
Note: Due to complex rotamers and diasteriosisomers the 13C NMR was tentatively assigned.  
N,N-Diisopropyl-3-(1-phenylethyl)furan-2-carboxamide (140a’) 
 
General Procedure L: The reaction was run at 100 °C for 24 h. Purification of the residue by FCC 
(hexane/Et2O 10−20%) afforded the title compound (36.2 mg, 85%, 86.5:13.5 e.r.) as a colourless oil. 
vmax/cm-1: 2968 (m), 2982 (m), 1622 (s), 1439 (s); 1H NMR (400 MHz, CDCl3): δ 7.31 – 7.25 (4H, m, 
C11-H, C12-H), 7.25 – 7.22 (1H, m, C5-H), 7.19 – 7.10 (1H, m, C13-H), 6.34 (1H, d, J = 1.5, Hz, C6-
H), 4.46 (1H, q, J = 7.0 Hz, C8-H), 3.58 (1H, br. ap. s, C2-H), 1.58 (3H, d, J = 7.0 Hz, C9-H3), 1.49 – 
0.85 (12H, m, C1-H3); 13C NMR (101 MHz, CDCl3): δ 161.9 (C3), 146.1 (C10), 144.6 (C4), 140.9 (C5), 
132.2 (C7), 128.4 (C12), 127.4 (C11), 126.1 (C13), 111.0 (C6), 49.8 (C2), 46.6 (C2), 34.9 (C8), 21.3 
(C9), 20.8 (C1); HRMS: (ESI+) calculated for C19H25NO2Na 322.1777. Found [M+Na]+ 322.1779; 
[α]25D = + 77.9 (c = 0.20, CHCl3). 




SFC Conditions: (DAICEL CHIRALPAK-IB column (25 cm), CO2:MeOH 99:1, 2 mL/min, 140 bars, 
60 °C). Retention times: 9.9 minutes (minor), 10.4 minutes (major), e.r. = 87:13. 
N-Isopropyl-3-(1-phenylethyl)furan-2-carboxamide (141a’) 
 
General Procedure L: The reaction was run at 120 °C for 48 h. Purification of the residue by FCC 
(hexane/EtOAc 5%) afforded the title compound (17.5 mg, 51%) as a colourless oil. vmax/cm-1: 3302 
(br.), 2868 (m), 2927 (m), 1644 (s); 1H NMR (400 MHz, CDCl3): δ 7.41 – 7.33 (2H, m, 11-H), 7.32 – 
7.21 (3H, m, C5-H, C12-H), 7.22 – 7.11 (1H, m, C13-H), 6.39 (1H, d, J = 2.0 Hz, C6-H), 6.13 (1H, br. 
d, J = 8.0 Hz, N-H), 5.14 (1H, q, J = 7.0 Hz, C8-H), 4.25 (1H, hept, J = 8.0, 6.5 Hz, C2-H), 1.57 (3H, 
d, J = 7.0 Hz, C9-H3), 1.27 – 1.20 (6H, m, C1-H3); 13C NMR (101 MHz, CDCl3): δ 158.8 (C3), 145.5 
(C10), 142.4 (C5), 141.4 (C4), 136.3 (C7), 128.5 (C12), 127.5 (C11), 126.3 (C13), 112.3 (C6), 40.9 




General Procedure L: The reaction was run at 120 °C for 48 h in the absence of styrene. Purification 
of the residue by FCC (hexane/EtOAc 0−15%) afforded the title compound (12.7 mg, 45%) as a yellow 
oil. vmax/cm-1: 3316 (m), 2957 (m), 2871 (m), 1644 (s); 1H NMR (400 MHz, CDCl3): δ 7.27 (1H. d, J = 
2.0 Hz, C5-H), 6.43 (1H, d, J = 2.0 Hz, C6-H), 6.14 (1H, s, N-H), 4.24 – 4.20 (1H, m, C2-H), 3.85 – 
3.77 (1H, m, C8-H), 1.23 (6H, d, J = 6.5 Hz, C1-H3), 1.19 (6H, d, J = 7.0 Hz, C9-H3); 13C NMR (101 
MHz, CDCl3): δ 158.9 (C3), 142.3 (C5), 141.0 (C4), 138.6 (C7), 111.3 (C6), 40.9 (C2), 24.3 (C8), 23.3 













A flame-dried tube, fitted with a magnetic stirrer, was charged with 131 (0.143 mmol), [Ir(cod)2]BARF 
(5.0 mol%) and (rac)-L-15a (5.0 mol%). The tube was fitted with a rubber septum and purged with 
nitrogen. Styrene (400 mol%) in anhydrous 1,4-dioxane (1.0 M concentration with respect to substrate) 
was added and the tube was fitted with a Young’s tap. The reaction mixture was then heated to 120 °C 
for 48 h before being cooled to ambient temperature and concentrated in vacuo. Purification of the 
residue by FCC (hexane/EtOAc 10−15%) afforded the title compound (30.9 mg, 68%, 0.7:0.3 mixture 
of regioisomers A:B) as a colourless oil. vmax/cm-1: 2967 (m), 2928 (m), 1625 (s), 1443 (s); 1H NMR 
(500 MHz, CDCl3): δ 7.32 – 7.20 (4.3H, m, ArCH), 7.20 – 7.12 (2H, m, ArCH), 7.10 (1H, d, J = 5.0 
Hz, C6-H, A, ArCH, B), 6.82 (0.7H, d, J = 5.0 Hz, C5-H, A), 4.70 (0.7H, q, J = 7.0 Hz, C8-H, A), 4.47 
(0.3H q, J = 7.0 Hz, C8-H, B), 3.63 – 3.51 (1H, m, C2-H, A+B), 3.41 – 3.21 (1H, m, C2-H, A+B), 1.67 
(2.1H, d, J = 7.0 Hz, C9-H3, A), 1.57 (0.9H d, J = 7.0 Hz, C9-H3, B), 1.54 – 0.98 (12H, m, C1-H3, A+B); 
13C NMR (126 MHz, CDCl3): δ 166.9 (C3, A), 166.6 (C3, B), 148.9 (C7, A), 146.2 (ArC) 146.0 (ArC), 
145.7 (C5, B), 138.5 (ArC), 135.1 (C4, A), 128.5 (C11/12, A), 128.4 (C13, A), 127.8 (C11/12, B), 127.4 
(C11/12, A), 126.4 (C11/12, B), 126.1 (C13, B), 125.4 (C5, A), 122.3 (C6, A), 122.2 (C6, B), 120.9 
(ArC), 50.5 (C2, A+B), 45.8 (C2, A+B), 38.9 (C8, B), 38.6 (C8, A), 23.7 (C9, A), 22.9 (C9, B), 20.9 
(C1, A+B), 20.6 (C1, A+B), 20.4 (C1, A+B), 20.1 (C1, A+B); HRMS: (ESI+) calculated for C19H26NOS 
316.1730. Found [M+H]+ 316.1727. 
N,N-Diisopropyl-2-(1-phenylethyl)benzo[b]thiophene-3-carboxamide (146a’) 
 
A flame-dried tube, fitted with a magnetic stirrer, was charged with 145 (0.143 mmol), [Ir(cod)2]BARF 
(5.0 mol%) and (rac)-L-15a (5.0 mol%). The tube was fitted with a rubber septum and purged with 
nitrogen. Styrene (400 mol%) in anhydrous 1,4-dioxane (1.0 M concentration with respect to substrate) 
was added and the tube was fitted with a Young’s tap. The reaction mixture was then heated to 120 °C 
for 48 h before being cooled to ambient temperature and concentrated in vacuo. Purification of the 
residue by FCC (hexane/EtOAc 10−15%) afforded the title compound (23.6 mg, 45%, 0.6:0.4 mixture 
of rotamers A:B) as a colourless oil. 1H NMR (400 MHz, CDCl3): δ 7.80 – 7.76 (0.6H, m, C6-H, A), 




7.72 – 7.67 (0.4H, m, C6-H, B), 7.58 – 7.52 (1H, m, C9-H, A+B), 7.47 (0.8H, dd, J = 8.0, 1.5 Hz, C15-
H, B), 7.40 – 7.33 (1.2H, m, C15-H, A), 7.34 – 7.24 (4H, m, C7-H, C8-H, C16-H, A+B), 7.24 – 7.17 
(1H, m, C17-H, A+B), 4.69 (0.6H, q, J = 7.0 Hz, C12-H, A), 4.56 (0.4H, q, J = 7.0 Hz, C12-H, B), 3.87 
(0.4H, hept, J = 6.5 Hz, C2-H, B), 3.66 – 3.55 (0.4H, m, C2-H, B), 3.55 – 3.47 (0.6H, m, C2-H, A), 3.47 
– 3.38 (0.6H, m, C2-H, A), 1.78 (1.2H d, J = 7.0 Hz, C13-H3, B), 1.73 (1.8H, d, J = 7.0 Hz, C13-H3, A), 
1.69 (1.4H, d, C1-H3), 1.67 – 1.64 (2H, m, C1-H3), 1.59 (2H, d, J = 6.5 Hz, C1-H3), 1.18 (1.8H, d, J = 
6.5 Hz, C1-H3), 1.15 – 1.09 (1.2H, m, C1-H3), 1.01 (1.8H, d, J = 6.5 Hz, C1-H3), 0.46 (1.8H, d, J = 6.5 
Hz, C1-H3); 13C NMR (101 MHz, CDCl3): δ 166.1 (C3), 147.8 (C11), 147.5 (C11), 145.3 (C14), 143.8 
(C14), 138.8 (C5), 138.2 (C5), 137.6 (C10), 137.3 (C10), 130.7 (C4), 129.9 (C4), 128.6 (C16), 128.5 
(C16), 127.4 (C15), 127.3 (C15), 126.7 (C17), 124.4 (C8), 124.3 (C8), 124.3 (C7) 124.2 (C7), 122.3 
(C6), 122.3 (C6), 122.0 (C9), 122.0 (C9), 50.9 (C2), 46.1 (C2), 46.0 (C2), 39.6 (C12), 39.2 (C12), 24.4 
(C13), 23.8 (C13), 21.8 (C1), 21.4 (C1), 21.2 (C1), 21.1 (C1), 20.8 (C1), 20.7 (C1), 20.7 (C1), 20.6 
(C1), 20.3 (C1). HRMS: (ESI+) calculated for C23H27NOSNa 388.1706. Found [M+Na]+ 388.1708. 



























7.6 − Experimental Procedures and Data for the Studies in Chapter 4 
7.6.1 − Ligand Synthesis 
(rac)-L-15f 
 
A flame dried resealable tube under an inert atmosphere was charged with biphenol (2.10 g, 11.3 mmol). 
PCl3 (4.93 mL, 56.5 mmol) was added and the mixture was heated at reflux for 2 h. The mixture was 
cooled to ambient temperature and concentrated under high vacuum for 2 h (a second trap, cooled with 
liquid nitrogen, was placed between the reaction tube and the vacuum line). The tube was refilled four 
times with nitrogen during this 2 h period. The oily chlorophosphite was directly used in the next step 
without further purification. 3,3'-Di-tert-butyl-5,5',6,6'-tetramethyl-[1,1'-biphenyl]-2,2'-diol (600 mg, 
2.26 mmol) and DMAP (55.2 mg, 0.452 mmol) were added and the reaction tube was evacuated and 
refilled with nitrogen (three times) and then cooled to 0 °C. THF was added, followed by dropwise 
addition of Et3N (2.52 mL, 18.7 mmol). The tube was sealed, and the reaction mixture was stirred at 
ambient temperature overnight. The reaction mixture was filtered through a pad of Celite® with Et2O. 
The solution was concentrated in vacuo and purified by FCC (hexane/EtOAc 5−8%, SiO2 deactivated 
with 10% of Et3N). (rac)-L-15f was azeotropically dried with toluene (twice) then pentane (twice) to 
remove any traces of Et3N to afford pure ligand (1.65 g, 93%) as a colourless solid. vmax/cm-1: 3064 (m), 
2958 (m), 2914 (m), 1434 (s); 1H NMR (400 MHz, C6D6): δ 7.40 (2H, s, C3-H), 7.23 – 7.12 (8H, m, 
ArCH), 7.05 (2H, td, J = 7.7, 1.7 Hz, ArCH), 6.98 (2H, td, J = 7.7, 1.8 Hz, ArCH), 6.92 (4H, tdd, J = 
7.3, 5.8, 1.3 Hz, ArCH), 2.19 (6H, s, C9-H3), 2.02 (6H, s, C10-H3), 1.52 (18H, s, C8-H3); 13C NMR 
(101 MHz, C6D6): δ 150.39 (t, J = 2.5 Hz, C1), 150.2 (ArC), 150.0 (ArC), 138.4 (C2), 136.6 (C5), 
132.36 – 131.63 (m, C11), 130.0 (ArC), 129.9 (ArCH), 129.9 (ArCH), 129.0 (ArCH), 125.2 (ArCH), 
125.1 (ArCH), 123.6 (ArCH), 122.9 (ArCH), 35.2 (C7), 30.9 (C8), 20.6 (C9), 17.7 (t, J = 3.6 Hz, C10); 
31P NMR (162 MHz, C6D6): δ 142.5; HRMS (MALDI) calculated for C48H48O6P2Na 805.2818 Found 








7.6.2 − Substrate Synthesis 
7.6.2.1 − Alkene Synthesis 
147a’, 147c’, 147h’−147j’ 147m’, 147n’, 147r’ and 147s’ were purchased from commercial sources 
(Sigma) 
147e’ and 147q’ were synthesised by Miss Ellie Lester 
147o’, 147t’ and 147u’ were synthesised by Dr. Simon Grélaud 
4-(Prop-1-en-2-yl)-1,1'-biphenyl (147b’) 
 
General Procedure M: Purification of the residue by FCC (hexane/EtOAc 5%) afforded the title 
compound (3.48 g, 88%) as a colourless solid. vmax/cm-1: 2974 (m), 2939 (m), 1627 (m), 1423 (s); 1H 
NMR (400 MHz, CDCl3): δ 7.63 – 7.60 (2H, m, C9-H), 7.60 – 7.54 (4H, m, C5-H, C6-H), 7.49 – 7.42 
(2H, m, C10-H), 7.39 – 7.31 (1H, m, C11-H), 5.44 (1H, dq, J = 1.5, 1.0 Hz, C1-(Ha)2), 5.12 (1H, p, J = 
1.5 Hz, C1-(Hb)2), 2.20 (3H, dd, J = 1.5, 1.0 Hz, C3-H3); 13C NMR (101 MHz, CDCl3): δ 142.9 (C2), 
140.9 (C8), 140.3 (C7), 140.3 (C4), 128.9 (C10), 127.4 (C11), 127.1 (C9), 127.1 (C6), 126.0 (C5), 
112.6 (C1), 22.0 (C3); HRMS: (EI+) calculated for C15H14 194.1090. Found [M]+ 194.1088; m.p. 118–




General Procedure M: Purification of the residue by FCC (hexane/EtOAc 10%) afforded the title 
compound (1.79 g, 91%) as a colourless oil. vmax/cm-1: 2973 (m), 1623 (m), 1488 (m); 1H NMR (400 
MHz, CDCl3): δ 7.48 – 7.42 (2H, m, C6-H), 7.36 – 7.29 (2H, m, C5-H), 5.36 (1H, s, C3-H2), 5.16 – 
5.04 (1H, m, C3-H2), 2.13 (3H, s, C1-H3); 13C NMR (101 MHz, CDCl3): δ 142.4 (C2), 140.3 (C4), 
131.4 (C6), 127.3 (C5), 121.5 (C7), 113.2 (C3), 21.8 (C1); HRMS: (EI) calculated for C9H979Br 
195.9882. Found [M] 195.9882. 
1-Chloro-3-(prop-1-en-2-yl)benzene (147f’) 
 
General Procedure M: Purification of the residue by FCC (hexane/EtOAc 10%) afforded the title 
compound (1.20 g, 79%) as a colourless oil. vmax/cm-1: 3088 (m), 2947 (m), 1593 (m), 1562 (s); 1H NMR 




(400 MHz, CDCl3): δ 7.44 – 7.40 (1H, m, C5-H), 7.35 – 7.29 (1H, m, C9-H), 7.24 – 7.22 (2H, m, C7-
H, C8-H), 5.38 – 5.34 (1H, m, C3-H2), 5.14 – 5.08 (1H, m, C3-H2), 2.15 – 2.08 (3H, m, C1-H3); 13C 
NMR (101 MHz, CDCl3): δ 143.3 (C4), 142.3 (C2), 134.4 (C6), 129.6 (C8), 127.5 (C7), 125.9 (C5), 
123.8 (C9), 113.8 (C3), 21.8 (C1); HRMS: (EI) calculated for C9H9Cl 215.0387. Found [M] 215.0388. 
1-Methoxy-3-(prop-1-en-2-yl)benzene (147g’) 
 
General Procedure M: Purification of the residue by FCC (hexane/EtOAc 5%) afforded the title 
compound (1.25 g, 85%) as a colourless oil. vmax/cm-1: 2943 (m), 2834 (m), 1576 (s), 1231 (s);1H NMR 
(400 MHz, CDCl3): δ 7.30 – 7.22 (1H, m, C8-H), 7.07 (1H, ddd J = 7.5, 2.0, 1.0 Hz, C7-H), 7.02 – 6.99 
(1H, m, C5-H), 6.83 (1H, ddd, J = 8.5, 2.0, 1.0 Hz, C9-H), 5.38- 5.36 (1H, m, C3-H2), 5.10 – 5.08 (1H, 
m, C3-H2), 3.83 (3H, s, C10-H3), 2.16 – 2.14 (1H, m, C1-H3); 13C NMR (101 MHz, CDCl3): δ 159.7 
(C6), 143.4 (C2), 143.0 (C4), 129.3 (C8), 118.3 (C7), 112.8 (C3), 112.8 (C9), 111.7 (C5), 55.4 (C10), 
22.0 (C1); HRMS: (APCI) calculated for C10H12O 149.0961. Found [M] 149.0959. 
1-Methyl-2-(prop-1-en-2-yl)benzene (147k’) 
 
General Procedure M: Purification of the residue by FCC (hexane/EtOAc 5%) afforded the title 
compound (885 mg, 67%) as a colourless oil. 1H NMR (400 MHz, CDCl3): δ 7.20 – 7.10 (4H, m), 5.23 
– 5.15 (1H, m,), 4.88 – 4.81 (1H, m), 2.32 (3H, s), 2.09 – 2.01 (3H, m); 13C NMR (101 MHz, CDCl3): 
δ 146.0, 144.0, 134.6, 130.2, 128.0, 126.9, 125.7, 114.8, 24.5, 19.9. The spectroscopic properties for 
this compound were consistent with the data available in the literature.258 
1-Fluoro-2-(prop-1-en-2-yl)benzene (147l’) 
 
General Procedure M: Purification of the residue by FCC (hexane/EtOAc 5%) afforded the title 
compound (543 mg, 40%) as a colourless oil.1H NMR (400 MHz, CDCl3): δ 7.30 (1H, td, J = 7.5, 2.0 
Hz), 7.26 – 7.20 (1H, m), 7.09 (1H, td, J = 7.5, 1.0 Hz), 7.10 – 6.98 (1H, m), 5.27 – 5.20 (2H, m), 2.15 
(3H, dd, J = 2.5, 1.0 Hz); 13C NMR (101 MHz, CDCl3): δ 160.1 (d, J = 248.1 Hz), 140.4, 130.4 (d, J = 
13.6 Hz), 129.5 (d, J = 4.4 Hz), 128.8 (d, J = 8.4 Hz), 124.0 (d, J = 3.5 Hz), 116.7 (d, J = 3.9 Hz), 116.0 
(d, J = 23.1 Hz), 23.2 (d, J = 3.4 Hz). The spectroscopic properties for this compound were consistent 










General Procedure M: Purification of the residue by FCC (hexane/EtOAc 0−5%) afforded the title 
compound (2.97 g, 75%) as an orange powder. 1H NMR (400 MHz, CDCl3): δ 5.13 (1H, s C3-H2), 4.84 
(1H, s, C3-H2), 4.47 – 4.34 (2H, m, ferrocenyl), 4.21 (2H, d, J = 3.5 Hz, ferrocenyl), 4.10 (5H, ap. s, 
ferrocenyl), 2.06 (3H, s, C1-H3); 13C NMR (101 MHz, CDCl3): δ 141.6 (C3), 108.4 (C3), 86.7 (C4), 
69.4 (ferrocenyl), 68.7 (ferrocenyl), 66.0 (ferrocenyl), 21.7 (C1); HRMS: (nanospray) calculated for 
C13H14Fe 226.0445. Found [M] 226.0440; m.p. 65–67 °C (CDCl3).  
 
7.6.2.2 − Synthesis of Benzamide Substrates 
90c−90g, 90h, 90m and 90o−90t, 90v and 90w were synthesised by Dr Giacomo Crisenza 
89b was purchased from commercial sources (Sigma) 
For the synthesis of 98 see Section 7.4.1 
N,N-Diisopropylbenzamide (90h) 
 
General Procedure N: Purification of the residue by FCC (hexane/EtOAc 20−30%) afforded the title 
compound (1.20 g, 98%) as a yellow solid. 1H NMR (400 MHz, CDCl3): δ 7.42 – 7.31 (3H, m), 7.33 – 
7.28 (2H, m), 4.07 – 3.31 (2H, m), 1.73 – 0.95 (12H, m); 13C NMR (101 MHz, CDCl3): δ 171.2, 139.1, 
128.7, 128.6, 125.7, 51.0, 45.9, 20.9; m.p. 68−70 °C (hexane/EtOAc) (Lit.260 58−60 °C, no 
recrystallisation solvent specified). The spectroscopic properties for this compound were consistent 
with the data available in the literature.260  
N-Benzylbenzamide (90i) 
 
To a flame-dried flask was added benzylamine (3.26 mL, 30.0 mmol) in dry THF (70 mL) under 
nitrogen. The solution was cooled to 0 °C, before the dropwise addition of benzoyl chloride (1.16 mL, 
10.0 mmol). The reaction was warmed to ambient temperature and stirred overnight. The solution was  
concentrated in vacuo and the residue was dissolved in EtOAc (30 mL), washed with aq. HCl (2 M, 30 
mL) and brine (30 mL), dried over Na2SO4 and concentrated in vacuo. Purification of the residue by 
FCC (hexane/EtOAc 30−40%) afforded the title compound (2.07 g, 98%) as a colourless solid. 1H NMR 




(400 MHz, CDCl3): δ 7.84 – 7.75 (2H, m), 7.56 – 7.38 (1H, m), 7.48 – 7.38 (2H, m), 7.36 (4H, d, J = 
4.5 Hz), 7.35 – 7.25 (1H, m), 6.44 (1H, br. s), 4.65 (2H, d, J = 5.5 Hz); 13C NMR (101 MHz, CDCl3): 
δ 167.5, 138.3, 134.5, 131.7, 128.9, 128.7, 128.1, 127.8, 127.1, 44.3; m.p. 102–104 °C (CDCl3) Lit. 
102–105 °C, no recrystallisation solvent specified). The spectroscopic properties for this compound 
were consistent with the data available in the literature.261 
N,N-Diethyl-3-methoxybenzamide (90k) 
 
General Procedure O: Purification of the residue by FCC (hexane/EtOAc 40%) afforded the title 
compound (878 mg, 65%) as a colourless oil. 1H NMR (400 MHz, CDCl3): δ 7.29 (1H, ddd, J = 8.0, 
7.5, 1.0 Hz), 6.95 – 6.89 (3H, m), 3.82 (3H, s), 3.54 (2H, br. s), 3.26 (2H, br. s), 1.25 (3H, br. s), 1.11 
(3H, br. s); 13C NMR (101 MHz, CDCl3): δ 171.1, 159.7, 138.7, 129.7, 118.6, 115.2, 111.8, 55.5, 43.3, 
39.3, 14.4, 13.0. The spectroscopic properties for this compound were consistent with the data available 
in the literature.262 
N,N-Diethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (90l) 
 
General Procedure O: Purification of the residue by FCC (1st column: hexane/EtOAc 60%; 2nd column: 
toluene/EtOAc 40%) afforded the title compound (461 mg, 46%) as colourless cubes. vmax/cm-1: 2976 
(m), 2934 (m), 1626 (m), 1409 (s); 1H NMR (400 MHz, CDCl3): δ 7.83 – 7.78 (2H, m, C5-H, C7-H), 
7.46 – 7.41 (1H, m, C9-H), 7.40 – 7.35 (1H, m, C8-H), 3.53 (2H, br. s, C2-H2), 3.23 (2H, br. s, C2-H2), 
1.33 (12H, s, C11-H3), 1.23 (3H, br. s, C1-H3), 1.08 (3H, br. s, C1-H3); 13C NMR (101 MHz, CDCl3): 
δ 171.5 (C3), 136.9 (C4), 135.5 (C7), 132.7 (C5), 129.0 (C8), 127.8 (C9), 84.1 (C10), 43.5 (C2), 39.4 
(C2), 25.0 (C11), 14.4 (C1), 13.1 (C1); HRMS: (ESI+) calculated for C17H27BNO3 304.2082. Found 












General Procedure N: Purification of the residue by FCC (hexane/EtOAc 50%) afforded the title 
compound (1.31 g, 98%) as a colourless oil. vmax/cm
-1: 3476 (m), 2971 (m), 1608 (m), 1424 (s); 1H 
NMR (400 MHz, CDCl3): δ 7.37 – 7.31 (2H, m, C5-H), 6.95 – 6.85 (2H, m, C6-H), 3.82 (3H, s, C8-
H3), 3.52 – 3.30 (4H, m, C2-H2), 1.24 – 1.11 (6H, m, C1-H3); 13C NMR (101 MHz, CDCl3): δ 171.3 
(C3), 160.4 (C7), 129.7 (C4), 128.3 (C5), 113.8 (C6), 55.4 (C8), 43.4 (C2), 39.3 (C2), 13.1 (C1); 
HRMS: (ESI+) calculated for C12H18NO2 208.1345. Found [M+H]+ 208.1332. 
N,N-Diethyl-2-methylbenzamide (90u) 
 
General Procedure N: Purification of the residue by FCC (hexane/EtOAc 50%) afforded the title 
compound (1.10 g, 89%) as a colourless oil. 1H NMR (400 MHz, CDCl3): δ 7.30 – 7.25 (1H, m,), 7.24 
– 7.20 (2H, m), 7.20 – 7.15 (1H, m), 3.90 – 3.37 (2H m), 3.15 (2H, q, J = 7.0 Hz), 2.31 (3H, s), 1.28 
(3H, t, J = 7.0 Hz), 1.05 (3H, t, J = 7.0 Hz); 13C NMR (101 MHz, CDCl3): δ 171.0, 137.3, 134.0, 130.4, 
128.6, 125.9, 125.6, 42.7, 38.8, 18.9, 14.1, 13.0. The spectroscopic properties for this compound were 
consistent with the data available in the literature.263-264 
 
7.6.2.3 − Synthesis of 5-Membered Heteroaromatic Substrates 
For the synthesis of substrates 126a, 129, 130, 131, 132, 134a, 139, 145 see Section 7.5.1. 
134b was synthesised by Miss Ellie Lester. 
N,N-Diisopropyl-1H-pyrrole-3-carboxamide (151c) 
 
General Procedure H: Purification of the residue by FCC (hexane/EtOAc 80%) afforded the title 
compound (1.23 g, 71%) as colourless needles. vmax/cm-1: 3178 (m), 2957 (m), 2940 (m), 1582 (s); 1H 
NMR (400 MHz, CDCl3): δ 10.02 (1H, br. s, N-H), 7.02 – 6.79 (1H, m, C6-H), 6.69 – 6.48 (1H, m, C7-
H), 6.32 – 6.08 (1H, m, C5-H), 4.74 – 3.09 (2H, m, C2-H), 1.35 (12H, s, C1-H3); 13C NMR (101 MHz, 




CDCl3): δ 168.2 (C3), 120.8 (C4), 120.4 (C6), 117.9 (C7), 107.7 (C5), 47.6 (C2), 21.2 (C1); HRMS: 
(ESI+) calculated for C11H19N2O 195.1492. Found [M+H]+ 195.1489; m.p. 78–80 °C (CDCl3). 
N,N-Diisopropyl-1-methyl-1H-pyrrole-3-carboxamide (151a) 
 
To a flame-dried flask was added NaH (125 mg, 3.12 mmol, 60% in oil) and dry THF (4.40 mL) under 
nitrogen. To the stirred solution was added 151b (500 mg, 2.60 mmol) portion-wise and the resulting 
solution was stirred for 1 h. Methyl iodide (0.453 mL, 7.28 mmol) was added dropwise and the solution 
was stirred for 3 h, before being quenched with H2O (10 mL) and extracted with Et2O (3 ×10 mL). The 
organic extracts were combined, dried over Na2SO4 and concentrated in vacuo. Purification of the 
residue by FCC (CH2Cl2/EtOAc 20−30%) afforded the title compound (453 mg, 84%) as white needles. 
vmax/cm-1: 2954 (m), 2931 (m), 1603 (s), 1286 (s); 1H NMR (400 MHz, CDCl3): δ 6.92 (1H, t, J = 2.0 
Hz, C7-H), 6.50 (1H, t, J = 2.5 Hz, C6-H), 6.24 (1H, dd, J = 2.5, 2.0 Hz, C5-H), 4.24 – 3.73 (2H, m, 
C2-H), 3.63 (3H, s, C8-H3), 1.34 (12H, d, J = 6.5 Hz, C1-H3); 13C NMR (101 MHz, CDCl3): δ 166.8 
(C3), 123.9 (C7), 121.4 (C4), 121.2 (C6), 108.4 (C5), 48.1 (C2), 36.2 (C8), 21.1 (C1); HRMS: (ESI+) 
calculated for C12H21N2O 209.1648. Found [M+H]+ 209.1649; m.p. 84–86 °C (CDCl3). 
N,N-Diisopropyl-1-(triisopropylsilyl)-1H-pyrrole-3-carboxamide (151b) 
 
To a stirred solution of 151b (500 mg, 2.60 mmol) in dry THF (4 mL) under nitrogen, was added n-
BuLi (1.32 mL, 3.12 mmol, 2.36 M in hexanes) dropwise at -78 °C. The solution was stirred for 30 
minutes, before TIPSCl (0.612 mL, 2.86 mmol) was added dropwise. The mixture was warmed to 
ambient temperature and stirred for an additional 30 minutes, before the reaction was quenched with 
saturated aq. NH4Cl (10 mL) and extracted with EtOAc (3 × 10 mL). The organic extracts were 
combined, dried over Na2SO4 and concentrated in vacuo. Purification of the residue by FCC 
(hexane/EtOAc 10%) afforded the title compound (772 mg, 85%) as a colourless oil. vmax/cm-1: 2950 
(m), 2868 (m), 1618 (s), 1243 (s); 1H NMR (400 MHz, CDCl3): δ 7.08 (1H, dd, J = 2.5, 1.5 Hz, C5-H), 
6.66 (1H, t, J = 2.5 Hz, C7-H), 6.37 (1H, dd, J = 2.5, 1.5 Hz, C6-H), 4.39 – 3.67 (2H, m, C2-H), 1.49 – 
1.22 (15H, m, C1-H3, C8-H), 1.08 (18H, d, J = 7.5 Hz, C9-H3); 13C NMR (101 MHz, CDCl3): δ 167.6 
(C3), 126.6 (C5), 123.7 (C7), 123.4 (C4), 110.2 (C6), 48.2 (C2), 21.3 (C1), 17.9 (C9), 11.7 (C8); HRMS: 
(ESI+) calculated for C20H39N2OSi 351.2826. Found [M+H]+ 351.2829. 






To a flame-dried flask was added pyrrole (1.57 mL, 22.6 mmol) in dry THF (36 mL) under nitrogen. n-
BuLi (17.3 mL, 22.1 mmol, 1.6 M in hexanes) was added dropwise at -78 °C and the solution was 
stirred for 30 minutes, before TIPSCl (5.33 mL, 24.9 mmol) was added dropwise. The solution was 
stirred for 4 h before being warmed to ambient temperature. The reaction was quenched by the addition 
of NH4Cl (50 mL) and extracted with EtOAc (3 × 50 mL). The organic extracts were combined, dried 
over Na2SO4 and concentrated in vacuo to afford 1-(triisopropylsilyl)-1H-pyrrole (4.57 g, 90%) as a 
colourless oil. The title compound was used in the next step without further purification. 
To a solution of 1-(triisopropylsilyl)-1H-pyrrole (4.50 g, 20.1 mmol) in dry THF (21 mL) was added 
NBS (3.94 mg, 22.2 mmol) at -78 °C. The solution was stirred for 1 h before being warmed to ambient 
temperature. The solution was concentrated in vacuo. The residue was dissolved in EtOAc and washed 
with saturated aq. NaHCO3 (15 mL). The organic extract was dried over Na2SO4 and concentrated in 
vacuo. Purification of the residue by FCC (hexane/EtOAc 3%) afforded the title compound (6.08 mg, 
quantitative) as a colourless oil. 1H NMR (400 MHz, CDCl3): δ 6.72 (1H, d, J = 1.5 Hz), 6.67 (1H, t, J 
= 2.5 Hz), 6.29 (1H, dd, J = 2.5, 1.5 Hz), 1.41 (3H, h, J = 7.5 Hz,), 1.09 (18H, d, J = 7.5 Hz); 13C NMR 
(101 MHz, CDCl3): δ 124.8, 123.4, 113.2, 98.0, 17.9, 11.7. The spectroscopic properties for this 
compound were consistent with the data available in the literature.265 
3-Bromo-N,N-diisopropyl-1H-pyrrole-1-carboxamide 
 
To a flame-dried flask was added 3-bromo-1-(triisopropylsilyl)-1H-pyrrole (1.00 g, 3.31 mmol) in THF 
(10 mL) under nitrogen. TBAF (1M in THF, 3.31 mL) was added dropwise and the resulting solution 
was stirred at ambient temperature for 30 minutes. The reaction mixture was diluted with Et2O (20 mL) 
and washed with water (10 mL) and brine (10 mL). The organic extract was dried over Na2SO4 and 
concentrated in vacuo. The resulting residue was used without further purification.  
To a suspension of NaH (60% in oil, 159 mg, 3.97 mmol) in dry THF (3 mL) at 0 °C was added the 
above residue in dry THF (3.7 mL), dropwise over 10 minutes. The resulting solution was stirred at 
0 °C for 2 h before diisopropyl carbomoyl chloride (596 mg, 3.64 mmol) in THF (3.0 mL) was added 
dropwise over 10 minutes. After stirring for 15 minutes the solution was warmed to ambient temperature 




and stirred for a further 1 h. The reaction was quenched by the addition of water (10 mL) and extracted 
with Et2O (3 × 10 mL). The organic extracts were combined, dried over Na2SO4 and concentrated in 
vacuo. Purification of the residue by FCC (toluene/CH2Cl2 15%) afforded the title product (550 mg, 
61%) as a colourless oil. vmax/cm-1: 2971 (m), 1685 (m), 1430 (s), 1321 (s); 1H NMR (400 MHz, CDCl3): 
δ 6.95 (1H, dd, J = 2.5, 1.5 Hz, C7-H), 6.90 (1H, dd, J = 3.0, 2.5 Hz, C4-H), 6.22 (1H, dd, J = 3.0, 1.5 
Hz, C5-H), 3.81 (1H, p, J = 6.5 Hz, C2-H), 1.36 (12H, d, J = 6.5 Hz, C1-H3); 13C NMR (101 MHz, 
CDCl3): δ 151.5 (C3), 120.9 (C4), 119.5 (C7), 112.9 (C5), 98.7 (C6), 48.8 (C2), 21.1 (C1); HRMS: 
(ESI+) calculated for C11H18N2O79Br 273.0597. Found [M+H]+ 273.0602. 
N,N-Diisopropyl-3-phenyl-1H-pyrrole-1-carboxamide (126e) 
 
An oven-dried re-sealable tube, fitted with a magnetic stirrer bar, was charged with 3-bromo-N,N-
diisopropyl-1H-pyrrole-1-carboxamide (100 mg, 0.366 mmol), phenylboronic acid (78.0 mg, 0.640 
mmol), Na2CO3 (77.6 mg, 0.732 mmol) and Pd(PPh3)4 (21.1 mg, 0.018 mmol). The tube was fitted with 
a rubber septum and purged with nitrogen. EtOH/H2O/DME (0.73:0.73:2.20 mL) was added and the 
tube was fitted with a Young’s tap. The reaction mixture was then heated to 100 °C for 16 h before 
being cooled to ambient temperature and quenched with water (5 mL). The mixture was extracted with 
Et2O (3 × 5 mL) and the organic extracts were combined, dried over Na2SO4 and concentrated in vacuo. 
Purification of the residue by FCC (hexane/EtOAc 10%) afforded the title compound (56 mg, 57%) as 
a colourless oil. vmax/cm-1: 2970 (m), 2981 (m), 1683 (s), 1431 (s); 1H NMR (400 MHz, CDCl3): δ 7.58 
– 7.48 (2H, m, C9-H), 7.35 (2H, dd, J = 8.5, 7.0 Hz, C10-H), 7.27 (1H, dd, J = 2.0, 2.0 Hz, C4-H), 7.24 
– 7.16 (1H, m, C11-H), 7.00 (1H, dd, J = 3.0, 2.0 Hz, C7-H), 6.54 (1H, dd, J = 3.0, 2.0 Hz, C5-H), 3.88 
(2H, hept, J = 6.5 Hz, C2-H), 1.39 (12H, d, J = 6.5 Hz, C1-H3); 13C NMR (101 MHz, CDCl3): δ 152.4 
(C3), 134.7 (C8), 128.7 (C10), 126.7 (C6), 126.7 (C15), 125.4 (C11), 121.0 (C7), 116.3 (C4), 108.5 









7.6.3 − Hydroarylation Reactions 
7.6.3.1 Alkene Hydroarylation with Benzamide Substrates 
N,N-Diethyl-2-(2-phenylpropan-2-yl)benzamide (148ca’) 
 
General Procedure P: The reaction was carried out with styrene derivative 147a’ (400 mol%) and was 
run for 72 h. Purification of the residue by FCC (hexane/EtOAc 20%) afforded the title compound (28.5 
mg, 67%) as an orange oil. vmax/cm-1: 2974 (m), 2939 (m), 1627 (m), 1423 (s); 1H NMR (400 MHz, 
CDCl3): δ 7.47 – 7.41 (1H, m, C8-H), 7.34 – 7.27 (1H, m, C7-H), 7.26 – 7.15 (4H, m, C13-H, C14-H), 
7.18 (1H, ddd, J = 7.5, 1.0, 1.0 Hz, C6-H), 7.16 – 7.10 (1H, m, C15-H), 7.03 (1H, dd, J = 7.5, 1.0 Hz, 
C5-H), 3.10 – 2.97 (2H, m, C2-H2), 2.86 (1H, dq, J = 14.5, 7.0 Hz, C2-H2), 2.36 (1H, dq, J = 14.5, 7.0 
Hz, C2-H2), 1.83 (3H, s, C11-H3), 1.69 (3H, s, C11-H3), 1.02 (3H, t, J = 7.0 Hz, C1-H3), 0.96 (3H, t, J 
= 7.0 Hz, C1-H3); 13C NMR (101 MHz, CDCl3): δ 171.6 (C3), 149.7 (C12), 146.6 (C9), 136.6 (C4), 
128.5 (C8), 128.5 (C7), 128.0 (C14), 127.5 (C5), 127.2 (C13), 125.8 (C6), 125.7 (C15), 44.3 (C10), 
44.0 (C2), 39.3 (C2), 33.0 (C11), 30.0 (C11), 13.6 (C1), 12.9 (C1); HRMS: (ESI+) calculated for 
C20H25NONa 318.1828. Found [M+Na]+ 318.1835. 
2-(2-([1,1'-Biphenyl]-4-yl)propan-2-yl)-N,N-diethylbenzamide (148cb’) 
 
General Procedure P: The reaction was carried out with styrene derivative 147b’ (400 mol%) and was 
run for 72 h. Purification of the residue by FCC (hexane/EtOAc 0−20%) afforded the title compound 
(27.7 mg, 75%) as a yellow wax. vmax/cm-1: 2970 (m), 2930 (m), 1628 (s), 1487 (s), 1423 (s); 1H NMR 
(400 MHz, CDCl3): δ 7.57 (2H, dd, J = 8.0, 1.5 Hz, C17-H), 7.52 (1H, d, J = 8.5 Hz, C8-H), 7.49 (2H, 
d, J = 8.5 Hz, C18-H), 7.43 (2H, dd, J = 8.5, 7.0 Hz, C14-H), 7.36 – 7.30 (4H, m, C7-H, C13-H, C19-
H), 7.21 (1H, ddd, J = 7.5, 7.5, 1.5 Hz, C6-H), 7.05 (1H, dd, J = 7.5, 1.5 Hz, C5-H), 3.17 (1H, dq, J = 
14.0, 7.0 Hz, C2-H2), 3.06 (1H, dq, J = 14.0, 7.0 Hz, C2-H2), 2.88 (1H, dq, J = 14.0, 7.0 Hz, C2-H2), 
2.37 (1H, dq, J = 14.0, 7.0 Hz, C2-H2), 1.89 (3H, s, C11-H3), 1.73 (3H, s, C11-H3), 1.01 – 0.98 (3H, m, 
C1-H3), 0.97 – 0.94 (3H, m, C1-H3); 13C NMR (101 MHz, CDCl3): δ 171.6 (C3), 148.8 (C12), 146.7 
(C9), 141.1 (C16), 138.5 (C15), 136.6 (C4), 128.9 (C14), 128.6 (C7), 128.2 (C8), 127.8 (C13), 127.6 
(C5), 127.2 (C19), 127.0 (C17), 126.6 (C18), 125.9 (C6), 44.2 (C2), 44.1 (C10), 39.3 (C2), 33.1 (C11), 








General Procedure P: The reaction was carried out with styrene derivative 147b’ (400 mol%) and was 
run for 72 h. Purification of the residue by FCC (hexane/EtOAc 10−30%) afforded the title compound 
(16.4 mg, 48%) as a colourless wax. vmax/cm-1: 2961 (m), 2925 (m), 1633 (s), 1487 (s); 1H NMR (400 
MHz, CDCl3): δ 7.63 (1H, dd, J = 7.5, 1.0 Hz, C7-H), 7.61 – 7.54 (2H, m, C16-H), 7.52 – 7.48 (2H, m, 
C13-H), 7.47 – 7.39 (2H, m, C17-H), 7.41 – 7.29 (4H, m, C6-H, C12-H, C18-H), 7.20 (1H, ddd, J = 
7.5, 1.5, 1.5 Hz, C5-H), 6.98 (1H, dd, J = 7.5, 1.5 Hz, C4-H), 2.57 (3H, s, C1-H3), 2.27 (3H, s, C1-H3), 
1.91 (3H, s, C10-H3), 1.74 (3H, s, C10-H3); 13C NMR (101 MHz, CDCl3): δ 171.4 (C2), 148.2 (C11), 
147.0 (C8), 141.1 (C15), 138.5 (C14), 136.3 (C3), 129.0 (C17), 128.7 (C6), 128.1 (C12), 128.0 (C4), 
127.4 (C7), 127.3 (C18), 127.0 (C16), 126.4 (C13), 126.0 (C5), 43.7 (C9), 39.4 (C1), 34.2 (C1), 33.1 
(C10), 29.8 (C10); HRMS: (ESI+) calculated for C24H25NO 344.2009. Found [M+H]+ 344.2011. 
(2-(2-([1,1'-Biphenyl]-4-yl)propan-2-yl)phenyl)(pyrrolidin-1-yl)methanone (148fb’) 
 
General Procedure P: The reaction was carried out with styrene derivative 147b’ (400 mol%) and was 
run for 72 h. Purification of the residue by FCC (hexane/EtOAc 0−40%) afforded the title compound 
(18.9 mg, 51%) as a colourless wax. vmax/cm-1: 2969 (m), 2871 (m), 1621 (s), 1417 (s); 1H NMR (400 
MHz, CDCl3): δ 7.66 (1H, d, J = 7.5 Hz, C8-H), 7.58 – 7.51 (2H, m, C17-H), 7.47 (2H, d, J = 8.0 Hz, 
C14-H), 7.45 – 7.41 (2H, m, C18-H), 7.42 – 7.28 (4H, m, C7-H, C13-H, C19-H), 7.27 – 7.16 (1H, m, 
C6-H), 7.06 (1H, dd, J = 7.5, 1.5 Hz, C5-H), 3.37 – 3.29 (1H, m, C2-H2), 2.97 – 2.87 (1H, m, C2-H2), 
2.86 – 2.75 (1H, m, C2-H2), 2.52 – 2.40 (1H, m, C2-H2), 1.96 (3H, s, C11-H3), 1.73 (3H, s, C11-H3), 
1.62 – 1.38 (3H, m, C1-H2), 1.29 – 1.15 (1H, m, C1-H2); 13C NMR (101 MHz, CDCl3): δ 169.9 (C3), 
148.2 (C12), 146.9 (C9), 141.1 (C16), 138.5 (C15), 137.5 (C4), 129.0 (C18), 128.8 (C7), 128.2 (C5), 
128.0 (C13), 127.3 (C19), 127.1 (C8), 127.0 (17), 126.4 (C14), 126.2 (C6), 48.2 (C2), 45.0 (C2), 43.6 
(C10), 33.4 (C11), 29.9 (C11), 25.4 (C1), 24.2 (C1); HRMS: (ESI+) calculated for C26H27NO 370.2165. 
Found [M+H]+ 370.2168. 
 
 






General Procedure P: The reaction was carried out with styrene derivative 147b’ (400 mol%) and was 
run for 72 h. Purification of the residue by FCC (hexane/EtOAc 0−20%) afforded the title compound 
(12.0 mg, 31%) as an orange oil. vmax/cm-1: 2930 (m), 2852 (m), 1627 (s), 1430 (s); 1H NMR (400 MHz, 
CDCl3): δ 7.60 – 7.55 (2H, m, C18-H), 7.55 – 7.51 (1H, m, C9-H), 7.51 – 7.47 (2H, m, C15-H), 7.47 – 
7.39 (2H, m, C19-H), 7.39 – 7.30 (4H, m, C8-H, C14-H, C20-H), 7.23 – 7.16 (1H, m, C7-H), 7.03 (1H, 
dd, J = 7.5, 1.5 Hz, C6-H), 4.18 – 4.02 (1H, m, C3-H2), 3.08 – 2.90 (1H, m, C3-H2), 2.43 – 2.27 (1H, 
m, C3-H2), 2.28 – 2.13 (1H, m, C3-H2), 1.88 (3H, s, C12-H3), 1.74 (3H, s, C12-H3), 1.71 – 1.60 (1H, 
m, C2-H2), 1.54 – 1.35 (2H, m, C2-H2), 1.35 – 1.25 (3H, m, C1-H2, C2-H2); 13C NMR (101 MHz, 
CDCl3): δ 170.1 (C4), 148.6 (C13), 146.8 (C10), 141.2 (C17), 138.5 (C16), 136.3 (C5), 128.9 (C19), 
128.6 (C8), 128.0 (C9), 128.0 (C14), 127.5 (C6), 127.2 (C20), 127.1 (C18), 126.6 (C15), 126.0 (C7), 
48.5 (C3), 43.9 (C11), 41.9 (C3), 33.0 (C12), 30.0 (C12), 25.8 (C1), 25.5 (C2), 24.7 (C2); HRMS: (ESI+) 




General Procedure P: The reaction was carried out with styrene derivative 147b’ (400 mol%) and was 
run for 72 h. Purification of the residue by FCC (hexane/EtOAc 0−20%) afforded the title compound 
(23.9 mg, 62%) as an orange oil. vmax/cm-1: 2968 (m), 2929 (m), 1628 (s), 1486 (s); 1H NMR (400 MHz, 
CDCl3): δ 7.62 – 7.53 (2H, m, C17-H), 7.48 (2H, d, J = 8.0 Hz, C14-H), 7.46 – 7.41 (2H, m, C18-H), 
7.38 (1H, d, J = 8.0 Hz, C8-H), 7.36 – 7.31 (3H, m, C13-H, C19-H), 7.13 (1H, dd, J = 8.0, 2.0 Hz, C7-
H), 6.91 – 6.84 (1H, m, C5-H), 3.26 – 3.03 (2H, m, C2-H2), 2.91 (1H, dq, J = 14.5, 7.5 Hz, C2-H2), 
2.39 (1H, dq, J = 14.5, 7.5 Hz, C2-H2), 2.31 (3H, s, C20-H3), 1.86 (3H, s, C11-H3), 1.71 (3H, s, C11-
H3), 1.09 – 0.92 (6H, m, C1-H3); 13C NMR (101 MHz, CDCl3): δ 171.8 (C3), 149.1 (C12), 143.7 (C9), 
141.1 (C16), 138.4 (C15), 136.4 (C4), 135.4 (C6), 129.3 (C7), 128.9 (C18), 128.3 (C8), 128.2 (C5), 
127.7 (C13), 127.2 (C19), 127.0 (C17), 126.6 (C14), 44.1 (C2), 43.7 (C10), 39.3 (C2), 33.0 (C11), 30.0 
(C11), 20.8 (C20), 13.7 (C1), 12.9 (C1); HRMS: (ESI+) calculated for C27H31NO 386.2478. Found 
[M+Na]+ 386.2475. 
 







General Procedure P: The reaction was carried out with styrene derivative 147b’ (400 mol%) and was 
run for 72 h. Purification of the residue by FCC (hexane/EtOAc 0−30%) afforded the title compound 
(21.0 mg, 52%) as a colourless oil. vmax/cm-1: 2966 (m), 2930 (m), 1630 (s), 1466 (s); 1H NMR (400 
MHz, CDCl3): δ 7.60 – 7.54 (2H, m, C17-H), 7.53 – 7.46 (2H, m, C14-H), 7.45 – 7.38 (3H, m, C8-H, 
C18-H), 7.36 – 7.30 (3H, m, C13-H, C19-H), 6.86 (1H, dd, J = 9.0, 3.0 Hz, C7-H), 6.58 (1H, d, J = 3.0 
Hz, C5-H), 3.79 (3H, s, C20-H3), 3.23 – 3.04 (2H, m, C2-H2), 2.93 (1H, dq, J = 14.5, 7.0 Hz, C2-H2), 
2.39 (1H, dq, J = 14.5, 7.0 Hz, C2-H2), 1.85 (3H, s, C11-H3), 1.70 (3H, s, C11-H3), 1.03 – 0.94 (6H, m, 
C1-H3); 13C NMR (101 MHz, CDCl3): δ 171.3 (C3), 157.3 (C6), 149.2 (C12), 141.1 (C16), 138.8 (C9), 
138.4 (C15), 137.5 (C4), 129.7 (C8), 128.9 (C18), 127.7 (C13), 127.2 (C19), 127.0 (C17), 126.6 (C14), 
114.1 (C7), 112.9 (C5), 55.4 (C20), 44.1 (C2), 43.4 (C10), 39.3 (C2), 33.2 (C11), 30.1 (C11), 13.8 (C1), 




General Procedure P: The reaction was carried out with styrene derivative 147b’ (400 mol%) and was 
run for 72 h. Purification of the residue by FCC (hexane/EtOAc 0−30%) afforded the title compound 
(9.10 mg, 18%) as a yellow oil. vmax/cm-1: 2974 (m), 2929 (m), 1629 (s), 1359 (s); 1H NMR (400 MHz, 
CDCl3): δ 7.75 (1H, dd, J = 8.0, 1.5 Hz, C7-H), 7.58 – 7.53 (2H, m, C17-H), 7.58 – 7.40 (6H, m, C5-
H, C8-H, C14-H, C18-H), 7.37 – 7.27 (3H, m, C13-H, C19-H), 3.18 – 3.05 (2H, m, C2-H2), 2.87 (1H, 
dq, J = 14.0, 7.0 Hz, C2-H2), 2.38 (1H, dq, J = 14.0, 7.0 Hz, C2-H2), 1.87 (3H, s, C11-H3), 1.72 (3H, s, 
C11-H3), 1.32 (12H, s, C21-H3), 1.01 – 0.91 (6H, m, C1-H3); 13C NMR (101 MHz, CDCl3): δ 171.7 
(C3), 149.8 (C9), 148.7 (C12), 141.1 (C6), 138.5 (C15), 136.0 (C4), 135.0 (C7), 134.3 (C5), 128.9 
(ArCH), 127.8 (C13), 127.7 (C8), 127.2 (C19), 127.1 (C17), 126.7 (ArCH), 84.0 (C20), 44.4 (C10), 
44.2 (C2), 39.3 (C2), 33.0 (C11), 29.9 (C11), 25.0 (C21), 13.6 (C1), 13.0 (C1); HRMS: (ESI+) 
calculated for C32H40NO3B 498.3174. Found [M+H]+ 498.3163. 
Note: C6 was not observed by 13C NMR. 
 






General Procedure P: The reaction was carried out with styrene derivative 147b’ (400 mol%) and was 
run for 72 h. Purification of the residue by FCC (hexane/EtOAc 0−20%) afforded the title compound 
(28.1 mg, 73%) as a yellow oil. vmax/cm-1: 2968 (m), 2934 (m), 1626 (s), 1423 (s); 1H NMR (400 MHz, 
CDCl3): δ 7.60 – 7.53 (2H, m, C17-H), 7.50 – 7.46 (2H, m, C14-H), 7.43 (2H, dd, J = 7.5, 1.5 Hz, C18-
H), 7.36 – 7.30 (4H, m, C8-H, C13-H, C19-H), 7.02 (1H, dd, J = 7.5, 1.5 Hz, C6-H), 6.94 (1H, d, J = 
7.5 Hz, C5-H), 3.20 – 2.97 (2H, m, C2-H2), 2.88 (1H, dq, J = 14.5, 7.5 Hz, C2-H2), 2.37 (3H, s, C20-
H3), 2.35 – 2.27 (1H, m, C2-H3), 1.88 (3H, s, C11-H3), 1.72 (3H, s, C11-H3), 1.01 – 0.91 (6H, m, C1-
H3); 13C NMR (101 MHz, CDCl3): δ 171.8 (C3), 148.9 (C12), 146.6 (C9), 141.2 (C16), 138.4 (C15), 
138.2 (C7), 133.8 (C4), 128.9 (C18), 128.8 (C8), 127.8 (C13), 127.6 (C5), 127.2 (C19), 127.0 (C17), 
126.6 (C14), 126.5 (C6), 44.2 (C2), 43.9 (C10), 39.3 (C2), 33.2 (C11), 30.0 (C11), 21.7 (C20), 13.7 
(C1), 13.0 (C1); HRMS: (ESI+) calculated for C27H31NO 386.2478. Found [M+H]+ 386.2474. 
2-(2-([1,1'-Biphenyl]-4-yl)propan-2-yl)-N,N-diethyl-4-methoxybenzamide (148nb’) 
 
General Procedure P: The reaction was carried out with styrene derivative 147b’ (400 mol%) and was 
run for 72 h. Purification of the residue by FCC (hexane/EtOAc 0−30%) afforded the title compound 
(26.2 mg, 65%) as an orange oil. vmax/cm-1: 2968 (m), 2938 (m), 1619 (s), 1423 (s); 1H NMR (400 MHz, 
CDCl3): δ 7.59 – 7.53 (2H, m, C17-H), 7.50 – 7.40 (4H, m, C14-H, C18-H), 7.36 – 7.29 (3H, m, C13-
H, C19-H), 7.10 (1H, d, J = 2.5 Hz, C8-H), 6.99 (1H, d, J = 8.5 Hz, C5-H), 6.73 (1H, dd, J = 8.5, 2.5 
Hz, C6-H), 3.82 (3H, s, C20-H3), 3.12 (1H, dq, J = 14.0, 7.0 Hz, C2-H2), 3.02 (1H, dq, J = 14.0, 7.0 
Hz, C2-H2), 2.87 (1H, dq, J = 14.0, 7.0 Hz, C2-H2), 2.31 (1H, dq, J = 14.0, 7.0 Hz, C2-H2), 1.90 (3H, 
s, C11-H3), 1.71 (3H, s, C11-H3), 0.94 (6H, t, J = 7.0 Hz, C1-H3); 13C NMR (101 MHz, CDCl3): δ 171.5 
(C3), 159.6 (C7), 148.9 (C9), 148.4 (C12), 141.1 (C16), 138.5 (C15), 129.4 (C4), 128.9 (C5), 128.9 
C18), 127.7 (C13), 127.2 (C19), 127.0 (C14), 126.6 (C17), 114.9 (C8), 109.8 (C6), 55.4 (C20), 44.2 
(C2), 44.1 (C10), 39.3 (C2), 33.3 (C11), 29.8 (C11), 13.8 (C1), 13.0 (C1); HRMS: (ESI+) calculated for 
C27H31NO2 402.2428. Found [M+H]+ 402.2423. 
 
 






General Procedure P: The reaction was carried out with styrene derivative 147b’ (400 mol%) and 
was run for 72 h. The title product was observed by 1H NMR analysis of the crude material. 
Characteristic 1H NMR peaks: 1H NMR (400 MHz, CDCl3): δ 3.07 – 2.97 (2H, m), 2.88 (1H, dq, J = 
14.5, 7.0 Hz), 2.69 (1H, dq, J = 14.5, 7.0 Hz), 1.79 (3H, s), 1.60 (3H, s), 0.85 (3H, t, J = 7.0 Hz), 0.82 
(3H, t, J = 7.0 Hz). 
N,N-Diethyl-2-(2-(4-fluorophenyl)propan-2-yl)benzamide (148cc’) 
 
General Procedure P: The reaction was carried out with styrene derivative 147c’ (400 mol%) and was 
run for 72 h. Purification of the residue by FCC (hexane/EtOAc 0−20%) afforded the title compound 
(23.1 mg, 74%) as a yellow oil. vmax/cm-1: 2970 (m), 2934 (m), 1627 (s), 1507 (s); 1H NMR (400 MHz, 
CDCl3): δ 7.42 (1H, dd, J = 8.0, 1.0 Hz, C8-H), 7.30 (1H, ddd, J = 8.0, 1.5, 1.0 Hz, C7-H), 7.24 – 7.16 
(3H, m, C6-H, C13-H), 7.03 (1H, dd, J = 7.5, 1.5 Hz, C5-H), 6.98 – 6.88 (2H, m, C14-H), 3.25 – 3.09 
(2H, m, C2-H2), 2.87 (1H, dq, J = 14.5, 7.0 Hz, C2-H2), 2.44 (1H, dq, J = 14.5, 7.0 Hz, C2-H2), 1.81 
(3H, s, C11-H3), 1.67 (3H, s, C11-H3), 1.03 (3H, t, J = 7.0 Hz, C1-H3), 0.99 (3H, t, J = 7.0 Hz, C1-H3); 
13C NMR (101 MHz, CDCl3): δ 171.6 (C3), 161.0 (d, J = 244.0 Hz, C15), 146.5 (C9), 145.6 (d, J = 3.0 
Hz, C12), 136.4 (C4), 128.77 (d, J = 7.5 Hz, C13), 128.7 (C7), 128.3 (C8), 127.6 (C5), 126.0 (C6), 
114.56 (d, J = 20.9 Hz, C14), 44.1 (C2), 43.9 (C10), 39.2 (C2), 33.0 (C11), 30.3 (C11), 13.7 (C1), 12.9 
(C1); 19F NMR (377 MHz, CDCl3) δ -118.07 (ddd, J = 8.5, 5.5 Hz); HRMS: (ESI+) calculated for 




General Procedure P: The reaction was carried out with styrene derivative 147d’ (400 mol%) and was 
run for 72 h. Purification of the residue by FCC (hexane/EtOAc 0–30%) afforded the title compound 
(9.50 mg, 25%) as a yellow oil. vmax/cm-1: 2968 (m), 2928 (m), 1628 (s), 1423 (s); 1H NMR (400 MHz, 
CDCl3): δ 7.43 (1H, dd, J = 8.0, 1.0 Hz, C8-H), 7.39 – 7.34 (2H, m, C14-H), 7.31 (1H, ddd, J = 8.0, 
1.5, 1.0 Hz, C7-H), 7.20 (1H, ddd, J = 8.0, 1.5, 1.0 Hz, C6-H), 7.17 – 7.09 (2H, m, C13-H), 7.04 (1H, 




dd, J = 8.0, 1.5 Hz, C5-H), 3.22 – 3.07 (2H, m, C2-H2), 2.87 (1H, dq, J = 14.5, 7.0 Hz, C2-H2), 2.44 
(1H, dq, J = 14.5, 7.0 Hz, C2-H2), 1.80 (3H, s, C11-H3), 1.66 (3H, s, C11-H3), 1.05 – 0.97 (6H, m, C1-
H3); 13C NMR (101 MHz, CDCl3): δ 171.5 (C3), 148.9 (C12), 146.2 (C9), 136.4 (C4), 131.0 (C14), 
129.2 (C13), 128.7 (C7), 128.3 (C8), 127.7 (C5), 126.1 (C6), 119.6 (C15), 44.1 (C10), 44.1 (C2), 39.2 
(C2), 32.8 (C11), 30.1 (C11), 13.7 (C1), 12.8 (C1); HRMS: (ESI+) calculated for C20H24NO79Br 
374.1114. Found [M+H]+ 374.1105. 
N,N-Diethyl-2-(2-(4-methoxyphenyl)propan-2-yl)benzamide (148ce’) 
 
General Procedure P: The reaction was carried out with styrene derivative 147e’ (400 mol%) and 
was run for 72 h. The title product was observed by 1H NMR analysis of the crude material. 
Characteristic 1H NMR peaks: 1H NMR (400 MHz, CDCl3): δ 3.21 – 3.09 (2H, m), 1.79 (3H, s), 1.65 
(3H, s), 1.05 – 0.99 (3H, m), 0.96 (3H, t, J = 7.1 Hz). 
2-(2-(3-Chlorophenyl)propan-2-yl)-N,N-diethylbenzamide (148cf’) 
  
General Procedure P: The reaction was carried out with styrene derivative 147f’ (400 mol%), 
Ir(cod)2]BARF (7.5 mol%) and (rac)-L-15f (7.5 mol%) and was run for 72 h. Purification of the residue 
by FCC (hexane/EtOAc 0−30%) afforded the title compound (21.5 mg, 65%) as a yellow oil. vmax/cm-
1: 2959 (m), 2931 (m), 1629 (s), 1423 (s); 1H NMR (400 MHz, CDCl3): δ 7.46 (1H, dd, J = 8.0, 1.0 Hz, 
C8-H), 7.32 (1H, ddd, J = 8.0, 1.5, 1.0 Hz, C7-H), 7.22 (1H, dd, J = 7.5, 1.0 Hz, C6-H), 7.20 – 7.15 
(3H, m, C13-H, C16-H, C17-H), 7.13 (1H, ddd, J = 7.5, 4.0, 2.0 Hz, C15-H), 7.05 (1H, dd, J = 7.5, 1.5 
Hz, C5-H), 3.23 – 3.05 (2H, m, C2-H2), 2.86 (1H, dq, J = 14.5, 7.0 Hz, C2-H2), 2.41 (1H, dq, J = 14.5, 
7.0 Hz, C2-H2), 1.82 (3H, s, C11-H3), 1.66 (3H, s, C11-H3), 1.06 – 0.95 (6H, m, C1-H3); 13C NMR (101 
MHz, CDCl3): δ 171.4 (C3), 151.9 (C12), 145.9 (C9), 136.5 (C4), 133.8 (C14), 129.3 (C16), 128.8 
(C7), 128.1 (C8), 127.7 (C5), 127.6 (ArCH), 126.1 (C6), 126.0 (C15), 125.6 (ArCH), 44.4 (C10), 43.9 
(C2), 39.4 (C2), 33.0 (C11), 29.9 (C11), 13.8 (C1), 13.0 (C1); HRMS: (ESI+) calculated for C20H24NOCl 











General Procedure P: The reaction was carried out with styrene derivative 147g’ (400 mol%) and was 
run for 72 h. Purification of the residue by FCC (hexane/EtOAc 0−30%) afforded the title compound 
(22.9 mg, 70%) as an orange oil. vmax/cm-1: 2967 (m), 2933 (m), 1627 (s), 1424 (s); 1H NMR (400 MHz, 
CDCl3): δ 7.40 (1H, dd, J = 8.0, 1.5 Hz, C8-H), 7.31 – 7.25 (1H, m, C7-H), 7.21 – 7.13 (2H, m, C6-H, 
C16-H), 7.03 (1H, dd, J = 7.5, 1.5 Hz, C5-H), 6.86 – 6.77 (2H, m, C13-H, C17-H), 6.69 (1H, dd, J = 
8.0, 3.5 Hz, C15-H), 3.76 (3H, s, C18-H3), 3.28 – 3.10 (2H, m, C2-H2), 2.91 (1H, dq, J = 14.5, 7.0 Hz, 
C2-H2), 2.44 (1H, dq, J = 14.5, 7.0 Hz, C2-H2), 1.80 (3H, s, C11-H3), 1.68 (3H, s, C11-H3), 1.03 (3H, 
t, J = 7.0 Hz, C1-H3), 0.98 (3H, t, J = 7.0 Hz, C1-H3);13C NMR (101 MHz, CDCl3): δ 171.7 (C3), 159.3 
(C14), 151.6 (C12), 146.4 (C9), 136.5 (C4), 128.9 (C16), 128.6 (C8), 128.5 (C7), 127.5 (C5), 125.8 
(C6), 120.0 (ArCH), 113.7 (ArCH), 110.5 (C15), 55.2 (C18), 44.4 (C10), 43.7 (C2), 39.1 (C2), 32.9 




General Procedure P: The reaction was carried out with styrene derivative 147h’ (400 mol%) and was 
run for 72 h. Purification of the residue by FCC (hexane/EtOAc 0−20%) afforded the title compound 
(6.00 mg, 23%) as a yellow oil. vmax/cm-1: 2957 (m), 2871 (m), 1633 (s), 1422 (s); 1H NMR (500 MHz, 
CDCl3): δ 7.40 (1H, dd, J = 8.0, 1.0 Hz, C8-H), 7.28 (1H, ddd, J = 8.0, 1.0, 1.0 Hz, C7-H), 7.17 (1H, 
ddd, J = 7.5, 1.0, 1.0 Hz, C6-H), 7.04 (1H, dd, J = 7.5, 1.0 Hz, C5-H), 3.77 (1H, dq, J = 13.5, 7.0 Hz, 
C2-H2), 3.34 (1H, dq, J = 13.5, 7.0 Hz, C2-H2), 3.19 (1H, dq, J = 13.5, 7.0 Hz, C2-H2), 3.04 (1H, dq, J 
= 13.5, 7.0 Hz, C2-H2), 1.81 (1H, ddd, J = 13.5, 11.5, 5.0 Hz, C12-H2), 1.60 – 1.50 (1H, m, C12-H2), 
1.35 (3H, s, C11-H3), 1.32 (3H, s, C11-H3), 1.24 (3H, t, J = 7.0 Hz, C1-H3), 1.19 – 1.10 (2H, m, C13-
H2), 1.08 (3H, t, J = 7.0 Hz, C1-H3), 0.83 (3H, t, J = 7.0 Hz, C14-H3); 13C NMR (126 MHz, CDCl3): δ 
173.1 (C3), 145.4 (C9), 136.3 (C4), 128.5 (C8), 128.3 (C7), 127.5 (C5), 125.6 (C6), 47.2 (C12), 43.4 
(C2), 39.8 (C10), 38.5 (C2), 29.4 (C11), 29.1 (Cf11), 18.3 (C13), 14.9 (C14), 13.4 (C1), 12.1 (C1); 
HRMS: (ESI+) calculated for C17H27NO 262.2165. Found [M+H]+ 262.2160. 
 
 






General Procedure P: The reaction was carried out with styrene derivative 147h’ (400 mol%) and 
was run for 72 h. Purification of the residue by FCC (hexane/EtOAc 0−20%) afforded the title 
compound (9.40 mg, 36%) as a colourless solid. vmax/cm
-1: 2956 (m), 2868 (m), 1633 (s), 1425 (s); 1H 
NMR (500 MHz, CDCl3): δ 7.38 – 7.30 (2H, m, C7-H, C8-H), 7.23 – 7.17 (1H, m, C6-H), 7.14 (1H, 
dd, J = 7.5, 1.5 Hz, C5-H), 3.99 – 3.82 (1H, m, C2-H2), 3.35 – 3.26 (2H, m, C2-H2), 3.25 – 3.02 (1H, 
m, C2-H2), 2.93 – 2.82 (1H, m, C10-H), 1.62 – 1.53 (1H, m, C13-H), 1.49 (2H, dq, J = 10.0, 7.0, 6.0 
Hz, C12-H2), 1.31 − 1.26 (3H, m, C1-H3), 1.22 – 1.16 (3H, m, C11-H3), 1.13 – 1.02 (3H, m, C1-H3), 
0.93 – 0.83 (6H, m, C14-H3); 13C NMR (126 MHz, CDCl3): δ 171.0 (C3), 170.8 (C3), 144.9 (C9), 144.3 
(C9), 136.7 (C4), 136.5 (C4), 129.0 (C8), 128.9 (C8), 126.5 (C7), 126.3 (C7), 125.9 (C6), 125.7 (C6), 
125.6 (C5), 125.4 (C5), 48.1 (C12), 46.9 (C12), 43.0 (C2), 43.0 (C2), 38.7 (C2), 38.6 (C2), 33.9 (C10), 
33.5 (C10), 25.9 (C13), 25.8 (C13), 23.3 (C14), 23.3 (C14), 23.0 (C14), 22.6 (C11), 22.4 (C14), 21.6 
(C11), 14.1 (C1), 14.0 (C1), 13.0 (C1), 12.9 (C1); HRMS: (ESI+) calculated for C17H27NO 
262.2165. Found [M+H]+ 262.2163. 
2-(2,3-Dimethylbutan-2-yl)-N,N-diethylbenzamide (148cn’) 
 
General Procedure P: The reaction was carried out with styrene derivative 147n’ (400 mol%) and was 
run for 72 h. The title product was observed by 1H NMR analysis of the crude material. Characteristic 
1H NMR peaks: 1H NMR (400 MHz, CDCl3): δ 3.13 – 3.02 (1H, m), 2.95 (1H, dq, J = 14.0, 7.0 Hz), 











7.6.3.2 Alkene Hydroarylation with Pyrrole Substrates 
N,N-Diisopropyl-1-methyl-2-(2-phenylpropan-2-yl)-1H-pyrrole-3-carboxamide (151aa’) 
 
General Procedure Q: The reaction was carried out with styrene derivative 147a’ (400 mol%) and 
was run for 48 h. Purification of the residue by FCC (hexane/EtOAc 30–50%) afforded the title 
compound (28.3 mg, 87%) as an orange oil. vmax/cm
-1: 2954 (m), 2929 (m), 1620 (s), 1440 (s); 1H NMR 
(400 MHz, CDCl3): δ 7.36 (2H, dd, J = 8.0, 1.0 Hz, C12-H), 7.23 (2H, dd, J = 8.0, 1.0 Hz, C13-H), 7.15 
– 7.06 (1H, m, C14-H), 6.41 (1H, d, J = 2.5 Hz, C6-H), 6.30 (1H, d, J = 2.5 Hz, C5-H), 3.99 – 3.10 
(2H, m, C2-H), 3.55 (3H, s, C8-H3), 1.70 (6H, s, C10-H3), 1.48 – 0.80 (12H, m, C1-H3); 13C NMR (101 
MHz, CDCl3): δ 168.2 (C3), 150.8 (C11), 132.8 (C7), 127.9 (C13), 126.7 (C12), 125.3 (C14), 119.9 
(C4), 119.7 (C5), 119.6 (C6), 39.1 (C9), 36.1 (C8), 31.2 (C10), 20.7 (C1); HRMS: (ESI+) calculated for 
C21H30N2ONa 349.2250. Found [M+H]+ 349.2267. 




General Procedure Q: The reaction was carried out with styrene derivative 147c’ (400 mol%) and was 
run for 48 h. Purification of the residue by FCC (hexane/EtOAc 20–40%) afforded the title compound 
(25.5 mg, 74%) as a colourless oil. vmax/cm-1: 2855 (m), 2932 (m), 1619 (s), 1506 (s); 1H NMR (400 
MHz, CDCl3): δ 7.37 – 7.28 (2H, m, C12-H), 6.94 – 6.83 (2H, m, C13-H), 6.41 (1H, d, J = 2.5 Hz, C6-
H), 6.31 (1H, d, J = 2.5 Hz, C5-H), 3.91 – 2.88 (2H, m, C2-H), 3.55 (3H, s, C8-H3), 1.68 (6H, s, C10-
H3), 1.32 – 0.92 (12H, m, C1-H3); 13C NMR (101 MHz, CDCl3): δ 168.0 (C3), 160.9 (d, J = 243.0 Hz, 
C14), 146.6 (d, J = 3.0 Hz, C11), 132.7 (C7), 128.2 (d, J = 7.5 Hz, C12), 119.8 (C4), 119.7 (C6), 119.6 
(C5), 114.36 (d, J = 21.0 Hz, C13), 49.2 (C2), 45.9 (C2), 38.7 (C9), 36.2 (C8), 31.4 (C10), 20.7 (C1); 
19F NMR (377 MHz, CDCl3): δ -119.29; HRMS: (ESI+) calculated for C21H29FNO 345.2337. Found 
[M+H]+ 345.2326. 






General Procedure Q: The reaction was carried out with styrene derivative 147j’ (400 mol%) and was 
run for 16 h. Purification of the residue by FCC (hexane/EtOAc 30%) afforded the title compound (25.0 
mg, 73%) as an orange oil. vmax/cm-1: 2954 (m), 2927 (m), 1619 (s), 1440 (s); 1H NMR (400 MHz, 
CDCl3): δ 7.31 (2H, dd, J = 8.0, 1.5 Hz, C14-H), 7.25 – 7.19 (2H, m, C15-H), 7.15 – 7.07 (1H, m, C16-
H), 6.41 (1H, d, J = 2.5 Hz, C6-H), 6.29 (1H, d, J = 2.5 Hz, C5-H), 4.01 – 3.58 (1H, m, C2-H), 3.55 
(3H, s, C8-H3), 3.40 – 2.96 (1H, m, C2-H), 2.35 – 2.20 (1H, m, C11-H2), 2.02 (1H, dq, J = 14.5, 7.5 
Hz, C11-H2), 1.65 (3H, s, C10-H3), 1.40 – 0.82 (12H, m, C1-H3), 0.71 (1H, t, J = 7.5 Hz, C12-H3); 13C 
NMR (101 MHz, CDCl3): δ 168.3 (C3), 149.4 (C13), 132.3 (C7), 127.8 (C15), 127.4 (C14), 125.2 
(C16), 120.3 (C5), 112.0 (C4), 119.6 (C6), 42.7 (C9), 36.2 (C8), 34.3 (C11), 26.6 (C10), 20.7 (C1), 9.2 
(C12); HRMS: (ESI+) calculated for C22H33N2O 341.2587. Found [M+H]+ 341.2582. 
Note: C2 was not observed by 13C NMR analysis. 
N,N-Diisopropyl-1-methyl-2-(2-methylpentan-2-yl)-1H-pyrrole-3-carboxamide (151ah’) 
 
General Procedure Q: The reaction was carried out with alkene derivative 147h’ (400 mol%) and was 
run for 48 h. Purification of the residue by FCC (hexane/EtOAc 20–30%) afforded the title compound 
(24.3 mg, 83%) as a yellow oil. vmax/cm-1: 2957 (m), 2929 (m), 1623 (s), 1439 (s); 1H NMR (400 MHz, 
CDCl3): δ 6.40 (1H, d, J = 2.5 Hz, C5/6-H), 6.29 (1H, d, J = 2.5 Hz, C5/6-H), 4.16 – 3.26 (2H, m, C2-
H), 3.54 (3H, s, C8-H3), 1.64 – 1.52 (2H, m, C11-H2), 1.39 – 1.07 (14H, m, C1-H3, C12-H2), 1.23 (6H, 
s, C10-H3), 0.86 (3H, t, J = 7.5 Hz, C13-H3); 13C NMR (101 MHz, CDCl3): δ 169.3 (C3), 131.8 (C7), 
119.7 (C4), 119.1 (C6/5), 118.9 (C6/5), 45.9 (C11), 36.1 (C8), 34.8 (C9), 29.2 (C10), 20.8 (C1), 18.3 
(C12), 15.0 (C13); HRMS: (ESI+) calculated for C18H32N2O 293.2587. Found [M+H]+ 293.2576. 
Note: C2 was not observed by 13C NMR analysis. 
 







General Procedure Q: The reaction was carried out with styrene derivative 147o’ (150 mol%) and 
was run for 72 h. Purification of the residue by FCC (hexane/EtOAc 20−40%) afforded the title 
compound (26.6 mg, 53%) as beige plates. vmax/cm-1: 2962 (m), 2928 (m), 2859(m), 1737 (s), 1611 (s); 
1H NMR (400 MHz, CDCl3): δ 7.15 – 7.08 (2H, m, C12-H, C13-H), 7.07 (1H, s, C16-H), 6.37 (1H, d, 
J = 2.5 Hz, C5/6-H), 6.31 (1H, d, J = 2.5 Hz, C5/6-H), 3.96 – 3.66 (1H, m, C2-H), 3.53 (3H, s, C8-H3), 
3.37 – 3.14 (1H, m, C2-H), 2.84 (2H, dd, J = 9.0, 4.0 Hz, C19-H2), 2.47 (1H, dd, J = 18.5, 9.0 Hz, C27-
H2), 2.42 – 2.32 (1H, m, C18-H), 2.30 – 2.17 (1H, m, CH), 2.17 – 2.08 (1H, m, CH), 2.08 – 1.85 (3H, 
m, CH), 1.67 (6H, d, J = 4.5 Hz, C10-H3), 1.64 – 1.12 (15H, m, CH, C1-H3), 0.87 (3H, s, C28-H3); 13C 
NMR (101 MHz, CDCl3): δ 221.2 (C25), 168.2 (C3), 148.1 (C11), 136.3 (C14), 135.4 (C15), 133.1 
(C7), 127.1 (C16), 124.8 (C12/13), 124.7 (C12/13), 119.9 (C4), 119.6 (C5/6), 119.6 (C5/6), 50.7 (CH), 
48.1 (C9), 44.5 (CH), 38.5 (CH), 38.4 (CH), 36.3 (C8), 36.0 (C27), 31.8 (CH), 31.2 (C10), 29.8 (C19), 
26.8 (CH), 25.8 (C18), 21.7 (C1), 20.7 (C23), 14.0 (C28); m.p. 268−270 °C (CDCl3). A mass could not 
be observed by ESI or MALDI. 
Note: C2 was not observed by 13C NMR analysis. 
(151ap’ C2) 
 
General Procedure Q: The reaction was carried out with styrene derivative 147p’ (400 mol%) and 
was run for 24 h. Purification of the residue by FCC (hexane/EtOAc 20−30%) afforded the title 
compound (14.3 mg, 33%) as an orange oil. vmax/cm
-1: 2956 (m), 2927 (m), 1602 (s), 1440 (s); 1H NMR 
(400 MHz, CDCl3): δ 6.65 (1H, d, J = 2.0 Hz, C6-H), 5.96 (1H, d, J = 2.0 Hz, C5-H), 4.64 – 4.22 (1H, 
m, C2-H), 4.19 (5H, ap. s, ferrocene), 4.12 – 4.07 (4H, m, ferrocene), 4.00 – 3.67 (1H, m, C2-H), 3.31 




(3H, s, C8-H3), 1.71 (6H, s, C10-H3), 1.41 – 1.19 (12H, m, C1-H3); 13C NMR (101 MHz, CDCl3): δ 
167.2 (C3), 140.8 (C7), 125.5 (C6), 118.2 (C4), 106.6 (C5), 68.7 (ferrocene), 67.6 (C11), 66.9 
(ferrocene), 49.1 (C2), 36.7 (C8), 34.4 (C9), 30.0 (C10), 21.3 (C1); HRMS: (ESI+) calculated for 




General Procedure Q: The reaction was carried out with styrene derivative 147p’ (400 mol%) and 
was run for 24 h. Purification of the residue by FCC (hexane/EtOAc 20−30%) afforded the title 
compound (11.0 mg, 25%, rotamers A:B) as an orange oil. vmax/cm-1: 2965 (m), 2928 (m), 1622 (s), 
1440 (s); 1H NMR (400 MHz, CDCl3): δ 6.37 (0.15H, d, J = 3.0 Hz, B, C6/7-H), 6.31 (0.85H, d, J = 3.0 
Hz, A, C6/7-H), 5.91 (0.15H, d, J = 3.0 Hz, B, C6/7-H), 5.73 (0.85H, d, J = 3.0 Hz, A, C6/7-H), 4.23 – 
4.07 (11H, m, A+B, ferrocene, C2-H), 3.55 (0.45H, s, B, C8-H3), 3.40 (2.55H, s, A, C8-H3), 2.04 (0.9H, 
s, B, C10-H3), 1.71 (5.1H s, A, C10-H3), 1.66 – 0.75 (12H, m, A+B, C1-H3); 13C NMR (101 MHz, 
CDCl3): δ 169.1 (C3), 133.7 (C5), 119.6 (pyrrole), 119.2 (pyrrole), 119.1 (C4), 68.6 (ferrocene), 67.0 
(C11), 66.7 (ferrocene), 46.6 (C2), 36.0 (C9), 34.4 (C8), 29.8 (C10), 20.8 (C1); HRMS: (ESI+) 
calculated for C25H35N2OFe 435.2094. Found [M+H]+ 435.2095. 
N,N-Diisopropyl-2-(2-phenylpropan-2-yl)-1H-pyrrole-1-carboxamide (152aa’) 
 
General Procedure Q: The reaction was carried out with styrene derivative 147a’ (400 mol%) and 
was run for 48 h. Purification of the residue by FCC (toluene/Et2O 1−2%) afforded the title compound 
(31. 3 mg, 72%) as a yellow oil. vmax/cm
-1: 2969 (m), 2933 (m), 1685 (s), 1423 (s), 1322 (s); 1H NMR 
(400 MHz, CDCl3): δ 7.32 – 7.28 (2H, m, C11-H), 7.27 – 7.21 (2H, m, C12-H), 7.17 – 7.10 (1H, m, 
C13-H), 6.57 (1H, dd, J = 3.0, 1.5 Hz, C4-H), 6.20 (1H, dd, J = 3.0, 1.5 Hz, C5-H), 6.14 – 6.07 (1H, m, 
C6-H), 3.30 (2H, h, J = 6.5 Hz, C2-H), 1.77 (6H, s, C9-H3), 1.12 (6H, d, J = 6.5 Hz, C1-H3), 1.04 – 
0.93 (6H, m, C1-H3); 13C NMR (101 MHz, CDCl3): δ 152.8 (C3), 148.8 (C10), 142.2 (C7), 128.2 (C12), 
126.7 (C11), 125.7 (C13), 120.1 (C4), 108.1 (C5), 107.4 (C6), 48.3 (C2), 40.0 (C8), 31.2 (C9), 20.7 
(C1), 20.1 (C1); HRMS: (ESI+) calculated for C20H29N2O 313.2274. Found [M+H]+ 313.2283. m.p. 63–
65 °C (CDCl3). 






General Procedure Q: The reaction was carried out with styrene derivative 147a’ (400 mol%) and 
was run for 48 h. Purification of the residue by FCC (hexane/Et2O 3%) afforded the title compound 
(3.50 mg, 8%) as an orange oil. vmax/cm-1: 2966 (m), 2928 (m), 1686 (s), 1430 (s); 1H NMR (400 MHz, 
CDCl3): δ 7.38 – 7.34 (2H, m, C9-H), 7.31 – 7.21 (6H, m, C9-H, C10-H), 7.20 – 7.09 (2H, m, C11-H), 
6.24 (1H, d, J = 2.0 Hz, C5-H), 6.03 (1H, d, J = 2.0 Hz, C5-H), 3.34 – 3.20 (2H, m, C2-H), 1.72 (6H, 
s, C7-H3), 1.62 (6H, s, C7-H3), 1.13 – 0.92 (12H, m, C1-H3); 13C NMR (101 MHz, CDCl3): δ 153.2 
(C3), 150.9 (C8), 148.9 (C8), 141.8 (C4), 132.7 (C4), 128.2 (C10), 127.9 (C10), 126.7 (C9), 126.5 (C9), 
125.6 (C11), 125.6 (C11), 116.9 (C5), 107.6 (C5), 40.1 (C7), 38.4 (C7), 31.2 (C2), 31.0 (C8), 20.7 (C1), 
20.2 (C1); HRMS: (ESI+) calculated for C29H38N2O 431.3057. Found [M+H]+ 431.3056. 
2-(2-(3-Chlorophenyl)propan-2-yl)-N,N-diisopropyl-1H-pyrrole-1-carboxamide (152af’) 
 
General Procedure Q: The reaction was carried out with styrene derivative (400 mol%) and was run 
for 48 h. Purification of the residue by FCC (hexane/EtOAc 0–2.5%) afforded the title compound (10.6 
mg, 31%) as a colourless oil. vmax/cm-1: 2971 (m), 2931 (m), 1688 (s), 1324 (s); 1H NMR (400 MHz, 
CDCl3): δ 7.26 – 7.23 (1H, m, C11-H), 7.20 – 7.17 (2H, m, C14-H, C15-H), 7.15 – 7.10 (1H, m, C13-
H), 6.57 (1H, dd, J = 3.5, 2.0 Hz, C4-H), 6.21 (1H, dd, J = 3.5, 2.0 Hz, C6-H), 6.12 – 6.09 (1H, m, C5-
H), 3.33 (1H, hept, J = 6.5 Hz, C2-H), 1.75 (6H, s, C9-H3), 1.14 (6H, d, J = 6.5 Hz, C1-H3), 1.05 – 0.95 
(6H, m, C1-H3); 13C NMR (101 MHz, CDCl3): δ 152.6 (C3), 151.0 (C10), 141.4 (C7), 134.0 (C12), 
129.4 (C15), 127.2 (C11), 126.0 (C13), 125.0 (C14), 120.4 (C4), 108.3 (C6), 107.6 (C5), 48.5 (C2), 
48.2 (C2), 40.1 (C8), 31.1 (C9), 20.8 (C1), 20.1 (C1); HRMS: (ESI+) calculated for C20H27N2OCl 











General Procedure Q: The reaction was carried out with styrene derivative (400 mol%) and was run 
for 72 h. Purification of the residue by FCC (hexane/EtOAc 0–5%) afforded the title compound (17.5 
mg, 53%) as a colourless oil. vmax/cm-1: 2970 (m), 2933 (m), 1685 (s), 1508 (s); 1H NMR (400 MHz, 
CDCl3): δ 7.25 – 7.06 (2H, m, C11-H), 6.94 – 6.75 (2H, m, C12-H), 6.49 (1H, dd, J = 3.5, 2.0 Hz, C4-
H), 6.11 (1H, dd, J = 3.5, 2.0 Hz, C6-H), 6.05 – 5.98 (1H, m, C5-H), 3.27 (2H, hept, J = 6.5 Hz, C2-
H), 1.67 (6H, s, C9-H3), 1.08 (6H, d, J = 6.5 Hz, C1-H3), 1.04 – 0.90 (6H, m, C1-H3); 13C NMR (101 
MHz, CDCl3): δ 161.09 (d, J = 243.5 Hz, C13), 152.8 (C3), 144.7 (d, J = 3.0 Hz, C10), 141.8 (C7), 
128.2 (d, J = 8.0 Hz, C11), 120.2 (C4), 114.7 (d, J = 20.9 Hz, C12), 108.2 (C6), 107.5 (C5), 48.5 (C2), 
39.7 (C8), 31.3 (C9), 20.7 (C1), 20.1 (C1); HRMS: (ESI+) calculated for C20H27N2OF 331.2180 Found 
[M+H]+ 331. 2169. 
2-(2-([1,1'-Biphenyl]-4-yl)propan-2-yl)-N,N-diisopropyl-1H-pyrrole-1-carboxamide (152ab’) 
 
General Procedure Q: The reaction was carried out with styrene derivative (400 mol%) and was run 
for 48 h. Purification of the residue by FCC (toluene/Et2O 0–2%) afforded the title compound (13.2 mg, 
34%) as a yellow oil. vmax/cm-1: 2968 (m), 2927 (m), 1687 (s), 1325 (s); 1H NMR (400 MHz, CDCl3): 
δ 7.58 – 7.51 (2H, m, C15-H), 7.49 – 7.45 (2H, m, C12-H), 7.44 – 7.39 (2H, m, C16-H), 7.39 – 7.35 
(2H, m, C11-H), 7.34 – 7.26 (1H, m, C17-H), 6.58 (1H, dd, J = 3.5, 2.0 Hz, C4-H), 6.24 (1H, dd, J = 
3.5, 2.0 Hz, C6-H), 6.17 – 6.08 (1H, m, C5-H), 3.38 – 3.23 (2H, m, C2-H), 1.81 (6H, s, C9-H3), 1.20 – 
1.06 (6H, m, C1-H3), 1.03 – 0.84 (6H, m, C1-H3); 13C NMR (101 MHz, CDCl3): δ 152.8 (C3), 147.9 
(C10), 142.2 (C7), 141.3 (C14), 138.5 (C13), 128.8 (C16), 127.2 (C11), 127.1 (C17), 127.1 (C15), 
127.0 (C12), 120.3 (C4), 108.1 (C6), 107.5 (C5), 48.4 (C2), 39.9 (C8), 31.1 (C9), 20.8 (C1), 20.1 (C1); 










General Procedure Q: The reaction was carried out with styrene derivative (400 mol%) and was run 
for 48 h. Purification of the residue by FCC (hexane/EtOAc 0–4%) afforded the title compound (14.8 
mg, 53%) as a colourless oil. vmax/cm-1: 2960 (m), 2934 (m), 1687 (s), 1324 (s); 1H NMR (400 MHz, 
CDCl3): δ 6.53 (1H, dd, J = 3.0, 2.0 Hz, C4-H), 6.09 – 6.04 (1H, m, C5-H), 5.95 (1H, dd, J = 3.0, 2.0 
Hz, C6-H), 3.51 (2H, hept, J = 6.5 Hz, C2-H), 1.76 – 1.61 (2H, m, C10-H2), 1.40 – 1.25 (12H, m, C1-
H3), 1.30 (6H, s, C9-H3), 1.24 – 1.12 (2H, m, C11-H2), 0.87 (3H, t, J = 7.0 Hz, C12-H3); 13C NMR (101 
MHz, CDCl3): δ 154.2 (C3), 141.5 (C7), 119.4 (C4), 107.6 (C5), 107.2 (C6), 48.6 (C2), 46.9 (C2), 45.0 
(C10), 36.0 (C8), 28.6 (C9), 20.6 (C1), 20.3 (C1), 18.3 (C11), 14.9 (C12); HRMS: (ESI+) calculated for 
C17H30N2O 279.2431. Found [M+H]+ 279.2425. 
N,N-Diisopropyl-2-(4-methylpentan-2-yl)-1H-pyrrole-1-carboxamide (152ah’’) 
 
General Procedure Q: The reaction was carried out with styrene derivative (400 mol%) and was run 
for 48 h. Purification of the residue by FCC (hexane/EtOAc 0–4%) afforded the title compound (5.5 
mg, 19%) as a colourless oil. vmax/cm-1: 2960 (m), 2928 (m), 1685 (s), 1327 (s); 1H NMR (500 MHz, 
CDCl3): δ 6.58 (1H, dd, J = 3.0, 1.5 Hz, C4-H), 6.11 – 6.06 (1H, m, C5-H), 5.97 – 5.90 (1H, m, C6-H), 
3.78 – 3.45 (2H, m, C2-H), 3.13 – 3.01 (1H, m, C8-H), 1.74 – 1.58 (1H, m, C11-H), 1.49 (1H, ddd, J = 
14.0, 8.0, 6.5 Hz, C10-H2), 1.40 – 1.29 (13H, m, C1-H3, C10-H2), 1.19 (3H, d, J = 7.0 Hz, C9-H3), 0.89 
(3H, d, J = 4.0 Hz, C12-H3), 0.87 (3H, d, J = 4.0 Hz, C12-H3); 13C NMR (126 MHz, CDCl3): δ 153.0 
(C3), 140.7 (C7), 117.7 (C4), 108.5 (C5), 105.1 (C6), 48.6 (C2), 47.2 (C10), 28.7 (C8), 25.7 (C11), 




General Procedure Q: The reaction was carried out with styrene derivative (400 mol%) and was run 
for 48 h. Purification of the residue by FCC (toluene/Et2O 0−5%) afforded the title compound (36.3 mg, 




99%) as a yellow oil. vmax/cm-1: 2958 (m), 2933 (m), 1674 (s), 1428 (s); 1H NMR (400 MHz, CDCl3): 
δ 7.54 (1H, d, J = 8.0 Hz, C10-H), 7.28 – 7.22 (2H, m, C15-H), 7.20 – 7.12 (2H, m, C16-H), 7.11 – 
7.03 (2H, m, C9-H, C17-H), 7.00 (1H, s, C4-H), 6.90 (1H, d, J = 8.0 Hz, C7-H), 6.83 (1H, ddd, J = 8.0, 
7.0, 1.0 Hz, C8-H), 3.75 (2H, hept, J = 6.5 Hz, C2-H), 1.67 (6H, s, C12-H3), 1.33 (12H, d, J = 6.5 Hz, 
C1-H3); 13C NMR (101 MHz, CDCl3): δ 153.2 (C3), 149.1 (C14), 137.2 (C11), 128.2 (C15), 128.1 (C5), 
127.6 (C6), 126.5 (C16), 125.9 (C17), 123.0 (C9), 122.0 (C4), 121.5 (C7), 120.7 (C8), 113.0 (C10), 
48.7 (C2), 39.0 (C12), 30.4 (C13), 21.5 (C1); HRMS: (ESI+) calculated for C24H30N2O 363.2431. Found 
[M+H]+ 363.2422. 
7.6.3.3 Alkene Hydroarylation with Thiophene Substrates 
(156a’/157a’) 
 
General Procedure Q: The reaction was carried out with styrene derivative (400 mol%) and was ran 
for 48 h. Purification of the residue by FCC (hexane/EtOAc 0–5%) afforded the title compound (28.1 
mg, 85%, 0.6:0.4, A:B) as a yellow oil. vmax/cm-1: 2968 (m), 2930 (m), 1626 (s), 1441 (s); 1H NMR (400 
MHz, CDCl3): δ 7.41 – 7.36 (1.2H, m, C11-H, A), 7.31 – 7.22 (2.8H, m, C11-H, B, C12-H, A+B), 7.21 
– 7.11 (1H, m, C13-H, A+B), 7.07 (0.4H, d, J = 3.0 Hz, C5-H, B), 7.06 (0.6H, d, J = 5.0 Hz, C6-H, A), 
7.01 (0.4H, d, J = 3.0 Hz, C6-H, B), 6.75 (0.6H, d, J = 5.0 Hz, C7-H, A), 3.70 (0.6H, hept, J = 6.5 Hz, 
C2-H, A), 3.62 – 3.50 (0.4H, m, C2-H, B), 3.39 – 3.19 (1H, m, C2-H, A+B), 2.08 – 1.66 (6H, m, C9-
H3, A+B), 1.49 – 1.18 (6H, m, C1-H3, A+B), 1.11 – 0.53 (6H, m, C1-H3, A+B); 13C NMR (101 MHz, 
CDCl3): δ 167.7 (C3, A), 167.4 (C3, B), 152.3 (C5, A), 149.6 (C7, B) , 138.7 (C4, B), 134.3 (C4, A), 
128.3 (C12, B), 128.2 (C12, A), 126.7 (C11, B), 126.6 (C11, A), 126.6 (C7, A), 126.2 (C13, A), 125.9 
(C13, B), 123.4 (C5, B), 122.4 (C6, A), 121.9 (C6, B), 50.5 (C2, A+B), 45.8 (C2, A+B), 42.7 (C8, A), 
42.0 (C8, B), 32.8 (C9, A), 30.9 (C9, A), 29.8 (C9, B), 29.5 (C9, B), 21.2 (C1, A+B), 20.4 (C1, A+B); 












7.6.3.4 Alkene Hydroarylation with Furan Substrates 
Hydroarylation products 159ag’, 159aq’, 159ae’, 159ah’, 159as’ and 159ba’ were synthesised by 
Miss Ellie Lester. 
N,N-Diisopropyl-2-(2-phenylpropan-2-yl)furan-3-carboxamide (159aa’) 
  
General Procedure Q: The reaction was carried out with styrene derivative (150 mol%) and was ran 
for 24 h. Purification of the residue by FCC (toluene/Et2O 5−10%) afforded the title compound (40.2 
mg, 94%) as a yellow oil. vmax/cm-1: 2969 (m), 2932 (m), 1623 (s), 1435 (s); 1H NMR (400 MHz, CDCl3): 
δ 7.29 – 7.21 (4H, m, C11-H, C12-H), 7.21 – 7.19 (1H, m, C6-H), 7.16 – 7.11 (1H, m, C13-H) 6.19 
(1H, d, J = 1.9 Hz, C5-H), 3.98 (1H, hept, J = 7.0 Hz, C2-H), 3.38 (1H, hept, J = 7.0 Hz, C2-H), 1.71 
(6H, s, C9-H), 1.43 (6H, d, J = 7.0 Hz, C1-H3), 1.06 (6H, d, J = 7.0 Hz, C1-H3); 13C NMR (101 MHz, 
CDCl3): δ 166.2 (C3), 157.5 (C7), 148.0 (C10), 140.2 (C6), 128.3 (C12), 126.2 (C13), 126.1 (C11), 
117.9 (C4), 109.6 (C5), 50.9 (C2), 45.8 (C2), 41.6 (C8), 28.4 (C9), 20.7 (C1), 20.32 (C1); HRMS: (ESI+) 
calculated for C20H27NO2 314.2115. Found [M+H]+ 314.2124.  
The structure of compound 159aa’ was confirmed by single crystal X-ray diffraction of crystals 















General Procedure Q: The reaction was carried out with styrene derivative (150 mol%) and was ran 
for 24 h. Purification of the residue by FCC (hexane/EtOAc 0−20%) afforded the title compound (33.7 
mg, 86%) as a colourless oil. vmax/cm
-1: 2969 (m), 2927 (m), 1626 (s), 1438 (s); 1H NMR (400 MHz, 
CDCl3): δ 7.58 – 7.54 (2H, m, C11-H), 7.53 – 7.50 (2H, m, C12-H), 7.44 – 7.39 (2H, m, C16-H), 7.39 
– 7.36 (2H, m, C15-H), 7.35 – 7.30 (1H, m, C17-H), 7.26 (1H, d, J = 2.0 Hz, C6-H), 6.24 (1H, d, J = 
2.0 Hz, C5-H), 4.01 (1H, hept, J = 6.5 Hz, C2-H), 3.39 (1H, hept, J = 6.5 Hz, C2-H), 1.76 (6H, s, C9-
H3), 1.44 (6H, d, J = 6.5 Hz, C1-H3), 1.09 (6H, d, J = 6.5 Hz, C1-H3); 13C NMR (101 MHz, CDCl3): δ 
166.2 (C3), 157.6 (C7), 147.1 (C10), 141.1 (C14), 140.2 (C6), 139.1 (C13), 128.8 (C16), 127.2 (C11), 
127.2 (C17) 127.1 (C12), 126.6 (C15), 118.0 (C4), 109.7 (C5), 50.9 (C2), 45.8 (C2), 41.5 (C8), 28.5 




General Procedure Q: The reaction was carried out with styrene derivative (150 mol%), (R)-L-16f 
and was ran for 24 h. Purification of the residue by FCC (hexane/EtOAc 0−20%) afforded the title 
compound (23.8mg, 73%, 90:10 e.r.) as a colourless oil. vmax/cm-1: 2968 (m), 2937 (m), 1629 (s), 1438 
(s); 1H NMR (400 MHz, CDCl3): δ 7.28 – 7.24 (4H, m, C13-H, C14-H), 7.23 (1H, d, J = 2.0 Hz, C6-
H), 7.18 – 7.11 (1H, m, C15-H), 6.20 (1H, d, J = 2.0 Hz, C5-H), 3.99 (1H, hept, J = 6.5 Hz, C2-H), 
3.38 (1H, hept, J = 6.5 Hz, C2-H), 2.38 – 2.21 (1H, m, C10-H2), 2.15 – 2.01 (1H, m, C10-H2), 1.63 (3H, 
s, C9-H3), 1.49 – 1.38 (6H, m, C1-H3), 1.09 (3H, d, J = 6.5 Hz, C1-H3), 1.03 (3H, d, J = 6.5 Hz, C1-
H3), 0.76 (3H, t, J = 7.5 Hz, C11-H3); 13C NMR (101 MHz, CDCl3): δ 166.3 (C3), 156.8 (C7), 147.5 
(C12), 140.2 (C6), 128.3 (C14), 126.6 (C13), 126.1 (C15), 119.2 (C4), 109.6 (C5), 50.8 (C2), 45.8 (C8), 




45.6 (C2), 32.8 (C10), 24.2 (C9), 20.8 (C1), 20.7 (C1), 20.4 (C1), 20.3 (C1), 9.2 (C11); HRMS: (ESI+) 
calculated for C21H29NO2 328.2271. Found [M+H]+ 328.2262; [α]25D = - 24.2 (c = 0.20, CHCl3). 
Chiral SFC Conditions: (DAICEL CHIRALPAK-IE column (25 cm), CO2:MeOH 97:3 to 94:6 over 
30 minutes, 2 mL/min, 140 bars, 60 °C). Retention times: 19.0 minutes (major), 20.4 minutes (minor), 
e.r. = 90:10. 
N,N-Diisopropyl-2-(2-phenylpentan-2-yl)furan-3-carboxamide (159ar’) 
 
General Procedure Q: The reaction was carried out with styrene derivative (150 mol%) and was ran 
for 24 h. Purification of the residue by FCC (hexane/EtOAc 0−10%) afforded the title compound (25.5 
mg, 75%) as an orange oil. vmax/cm-1: 2961 (m), 2872 (m), 1630 (s), 1437 (s); 1H NMR (400 MHz, 
CDCl3): δ 7.30 – 7.24 (4H, m, C14-H, C15-H), 7.23 (1H, d, J = 2.0 Hz, C6-H), 7.19 – 7.11 (1H, m, 
C16-H), 6.20 (1H, d, J = 2.0 Hz, C5-H), 4.01 (1H, hept, J = 6.5 Hz, C2-H), 3.39 (1H, hept, J = 6.5 Hz, 
C2-H), 2.26 – 1.92 (2H, m, C10-H2), 1.66 (3H, s, C9-H3), 1.49 – 1.42 (6H, m, C1-H3), 1.29 – 1.13 (2H, 
m, C11-H2), 1.12 – 1.02 (6H, m, C1-H3), 0.88 (3H, t, J = 7.0 Hz, C12-H3); 13C NMR (101 MHz, CDCl3): 
δ 166.4 (C3), 157.0 (C7), 147.5 (C13), 140.3 (C6), 128.3 (C15), 126.6 (C14), 126.1 (C16), 118.9 (C4), 
109.6 (C5), 50.9 (C2), 45.8 (C2), 45.3 (C8), 42.6 (C10), 24.7 (C9), 20.8 (C1), 20.7 (C1), 20.4 (C1), 




General Procedure Q: The reaction was carried out with styrene derivative (150 mol%) and was ran 
for 24 h. Purification of the residue by FCC (hexane/EtOAc 0−5%) afforded the title compound (19.1 
mg, 43%) as a colourless oil. vmax/cm
-1: 2968 (m), 2929 (m), 1634 (s), 1438 (s); 1H NMR (400 MHz, 
CDCl3): δ 7.37 – 7.29 (2H, m, C11-H), 7.28 – 7.23 (2H, m, C12-H), 7.21 (1H, d, J = 2.0 Hz, C5-H), 
7.19 – 7.10 (1H, m, C13-H), 6.19 (1H, d, J = 2.0 Hz, C6-H), 3.58 – 3.48 (1H, m, C2-H), 3.43 – 3.29 
(1H, m, C2-H), 1.68 (6H, s, C9-H3), 1.37 (6H, d, J = 6.5 Hz, C1-H3), 1.09 (6H, d, J = 6.5 Hz, C1-H3); 
13C NMR (101 MHz, CDCl3): δ 162.8 (C3), 149.6 (C10), 144.6 (C4), 140.2 (C5), 133.2 (C7), 128.1 




(C12), 126.5 (C11), 125.8 (C13), 111.7 (C6), 50.8 (C2), 46.0 (C2), 38.2 (C8), 30.3 (C9), 20.8 (C1), 
20.2 (C1); HRMS: (ESI+) calculated for C20H27NO2Na 336.1934. Found [M+Na]+ 336.1942. 
N-Isopropyl-3-(2-phenylpropan-2-yl)furan-2-carboxamide (161a’) 
 
General Procedure Q: The reaction was carried out with styrene derivative (150 mol%) and was ran 
for 24 h. Purification of the residue by FCC (hexane/EtOAc 0−10%) afforded the title compound (8.4 
mg, 19%) as a colourless oil. vmax/cm-1: 3316 (m), 2972 (m), 2925 (m), 1660 (s); 1H NMR (400 MHz, 
CDCl3): δ 7.34 (1H, d, J = 2.0 Hz, C5-H), 7.32 – 7.26 (4H, m, C11-H, C12-H), 7.22 – 7.13 (1H, m, 
C13-H), 6.45 (1H, d, J = 2.0 Hz, C6-H), 5.76 (1H, br. s, N-H), 4.03 (1H, hept, J = 6.5 Hz, C2-H), 1.75 
(6H, s, C9-H3), 1.03 (6H, d, J = 6.5 Hz, C1-H3); 13C NMR (126 MHz, CDCl3): δ 158.0 (C3), 149.9 
(C10), 142.8 (C4), 141.4 (C5), 138.6 (C7), 128.3 (C12), 126.2 (C11), 126.0 (C13), 113.4 (C6), 40.9 
(C2), 38.7 (C8), 30.3 (C9), 22.8 (C1); HRMS: (ESI+) calculated for C17H22NO2 272.1645. Found 
[M+H]+ 272.1645. 
 
7.6.4 – Synthesis of Alternative SPINOL Ligands 
2,6-Bis((E)-2-bromo-5-methoxybenzylidene)cyclohexan-1-one (171) 
 
The title compound was synthesised following a literature procedure.167 To a stirred solution of NaOH 
(186 mg, 4.64 mmol) dissolved on EtOH (2.20 mL) and water (2.20 mL) was added a solution of 
cyclohexanone (120 µL, 1.16 mmol) and 2-bromo-5-methoxy benzaldehyde (500 mg, 2.33 mmol) in 
EtOH (6.0 mL) dropwise. The solution was stirred overnight. The resulting solution was filtered and 
the solid was washed with H2O and dried under vacuum to afford the title compound (366 mg, 64%) as 
yellow crystals. 1H NMR (400 MHz, CDCl3): δ 7.79 (2H, s), 7.51 (2H, d, J = 9.0 Hz), 6.84 (2H, d, J = 
3.0 Hz), 6.76 (2H, dd, J = 9.0, 3.0 Hz), 3.80 (6H, s), 2.76 (4H, t, J = 5.0 Hz), 1.87 – 1.70 (2H, m); 13C 
NMR (101 MHz, CDCl3): δ 189.7, 158.5, 137.7, 137.2, 136.5, 133.6, 116.5, 115.6, 115.3, 55.7, 28.4, 
23.2; m.p. 113−116 °C (CDCl3). (Lit. 165−166 °C, no recrystallisation solvent specified). The 










The title compound was synthesised following a literature procedure.266 To a round-bottomed flask was 
added Na2CO3 (2.39 g, 22.5 mmol) dissolved in H2O (19 mL). A solution of (S)-t-leucinol (0.960 mL, 
7.50 mmol) in CH2Cl2 (25 mL) was added, followed by dropwise addition of 2-bromobenzoyl chloride 
(1.73 mL, 8.63 mmol). The biphasic mixture was stirred vigorously for 2 h, before the organic layer 
was collected and the aqueous layer was extracted with CH2Cl2 (2 × 20 mL). The organic extracts were 
combined, dried over Na2SO4 and concentrated in vacuo. Purification of the residue by FCC 
(hexane/acetone 25%) afforded the title compound (2.06 g, 91%) as a colourless solid. 1H NMR (400 
MHz, CDCl3): δ 7.61 – 7.54 (2H, m), 7.41 – 7.33 (1H, m), 7.28 (1H, dd, J = 7.5, 1.5 Hz), 6.12 (1H, br. 
s), 4.06 (1H, ddd, J = 9.5, 7.5, 3.5 Hz), 4.01 – 3.89 (1H, m), 3.74 – 3.62 (1H, m), 2.25 – 2.13 (1H, m), 
1.03 (9H, s); 13C NMR (126 MHz, CDCl3) δ 168.8, 138.1, 133.5, 131.5, 129.9, 127.8, 119.2, 63.3, 60.5, 
33.9, 27.3; m.p. 116−118 °C (CDCl3) (Lit.267 110–112 °C, hexane/acetone); [α]25D = + 2.1 (c = 0.13, 




The title compound was synthesised following a literature procedure.266 To a round-bottom flask fitted 
with a condenser was added (S)-2-Bromo-N-(1-hydroxy-3,3-dimethylbutan-2-yl)benzamide (2.00 g, 
6.66 mmol), p-toluenesulfonyl chloride (1.65 g, 8.66 mmol), CH2Cl2 (50 mL) and NEt3 (4.64 mL, 33.3 
mmol). The solution was heated at reflux overnight. H2O (7 mL) was added and the solution was heated 
to 75 °C for a further 2 h. The reaction mixture was cooled to ambient temperature, the organic layer 
was collected, and the aqueous layer was extracted with CH2Cl2 (2 × 25 mL). The organic extracts were 
combined, dried over Na2SO4 and concentrated in vacuo. Purification of the residue by FCC 
(hexane/EtOAc 5−10%) afforded the title compound (1.85 g, 99%) as a colourless oil. 1H NMR (400 
MHz,CDCl3): δ 7.64 (2H, m), 7.33 (1H, m), 7.27 (1H, m), 4.38 (1H, dd, J = 10.5, 8.5 Hz), 4.31 – 4.19 
(1H, m), 4.11 (1H, dd, J = 10.5, 8.5 Hz), 1.00 (9H, s); 13C NMR (101 MHz, CDCl3): δ 162.9, 133.8, 
131.6, 131.4, 130.4, 127.2, 122.0, 76.8, 69.1, 34.2, 26.1. The spectroscopic properties for this compound 










The title compound was synthesised following a literature procedure.266 To an oven dried Schlenk tube 
was added CuI (156 mg, 0.818 mmol), HPPh2 (2.14 mL, 12.3 mmol), DMEDA (0.625 mL, 5.72 mmol) 
and toluene (28 mL) under nitrogen. The reaction mixture was stirred at ambient temperature for 30 
minutes before Cs2CO3 (7.99 g, 24.5 mmol) and (S)-2-(2-Bromophenyl)-4-(tert-butyl)-4,5-
dihydrooxazole (1.84 g, 6.54 mmol) in toluene (28 mL) was added dropwise. The tube was sealed and 
heated at 110 °C for 5 h. The solution was cooled to ambient temperature, filtered and the filtrate was 
concentrated in vacuo. Purification of the residue by FCC (toluene/Et2O 1%) afforded the title 
compound (1.51 g, 60%) as a colourless solid. 1H NMR (400 MHz, CDCl3): δ 7.99 – 7.89 (1H, m), 7.41 
– 7.20 (12H, m), 6.92 – 6.82 (1H, m), 4.13 – 4.05 (2H, m), 4.04 – 3.99 (1H, m), 3.90 – 3.84 (1H, m), 
0.73 (9H, s); 31P NMR (162 MHz, CDCl3): δ -5.34. m.p. 113−116 °C (CDCl3). (Lit. 114–116 °C, no 
recrystallisation solvent specified); [α]25D = - 60.0 (c = 0.30, CHCl3). The spectroscopic properties for 
this compound were consistent with the data available in the literature.268-269 
[Ircod(S)-t-Bu-PHOX]BARF 
The title compound was synthesised following a literature procedure.270 To a flame dried resealable 
Schlenk tube was added [Ir(cod)Cl]2 (80.0 mg, 0.119 mmol), (S)-t-Bu-PHOX (92.2 mg, 0.238 mmol) 
and dry CH2Cl2 (2.50 mL) under nitrogen. The solution was heated at reflux and stirred for 1 h. The 
mixture was cooled to ambient temperature and NaBARF (339 mg, 0.372 mmol) and H2O (2.50 mL) 
were added and the tube was vigorously stirred for 10 minutes. The mixture was extracted with CH2Cl2 
(2 × 10 mL). The organic extracts were combined, dried over Na2SO4 and concentrated in vacuo. 
Purification of the residue by recrystallisation (EtOH/H2O) afforded the title compound (270 mg, 74%) 
as a bright orange powder. vmax/cm
-1: 2970 (m), 1354 (s), 1277 (s), 1124 (s); 1H NMR (400 MHz, 
CDCl3): δ 8.24 – 8.14 (1H, m), 7.74 – 7.68 (8H, m), 7.66 – 7.53 (3H, m), 7.53 – 7.50 (6H, m), 7.50 – 
7.40 (5H, m), 7.36 – 7.29 (1H, m), 7.17 – 7.05 (2H, m), 5.00 – 4.89 (2H, m), 4.57 (1H, dd, J = 10.0, 3.0 
Hz), 4.35 – 4.25 (1H, m), 3.94 (1H, dd, J = 9.0, 3.0 Hz), 3.54 – 3.44 (1H, m), 3.12 – 2.98 (1H, m), 2.66 
– 2.30 (4H, m), 2.09 – 1.88 (2H, m), 1.69 – 1.59 (1H, m), 1.51 – 1.34 (1H, m), 0.62 (9H, s); 
Characteristic 13C NMR (126 MHz, CDCl3): δ 161.8 (1:1:1:1 pattern, 1 JB-C = 50.0 Hz), 134.9, 123.6 (q, 
1JF-C = 272.5 Hz), Note: 
13C NMR analysis was complex to assign but characteristic BARF signals have 
been identified by comparison to similar complexes;116 31P NMR (162 MHz, CDCl3): δ 17.34; HRMS: 
(Nanospray+) calculated for C33H38NOP 688.2320. Found [M]+ 688.2341, Note: mass was observed in 
the absence of BARF; m.p. 180–182 °C (CH2Cl2). 
 
 




7.6.5 – Mechanistic Studies 
7.6.5.1 − Deuterium Labelling Experiments 
Methyl-d3-triphenylphosphonium iodide 
 
The title compound was prepared following a literature procedure.271 To a suspension of PPh3 (5.00 g, 
19.1 mmol) in THF (33 mL) was added CD3I (1.40 mL, 22.9 mmol). The mixture was heated to reflux 
for 1 h, before being cooled to ambient temperature. The resulting white solid was filtered and washed 
with benzene (2 × 20 mL) and dried under reduced pressure to afford the title compound (7.50 g, 97%) 
as a white solid. The material was used in the next step without further purification. 
4-(Prop-1-en-2-yl-1,1-d2)-1,1'-biphenyl (deuterio-147b’) 
 
To a suspension of methyl-d3-triphenylphosphonium iodide (2.75 g, 9.21 mmol) in THF (25 mL), under 
nitrogen, was added n-BuLi (5.76 mL, 9.21 mmol, 1.6 M in hexanes) dropwise at 0 ˚C. The resulting 
solution was stirred for 1 h, before 4-acetylbiphenyl (1.51 g, 7.67 mmol) in THF (25 mL) was added 
dropwise. The reaction was slowly warmed to ambient temperature and stirred for 4 h. NH4Cl (10 mL) 
was added and the mixture was extracted with EtOAc (3 × 10 mL). The organic extracts were combined, 
washed with brine (20 mL), dried over Na2SO4, filtered and concentrated in vacuo. Purification of the 
residue by FCC (hexane/EtOAc 5%) provided deuterio-147b’ (600 mg, 40% yield, 86% deuteration) 
as a colourless solid. 1H NMR (400 MHz, CDCl3): δ 7.66 – 7.53 (6H, m), 7.50 – 7.40 (2H, m), 7.38 – 
7.32 (1H, m), 5.45 – 5.42 (0.14H, m), 5.15 – 5.10 (0.14H, m), 2.20 (3H, s); 2H NMR (61 MHz, CHCl3): 











Deuterium Labelling Experiment of 134a 
 
A flame-dried re-sealable tube, fitted with a magnetic stirrer, was charged with substrate 134a (19.5mg, 
0.1 mmol), [Ir(cod)2]BARF (5.0 mol%) and (rac)-L-15f (5.0 mol%). The tube was fitted with a rubber 
septum and purged with nitrogen. Deuterio-147b’ derivative (29.4 mg, 0.15 mmol) in anhydrous 1,4-
dioxane (0.1 mL) was added and the tube was fitted with a Young’s tap. The reaction mixture was then 
heated to 120 °C for 24 h before being cooled to ambient temperature and concentrated in vacuo. 
Purification of the residues by FCC (hexane/EtOAc 10–20%) afforded the deuterio-products.  
The data for the deuterated products is presented below:  
deuterio-159ab’ 
 
1H NMR (400 MHz, CDCl3): δ 7.57 – 7.53 (2H, m), 7.53 – 7.49 (2H, m), 7.44 – 7.39 (2H, m), 7.39 – 
7.36 (2H, m), 7.34 – 7.29 (1H, m), 7.26 (1H, d, J = 2.0 Hz), 6.23 (0.79H, d, J = 2.0 Hz), 4.01 (1H, hept, 
J = 6.5 Hz), 3.38 (1H, hept, J = 6.5 Hz), 1.82 – 1.68 (4.59H, m), 1.44 (6H, d, J = 6.5 Hz), 1.08 (6H, d, 
J = 6.5 Hz); 2H NMR (77 MHz, CHCl3): δ 6.28 (0.21D, s), 1.74 (1.41D, s). Deuterium incorporation 
was calculated by integration of both 1H NMR and 2H NMR signals. 
deuterio-147b’ 
  
1H NMR (400 MHz, CDCl3): δ 7.70 – 7.53 (6H, m), 7.49 – 7.41 (2H, m), 7.40 – 7.31 (1H, m), 5.48 – 
5.41 (0.67H, m, Hb), 5.15 – 5.06 (0.67H, m, Ha), 2.25 – 2.16 (1.9H, m); 2H NMR (77 MHz, CHCl3): δ 
5.49 (0.33D, s), 5.16 (0.33D, s), 2.19 (1.10D, d, J = 2.5 Hz). 




7.6.5.2 − 13C-KIE Determination Experiments (Singleton Method) 
Procedure for large scale reactions: 
An oven-dried re-sealable tube, fitted with a magnetic stirrer, was charged with furan substrate 134a 
(391 mg, 2.00 mmol), 147b’ (389 mg, 2.00 mmol), [Ir(cod)2]BARF (0.10 mmol, 5 mol%) and (rac)-L-
15f (0.10 mmol, 5 mol%). The tube was fitted with a rubber septum and purged with nitrogen. 
Anhydrous 1,4-dioxane (2.0 mL) was added via syringe and the tube was sealed with a Young’s tap. 
The reaction vessel was placed into a pre-heated heating block at 120 oC and stirred for 6 h. The reaction 
mixture was cooled to ambient temperature and concentrated in vacuo. The crude mixture was 
transferred into a 20 mL volumetric flask, which was previously charged with a known amount of 
internal standard (1,3,5-trimethoxybenzene, ~85 mg), and the flask was filled with CDCl3, pre-treated 
over anhydrous K2CO3. Six aliquots of 0.4 mL each were taken from the solution and transferred into 
six NMR tubes, which were subsequently diluted with additional 0.3 mL of pre-treated CDCl3 each. A 
1H NMR spectrum was recorded for each sample employing a 500 MHz instrument, using the following 
parameters: 16 scans, π/2 pulse, 6.5 s acquisition time and 40 s relaxation delay. The conversion of the 
alkene starting material (F) was determined by integration of the C1-Hb signal of 159ab’ against the 
aromatic C-H signal of the internal standard. The remaining crude material was purified by FCC to 
recover unreacted 147b’. 
Quantitative 13C NMR analysis: All NMR samples were prepared employing ~100 mg of recovered 
147b’ in 0.7 mL of pre-treated CDCl3. The 13C NMR spectra were recorded at 126 MHz using inverse 
gated decoupling and employing a 500 MHz instrument equipped with a CryoProbeTM. The spectra 
were recorded according to the following parameters: 1024 scans, π/6 pulse, 15 s relaxation delay. A 
total of five spectra were recorded for each sample. The resulting five FIDs were processed at the same 
time applying the same phase correction, a fifteenth order polynomial fit baseline correction and 256K 
zero filling. Integrations were numerically determined using a constant region for each peak 
corresponding to eight times of the peak widths at half height (± 8w1/2). The peak belonging to C8 of 
147b’ was chosen as the internal standard and was set with an integration of 1000. 
Formulas applied for the determination of 13C KIEs: The formulas employed in the calculations for 
the determination of the KIE were reported by Saunders171 and Singleton177 and are summarized as 
follows: 
F = conversion of starting material. 
R/R0 = proportion of the minor isotopic component in recovered material compared to the original 
starting material. 
Δ(R/R0) = R/R0((ΔR/R)2 + (ΔR0/R0)2)1/2 













































13C KIE determination for the hydroarylation of 147b’ with 134a: 
 
1H NMR analysis provided a conversion of 59.7 ± 0.2% for the first experiment and of 64.0 ± 0.4% for 
the second experiment. Purification of the crude mixture by FCC (hexane/EtOAc 0−5%) afforded 128 
mg (38% recovered) for the first sample and 122 mg (36% recovered) for the second sample. 




















Conversion (F)  
fid1 fid2 fid3 fid4 fid5 F ΔF  
59.7 60.0 59.4 59.7 59.7 59.7 0.2  
        
13C-NMR integration of alkene starting material (R0) 
ppm peaks fid1 fid2 fid3 fid4 fid5 R0 ΔR0 
142.8 (C2) 1037.3 1037.5 1040.8 1040.4 1040.7 1039.3 1.8 
140.2 (C7/4) 2052.9 2054.5 2056.9 2058.0 2057.4 2055.9 2.2 
112.6 (C1) 900.7 899.0 899.0 901.4 899.8 900.0 1.1 
21.9 (C3) 955.7 956.5 957.3 957.7 957.9 957.0 0.9 
140.8 (C8) 1000.0 1000.0 1000.0 1000.0 1000.0 1000.0 0.0 
        
13C-NMR integration of alkene from 59.7 ± 0.2 % conversion reaction (R) 
ppm peaks fid1 fid2 fid3 fid4 fid5 R ΔR 
142.8 (C2) 1052.1 1051.8 1052.3 1051.5 1051.4 1051.8 0.4 
140.2 (C7/4) 2058.1 2057.8 2057.3 2058.8 2056.7 2057.7 0.8 
112.6 (C1) 927.1 927.6 928.3 927.3 928.7 927.8 0.7 
21.9 (C3) 938.2 938.7 938.0 938.6 937.4 938.2 0.5 
140.8 (C8) 1000.0 1000.0 1000.0 1000.0 1000.0 1000.0 0.0 
        
Determination of 13C KIEs  
ppm peaks R/R0 Δ(R/R0) ΔKIEF ΔKIER KIE ΔKIE  
142.8 (C2) 1.012008 0.001771 
-
0.000078 0.001977 1.013308 0.001978  
140.2 (C7/4) 1.000876 0.001119 
-
0.000006 0.001233 1.000964 0.001233  
112.6 (C1) 1.030912 0.001428 
-
0.000208 0.001632 1.034659 0.001645  
21.9 (C3) 0.980314 0.001082 0.000121 0.001163 0.978591 0.001169  
140.8 (C8) 1 0 0 0 1 0  
   
 





C KIE   
C2 1.013 ± 0.002   
C7/4 1.001 ± 0.001   
C1 1.035 ± 0.002   
C3 0.979 ± 0.001   
 
 




Second experiment:  
Conversion (F) 
 
fid1 fid2 fid3 fid4 fid5 F ΔF  
64.4 63.6 64.1 64.1 63.6 64.0 0.4  
        
13C-NMR integration of alkene SM (R0) 
ppm peaks fid1 fid2 fid3 fid4 fid5 R0 ΔR0 
142.8 (C2) 1037.3 1037.5 1040.8 1040.4 1040.7 1039.3 1.8 
140.2 (C7/4) 2052.9 2054.5 2056.9 2058.0 2057.4 2055.9 2.2 
112.6 (C1) 900.7 899.0 899.0 901.4 899.8 900.0 1.1 
21.9 (C3) 955.7 956.5 957.3 957.7 957.9 957.0 0.9 
140.8 (C8) 1000.0 1000.0 1000.0 1000.0 1000.0 1000.0 0.0 
        
13C-NMR integration of alkene from 64.0 ± 0.4 % conversion reaction (R) 
ppm peaks fid1 fid2 fid3 fid4 fid5 R ΔR 
142.8 (C2) 1053.1 1052.1 1052.3 1054.3 1054.1 1053.2 1.0 
140.2 (C7/C4) 2060.6 2062.7 2064.9 2068.0 2066.7 2064.6 3.0 
112.6 (C1) 929.9 931.3 930.3 931.1 931.7 930.9 0.7 
21.9 (C3) 940.3 941.2 939.0 940.4 940.8 940.3 0.8 
140.8 (C8) 1000.0 1000.0 1000.0 1000.0 1000.0 1000.0 0.0 
        
Determination of 13C KIEs  
ppm peaks R/R0 Δ(R/R0) ΔKIEF ΔKIER KIE ΔKIE  
142.8 (C2) 1.013316 0.001986 
-
0.000127 0.001971 1.013132 0.001975  
140.2 (C7/4) 1.004202 0.001794 
-
0.000040 0.001765 1.004126 0.001766  
112.6 (C1) 1.034312 0.001469 
-
0.000337 0.001489 1.034187 0.001526  
21.9 (C3) 0.982571 0.001276 0.000159 0.001230 0.983063 0.001240  
140.8 (C8) 1 0 0 0 1 0  





C KIE   
C2 1.013 ± 0.002   
C7/4 1.004 ± 0.002   
C1 1.034 ± 0.002   








13C KIE determination for 147b’ under Ir(I)-catalysis  
 
The reaction was carried out on a 1.00 mmol scale, in the absence of furan 134a. Purification of the 
crude mixture by FCC (hexane/EtOAc 0−1%) afforded 193 mg (97% recovered). 
13C-NMR integration of alkene SM (R0)  
ppm peaks fid1 fid2 fid3 fid4 fid5 fid6 R0 ΔR0  
142.8 (C2) 1038.3 1042.3 1046.1 1047.6 1041.8 1039.7 1042.6 3.6  
140.2 (C7/4) 2058.6 2061.6 2067.7 2070.1 2062.7 2061.2 2063.7 4.4  
112.6 (C1) 892.3 896.8 902.4 907.6 905.5 905.0 901.6 5.9  
21.9 (C3) 957.5 959.0 961.1 961.4 959.6 959.4 959.7 1.4  
140.8 (C8) 1000.0 1000.0 1000.0 1000.0 1000.0 1000.0 1000.0 0.0  
          
13C-NMR integration of recovered alkene  
ppm peaks fid1 fid2 fid3 fid4 fid5 fid6 R ΔR  
142.8 (C2) 1040.6 1043.6 1043.0 1041.5 1043.5 1042.7 1042.5 1.2  
140.2 (C7/4) 2057.0 2057.9 2059.0 2057.6 2060.7 2060.9 2058.9 1.6  
112.6 (C1) 918.2 920.3 920.5 919.5 918.9 919.7 919.5 0.9  
21.9 (C3) 942.3 942.8 944.4 945.3 946.2 946.9 944.7 1.8  
140.8 (C8) 1000.0 1000.0 1000.0 1000.0 1000.0 1000.0 1000.0 0.0  
          
ppm peaks R/R0 Δ(R/R0)        
142.8 (C2) 0.999856 0.003639        
140.2 (C7/4) 0.997674 0.002249        
112.6 (C1) 1.019872 0.006721        
21.9 (C3) 0.984352 0.002415        
140.8 (C8) 1 0        
          
Output 
 
    
C KIE     
C2 1.000 ± 0.004     
C7/4 0.998 ± 0.002     
C1 1.020 ± 0.007     
C3 0.984 ± 0.002     
       




7.7 − Experimental Procedures and Data for the Studies in Chapter 5 
7.7.1 − Ligand Synthesis 
 




General Procedure R: The reaction was carried out with 1-bromo-4-fluorobenzene (1.17 mL, 10.6 
mmol) to afford the title compound (157 mg, 14%) as an orange powder. vmax/cm-1: 3075 (m), 1587 (s), 
1493 (m), 1224 (s), 1158 (s); 1H NMR (400 MHz, CDCl3): δ 7.34 – 7.23 (8H, m, C6-H), 7.09 – 6.99 
(8H, m, C5-H), 4.35 (4H, app. t, J = 2.0 Hz, C3-H), 3.97 (4H, app. q, J = 2.0 Hz, C2-H); 13C NMR (126 
MHz, CDCl3): δ 163.4 (d, 1JC-F = 249.0 Hz, C7), 135.3 (dd, 2JC-F = 21.0, 3JC-P = 8.0 Hz, C6), 134.2 (dd, 
1JC-P = 10.0,
 4JC-F = 3.5 Hz, C4), 115.5 (dd, 3JC-F = 21.0, 2JC-P = 8.0 Hz, C5), 76.8 (C1), 73.7 (d, 2JC-P = 
15.0 Hz, C2), 72.7 (dd, 3JC-P = 3.5, 4JC-P = 1.5 Hz, C3); 19F NMR (377 MHz, CDCl3): δ -112.3 (tq, J = 
9.5, 5.5 Hz); 31P NMR (162 MHz, CDCl3): δ -19.3; HRMS: (MALDI) calculated for C34H24F4FeP2 
626.0634. Found [M] 626.0628; m.p. 140−141 °C (cyclohexane). 
L-20b 
  
General Procedure R: The reaction was carried out with 4-bromobenzotrifluoride (1.48 mL, 10.6 
mmol) to afford the title compound (179 mg, 12%) as an orange powder. vmax/cm
-1: 2926 (m), 1606 
(s), 1319 (s), 1121 (s), 1059 (s); 1H NMR (500 MHz, CDCl3): δ 7.55 (8H, d, J = 7.5 Hz, C6-H), 7.38 
(8H, app. t, J = 7.5 Hz, C5-H), 4.33 (4H, app. t, J = 2.0 Hz, C3-H), 3.99 (4H, app. q, J = 2.0 Hz, C2-
H); 13C NMR (126 MHz, CDCl3): δ 143.0 (d, 
1JC-P = 13.0 Hz, C4), 133.8 (d, 
2JC-P = 20.0 Hz, C5), 131.1 
(q, 2JC-F = 32.5 Hz, C7), 125.2 (dd, 
3JC-F = 7.0, 
4JC-F = 3.5 Hz, C6), 125.1 (q, 
1JC-F = 273 Hz, C8), 75.0 
(d, 1JC-P = 7.5 Hz, C1), 74.0 (d, 2JC-P = 15.0 Hz, C2), 73.0 – 72.9 (m, C3); 19F NMR (377 MHz, CDCl3): 
δ -62.7, 31P NMR (162 MHz, CDCl3): δ -16.6; HRMS: (MALDI) calculated for C38H24F12FeP2 










General Procedure R: The reaction was carried out with (1,3)-bis(trifluoromethyl)-5-bromobenzene 
(1.42 mL, 8.22 mmol) to afford the title compound (632 mg, 42%) as an orange powder. vmax/cm-1: 2923 
(m), 2858 (m), 1352 (s), 1273 (s), 1095 (s); 1H NMR (500 MHz, CDCl3): δ 7.89 (4H, s, C7-H), 7.69 
(8H, app. d, J = 6.5 Hz, C5-H), 4.44 (4H, app. t, J = 2.0 Hz, C3-H), 4.00 (4H, app. q, J = 2.0 Hz, C2-
H); 13C NMR (126 MHz, CDCl3): δ 140.3 (d, 1JC-P = 17.5 Hz, C4), 132.9 (dd, 2JC-P = 21.0, 3JC-F = 3.5 
Hz, C5), 132.1 (qd, 2JC-F = 33.5, 3JC-P = 6.5 Hz, C6), 123.4 (q, 3JC-F = 3.5 Hz, C7), 122.9 (q, 
1JC-F = 278.0 
Hz, C8) 73.8 (d, 1JC-P = 7.0 Hz, C1), 73.6 (d, 2JC-P = 15.5 Hz, C2), 73.3 – 73.2 (m, C3); 19F NMR (377 
MHz, CDCl3): δ -62.9; 31P NMR (162 MHz, CDCl3): δ -14.9; HRMS: (MALDI) calculated for 
C42H20F24FeP2 1098.0002. Found [M] 1098.0014; m.p. 145−147 °C (cyclohexane). 
L-20d 
 
General Procedure R: The reaction was carried out with bromopentafluorobenzene (1.32 mL, 10.6 
mmol) to afford the title compound (40.8 mg, 3%) as an orange powder. vmax/cm-1: 2929 (m), 1638 (m), 
1514 (s), 1469 (s), 1086 (s); 1H NMR (500 MHz, CDCl3): δ 4.42 (4H, app. t, J = 2.0 Hz, C3-H), 4.29 
(4H, app. q, J = 2.0 Hz, C2-H); 13C NMR (126 MHz, CDCl3): δ 147.5 (d, 
1JC-F = 242.0 Hz, C6), 142.7 
(d, 1JC-F = 257.5 Hz, C7), 137.8 (d, 
1JC-F = 256.0 Hz, C5), 109.0 (dt, 
1JC-P = 34.5, 
2JC-F = 20.5 Hz, C4), 
74.8 (d, 2JC-P = 20.5 Hz, C2), 73.2 (C3), 68.9 (C1); 19F NMR (377 MHz, CDCl3): δ -129.2 (–) -129.5 
(8F, m, Fmeta), -149.0 – -149.2 (4F, m, Fpara), -159.5 (–) -159.8 (8F, m, Fortho); 31P NMR (162 MHz, 
CDCl3): δ -58.4; HRMS: (MALDI) calculated for C34H8F20FeP2 913.9126. Found [M] 913.9120; m.p. 
194−196 °C (cyclohexane). 
 
7.7.2 − Substrate Synthesis 
7.7.2.1 − Alkene Synthesis  
91a’, 91c’, 91e’ 91g’, 91i’, , 91n−91p’, 91r’, 91s’, 91t’, 91v’−91x’, 91ab’−91ad’, 197 were purchased 
from commercial sources (Sigma or Alfa). 
91z and 91aa’ were synthesised by Dr. Giacomo Crisenza. 
 






To a suspension of methyltriphenylphosphonium iodide (4.72 mg, 13.2 mmol) and biphenyl-4-
carboxaldehyde (2.00 g, 11.0 mmol) in THF (50 mL) at 0 °C, was added NaH (1.93 g, 48.3 mmol, 60% 
in oil) portion-wise. The solution was warmed to ambient temperature and stirred for 5 h. The mixture 
was diluted with CH2Cl2 (90 mL), washed with water (50 mL) and brine (3 × 20 mL), dried over Na2SO4 
and concentrated in vacuo. Purification of the residue by recrystallisation (iPrOH) afforded the title 
compound (1.80 g, 91%) as colourless plates. 1H NMR (400 MHz, CDCl3): δ 7.65 – 7.55 (4H, m), 7.50 
(2H, d, J = 8.0 Hz), 7.45 (2H, ddd, J = 7.5, 6.5, 1.5 Hz), 7.39 – 7.30 (1H, m), 6.77 (1H, dd, J = 17.5, 
11.0 Hz), 5.81 (1H, dd, J = 17.5, 1.0 Hz), 5.29 (1H, dd, J = 11.0, 1.0 Hz); 13C NMR (101 MHz, CDCl3): 
δ 140.9, 140.7, 136.7, 136.5, 128.9, 127.5, 127.4, 127.1, 126.8, 114.0; m.p. 118–120 °C (iPrOH) (Lit.272 
118–119 °C, no recrystallisation solvent specified). The spectroscopic proprieties of this compound 
were consistent with the data available in the literature.272 
Trimethyl(4-vinylphenyl)silane (91q’) 
 
The title compound was prepared following a literature procedure.273 To an oven-dried Schlenk tube 
was added magnesium turnings (265 mg, 10.9 mmol), THF (11 mL), chlorotrimethylsilane (0.693 mL, 
5.46 mmol) and 4-bromostyrene (0.714 mL, 5.46 mmol) under nitrogen. The Schlenk tube was placed 
in a commercial ultrasonic cleaning bath (Ultrawave Ltd. SFE 510/1, 220−240 KHz, 275 W) and 
sonicated for 3 h. The mixture was washed with aq. saturated NaCl solution (10 mL) and extracted with 
Et2O (3 × 20 mL). The organic extracts were combined, dried over Na2SO4 and concentrated in vacuo. 
Purification of the residue by FCC (hexane/Et2O 0−5%) afforded the title compound (673 mg, 70%) as 
a colourless oil. vmax/cm-1: 3063 (m), 2956 (m), 1629 (m), 824 (s); 1H NMR (400 MHz, CDCl3): δ 7.51 
(2H, d, J = 8.0 Hz, C4-H), 7.42 (2H, d, J = 8.0 Hz, C5-H), 6.74 (1H, dd, J = 17.5, 11.0 Hz, C2-H), 5.80 
(1H, dd, J = 17.5, 1.0 Hz, C1-H), 5.27 (1H, dd, J = 11.0, 1.0 Hz, C1-H), 0.29 (9H, s, C7-H3); 13C NMR 
(101 MHz, CDCl3): δ 140.3 (C6), 138.1 (C3), 137.0 (C2), 133.7 (C4), 125.7 (C5), 114.2 (C1), -0.9 (C7). 










General Procedure S: Purification of the residue by FCC (hexane) afforded the title compound (350 
mg, 90%) as a colourless solid. vmax/cm-1: 2959 (m), 2921 (m), 1627 (s), 1426 (s); 1H NMR (500 MHz, 
CDCl3): δ 7.82 (1H, dd, J = 8.5, 1.0 Hz, C8-H), 7.81 (1H, d, J = 1.0 Hz, C4-H), 7.46 (1H, dd, J = 8.5, 
1.0 Hz, C7-H), 7.44 (1H, d, J = 5.5 Hz, C9-H), 7.32 (1H, dd, J = 5.5, 1.0 Hz, C10-H), 6.84 (1H, dd, J 
= 17.5, 11.0 Hz, C2-H), 5.81 (1H, dd, J = 17.5, 1.0 Hz, C1-H2), 5.28 (1H, dd, J = 11.0, 1.0 Hz, C1-H2); 
13C NMR (126 MHz, CDCl3): δ 140.1 (C5), 139.3 (C6), 137.1 (C2), 134.1 (C3), 127.0 (C9), 124.1 
(C10), 122.6 (ArCH), 122.4 (C7), 121.8 (ArCH), 113.6 (C1); m.p. 34−36 °C (CDCl3); A mass could 
not be observed by ESI or MALDI. 
6-Vinylquinoline (91y’) 
 
General Procedure S: Purification of the residue by FCC (CH2Cl2/EtOAc 10%) afforded the title 
compound (325 mg, 87%) as a colourless oil. 1H NMR (400 MHz, CDCl3): δ 8.87 (1H, dd, J = 4.5, 1.5 
Hz), 8.12 (1H, dd, J = 8.5, 2.0 Hz), 8.06 (1H, d, J = 8.5 Hz), 7.87 (1H, dd, J = 8.5, 2.0 Hz), 7.72 (1H, 
d, J = 2.0 Hz), 7.38 (1H, dd, J = 8.5, 4.5 Hz), 6.89 (1H, dd, J = 17.5, 11.0 Hz), 5.91 (1H, d, J = 17.5 
Hz), 5.40 (1H, d, J = 11.0 Hz); 13C NMR (101 MHz, CDCl3): δ 150.4, 148.3, 136.3, 136.2, 135.9, 129.8, 
128.5, 127.1, 125.9, 121.6, 115.6. The spectroscopic properties for this compound were consistent with 
the data available in the literature.274 
7.7.2.2 − Synthesis of Acetanilide Substrates 
60a, 60c, 60e, 60k, 60y, 60aa and 60ah were purchased from commercial sources (Sigma or Alfa). 




The title compound was synthesised following a modified literature procedure.275 To a solution of 
aniline (1.10 mL, 12.0 mmol), CH2Cl2 (20 mL), and triethylamine (1.60 mL, 12.0 mmol), was added 
dropwise isobutryl chloride (1.05 mL, 10.0 mmol). The resulting solution was stirred at ambient 
temperature overnight. The resulting mixture was washed with aq. HCl (1 M, 3 × 50 mL), aq. KOH (2 
M, 3 × 50 mL), dried over Na2SO4 and concentrated in vacuo. Purification of the residue by FCC 




(hexane/EtOAc 40%) afforded the title compound (1.63 g, quantitative) as a colourless powder. 1H 
NMR (400 MHz, CDCl3): δ 7.54 (1H, s), 7.52 (1H, s), 7.34 – 7.27 (2H, m), 7.14 – 7.04 (1H, m), 2.51 
(1H, hept, J = 7.0 Hz), 1.26 (3H, s), 1.24 (3H, s); 13C NMR (101 MHz, CDCl3): δ 175.4, 138.2, 129.1, 
124.3, 119.9, 36.8, 19.8; m.p. 102−104 °C (hexane/EtOAc) (Lit.276 98–99 °C, recrystallisation solvent 
not specified). The spectroscopic properties for this compound were consistent with the data available 
in the literature.276  
N-Phenylcyclobutanecarboxamide (60n) 
 
To an oven-dried flask was added EDCI (1.07 g, 5.57 mmol) and DMAP (6.18 mg, 0.051 mmol) under 
nitrogen. CH2Cl2 (27 mL), aniline (0.461 mL, 5.07 mmol) and cyclobutene carboxylic acid (0.509 mL, 
5.32 mmol) were added. The resulting solution was stirred at ambient temperature until full 
consumption of aniline was observed by TLC. The reaction mixture was washed with aq. saturated 
NaHCO3 solution (20 mL), before being dried over Na2SO4 and concentrated in vacuo. Purification of 
the residue by FCC (hexane/EtOAc 60%) afforded the title compound (602 mg, 68%) as colourless 
needles. vmax/cm-1: 3249 (m), 2943 (m), 1655 (s), 1443 (s); 1H NMR (400 MHz, CDCl3): δ 7.53 (2H, d, 
J = 8.0 Hz, C6-H), 7.31 (2H, t, J = 8.0 Hz, C7-H), 7.13 – 7.04 (2H, m, C8-H, N-H), 3.16 (1H, p, J = 8.5 
Hz, C1-H), 2.48 – 2.32 (2H, m, C2-H2), 2.29 – 2.18 (2H, m, C2-H2), 2.08 – 1.82 (2H, m, C3-H2); 13C 
NMR (101 MHz, CDCl3): δ 207.1 (C4), 138.2 (C5), 129.1 (C7), 124.1 (C8), 119.8 (C6), 41.0 (C1), 25.4 
(C2), 18.2 (C3); HRMS: (ESI+) calculated for C11H13NONa 198.0889. Found [M+Na]+ 198.0892; m.p. 





General Procedure T: Purification of the residue by recrystallisation (hexane/EtOAc) afforded the title 
compound (842 mg, 89% yield) as a colourless powder. 1H NMR (400 MHz, CDCl3): δ 7.53 (2H, d, J 
= 8.0 Hz), 7.30 (3H, t, J = 8.0 Hz), 7.08 (1H, t, J = 8.0 Hz,), 2.68 (1H, p, J = 8.0 Hz), 2.00 – 1.84 (4H, 
m), 1.84 – 1.71 (2H, m), 1.68 – 1.53 (2H, m); 13C NMR (101 MHz, CDCl3): δ 174.8, 138.3, 129.1, 
124.1, 119.8, 47.0, 30.7, 26.2; m.p. 159−161 °C (hexane/EtOAc) (Lit.277 162−163 °C, no 
recrystallisation solvent specified). The spectroscopic properties for this compound were consistent 
with the data available in the literature.277 
 






General Procedure T: Purification if the residue by recrystallisation (hexane/EtOAc) afforded the title 
compound (936 mg, 85% yield) as white needles. 1H NMR (400 MHz, CDCl3): δ 7.52 (2H, d, J = 7.5 
Hz), 7.36 – 7.25 (2H, m), 7.21 (1H, br. s), 7.09 (1H, t, J = 7.5 Hz), 2.30 – 2.16 (1H, m), 2.01 – 1.91 
(2H, m), 1.89 – 1.78 (2H, m), 1.77 – 1.67 (1H, m), 1.64 – 1.46 (2H, m), 1.41 – 1.15 (3H, m); 13C NMR 
(101 MHz,CDCl3): δ 174.5, 138.2, 129.1, 129.1, 124.2, 119.9, 46.7, 29.8, 25.8, 25.8; m.p. 144−146 °C 
(hexane/EtOAc) (Lit.277 145−146 °C no recrystallisation solvent specified) The spectroscopic 




To a solution of K2CO3 (207 mg, 1.50 mmol), aniline (0.091 mL, 1.00 mmol), N-dimethylimidazole 
(8.0 µL, 0.1 mmol), TMEDA (11 µL, 0.100 mmol) and CH3CN (1 mL) at 0 °C, was added 
hydrocinnamoyl chloride (0.222 mL, 1.50 mmol) dropwise. The solution was stirred for 1 h, before 
warmed to ambient temperature. The reaction was quenched by the addition of H2O (3 mL) and 
extracted with EtOAc (3 × 5 mL). The organic extracts were combined, washed with water (5 mL), 
brine (5 mL), dried over Na2SO4 and concentrated in vacuo. Purification of the residue by 
recrystallisation (hexane/EtOAc) afforded the title compound (175 mg, 78%) as colourless plates. 1H 
NMR (400 MHz, CDCl3): δ 7.36 (2H, d, J = 8.0 Hz), 7.30 – 7.21 (4H, m), 7.20 – 7.14 (3H, m), 7.03 
(1H, t, J = 7.5 Hz), 6.95 (1H, br. s), 3.00 (2H, t, J = 7.5 Hz), 2.60 (2H, t, J = 7.5 Hz); 13C NMR (101 
MHz, CDCl3): δ 170.4, 140.8, 137.9, 129.1, 128.8, 128.5, 126.5, 124.4, 120.04, 39.6, 31.7; m.p. 96−98 
°C (hexane/EtOAc) (Lit. 92−93 °C, no recrystallisation solvent specified). The spectroscopic properties 




The title compound was prepared following a literature procedure.278 Aniline (0.290 mL, 3.22 mmol) 
and K2CO3 (534 mg) were suspended in dry MeCN (26 mL). Cyclopropane carboxylic acid chloride 
(0.290 mL, 3.22 mmol) was added dropwise at ambient temperature over 5 minutes. The resulting 
solution was stirred for 2.5 hours. The solvent was removed in vacuo, before the residue was taken up 
in CH2Cl2 (13 mL). The organic extract was washed with water (2 × 13 mL), dried over Na2SO4 and 




concentrated in vacuo. Purification of the residue by FCC (hexane/EtOAc 30%) afforded the title 
compound (258 mg, 50% yield) as colourless needles. 1H NMR (400 MHz, CDCl3): δ 7.51 (3H, d, J = 
8.0 Hz,), 7.30 (2H, t, J = 8.0 Hz), 7.09 (1H, t, J = 8.0 Hz), 1.55 – 1.45 (1H, m), 1.22 – 1.01 (2H, m), 
0.91 – 0.76 (2H, m); 13C NMR (101 MHz, CDCl3): δ 172.0, 138.3, 129.1, 124.2, 119.8, 15.9, 8.1; m.p. 
109−110 °C (Lit.279 110 °C, CHCl3/hexane). The spectroscopic properties for this compound were 
consistent with the data available in the literature.279  
N-Phenylacrylamide (60u) 
 
The title compound was prepared following a literature procedure.280 To a solution of K2CO3 (1.00 g, 
10.0 mmol) and acryloyl chloride (0.809 mL, 10.0 mmol) in H2O (2.5 mL) and acetone (10 mL) at 0 
°C was added aniline (0.456 mL, 5.00 mL) dropwise over 5 minutes. The solution was stirred at 0 °C 
for 2 hours before the resulting white precipitate was filtered off. The solution was concentrated in 
vacuo, suspended in water (10 mL) and extracted with CH2Cl2 (3 × 10 mL). The organic extracts were 
combined, dried over Na2SO4 and concentrated in vacuo. The residue was purified by FCC (hexane/ 
EtOAc 40%) to afford the title compound (304 mg, 41% yield) as a white solid. 1H NMR (400 MHz, 
CDCl3): δ 7.63 – 7.54 (2H, m), 7.42 (1H, br. s), 7.37 – 7.29 (2H, m), 7.13 (1H, t, J = 7.5 Hz), 6.43 (1H, 
dd, J = 17.0, 1.5 Hz,), 6.26 (1H, dd, J = 17.0, 10.0 Hz), 5.76 (1H, dd, J = 10.0, 1.5 Hz); 13C NMR (101 
MHz, CDCl3): δ 163.7, 137.9, 131.4, 129.2, 127.9, 124.7, 120.2; m.p. 101−103 °C (hexane/EtOAc) 
(Lit.281 103−104 °C, no recrystallisation solvent specified) The spectroscopic properties for this 
compound were consistent with the data available in the literature.282  
N-(3-Isopropylphenyl)cyclopentanecarboxamide (60w) 
 
General Procedure T: Purification of the residue by recrystallisation (hexane/EtOAc) afforded the title 
compound (1.16 g, quantitative) as colourless needles. vmax/cm-1: 3295 (m), 2958 (m), 2858 (m), 1656 
(s), 1510 (s); 1H NMR (400 MHz, CDCl3): δ 7.48 – 7.42 (1H, m, C8-H), 7.41 (1H, s, N-H), 7.36 – 7.29 
(1H, m, C10-H), 7.28 – 7.17 (1H, m, C9-H), 6.95 (1H, d, J = 7.5 Hz, C6-H), 2.86 (1H, hept, J = 6.5 Hz, 
C11-H), 2.67 (1H, p, J = 8.0 Hz, C1-H), 1.98 – 1.49 (8H, m, C2-H2, C3-H2), 1.23 (6H, d, J = 6.5 Hz, 
C12-H3); 13C NMR (101 MHz, CDCl3): δ 174.8 (C4), 150.0 (C7), 138.3 (C5), 128.9 (C9), 122.3 (C6), 
118.0 (C8), 117.3 (C10), 47.0 (C1), 34.3 (C11), 30.7 (cyclopentyl), 26.2 (cyclopentyl), 24.0 (C12); 








General Procedure T: Purification of the residue by recrystallisation (hexane/EtOAc) afforded the title 
compound (1.14 g, 88%) as a colourless powder. vmax/cm-1: 3296 (m), 2951 (m), 1658 (s), 1550 (s); 1H 
NMR (400 MHz, CDCl3): δ 7.83 (1H, s, C6-H), 7.61 – 7.56 (2H, m, C12-H), 7.48 (1H, dd, J = 8.0, 2.0 
Hz, ArCH), 7.45 – 7.39 (2H, m, C13-H), 7.38 – 7.31 (2H, m, C9-H, ArCH), 7.27 (1H, s, N-H), 2.71 
(1H, p, J = 8.0 Hz, C1-H), 2.02 – 1.87 (4H, m, cyclopentyl), 1.86 – 1.71 (2H, m, cyclopentyl), 1.69 – 
1.58 (2H, m, cyclopentyl); 13C NMR (101 MHz, CDCl3): δ 174.8 (C4), 142.3 (C7), 140.8 (C11), 138.7 
(C5), 129.5 (ArCH), 128.9 (C13), 127.6 (ArCH), 127.3 (C12), 123.0 (ArCH), 118.6 (ArCH), 47.1 (C1), 
30.7 (cyclopentyl), 26.2 (cyclopentyl); HRMS: (ESI+) calculated for C18H20NO 266.1539. Found 
[M+H]+ 266.1541; m.p. 110−112 °C (hexane/EtOAc). 
Preparation of 2,3-Dihydro-4-benzofuranacetanilide (60d) 
 
The title compound was prepared following a literature procedure.116 
Step 1: To a solution of m-anisidine (5.00 mL, 44.5 mmol) and triethylamine (7.40 mL, 53.4 mmol) in 
CH2Cl2 (114 mL) at 0 °C was added pivaloyl chloride (6.58 mL, 53.4 mmol) dropwise over 15 minutes. 
The resulting suspension was stirred at ambient temperature for 3 hours, before being quenched with 
aq. HCl (1 M, 70 mL) and extracted with CH2Cl2 (3 × 100 mL). The organic extracts were combined, 
washed with brine (70 mL), dried over Na2SO4 and concentrated in vacuo to afford the title compound 
(9.46 g, quantitative) as a beige solid. 1H NMR (400 MHz,CDCl3): δ 7.39 (1H, t, J = 2.5 Hz), 7.31 (1H, 
br. s,), 7.20 (1H, t, J = 8.0 Hz), 6.93 (1H, dd, J = 8.0, 2.5 Hz), 6.66 (1H, dd, J = 8.0, 2.5 Hz), 3.81 (3H, 
s), 1.32 (9H, s); 13C NMR (101 MHz, CDCl3): δ 176.7, 160.3, 139.5, 129.7, 111.9, 110.5, 105.4, 55.5, 
39.8, 27.8; m.p. 114−116 °C (CHCl3) (Lit.283 106−108 °C, hexane/EtOAc). The spectroscopic 
properties for this compound were consistent with the data available in the literature.283  
 
Step 2: Methyl 4-acetamido-3-(1-phenylvinyl)benzoate (9.60 g, 46.3 mmol) was dissolved in THF (175 
mL) and cooled to 0 °C. n-BuLi (1.6 M in hexanes, 72 mL) was added dropwise over 1 h with vigorous 
stirring and the resulting solution was stirred for 2 hours. Ethylene oxide (2.5 M in THF, 28 mL) was 




added dropwise over 1 h, before the solution was warmed to ambient temperature and stirred overnight. 
The reaction was quenched by the addition of water (25 mL) before being concentrated in vacuo. The 
residue was re-suspended in water (50 mL) and extracted with EtOAc (3 × 100 mL). The organic 
extracts were combined, washed with saturated aq. Na2CO3 (35 mL), dried over Na2SO4 and 
concentrated in vacuo. The residue was purified by FCC (hexane/EtOAc 30%) to afford the title 
compound (9.56 g, 82%) as a colourless solid. 1H NMR (400 MHz, CDCl3): δ 8.86 (1H, br. s), 7.43 
(1H, dd, J = 8.0, 1.0 Hz), 7.18 (1H, t, J = 8.0 Hz), 6.67 (1H, dd, J = 8.0, 1.0 Hz), 3.94 – 3.85 (2H, m), 
3.80 (3H, s,), 2.92 – 2.80 (2H, m), 2.22 (1H, t, J = 4.0 Hz), 1.30 (9H, s); 13C NMR (101 MHz, CDCl3): 
δ 177.4, 157.7, 138.3, 127.2, 120.6, 117.0, 106.9, 77.5, 77.2, 76.8, 63.9, 55.7, 39.7, 27.8, 27.3; HRMS: 
(ESI+) calculated for C17H17NO2Na 290.1151. Found [M+Na]+ 290.1146; m.p. 117−119 °C (CDCl3) 
(Lit.284 118−119.5 °C, no recrystallisation solvent specified). The spectroscopic properties for this 
compound were consistent with the data available in the literature.284  
Step 3: N-(2-(2-Hydroxyethyl)-3-methoxyphenyl)pivalamide (9.56 g, 38.0 mmol) was suspended in 
aq. HBr (48%, 103 mL) and the solution was heated to 100 °C overnight. The reaction mixture was 
cooled to ambient temperature and the pH of the solution was adjusted to 9 by the slow addition of 
NaOH pellets. The mixture was extracted with EtOAc (3 × 100 mL). The organic extracts were 
combined, washed with aq. NaOH (2M, 100 mL) and water (60 mL), dried over Na2SO4 and 
concentrated in vacuo to provide the crude title product (5.10 g, 99%) as a brown oil. The crude material 
was employed in the next step without any further purification. 1H NMR (400 MHz, CDCl3): δ 6.94 
(1H, t, J = 8.0 Hz), 6.28 (1H, d, J = 8.0 Hz), 6.22 (1H, dd, J = 8.0, 1.0 Hz), 4.59 (2H, t, J = 8.5 Hz), 
3.77 – 3.41 (2H, m,), 3.02 (2H, t, J = 8.5 Hz); 13C NMR (101 MHz, CDCl3): δ 161.2, 143.4, 129.1, 
111.3, 107.7, 100.3, 71.1, 27.3. The spectroscopic properties for this compound were consistent with 
the data available in the literature.116 
Step 4: 2,3-Dihydrobenzofuran-4-amine (5.10 g, 37.7 mmol) was dissolved in CH2Cl2 (54 mL) and 
pyridine (1.80 mL) and cooled to 0 °C. Acetic anhydride (3.92 mL, 41.5 mmol) was added dropwise 
over 10 minutes. The solution was warmed to ambient temperature and stirred for 2 hours. The reaction 
was quenched by the addition of water (75 mL) and extracted with CH2Cl2 (3 × 180 mL). The organic 
extracts were combined, washed with saturated aq. NaHCO3 (3 × 75 mL) and brine (75 mL), dried over 
Na2SO4 and concentrated in vacuo. Purification of the residue by recrystallisation (hexane/EtOAc) 
afforded the title compound (4.27 g, 64%) as white plates. 1H NMR (400 MHz, CDCl3): δ 7.20 (1H, d, 
J = 8.0 Hz), 7.10 (1H, t, J = 8.0 Hz), 6.94 (1H, br. s), 6.62 (1H, d, J = 8.0 Hz), 4.60 (2H, t, J = 8.5 Hz), 
3.14 (2H, t, J = 8.5 Hz), 2.18 (3H, s); 13C NMR (101 MHz, CDCl3): δ 168.1, 160.9, 134.4, 128.9, 118.9, 
114.2, 106.5, 71.2, 28.4, 24.4; m.p. 125−126 °C (hexane/EtOAc) (Lit.116 126−127 °C, hexane/EtOAc). 
The spectroscopic properties for this compound were consistent with the data available in the 
literature.116  
 






General Procedure T: Purification of the residue by recrystallisation (hexane/EtOAc) afforded the title 
compound (878 mg, 68%) as a colourless powder. vmax/cm-1: 3300 (m), 2970 (m), 1668 (s), 1527 (s); 
1H NMR (500 MHz, CDCl3): δ 7.65 (2H, d, J = 8.5 Hz, C6-H), 7.55 (2H, d, J = 8.5 Hz, C7-H), 7.42 
(1H, s, N-H), 2.70 (1H, p, J = 8.0 Hz, C1-H), 2.00 – 1.84 (4H, m, cyclopentyl), 1.84 – 1.73 (2H, m, 
cyclopentyl), 1.69 – 1.54 (2H, m, Cyclopentyl); 13C NMR (126 MHz, CDCl3): δ 175.1 (C4), 141.3 (C5), 
126.4 (q, J = 4.0 Hz, C7), 125.9 (q, J = 32.0 Hz, C8), 124.2 (q, J = 271.0 Hz, C9), 119.4 (C6), 47.0 
(C1), 30.7 (cyclopentyl), 26.2 (cyclopentyl); HRMS: (ESI+) calculated for C13H15NOF3 258.1103. 
Found [M+H]+ 258.1098; m.p. 170−172 °C (hexane/EtOAc). 
N-(4-(tert-Butyl)phenyl)cyclopentanecarboxamide (60ac) 
 
General Procedure T: Purification of the residue by recrystallisation (hexane/EtOAc) afforded the title 
compound (885 mg, 72%) as colourless crystals. 1H NMR (400 MHz, CDCl3): δ 7.44 (2H, d, J = 8.5 
Hz), 7.33 (2H, d, J = 8.5 Hz), 7.13 (1H, s), 2.66 (1H, p, J = 8.0 Hz), 1.99 – 1.49 (8H, m), 1.30 (9H, s); 
13C NMR (101 MHz, CDCl3): δ 174.7, 147.1, 135.7, 125.9, 119.7, 46.9, 34.5, 31.5, 30.7, 26.1; m.p. 
151−153 °C (hexane/EtOAc). (Lit. m.p., not stated). The spectroscopic properties for this compound 
were consistent with the data available in the literature. 285 
N-(o-Tolyl)cyclopenanecarboxamide (60ad) 
 
General Procedure T: Purification of the residue by recrystallisation (hexane/EtOAc) afforded the title 
compound (742 mg, 74%) as a colourless powder. vmax/cm-1: 3270 (m), 2956 (m), 2864 (m), 1650 (s), 
1532 (s); 1H NMR (400 MHz, CDCl3): δ 7.86 – 7.80 (1H, m, C10-H), 7.21 – 7.13 (2H, m, C7-H, C9-
H), 7.09 – 7.00 (1H, m, C8-H), 6.98 (1H, s,nH), 2.72 (1H, p, J = 8.0 Hz, C1-H), 2.24 (3H, s, C11-H3), 
1.99 – 1.54 (8H, m, C2-H2, C3-H2); 13C NMR (101 MHz, CDCl3): δ 174.6 (C4), 136.0 (C5), 130.5 (C7), 
128.8 (C6), 126.9 (C9), 125.0 (C8), 123.1 (C10), 46.9 (C1), 30.7 (cyclopentyl), 26.1 (cyclopentyl), 17.9 








General Procedure T: Purification of the residue by recrystallisation (hexane/EtOAc) afforded the title 
compound (972 mg, 87%) as a colourless powder. vmax/cm-1: 3288 (m), 2959 (m), 2869 (m), 1661 (s), 
1593 (s); 1H NMR (400 MHz, CDCl3): δ 7.66 (1H, s, C6-H), 7.42 – 7.30 (2H, m, C10-H, N-H), 7.26 – 
7.16 (1H, m, C9-H), 7.05 (1H, dd, J = 8.0, 1.0 Hz, C8-H), 2.67 (1H, p, J = 8.0 Hz, C1-H), 2.01 – 1.84 
(4H, m, cyclopentyl), 1.83 – 1.68 (2H, m, cyclopentyl), 1.68 – 1.48 (2H, m, cyclopentyl); 13C NMR 
(101 MHz, CDCl3): δ 174.9 (C4), 139.4 (C5), 134.7 (C7), 130.0 (C9), 124.2 (C8), 120.0 (C6), 117.8 
(C10), 47.0 (C1), 30.7 (cyclopentyl), 26.1 (cyclopentyl); HRMS: (ESI+) calculated for C12H14NO35ClNa 
246.0656. Found [M+Na]+ 246.0665; m.p. 109−111 °C (hexane/EtOAc). 
N-(3-Bromophenyl)acetamide (60i) 
 
The title compound was prepared following a literature procedure.286 To a solution of 3-bromoaniline 
(0.633 mL, 5.81 mmol) and acetic anhydride (1.10 mL, 11.6 mmol) at 0 °C was added sulfuric acid (0.1 
mL). The solution was stirred for 1 h, before ice (~5.00 g) was added. The resulting white precipitate 
was collected by filtration, dissolved in EtOAc (10 mL), washed with water (10 mL) and concentrated 
in vacuo. Purification of the residue by recrystallisation (hexane/EtOAc) afforded the title compound 
(1.10 g, 89%) as a white powder. 1H NMR (400 MHz, CDCl3): δ 7.77 – 7.74 (1H, m), 7.66 (1H, br. s), 
7.40 (1H, d, J = 8.0 Hz), 7.22 (1H, d, J = 8.0 Hz), 7.15 (1H, t, J = 8.0 Hz), 2.17 (3H, s); 13C NMR (101 
MHz, CDCl3): δ 168.8, 139.3, 130.4, 127.4, 123.0, 122.7, 118.5, 24.7; m.p. 85−87 °C (hexane/EtOAc) 
(Lit.287 85−86 °C, no recrystallisation solvent specified). The spectroscopic properties for this 
compound were consistenet with the data available in the literature.288  
N-(4-Nitrophenyl)acetamide (60ai) 
 
To pyridine (1.10 mL) and acetyl chloride (0.240 mL, 4.34 mmol) in dry CH2Cl2 (5.5 mL) was added 
4-nitroaniline (500 mg, 3.62 mmol) and pyridine (1.10 mL) dropwise at 0 °C over 10 minutes. The 
solution was stirred at ambient temperature overnight. The resulting slurry was concentrated in vacuo 




before being taken up in CH2Cl2 (20 mL). The solution was washed with water (2 × 10 mL), dried over 
Na2SO4 and concentrated in vacuo. Purification of the residue by FCC (hexane/EtOAc 50%) afforded 
the title compound (518 mg, 79% yield) as a white solid. 1H NMR (400 MHz, DMSO-d6): δ 10.55 (1H, 
br. s), 8.25 – 8.16 (2H, m), 7.86 – 7.78 (2H, m), 2.12 (3H, s); 13C NMR (101 MHz, DMSO-d6): δ 169.3, 
145.4, 142.0, 125.0, 118.5, 24.2; m.p. 210−211 °C (CDCl3) (Lit.289 209–211, no recrystallisation 
solvent specified). The spectroscopic properties for this compound were consistent with the data 
available in the literature.290  
N-(3,4-Dihydronaphthalen-2-yl)acetamide (195) 
  
The title compound was prepared following a modified literature procedure.291 A flame-dried round-
bottomed flask equipped with a Dean-Stark apparatus was charged with β-tetralone (820 μL, 6.20 
mmol), acetamide (916 mg, 15.5 mmol), p-toluenesulfonic acid monohydrate (118 mg, 0.620 mmol) 
and toluene (40 mL). The mixture was heated at reflux for 16 h under a nitrogen atmosphere. The 
reaction was cooled to ambient temperature, quenched with saturated aq. NaHCO3 (100 mL) and then 
extracted with EtOAc (3 × 30 mL). The organic extracts were combined, washed with brine (20 mL), 
dried over Na2SO4 and concentrated in vacuo to provide the crude material. Purification of the residue 
by FCC (hexane/EtOAc 50%) afforded the title compound (1.12 g, 97% yield) as an off-white solid. 1H 
NMR (CDCl3, 400 MHz): δ 7.16 – 6.95 (5H, m), 6.81 (1H, br. s), 2.87 (2H, t, J = 8.0 Hz), 2.44 (2H, t, 
J = 8.0 Hz), 2.10 (3H, s); 13C NMR (CDCl3, 100 MHz): δ 168.5, 134.9, 134.6, 132.6, 127.0, 126.7, 
126.1, 125.7, 111.3, 27.9, 27.5, 24.7; m.p. 98−100 ˚C (hexane/EtOAc) (Lit.291 99−101 ˚C, no 
recrystallisation solvent specified). The spectroscopic properties were consistent with the data 




The title compound was prepared following a literature procedure.292 To a flame-dried round-bottomed 
flask was added estrone (2.00 g, 7.40 mmol) in dry CH2Cl2 (37 mL) under nitrogen. Pyridine (1.20 mL, 
14.8 mmol) was added and the solution was cooled to 0 °C. Triflic anhydride (1.50 mL, 8.88 mmol) 
was added dropwise over 5 minutes. The solution was warmed to ambient temperature and was stirred 




for 1.5 h. The reaction was quenched by the addition of water (20 mL). The layers were separated, and 
the aqueous phase was extracted with CH2Cl2 (3 × 30 mL). The organic extracts were combined, washed 
with brine (30 mL), dried over Na2SO4 and concentrated in vacuo. Purification of the residue by FCC 
(hexane/EtOAc 30%) afforded the title compound (3.04 g, quantitative) as an orange solid. 1H NMR 
(400 MHz, CDCl3): δ 7.33 (1H, d, J = 8.5 Hz), 7.06 – 6.95 (2H, m), 2.98 – 2.93 (2H, m), 2.61 – 2.46 
(1H, m), 2.44 – 2.35 (1H, m), 2.35 – 2.25 (1H, m), 2.22 – 2.00 (3H, m), 2.00 – 1.92 (1H, m), 1.69 – 
1.38 (6H, m), 0.91 (3H, s); 13C NMR (101 MHz, CDCl3): δ 220.4, 147.7, 140.4, 139.4, 127.3, 121.3, 
118.8 (q, J = 321.0 Hz), 118.4, 50.5, 47.9, 44.2, 37.8, 35.9, 31.6, 29.5, 26.2, 25.8, 21.7, 13.9; m.p. 85−87 
°C (CH2Cl2) (Lit.293 87−89 °C, no recrystallisation solvent specified); [α]22D = + 114.6 (c = 0.20, 





The title compound was prepared following a literature procedure.19 An oven dried resealable tube was 
charged with (13S)-13-methyl-17-oxo-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a] 
phenanthrene-3-yl trifluoromethanesulfonate (805 mg, 2.00 mmol), the preceding acetanilide (177 mg, 
3.00 mmol), Pd2(dba)3 (18.0 mg, 0.020 mmol), Me4t-BuXPhos (48.0 mg, 0.100 mmol) and K3PO4 (1.06 
g, 5.00 mmol). The tube was fitted with a rubber septum and purged with nitrogen before t-BuOH 
(deoxygenated with Ar for 10 minutes) was added and the tube was sealed with a Young’s tap. The 
reaction mixture was heated at 110 °C for 18 h, cooled to ambient temperature and filtered over a pad 
of Celite®, washing with EtOAc and CH2Cl2/MeOH (1:1). The resulting solution was concentrated in 
vacuo and purification of the residue by FCC (toluene/EtOAC 40−50%) afforded the desired product 
(526 mg, 84%) as a colourless solid. vmax/cm-1: 3291 (m), 2936 (m), 2920 (m), 1734 (s), 1658 (s); 1H 
NMR (400 MHz, DMSO-d6): δ 9.74 (1H, s, N-H), 7.33-7.25 (2H, m, C4-H, C8-H), 7.17 (1H, d, J = 8.5 
Hz, C7-H), 2.85-2.76 (2H, m, C9-H2), 2.44 (1H, dd, J = 19.0, 8.5 Hz, C18-H2), 2.38-2.28 (1H, m, C16-
H2), 2.24-2.14 (1H, m, C12-H), 2.05 (1H, dd, J = 19.0, 8.5 Hz, C18-H2), 2.00 (3H, s, C1-H3), 1.98-1.88 
(2H, m, C10-H2, C17-H2), 1.78-1.70 (1H, m, C15-H2), 1.61-1.28 (6H, m, C10-H2, C11-H, C13-H, C15-
H2, C16-H2, C17-H2), 0.83 (3H, s, C20-H3); 13C NMR (101 MHz, DMSO-d6): δ 219.6 (C19), 167.9 
(C2), 136.9 (C5), 136.3 (C3), 134.3 (C6), 125.4 (C7), 119.1 (C4), 116.6 (C8), 49.6 (C13), 47.3 (C14), 
43.6 (C12), 37.7 (C11), 35.3 (C18), 31.3 (C15), 29.1 (C9), 26.0 (C10), 25.3 (C16), 23.9 (C1), 21.1 




(C17), 13.5 (C20); HRMS (ESI+) calculated for C20H26NO2 312.1958. Found [M+H]+ 312.1979; m.p. 
230 °C (degradation) (CDCl3); [α]20D = + 134.7 (c = 0.20, CH2Cl2).  
For heteroaromatic substrates 126a−d, 131, 134a and 145 see Section 7.5.1 
For heteroaromatic substrates 126e and 150a−c see Section 7.6.2 
7.7.2 − -Arylation of Styrenes with Acetanilide Substrates 
For branched hydroarylation product 96aa’ see Section 7.4.3 
N-(2-(1-Phenylvinyl)phenyl)acetamide (104aa’) 
  
General Procedure U: The reaction was carried out with Ir(cod)2OTf (7.5 mol%), L-20c (7.5 mol%) 
and 1,4-dioxane (0.5 M with respect to substrate) and was run for 72 h. Purification of the residue by 
FCC (hexane/EtOAc 10−40%) afforded the title compound (25.0 mg, 74%) as a colourless solid. 1H 
NMR (400 MHz, DMSO-d6): δ 8.83 (1H, s), 7.49 (1H, d, J = 8.0 Hz), 7.39 – 7.26 (4H, m), 7.24 – 7.13 
(4H, m), 5.76 (1H, d, J = 1.0 Hz), 5.31 (1H, d, J = 1.0 Hz), 1.60 (3H, s); 13C NMR (101 MHz, DMSO-
d6): δ 167.9, 146.3, 140.0, 135.5, 130.2, 128.1, 127.9, 127.6, 126.5, 125.9, 125.0, 116.7, 22.7; m.p. 
120−122 °C (hexane/EtOAc). The spectroscopic properties for this compound were consistent with the 




General Procedure U: The reaction was carried out with Ir(cod)2OTf (7.5 mol%), L-20c (7.5 mol%) 
and 1,4-dioxane (0.5 M with respect to substrate) and was run for 72 h. The crude material was purified 
by FCC (1st column: hexane/EtOAc 0−30%; 2nd column: hexane/EtOAc 30%) to afford the title 
compound (24.7 mg, 69%, 0.96:0.04 mixture of rotamers A:B) as golden plates. vmax/cm-1: 3415 (m), 
3288 (m), 1668 (s), 1516 (s), 1448 (s); Signals for rotamer A: 1H NMR (400 MHz, CDCl3): δ 8.22 (1H, 
d, J = 8.0 Hz, C5-H), 7.38 (1H, ddd, J = 8.0, 8.0, 2.0 Hz, C6-H), 7.35 – 7.31 (5H, m, C13-H, C14-H, 
C15-H), 7.29 – 7.25 (1H, m, C8-H), 7.19 – 7.12 (1H, m, C7-H), 6.99 (1H, br. s, N-H), 5.88 (1H, d, J = 
1.5 Hz, C11-H2), 5.37 (1H, d, J = 1.5 Hz, C11-H2), 2.01 (2H, q, J = 7.5 Hz, C2-H2), 0.92 (3H, t, J = 7.5 
Hz, C1-H3); 13C NMR (101 MHz, CDCl3): δ 171.7 (C3), 146.5 (C10), 139.3 (C12), 135.4 (C4), 131.8 
(C9), 130.4 (C8), 129.0 (ArCH), 128.9 (ArCH), 128.7 (C6), 126.6 (ArCH), 124.2 (C7), 121.7 (C5), 




117.4 (C11), 30.8 (C2), 9.4 (C1); HRMS: (ESI+) calculated for C17H18NO 252.1383. Found [M+H]+ 
252.1386; m.p. 113−115 °C (CDCl3). 
Characteristic signals for rotamer B: 1H NMR (400 MHz, CDCl3): δ 8.08 (1H, d, J = 8.5 Hz, C5-H), 
5.84 (1H, s, C11-H2), 5.33 (1H, s, C11-H2). 
The structure of compound 104ka’ was confirmed by single crystal X-ray diffraction of crystals 





General Procedure U: The reaction was carried out with Ir(cod)2OTf (7.5 mol%), L-20c (7.5 mol%) 
and 1,4-dioxane (0.5 M with respect to substrate) and was run for 72 h. The crude material was purified 
by FCC (2 columns; hexane/EtOAc 20%) to afford the title compound (30.7 mg, 81%, 0.98:0.02 
mixture of rotamers A:B) as an orange oil. vmax/cm
-1: 3418 (m), 2966 (m), 1676 (s), 1515 (s), 1444 (s); 
Signals for rotamer A: 1H NMR (400 MHz, CDCl3): δ 8.26 (1H, d, J = 8.0 Hz, C5-H), 7.41 – 7.35 (1H, 
m, C6-H), 7.35 – 7.31 (5H, m, C13-H, C14-H, C15-H), 7.30 – 7.25 (1H, m, C8-H), 7.15 (1H, ddd, J = 
8.0, 8.0, 1.0 Hz, C7-H), 7.03 (1H, s, N-H), 5.90 (1H, d, J = 1.5 Hz, C11-H2), 5.38 (1H, d, J = 1.5 Hz, 
C11-H2), 2.13 (1H, sept, J = 7.0 Hz, C2-H), 0.91 (6H, d, J = 7.0 Hz, C1-H3); 13C NMR (101 MHz, 
CDCl3): δ 174.8 (C3), 146.5 (C10), 139.2 (C12), 135.4 (C4), 131.7 (C9), 130.5 (C8), 129.0 (ArCH), 
128.9 (ArCH), 128.7 (ArCH), 126.6 (ArCH), 124.1 (C7), 121.4 (C5), 117.5 (C11), 36.8 (C2), 19.2 (C1); 
HRMS: (ESI+) calculated for C18H19NONa 288.1359. Found [M+Na]+ 288.1362. 
Characteristic signals for rotamer B: 1H NMR (400 MHz, CDCl3): δ 8.13 (1H, d, J = 8.5 Hz, C5-H), 
5.86 (1H, d, J = 1.0 Hz, C11-H2), 5.33 (1H, d, J = 1.0 Hz, C11-H2). 
 
 






General Procedure U: The reaction was carried out with Ir(cod)2OTf (7.5 mol%), L-20c (7.5 mol%) 
and 1,4-dioxane (0.5 M with respect to substrate) and was run for 96 h. The crude material was purified 
by FCC (2 columns; hexane/EtOAc 0−10%) to afford the title compound (26.0 mg, 65%, 0.97:0.03 
mixture of rotamers A:B) as a brown oil. vmax/cm-1: 3431 (m), 2959 (m), 1686 (s), 1516 (s), 1300 (s); 
Signals for rotamer A: 1H NMR (400 MHz, CDCl3): δ 8.29 (1H, dd, J = 8.0, 1.0 Hz, C5-H), 7.40 – 7.36 
(1H, m, C6-H), 7.37 – 7.30 (6H, m, C13-H, C14-H, C15-H, N-H), 7.29 – 7.24 (1H, m, C8-H), 7.14 (1H, 
ddd, J = 8.0, 8.0, 1.0 Hz, C7-H), 5.92 (1H, d, J = 1.5 Hz, C11-H2), 5.38 (1H, d, J = 1.5 Hz, C11-H2), 
0.94 (9H, s, C1-H3); 13C NMR (101 MHz, CDCl3): δ 176.4 (C3), 146.5 (C10), 138.8 (C12), 135.6 (C4), 
131.7 (C9), 130.6 (C8), 129.1 (ArCH), 129.0 (ArCH), 128.8 (ArCH), 126.61 (ArCH), 124.1 (C7), 121.3 
(C5), 117.4 (C11), 39.7 (C2), 27.3 (C1); HRMS: (ESI+) calculated for C19H21NONa 302.1515. Found 
[M+Na]+ 302.1518.  
Characteristic signals for rotamer B: 1H NMR (400 MHz, CDCl3): δ 8.17 (1H, d, J = 8.0 Hz, C5-H), 
5.88 (1H, s, C11-H2), 5.33 (1H, s, C11-H2). 
N-(2-(1-Phenylvinyl)phenyl)cyclobutanecarboxamide (104na’) 
  
General Procedure U: The reaction was carried out with Ir(cod)2OTf (7.5 mol%), L-20c (7.5 mol%) 
and 1,4-dioxane (0.5 M with respect to substrate) and was run for 72 h. The crude material was purified 
by FCC (toluene/Et2O 0−2%) to afford the title compound (22.9 mg, 57%) as a yellow oil. vmax/cm-1: 
3411 (m), 2942 (m), 1680 (s), 1515 (s); 1H NMR (400 MHz, CDCl3): δ 8.26 (1H, d, J = 7.5 Hz, C6-H), 
7.41 – 7.35 (1H, m, C7-H), 7.34 – 7.31 (5H, m, C14-H, C15-H, C16-H), 7.30 – 7.24 (1H, m, C9-H), 
7.14 (1H, ddd, J = 7.5, 7.5, 1.0 Hz, C8-H), 6.90 (1H, s, N-H), 5.87 (1H, d, J = 1.5 Hz, C12-H2), 5.37 
(1H, d, J = 1.5 Hz, C12-H2), 2.79 (1H, app. p, J = 8.5 Hz, C1-H), 2.04 – 1.59 (6H, m, C2-H2, C3-H2); 
13C NMR (101 MHz, CDCl3): δ 173.0 (C4), 146.4 (C11), 139.3 (C13), 135.4 (C5), 131.6 (C10), 130.5 
(C9), 129.0 (C15), 129.0 (C7), 128.7 (C16), 126.6 (C14), 124.1 (C8), 121.3 (C6), 117.5 (C12), 40.8 











General Procedure U: The reaction was carried out with Ir(cod)2OTf (7.5 mol%), L-20c (7.5 mol%) 
and 1,4-dioxane (0.5 M with respect to substrate) and was run for 72 h. The crude material was purified 
by FCC (hexane/EtOAc 0−5%) to afford the title compound (33.0 mg, 79%) as a yellow oil. vmax/cm-1: 
3415 (m), 2952 (m), 1681 (s), 1514 (s), 1443 (s); 1H NMR (400 MHz, CDCl3): δ 8.26 (1H, d, J = 7.5 
Hz, C6-H), 7.42 – 7.28 (6H, m, C7-H, C14-H, C15-H, C16-H), 7.26 (1H, d, J = 7.5 Hz, C9-H), 7.13 
(1H, dd, J = 7.5, 7.5 Hz, C8-H), 7.02 (1H, br s, N-H), 5.89 (1H, s, C12-H2), 5.37 (1H, s, C12-H2), 2.37 
– 2.19 (1H, m, C1-H), 1.69 – 1.34 (8H, m, C2-H2, C3-H2); 13C NMR (101 MHz, CDCl3): δ 174.1 (C4), 
146.5 (C11), 139.3 (C13), 135.6 (C5), 131.5 (C10), 130.4 (C9), 129.0 (ArCH), 128.9 (ArCH), 128.7 
(ArCH), 126.6 (ArCH), 124.0 (C8), 121.4 (C6), 117.4 (C12), 47.0 (C1), 30.0 (cyclopentyl), 25.9 
(cyclopentyl); HRMS: (ESI+) calculated for C20H22NO 292.1696. Found [M+H]+ 292.1685. 
N-(2-(1-Phenylvinyl)phenyl)cyclohexanecarboxamide (104pa’) 
  
General Procedure U: The reaction was carried out with Ir(cod)2OTf (7.5 mol%), L-20c (7.5 mol%) 
and 1,4-dioxane (0.5 M with respect to substrate) and was run for 72 h. The crude material was purified 
by FCC (2 columns; hexane/EtOAc 0−10%) to afford the title compound (31.2 mg, 71%) as a yellow 
powder. vmax/cm
-1: 3418 (m), 2926 (m), 1679 (s), 1515 (s), 1279 (s); 1H NMR (400 MHz, CDCl3): δ 
8.27 (1H, d, J = 8.0 Hz, C7-H), 7.41 – 7.36 (1H, m, C8-H), 7.34 – 7.30 (5H, m, C15-H, C16-H, C17-
H), 7.29 – 7.25 (1H, m, C10-H), 7.14 (1H, ddd, J = 8.0, 8.0, 1.0 Hz, C9-H), 7.03 (1H, br. s, N-H), 5.89 
(1H, d, J = 1.0 Hz, C13-H2), 5.38 (1H, d, J = 1.0 Hz, C13-H2), 1.94 – 1.78 (1H, m, C1-H), 1.74 – 1.62 
(2H, m, cy), 1.63 – 1.49 (3H, m, cy), 1.22 – 1.01 (5H, m, cy); 13C NMR (101 MHz, CDCl3): δ 174.0 
(C5), 146.6 (C12), 139.3 (C14), 135.5 (C6), 131.6 (C11), 130.5 (ArCH), 129.0 (ArCH), 128.9 (ArCH), 
128.7 (ArCH), 126.7 (C9), 124.1 (C7), 117.6 (C13), 46.6 (C1), 29.3 (Cy), 25.7 (Cy), 25.7 (Cy); HRMS: 
(ESI+) calculated for C21H23NONa 328.1672. Found [M+Na]+ 328.1671; m.p. 57−59 °C (CDCl3). 
3-Phenyl-N-(2-(1-phenylvinyl)phenyl)propanamide (104qa’) 
  
General Procedure U: The reaction was carried out with Ir(cod)2OTf (7.5 mol%), L-20c (7.5 mol%) 
and 1,4-dioxane (0.5 M with respect to substrate) and was run for 72 h. The crude material was purified 




by FCC (hexane/EtOAc 0−10%) to afford the title compound (33.9 mg, 74%) as a yellow oil. vmax/cm-
1: 3416 (m), 3026 (m), 2923 (s) 1669 (s), 1516 (s); 1H NMR (400 MHz, CDCl3): δ 8.21 (1H, d, J = 8.0 
Hz, C9-H), 7.41 – 7.36 (1H, m, C10-H), 7.35 – 7.23 (8H, m, C3-H, C12-H, C17-H, C18-H, C19-H), 
7.22 – 7.14 (2H, m, C11-H, C4-H), 7.12 – 7.08 (2H, m, C2-H), 6.95 (1H, s, N-H), 5.83 (1H, s, C15-H2), 
5.30 (1H, s, C15-H2), 2.78 – 2.71 (2H, m, C5-H2), 2.32 – 2.23 (2H, m, C6-H2); 13C NMR (101 MHz, 
CDCl3): δ 170.1 (C7), 146.3 (C14), 140.6 (C1), 139.4 (C16), 135.2 (C8), 131.9 (C13), 130.4 (C12), 
129.0 (ArCH), 128.9 (ArCH), 128.7 (ArCH), 128.6 (ArCH), 128.3 (C2), 126.6 (ArCH), 126.3 (C4), 
124.4 (C11), 121.8 (C9), 117.5 (C15), 39.4 (C6), 31.4 (C5); HRMS: (ESI+) calculated for C23H22NO 
328.1696. Found [M+H]+ 328.1696. 
N-(5-Methyl-2-(1-phenylvinyl)phenyl)acetamide (104ca’) 
 
General Procedure U: The reaction was carried out with Ir(cod)2OTf (7.5 mol%), L-20c (7.5 mol%) 
and 1,4-dioxane (0.5 M with respect to substrate) and was run for 72 h. Purification of the residue by 
FCC (toluene/EtOAc 10−30%) afforded the title compound (27.5 mg, 77%) as a colourless solid. 
vmax/cm
-1: 2253 (m), 1686 (m), 1381 (m), 904 (m); 1H NMR (CDCl3, 400 MHz): δ 7.97 (1H, s, C4-H 
), 7.40 – 7.25 (5H, m, C12-H, C13-H, 14-H), 7.15 (1H, d, J = 8.0 Hz, C7-H), 6.97 (1H, d, J = 8.0 Hz, 
C6-H), 6.90 (1H, s, N-H), 5.83 (1H, s, C10-H2), 5.35 (1H, s, C10-H2), 2.39 (3H, s, C15-H3), 1.77 (3H, 
s, C1-H3); 13C NMR (CDCl3, 100 MHz): 168.4 (C2), 146.8 (C11), 140.0 (C9), 139.2 (C8), 135.3 (C5), 
130.5 (C7), 129.5 (C3), 129.2 (ArCH), 128.8 (ArCH), 126.9 (ArCH), 125.5 (C6), 122.8 (C4), 117.5 
(C10), 24.7 (C1), 21.9 (C15); HRMS: (ESI+) calculated for C17H18NO: 252.1383. Found [M+H]+; 
252.1383; m.p. 98−100 °C (CDCl3). 
N-(5-Methoxy-2-(1-phenylvinyl)phenyl)acetamide (104ba’) 
  
General Procedure U: The reaction was carried out with Ir(cod)2OTf (7.5 mol%), L-20c (7.5 mol%) 
and 1,4-dioxane (0.5 M with respect to substrate) and was run for 72 h. The crude material was purified 
by FCC (hexane/EtOAc 10−30%) to afford the title compound (24.9 mg, 65%, 0.97:0.03 mixture of 
rotamers A:B) as a brown oil. vmax/cm
-1: 3280 (m), 2936 (m), 1676 (s), 1524 (s), 1239 (s); Signals for 
rotamer A: 1H NMR (400 MHz, CDCl3): δ 7.88 (1H, d, J = 2.5 Hz, C4-H), 7.38 – 7.28 (5H, m, C12-H, 
C13-H, C14-H), 7.16 (1H, d, J = 8.5 Hz, C7-H), 7.01 (1H, br. s, N-H), 6.70 (1H, dd, J = 8.5, 2.5 Hz, 
C6-H), 5.81 (1H, d, J = 1.5 Hz, C10-H2), 5.34 (1H, d, J = 1.5 Hz, C10-H2), 3.84 (3H, s, C15-H3), 1.79 




(3H, s, C1-H3); 13C NMR (101 MHz, CDCl3): δ 168.2 (C2), 160.0 (C5), 146.2 (C9), 139.9 (C11), 136.4 
(C3), 131.1 (C7), 128.9 (ArCH), 128.6 (C14), 126.8 (ArCH), 123.9 (C8), 117.2 (C10), 110.5 (C6), 




General Procedure U: The reaction was carried out with Ir(cod)2OTf (7.5 mol%), L-20c (7.5 mol%) 
and 1,4-dioxane (0.5 M with respect to substrate) and was run for 72 h. The crude material was purified 
by FCC (hexane/Et2O 0−10%) to afford the title compound (38.6 mg, 78%) as a yellow oil. vmax/cm
-1: 
3414 (m), 2958 (m), 1683 (s), 1523 (s); 1H NMR (400 MHz, CDCl3): δ 8.20 (1H, s, C6-H), 7.23 (2H, 
d, J = 8.0 Hz, C14-H), 7.19 – 7.11 (3H, m, C9-H, C15-H), 7.07 (1H, s, N-H), 6.99 (1H, dd, J = 7.5, 2.0 
Hz, C8-H), 5.81 (1H, d, J = 1.5 Hz, C12-H2), 5.30 (1H, d, J = 1.5 Hz, C12-H2), 2.95 (1H, hept, J = 7.0 
Hz, C18-H), 2.35 (3H, s, C17-H3), 2.34 – 2.23 (1H, m, C1-H), 1.67 – 1.42 (8H, m, C3-H2, C2-H2), 1.30 
(6H, d, J = 7.0 Hz, C19-H3); 13C NMR (101 MHz, CDCl3): δ 174.2 (C4), 149.8 (C7), 146.4 (C11), 138.6 
(C16), 136.7 (C13), 135.5 (C5), 130.2 (C9), 129.6 (C15), 129.1 (C10), 126.7 (C14), 121.9 (C8), 119.4 
(C6), 116.3 (C12), 47.0 (C1), 34.3 (C18), 30.0 (cyclopentyl), 25.9 (cyclopentyl), 24.0 (C19), 21.3 
(C17); HRMS: (ESI+) calculated for C24H30NO 348.2322. Found [M+H]+ 348.2332. 
N-(4-(1-(p-Tolyl)vinyl)-[1,1'-biphenyl]-3-yl)cyclopentanecarboxamide (104xe’) 
 
General Procedure U: The reaction was carried out with Ir(cod)2OTf (7.5 mol%), L-20c (7.5 mol%) 
and 1,4-dioxane (0.5 M with respect to substrate) and was run for 72 h. The crude material was purified 
by FCC (hexane/Et2O 0−10%) to afford the title compound (38.3 mg, 70%) as a yellow oil. vmax/cm
-1: 
3412 (m), 2952 (m), 1683 (s), 1525 (s); 1H NMR (400 MHz, CDCl3): δ 8.62 (1H, d, J = 2.0 Hz, C6-H), 
7.73 – 7.66 (2H, m, C19-H), 7.47 – 7.41 (2H, m, C20-H), 7.41 – 7.32 (3H, m, C8-H, C9-H, C21-H), 
7.28 (2H, d, J = 8.0 Hz, C14-H), 7.17 (2H, d, J = 8.0 Hz, C15-H), 7.13 (1H, s, N-H), 5.87 (1H, d, J = 
1.5 Hz, C12-H2), 5.37 (1H, d, J = 1.5 Hz, C12-H2), 2.37 (3H, s, C17-H3), 2.38 – 2.25 (1H, m, C1-H), 
1.69 – 1.46 (8H, m, C3-H2, C2-H2); 13C NMR (101 MHz, CDCl3): δ 174.3 (C4), 146.1 (C11), 141.7 
(C7), 140.6 (C18), 138.8 (C16), 136.5 (C13), 136.0 (C5), 130.8 (C10), 130.5 (C8), 129.7 (C15), 128.8 
(C20), 127.6 (C21), 127.3 (C19), 126.7 (C14), 122.5 (C9), 119.9 (C6), 116.6 (C12), 47.0 (C1), 30.1 








General Procedure U: The reaction was carried out with Ir(cod)2OTf (7.5 mol%), L-20c (7.5 mol%) 
and 1,4-dioxane (0.5 M with respect to substrate) and was run for 72 h. The crude material was purified 
by FCC (1st column: hexane/EtOAc 10−40%; 2nd column: hexane/EtOAc 40%) to afford the title 
compound (33.1 mg, 83%, 0.92:0.08 mixture of rotamers A:B) as an off-white solid. vmax/cm-1: 3255 
(m), 2952 (m), 1660 (s), 1524 (s), 1289 (s); Signals for rotamer A: 1H NMR (400 MHz, CDCl3): δ 7.35 
– 7.27 (5H, m, C12-H, C13-H, C14-H), 7.20 – 7.14 (2H, m, C6-H, C7-H), 6.51 (1H, br. s, N-H), 5.70 
(1H, d, J = 1.5 Hz, C10-H2), 5.31 (1H, d, J = 1.5 Hz, C10-H2), 3.03 – 2.95 (2H, m, C17-H2), 2.85 – 2.77 
(2H, m, C15-H2), 2.14 – 2.01 (2H, m, C16-H2), 1.63 (3H, s, C1-H3); 13C NMR (101 MHz, CDCl3): δ 
167.9 (C2), 147.7 (C9), 146.1 (C5), 142.2 (C4), 140.7 (C11), 135.0 (C8), 130.6 (C3), 128.8 (C6), 128.8 
(ArCH), 128.1 (ArCH), 126.5 (ArCH), 122.9 (C7), 116.5 (C10), 33.4 (C17), 32.0 (C15), 25.4 (C16), 
22.9 (C1); HRMS: (ESI+) calculated for C19H19NONa 300.1359. Found [M+Na]+ 300.1356; m.p. 
106−108 °C (CDCl3). 
Characteristic signals for rotamer B: 1H NMR (400 MHz, CDCl3): δ 6.35 (1H, s, N-H), 5.66 (1H, s, 
C10-H2), 5.26 (1H, s, C10-H2). 
N-(5-(1-Phenylvinyl)-2,3-dihydrobenzofuran-4-yl)acetamide (104da’) 
  
General Procedure U: The reaction was carried out with Ir(cod)2OTf (7.5 mol%), L-20c (7.5 mol%) 
and 1,4-dioxane (0.5 M with respect to substrate) and was run for 72 h. The crude material was purified 
by FCC (hexane/EtOAc 30−50%) to afford the title compound (27.2 mg, 68%, 0.98:0.02 mixture of 
rotamers A:B) as an off-white solid. vmax/cm
-1: 3259 (m), 2927 (m), 1746 (s), 1666 (s), 1462 (s); Signals 
for rotamer A: 1H NMR (400 MHz, CDCl3): δ 7.42 – 7.28 (5H, m, C12-H, C13-H, C14-H), 7.13 (1H, 
d, J = 8.0 Hz, C7-H), 6.72 (1H, d, J = 8.0 Hz, C6-H), 6.52 (1H, s, N-H), 5.67 (1H, d, J = 1.5 Hz, C10-
H2), 5.29 (1H, d, J = 1.5 Hz, C10-H2), 4.61 (2H, t, J = 8.5 Hz, C16-H2), 3.15 (2H, t, J = 8.5 Hz, C15-
H2), 1.60 (3H, s, C1-H3); 13C NMR (101 MHz, CDCl3): δ 167.6 (C2), 161.3 (C5), 147.2 (C9), 140.7 
(C11), 131.4 (C3), 130.4 (C7), 128.9 (ArCH), 128.6 (C8), 128.2 (C14), 126.5 (ArCH), 124.8 (C4), 




116.6 (C10), 107.3 (C6), 71.9 (C16), 29.8 (C15), 23.0 (C1); HRMS: (ESI+) calculated for C18H17NO2Na 
302.1151. Found [M+Na]+ 302.1148; m.p. 143−145 °C (CDCl3). 
Characteristic signals for rotamer B: 1H NMR (400 MHz, CDCl3): 6.66 (1H, d, J = 8.0 Hz, C6-H), 5.63 
(1H, s, C10-H2), 5.24 (1H, s, C10-H2). 
N-(3-(1-Phenylvinyl)naphthalen-2-yl)acetamide (104fa’) 
  
General Procedure U: The reaction was carried out with Ir(cod)2OTf (7.5 mol%), L-20c (7.5 mol%) 
and 1,4-dioxane (0.5 M with respect to substrate) and was run for 72 h. The crude material was purified 
by FCC (1st column: hexane/EtOAc 30−50%; 2nd column: hexane/EtOAc 10−30%) to afford the title 
compound (29.6 mg, 72%) as a brown solid. vmax/cm
-1: 3416 (m), 3054 (m), 1673 (s), 1525 (s), 1483 
(s); 1H NMR (400 MHz, CDCl3): δ 8.70 (1H, s, C4-H), 7.87 (1H, d, J = 8.0 Hz, C15-H), 7.82 – 7.75 
(2H, m, C7-H, C18-H), 7.52 – 7.40 (2H, m, C16-H, C17-H), 7.39 – 7.31(5H, m, C12-H, C13-H, C14-
H), 7.10 (1H, br. s, N-H), 5.96 (1H, s, C10-H2), 5.50 (1H, s, C10-H2), 1.84 (3H, s, C1-H3); 13C NMR 
(101 MHz, CDCl3): δ 168.1 (C2), 146.3 (C9), 139.3 (C11), 133.7 (C5), 132.9 (C3), 131.9 (C8), 130.3 
(C6), 129.4 (ArCH), 129.0 (ArCH), 128.7 (ArCH), 127.8 (C15), 127.5 (ArCH), 126.6 (ArCH), 126.5 
(C16), 125.4 (C17), 118.5 (C4), 117.8 (C10), 24.4 (C1); HRMS: (ESI+) calculated for C20H17NONa 
310.1202. Found [M+Na]+ 310.1213; m.p. 101−103 °C (CDCl3). 
N-(4-Bromo-2-(1-phenylvinyl)phenyl)acetamide (104ya’) 
  
General Procedure U: The reaction was carried out with Ir(cod)2OTf (10 mol%), L-20c (10 mol%). 
1,4-dioxane (0.5 M with respect to substrate) and was run for 72 h. The crude material was purified by 
FCC (hexane/EtOAc 10−30%) to afford the title compound (27.7 mg, 61%) as off-white needles. 
vmax/cm-1: 3286 (m), 3027 (m), 1670 (s), 1506 (s), 1293 (s); 1H NMR (400 MHz, CDCl3): δ 8.09 (1H, 
d, J = 9.0 Hz, C4-H), 7.48 (1H, dd, J = 9.0, 2.5 Hz, C5-H), 7.41 (1H, d, J = 2.5 Hz, C7-H), 7.39 – 7.28 
(5H, m, C12-H, C13-H, C14-H), 6.90 (1H, br. s, N-H), 5.89 (1H, s, C10-H2), 5.38 (1H, s, C10-H2), 1.78 
(3H, s, C1-H3); 13C NMR (101 MHz, CDCl3): δ 168.1 (C2), 145.3 (C9), 138.7 (C11), 134.5 (C3), 133.7 
(C8), 132.9 (C7), 131.8 (C5), 129.2 (ArCH), 129.0 (C14), 126.6 (ArCH), 123.3 (C4), 118.2 (C10), 




117.1 (C6), 24.4 (C1); HRMS: (ESI+) calculated for C16H1479BrNONa 338.0151. Found [M+Na]+ 
338.0156; m.p. 118−120 °C (CDCl3). 
Methyl 4-acetamido-3-(1-phenylvinyl)benzoate (104za’) 
  
General Procedure U: The reaction was carried out with Ir(cod)2OTf (7.5 mol%), L-20c (7.5 mol%) 
and 1,4-dioxane (0.5 M with respect to substrate) and was run for 72 h. The crude material was purified 
by FCC (1st column: hexane/EtOAc 30−50%; 2nd column: hexane/EtOAc 40−50%) to afford the title 
compound (22.2 mg, 58%) as a yellow oil. vmax/cm
-1: 3332 (m), 2951 (m), 1710 (s), 1512 (s), 1256 (s); 
1H NMR (400 MHz, CDCl3): δ 8.38 (1H, d, J = 8.5 Hz, C4-H), 8.04 (1H, dd, J = 8.5, 2.0 Hz, C5-H), 
7.95 (1H, d, J = 2.0 Hz, C7-H), 7.38 – 7.28 (5H, m, C12-H, C13-H, C14-H), 7.17 (1H, s, N-H), 5.94 
(1H, d, J = 1.0 Hz, C10-H2), 5.42 (1H, d, J = 1.0 Hz, C10-H2), 3.90 (3H, s, C16-H3), 1.83 (3H, s, C1-
H3); 13C NMR (101 MHz, CDCl3): δ 168.3 (C2), 166.7 (C15), 145.5 (C9), 139.6 (C3), 138.8 (C11), 
131.8 (C7), 130.9 (C8), 130.6 (C5), 129.2 (ArCH), 129.0 (C14), 126.6 (ArCH), 125.6 (C6), 120.4 (C4), 




General Procedure U: The reaction was carried out with Ir(cod)2OTf (7.5 mol%), L-20c (7.5 mol%) 
and 1,4-dioxane (0.5 M with respect to substrate) and was run for 72 h. The crude material was purified 
by FCC (hexane/EtOAc 10−30%) to afford the title compound (25.4 mg, 71%) as a brown oil. vmax/cm
-
1: 3414 (m), 3024 (m), 1664 (s), 1514 (s), 1498 (s); 1H NMR (400 MHz, CDCl3): δ 7.98 (1H, d, J = 8.5 
Hz, C4-H), 7.41 – 7.22 (5H, m, C12-H, C13-H, C14-H), 7.18 (1H, dd, J = 8.5, 2.0 Hz, C5-H), 7.12 – 
7.03 (1H, m, C7-H), 6.88 (1H, br. s, N-H), 5.84 (1H, s, C10-H2), 5.35 (1H, s, C10-H2), 2.34 (3H, s, C1-
H3), 1.77 (3H, s, C15-H3); 13C NMR (101 MHz, CDCl3): δ 168.1 (C2), 146.6 (C9), 139.6 (C11), 134.1 
(C6), 132.7 (C3), 132.2 (C8), 130.8 (C7), 129.4 (C5), 128.9 (ArCH), 128.6 (C14), (ArCH), 122.2 (C4), 
117.1 (C10), 24.3 (C15), 21.0 (C1); HRMS: (ESI+) calculated for C17H17NONa 274.1202. Found 
[M+Na]+ 274.1199. 
 






General Procedure U: The reaction was carried out with Ir(cod)2OTf (7.5 mol%), L-20c (7.5 mol%) 
and 1,4-dioxane (0.5 M with respect to substrate) and was run for 72 h. The crude material was purified 
by FCC (hexane/EtOAc 30−50%) to afford the title compound (8.31 mg, 19%) as a brown oil. vmax/cm-
1: 3414 (m), 2925 (m), 1683 (s), 1520 (s), 1120 (s); 1H NMR (500 MHz, CDCl3): δ 8.40 (1H, d, J = 8.5 
Hz, C4-H), 7.62 (1H, dd, J = 8.5, 2.0 Hz, C5-H), 7.53 (1H, d, J = 2.0 Hz, C7-H), 7.39 – 7.35 (3H, m, 
C13-H, C14-H), 7.32 – 7.29 (2H, m, C12-H), 7.09 (1H, s, N-H), 5.95 (1H, d, J = 1.0 Hz, C10-H2), 5.43 
(1H, d, J = 1.0 Hz, C10-H2), 1.83 (3H, s, C1-H3); 13C NMR (126 MHz, CDCl3): δ 168.3 (C2), 145.3 
(C9), 138.5 (C11), 138.5 (C3), 131.5 (C8), 129.3 (C13), 129.1 (C14), 127.3 (q, 3JC-F = 4.0 Hz, C7), 
126.6 (C12), 126.1 (q, 3JC-F = 4.0 Hz, C5), 124.2 (q, 
1JC-F = 270 Hz, C15), 121.2 (C4), 118.6 (C10), 24.6 
(C1); 19F NMR (377 MHz, CDCl3): δ -61.96; HRMS: (ESI+) calculated for C17H14F3NONa 328.0920. 
Found [M+Na]+ 328.0922. 
Note: C6 was not observed by 13C NMR analysis. 
N-(2-(1-(p-Tolyl)vinyl)-4-(trifluoromethyl)phenyl)cyclopentanecarboxamide (104abe’) 
 
General Procedure U: The reaction was carried out with Ir(cod)2OTf (10.0 mol%), L-20c (10.0 mol%) 
and 1,4-dioxane (0.5 M with respect to substrate) and was run for 96 h. The crude material was purified 
by FCC (hexane/Et2O 0−10%) to afford the title compound (21.9 mg, 43%) as a yellow solid. vmax/cm-
1: 3413 (m), 2955 (m), 1701 (s), 1519 (s); 1H NMR (400 MHz, CDCl3): δ 8.47 (1H, d, J = 8.5 Hz, C6-
H), 7.61 (1H, dd, J = 8.5, 2.0 Hz, C7-H), 7.51 (1H, d, J = 2.0 Hz, C9-H), 7.21 – 7.11 (5H, m, C14-H, 
C15-H, N-H), 5.91 (1H, d, J = 1.0 Hz, C12-H2), 5.36 (1H, d, J = 1.0 Hz, C12-H2), 2.36 (3H, s, C17-
H3), 2.35 – 2.26 (1H, m, C1-H), 1.77 – 1.39 (8H, m, C2-H2, C3-H2); 13C NMR (101 MHz, CDCl3): δ 
174.5 (C4), 145.2 (C11), 139.3 (C16), 138.8 (C5), 135.5 (C13), 131.4 (C10), 129.9 (C15), 127.3 (C9), 
126.5 (C14), 126.0 (C7), 125.7 (q, J = 18.2 Hz, C8), 120.7 (C6), 117.6 (C12), 47.1 (C1), 30.0 
(cyclopentyl), 25.9 (cyclopentyl), 21.3 (C17); 19F NMR (377 MHz, CDCl3): δ -61.9; HRMS: (ESI+) 
calculated for C22H23NOF3 374.1726. Found [M+H]+ 374.1734. m.p. 34−36 °C (CDCl3). 
Note: C18 was not observed by 13C NMR analysis. 






General Procedure U: The reaction was carried out with Ir(cod)2OTf (7.5 mol%), L-20c (7.5 mol%) 
and 1,4-dioxane (0.5 M with respect to substrate) and was run for 72 h. The crude material was purified 
by FCC (hexane/Et2O 0−10%) to afford the title compound (48.8 mg, 94%) as a yellow oil. vmax/cm-1: 
3311 (m), 2957 (m), 1683 (s), 1511 (s); 1H NMR (400 MHz, CDCl3): δ 8.13 (1H, d, J = 8.5 Hz, C6-H), 
7.38 (1H, dd, J = 8.5, 2.5 Hz, C7-H), 7.26 – 7.23 (2H, m, C14-H), 7.22 (1H, s, C9-H), 7.14 (2H, d, J = 
8.0 Hz, C15-H), 6.98 (1H, s, N-H), 5.84 (1H, d, J = 1.5 Hz, C12-H2), 5.30 (1H, d, J = 1.5 Hz, C12-H2), 
2.35 (3H, s, C17-H3), 2.33 – 2.24 (1H, m, C1-H), 1.73 – 1.40 (8H, m, C3-H2, C2-H2), 1.32 (9H, s, C19-
H3); 13C NMR (101 MHz, CDCl3): δ 174.1 (C4), 146.9 (C8), 146.8 (C11), 138.6 (C16), 136.5 (C13), 
133.0 (C5), 131.4 (C10), 129.6 (C15), 127.2 (C9), 127.2 (C14), 125.7 (C7), 121.1 (C6), 116.2 (C12), 
46.9 (C1), 34.5 (C18), 31.5 (C19), 30.1 (cyclopentyl), 25.9 (cyclopentyl), 21.3 (C17); HRMS: (ESI+) 
calculated for C25H32NO 362.2478. Found [M+H]+ 362.2482. 
N-(5-Methyl-2-(1-phenylvinyl)phenyl)acetamide (104ea’) 
 
General Procedure U: The reaction was carried out with Ir(cod)2OTf (7.5 mol%), L-20c (7.5 mol%) 
and 1,4-dioxane (0.5 M with respect to substrate) and was run for 72 h. Purification of the residue by 
FCC (1st column: hexane/EtOAc 10−40%; 2nd column: hexane/Et2O 60−70%) afforded the title 
compound (20.0 mg, 56%, 0.86:0.14 mixture of rotamers A:B) as an off-white solid. vmax/cm
-1: 3250 
(m), 3023 (m), 1659 (s), 1521 (s), 1444 (s); Signals for rotamer A: 1H NMR (400 MHz, CDCl3): δ 7.36 
– 7.27 (6H, m, ArCH), 7.25 – 7.20 (2H, m, ArCH), 6.41 (1H br. s, N-H), 5.73 (1H, d, J = 1.5 Hz, C10-
H2), 5.32 (d, J = 1.5 Hz, C10-H2), 2.25 (3H, s, C1-H3), 1.67 (3H, s, C15-H3); 13C NMR (101 MHz, 
CDCl3): δ 168.4 (C2), 147.9 (C9), 140.5 (C8), 138.9 (C11), 136.7 (C4), 133.2 (C3), 130.8 (C5), 128.8 
(ArCH), 128.3 (ArCH), 128.1 (ArCH), 127.4 (ArCH), 126.5 (ArCH), 116.6 (C10), 22.9 (C1), 18.7 
(C15); HRMS: (ESI+) calculated for C17H17NONa 274.1202. Found [M+Na]+ 274.1207; m.p. 108−110 
°C (CDCl3). 
Characteristic signals for rotamer B: 1H NMR (400 MHz, CDCl3): δ 6.26 (1H, s, N-H), 5.69 (1H, d, J 
= 1.0 Hz, C10-H2), 5.28 (1H, d, J = 1.0 Hz, C10-H2). 






General Procedure U: The reaction was carried out with Ir(cod)2OTf (10 mol%), L-20c (10 mol%) 
and 1,4-dioxane (0.5 M with respect to substrate) and was run for 96 h. The crude material was purified 
by FCC (hexane/EtOAC 0−10%) to afford the title compound (22.9 mg, 50%) as a yellow oil. vmax/cm-
1: 3263 (m), 2953 (m), 1652 (s), 1511 (s); 1H NMR (400 MHz, CDCl3): δ 7.23 – 7.20 (1H, m, C7-H), 
7.20 – 7.12 (4H, m, C8-H, C9-H, C14-H), 7.13 – 7.03 (2H, m, C15-H), 6.46 (1H, s, N-H), 5.69 (1H, d, 
J = 1.5 Hz, C12-H2), 5.19 (1H, d, J = 1.5 Hz, C12-H2), 2.31 (3H, s, C17-H3), 2.27 – 2.22 (1H, m, C1-
H), 2.20 (3H, s, C18-H3), 1.68 – 1.35 (8H, m, C2-H2, C3-H2); 13C NMR (101 MHz, CDCl3): δ 174.0 
(C4), 147.5 (C11), 138.8 (C10), 138.0 (C16), 137.2 (C13), 136.4 (C6), 133.3 (C5), 130.6 (C7), 129.4 
(C15), 128.2 (C9), 127.0 (C8), 126.3 (C14), 115.3 (C12), 45.9 (C1), 30.2 (cyclopentyl), 25.9 





General Procedure U: The reaction was carried out with Ir(cod)2OTf (10 mol%), L-20c (10 mol%) 
and 1,4-dioxane (0.5 M with respect to substrate) and was run for 96 h. The crude material was purified 
by FCC (hexane/Et2O 0−10%) to afford the title compound (15.8 mg, 36%) as a yellow wax. vmax/cm-1: 
3411 (m), 2953 (m), 1693 (s), 1571 (s); 1H NMR (400 MHz, CDCl3): δ 8.40 (1H, d, J = 2.0 Hz, C6-H), 
7.22 – 7.17 (2H, m, C14-H), 7.16 – 7.13 (3H, m, C9-H, C15-H), 7.09 (1H, dd, J = 8.0, 2.0 Hz, C8-H), 
7.06 (1H, s, N-H), 5.85 (1H, d, J = 1.0 Hz, C12-H2), 5.30 (1H, d, J = 1.0 Hz, C12-H2), 2.35 (3H, s, C17-
H3), 2.33 – 2.25 (1H, m, C1-H), 1.68 – 1.44 (8H, m, C2-H2, C3-H2); 13C NMR (101 MHz, CDCl3): δ 
174.3 (C4), 145.4 (C11), 139.0 (C16), 136.6 (C5), 136.0 (C13), 134.5 (C7), 131.2 (C9), 129.8 (C15), 
129.7 (C10), 126.6 (C14), 123.9 (C8), 120.9 (C6), 117.0 (C12), 47.0 (C1), 30.0 (cyclopentyl), 25.9 











General Procedure U: The reaction was carried out with Ir(cod)2OTf (7.5 mol%), L-20c (7.5 mol%) 
and 1,4-dioxane (0.5 M with respect to substrate) and was run for 72 h. The title product was observed 
by 1H NMR analysis of the crude material. Characteristic 1H NMR peaks: 1H NMR (400 MHz, CDCl3): δ 
6.72 (1H, br. s), 5.82 (1H, d, J = 1.0 Hz), 5.39 (1H, d, J = 1.0 Hz). 
N-(5-Bromo-2-(1-phenylvinyl)phenyl)acetamide (104ia’) 
 
General Procedure U: The reaction was carried out with Ir(cod)2OTf (7.5 mol%), L-20c (7.5 mol%) 
and 1,4-dioxane (0.5 M with respect to substrate) and was run for 72 h. The title product was observed 
by 1H NMR analysis of the crude material. Characteristic 1H NMR peaks: 1H NMR (400 MHz, CDCl3): δ 
8.42 (1H, s), 5.87 (1H, s), 5.36 (1H, s), 1.78 (3H, s). 
4-Acetamido-N,N-diethyl-3-(1-phenylvinyl)benzamide (104aga’) 
 
General Procedure U: The reaction was carried out with Ir(cod)2OTf (7.5 mol%), L-20c (7.5 mol%) 
and 1,4-dioxane (0.5 M with respect to substrate) and was run for 72 h. The title product was observed 
by 1H NMR analysis of the crude material. Characteristic 1H NMR peaks: 1H NMR (400 MHz, CDCl3): δ 
5.85 (1H, s), 5.34 (1H, s), 1.78 (1H, s), 0.86 – 0.66 (6H, m). 
Tandem dehydrogenation/C−H arylation process depicted in Scheme 86 
 
General Procedure U: The reaction was carried out with Ir(cod)2OTf (7.5 mol%), L-20c (7.5 mol%) 
and 1,4-dioxane (0.5 M with respect to substrate) and was run for 72 h. The crude material was purified 
by FCC (1st column: hexane/EtOAc 30−50%; 2nd column: hexane/EtOAc 10−30%) to afford the title 
compound (24.6 mg, 60%) as a brown solid. Data for 104fa’ is the same as described previously. 







General Procedure U: The reaction was carried out with Ir(cod)2OTf (7.5 mol%), L-20c (7.5 mol%) 
and 1,4-dioxane (0.5 M with respect to substrate) and was run for 72 h. The crude material was purified 
by FCC (hexane/EtOAc 0−5%) to afford the title compound (33.5 mg, 77%, 0.93:0.07 mixture of 
rotamers A:B) as an orange oil. vmax/cm-1: 3418 (m), 2953 (m), 1682 (s) 1512 (s), 1445 (s); Signals for 
rotamer A: 1H NMR (400 MHz, CDCl3): δ 8.42 (1H, d, J = 8.0 Hz, C6-H), 7.52 (1H, ddd, J = 8.0, 8.0, 
1.5 Hz, C7-H), 7.45 – 7.34 (3H, m, C9-H, C14-H), 7.32 – 7.24 (3H, m, C8-H, C15-H), 7.22 (1H, s, N-
H), 6.01 (1H, d, J = 1.5 Hz, C12-H2), 5.46 (1H, d, J = 1.5 Hz, C12-H2), 2.50 (3H, s, C17-H3), 2.49 – 
2.41 (1H, m, C1-H), 1.84 – 1.56 (8H, m, C2-H2, C3-H2); 13C NMR (101 MHz, CDCl3): δ 174.2 (C4), 
146.3 (C11), 138.7 (C16), 136.4 (C13), 135.6 (C5), 131.7 (C10), 130.4 (C9), 129.6 (C15), 128.8 (C7), 
126.6(C14), 123.9 (C8), 121.2 (C6), 116.4 (C12), 47.0 (C1), 30.1 (C2), 25.9 (C3), 21.3 (C17); HRMS: 
(ESI+) calculated for C21H24NO 306.1852. Found [M+H]+ 306.1861. 
Characteristic signals for rotamer B: 1H NMR (400 MHz, CDCl3): δ 8.28 (1H, d, J = 8.5 Hz, C6-H), 
5.97 (1H, s, C12-H2), 5.42 (1H, s, C12-H2). 
N-(2-(1-([1,1’-Biphenyl]-4-yl)vinyl)phenyl)cyclopentanecarboxamide (104ok’) 
  
General Procedure U: The reaction was carried out with Ir(cod)2OTf (7.5 mol%), L-20c (7.5 mol%) 
and 1,4-dioxane (0.5 M with respect to substrate) and was run for 72 h. The crude material was purified 
by FCC (1st column: hexane/EtOAc 0−5%; 2nd column: hexane/EtOAc 5%) to afford the title compound 
(32.5 mg, 62%) as an off-white powder. vmax/cm
-1: 3415 (m), 3029 (m), 2953 (m), 1684 (s), 1515 (s); 
1H NMR (400 MHz, CDCl3): δ 8.28 (1H, d, J = 8.5 Hz, C6-H), 7.65 – 7.54 (4H, m, ArCH), 7.52 – 7.34 
(6H, m, ArCH), 7.30 (1H, dd, J = 7.5, 1.5 Hz, C9-H), 7.16 (1H, dd, J = 7.5, 7.5 Hz, C8-H), 7.07 (1H, 
br. s, N-H), 5.96 (1H, s, C12-H2), 5.40 (1H, s, C12-H2), 2.34 (1H, app. p, J = 7.5 Hz, C1-H), 1.68 – 1.36 
(8H, m, C2-H2, C3-H2); 13C NMR (101 MHz, CDCl3): δ 174.2 (C4), 146.1 (C11), 141.6 (ArCH), 140.5 
(ArCH), 138.1 (C13), 135.6 (C5), 131.5 (C10), 130.5 (C9), 129.0 (ArCH), 129.0 (ArCH), 127.7 
(ArCH), 127.7 (ArCH), 127.1 (ArCH), 127.1 (ArCH), 124.1 (C8), 121.5 (C6), 117.3 (C12), 47.0 (C1), 
30.1 (C2), 25.9 (C3); HRMS: (ESI+) calculated for C26H25NONa 390.1828. Found [M+Na]+ 390.1829; 
m.p. 100−102 °C (CDCl3). 
 







General Procedure U: The reaction was carried out with Ir(cod)2OTf (7.5 mol%), L-20c (7.5 mol%) 
and 1,4-dioxane (0.5 M with respect to substrate) and was run for 72 h. The crude material was purified 
by FCC (2 columns; hexane/EtOAc 0−10%) to afford the title compound (33.2 mg, 75%, 0.96:0.04 
mixture of rotamers A:B) as a yellow oil. vmax/cm-1: 3062 (m), 2953 (m), 1666 (s), 1506 (s); Signals for 
rotamer A: 1H NMR (400 MHz, CDCl3): δ 8.24 (1H, d, J = 8.0 Hz, C6-H), 7.37 (1H, ddd, J = 8.0, 8.0, 
2.0 Hz, C7-H), 7.33 – 7.27 (2H, m, C14-H), 7.25 – 7.21 (1H, m, C9-H), 7.18 – 7.09 (1H, m, C8-H), 
7.06 – 6.97 (3H, m, C15-H, N-H), 5.85 (1H, s, C12-H2), 5.34 (1H, s, C12-H2), 2.42 – 2.26 (1H, m, C1-
H), 1.70 – 1.37 (8H, m, C2-H2, C3-H2); 13C NMR (101 MHz, CDCl3): δ 174.2 (C4), 163.0 (d, 1JC-F = 
248.5 Hz, C16), 145.4 (C11), 135.5 (C5),135.4 (d, 4JC-F = 3.5 Hz, C13), 131.4 (C10), 130.3 (C9), 129.0 
(C7), 128.4 (d, 3JC-F = 8.0 Hz, C14), 124.1 (C8), 121.6 (C6), 117.0 (C12), 115.8 (d, 2JC-F = 21.5 Hz, 
C15), 46.97 (C1), 30.10 (C2), 25.90 (C3); HRMS: (ESI+) calculated for C20H21FNO 310.1602. Found 
[M+H]+ 310.1606. 
Characteristic signals for rotamer B: 1H NMR (400 MHz, CDCl3): 8.12 (1H, d, J = 8.5 Hz, C6-H), 5.81 




General Procedure U: The reaction was carried out with Ir(cod)2OTf (10 mol%), L-20c (10 mol%) 
and 1,4-dioxane (1.0 M with respect to substrate) and was run for 72 h. The crude material was purified 
by FCC (2 columns; hexane/EtOAc 0−10%) to afford the title compound (29.5 mg, 57%, 0.85:0.15 
mixture of rotamers A:B) as a yellow oil. vmax/cm
-1: 3282 (m), 2956 (m), 1658 (s), 1518 (s), 1322 (s); 
1H NMR (400 MHz, CDCl3): δ 8.19 (1H, d, J = 8.0 Hz, C6-H, A+B), 7.58 (1.7H, d, J = 8.0 Hz, C15-H, 
A), 7.52 (0.3H, d, J = 8.0 Hz, C15-H, B), 7.43 (1.7H, d, J = 8.0 Hz, C14-H, A+B), 7.40 – 7.37 (0.85H, 
m, C7-H, A), 7.31 (0.15H, dd, J = 7.5, 7.5 Hz, C7-H, B), 7.24 (1H, m, C9-H, A+B), 7.16 (0.85H, dd, J 
= 7.5, 7.5 Hz, C8-H, A), 7.08 (0.15H, dd, J = 7.5, 7.5 Hz, C8-H, B), 6.91 (1H, s, N-H, A+B), 5.99 (1H, 
s, C12-H2, A+B), 5.50 (1H, s, C12-H2, A+B), 2.68 (0.15H, app. p, J = 8.0 Hz, C1-H, B), 2.31 (0.85H, 
app. p, J = 8.0 Hz, C1-H, A), 1.98 – 1.85 (0.85H, m, cyclopentyl, A), 1.84 – 1.75 (0.15H m, cyclopentyl, 
B), 1.68 – 1.42 (5.95H, m, cyclopentyl, A), 1.29 – 1.23 (1.05H, m, cyclopentyl, B); 13C NMR (101 MHz, 
CDCl3): δ 174.0 (C4, A), 173.9 (C4, B), 145.3 (C11, A), 145.27 (C11, B), 144.11 (C13, B), 142.68 (C13, 




A), 135.22 (C5, A+B), 130.95 (C10, A+B), 130.93 (C16, A+B), 130.58 (C9, B), 130.30 (C9, A), 129.14 
(C7, A), 128.93 (C7, B), 126.75 (C14, A+B), 125.7 (q, 3JC-F = 3.5 Hz, C15, A+B), 124.3 (C8, A+B), 
122.6 (C17, A+B), 122.0 (C6, A+B), 119.6 (C12, B), 119.2 (C12, A), 46.7 (C1, A+B), 30.5 (C2, B), 29.9 
(C2, A), 26.0 (C3, B), 25.7 (C3, A); 19F NMR (377 MHz, CDCl3): δ -62.61; HRMS: (ESI+) calculated 
for C21H21F3NO 360.1570. Found [M+H]+ 360.1576. 
N-(2-(1-(4-(tert-Butyl)phenyl)vinyl)phenyl)cyclopentanecarboxamide (104op’) 
  
General Procedure U: The reaction was carried out with Ir(cod)2OTf (7.5 mol%), L-20c (7.5 mol%) 
and 1,4-dioxane (1.0 M with respect to substrate) and was run for 96 h. The crude material was purified 
by FCC (toluene/Et2O 0−2%) to afford the title compound (39.6 mg, 80%) as a yellow oil. vmax/cm-1: 
3415 (m), 2958 (m), 1686 (s), 1513 (s); 1H NMR (400 MHz, CDCl3): δ 8.26 (1H, d, J = 8.0 Hz, C6-H), 
7.39 – 7.32 (3H, m, C15-H, C7-H), 7.29 – 7.24 (3H, m, C14-H, C9-H), 7.19 – 7.09 (1H, m, C8-H), 7.00 
(1H, s, N-H), 5.85 (1H, d, J = 1.5 Hz, C12-H2), 5.33 (1H, d, J = 1.5 Hz, C12-H2), 2.32 – 2.23 (1H, m, 
C1-H), 1.63 – 1.51 (4H, m, C3-H2), 1.47 – 1.40 (4H, m, C2-H2), 1.31 (9H, s, C18-H3); 13C NMR (101 
MHz, CDCl3): δ 174.1 (C4), 152.0 (C16), 146.3 (C11), 136.3 (C13), 135.6 (C5), 131.6 (C10), 130.5 
(C9), 128.9 (C7), 126.4 (C14), 125.9 (C15), 123.9 (C8), 121.2 (C6), 116.7 (C12), 47.0 (C1), 34.8 (C17), 




General Procedure U: The reaction was carried out with Ir(cod)2OTf (7.5 mol%), L-20c (7.5 mol%) 
and 1,4-dioxane (0.5 M with respect to substrate) and was run for 96 h. The crude material was purified 
by FCC (toluene/Et2O 0−2%) to afford the title compound (27.4 mg, 53%) as a yellow oil. vmax/cm-1: 
3418 (m), 2954 (m), 1682 (s), 1516 (s); 1H NMR (400 MHz, CDCl3): δ 8.25 (1H, d, J = 8.0 Hz, C6-H), 
7.52 – 7.46 (2H, m, C15-H), 7.41 – 7.34 (1H, m, C7-H), 7.34 – 7.23 (3H, m, C9-H, C14-H), 7.14 (1H, 
ddd, J = 7.5, 7.5, 1.0 Hz, C8-H), 6.98 (1H, s, N-H), 5.90 (1H, d, J = 1.5 Hz, C12-H2), 5.38 (1H, d, J = 
1.5 Hz, C12-H2), 2.33 – 2.20 (1H, m, C1-H), 1.60 – 1.42 (8H, m, C2-H2, C3-H2), 0.26 (9H, s, C17-H3); 
13C NMR (101 M Hz, CDCl3): δ 174.0 (C4), 146.5 (C11), 141.2 (C16), 139.5 (C13), 135.4 (C5), 133.9 
(C15), 131.3 (C7), 130.3 (C9), 128.8 (C10), 125.7 (C14), 123.9 (C8), 121.3 (C6), 117.4 (C12), 46.9 








General Procedure U: The reaction was carried out with Ir(cod)2OTf (7.5 mol%), L-20c (7.5 mol%) 
and 1,4-dioxane (0.5 M with respect to substrate) and was run for 72 h. The crude material was purified 
by FCC (2 columns; hexane/EtOAc 0−10%) to afford the title compound (30.5 mg, 70%, 0.93:0.07 
mixture of rotamers A:B) as a yellow oil. vmax/cm-1: 3414 (m), 2953 (m), 1682 (s), 1515 (s), 1446 (s); 
Signals for rotamer A: 1H NMR (400 MHz, CDCl3): δ 8.26 (1H, d, J = 8.0 Hz, C6-H), 7.37 (1H, ddd, J 
= 8.0, 8.0, 1.5 Hz, C7-H), 7.29 – 7.18 (2H, m, C9-H, ArCH), 7.17 – 7.10 (4H, m, ArCH), 7.05 (1H, br. 
s, N-H), 5.86 (1H, s, C12-H2), 5.35 (1H, s, C12-H2), 2.38 – 2.25 (4H, m, C1-H, C19-H3), 1.69 – 1.42 
(8H, m, C2-H2, C3-H2); 13C NMR (101 MHz, CDCl3): δ 174.2 (C4), 146.7 (C11), 139.3 (C13), 138.7 
(C15), 135.6 (C5), 131.7 (C10), 130.4 (C9), 129.5 (ArCH), 128.9 (C7), 128.9 (ArCH), 127.3 (ArCH), 
124.0 (C8), 123.8 (ArCH), 121.3 (C6), 117.3 (C12), 47.0 (C1), 30.0 (C2), 25.9 (C3), 21.5 (C19); HRMS: 
(ESI+) calculated for C21H24NO 306.1852. Found [M+H]+ 306.1864. 
Characteristic signals for rotamer B: 1H NMR (400 MHz, CDCl3): 8.14 (1H, d, J = 8.5 Hz, C6-H), 5.83 
(1H, s, C12-H2), 5.31 (1H, s, C12-H2). 
N-(2-(1-(3-Chlorophenyl)vinyl)phenyl)cyclopentanecarboxamide (104os’) 
  
General Procedure U: The reaction was carried out with Ir(cod)2OTf (10 mol%), L-20c (10 mol%) 
and 1,4-dioxane (1.0 M with respect to substrate) and was run for 72 h. The crude material was purified 
by FCC (hexane/EtOAc 0−5%) to afford the title compound (29.8 mg, 64%, 0.95:0.05 mixture of 
rotamers A:B) as a yellow oil. vmax/cm-1: 3290 (m), 3062 (m), 2954 (s), 1663 (s), 1515 (s); Signals for 
rotamer A: 1H NMR (400 MHz, CDCl3): δ 8.23 (1H, d, J = 8.0 Hz, C6-H), 7.43 – 7.34 (2H, m, C7-H, 
C14-H), 7.32 – 7.26 (1H, m, C17-H), 7.26 – 7.20 (2H, m, C9-H, C16-H), 7.18 – 7.10 (2H, m, C8-H, 
C18-H), 6.98 (1H, s, N-H), 5.90 (1H, s, C12-H2), 5.42 (1H, s, C12-H2), 2.41 – 2.28 (1H, m, C1-H), 1.72 
– 1.35 (8H, m, C2-H2, C3-H2); 13C NMR (101 MHz, CDCl3): δ 174.2 (C4), 145.4 (C11), 141.3 (C13), 
135.5 (C5), 135.0 (C15), 131.0 (C10), 130.4 (ArCH), 130.2 (ArCH), 129.2 (ArCH), 128.7 (C17), 126.6 
(ArCH), 125.0 (ArCH), 124.2 (C8), 121.8 (C6), 118.5 (C12), 47.0 (C1), 30.1 (C2), 25.9 (C3); HRMS: 
(ESI+) calculated for C20H21ClNO 326.1306. Found [M+H]+ 326.1303. 




Characteristic signals for rotamer B: 1H NMR (400 MHz, CDCl3): 8.37 (1H, d, J = 8.0 Hz, C6-H), 5.43 
(1H, s, C12-H2), 1.91 (1H, app. p, J = 7.5 Hz, C1-H). 
N-(2-(1-(2-Fluorophenyl)vinyl)phenyl)cyclopentanecarboxamide (104og’) 
  
General Procedure U: The reaction was carried out with Ir(cod)2OTf (10 mol%) and L-20c (10 mol%) 
and 1,4-dioxane (0.5 M with respect to substrate) and was run for 72 h. The crude material was purified 
by FCC (2 columns; hexane/EtOAc 0−10%) to afford the title compound (22.2 mg, 50%, 0.97:0.03 
mixture of rotamers A:B) as an orange oil. vmax/cm
-1: 3288 (m), 2952 (m) 1665 (s), 1514 (s), 1445 (s); 
Signals for rotamer A: 1H NMR (400 MHz, CDCl3): δ 8.23 (1H, d, J = 8.0 Hz, C6-H), 7.34 (1H, ddd, J 
= 8.0, 8.0, 1.5 Hz, C7-H), 7.31 – 7.26 (1H, m, C17-H), 7.25 – 7.17 (2H, m, C9-H, N-H), 7.15 – 7.05 
(4H, m, C8-H, C15-H, C16-H, C18-H), 5.95 (1H, s, C12-H2), 5.61 (1H, s, C12-H2), 2.42 (1H, app. p, J 
= 7.5 Hz, C1-H), 1.80 – 1.45 (8H, m, C2-H2, C3-H2); 13C NMR (101 MHz, CDCl3): δ 174.2 (C4), 160.3 
(d, 1JC-F = 249.5 Hz, C14), 140.8 (C11), 135.2 (C5), 132.0 (C10), 130.4 (d, 4JC-F = 3.0 Hz, C17), 129.9 
(d, 3JC-F = 3.0 Hz, ArCH), 129.84 (C9), 128.3 (C7), 127.7 (d, 2JC-F = 12.0 Hz, C13), 124.6 (d, 3JC-F = 3.5 
Hz, ArCH), 124.0 (C8), 122.4 (d, 4J = 6.5 Hz, C12), 121.6 (C6), 116.3 (d, 2JC-F = 22.5 Hz, C15), 47.0 
(C1), 30.2 (C3), 26.0 (C2); 19F NMR (377 MHz, CDCl3): δ -114.17 (–) -114.33 (m); HRMS: (ESI+) 
calculated for C20H21FNO 310.1612. Found [M+H]+ 310.1608. 
Characteristic signals for rotamer B: 1H NMR (400 MHz, CDCl3): 8.36 (1H, d, J = 8.5 Hz, C6-H), 5.98 
(1H, s, C12-H2), 5.98 (1H, s, C12-H2). 
N-(2-(1-(2-Methoxyphenyl)vinyl)phenyl)cyclopentanecarboxamide (104ot’) 
 
General Procedure U: The reaction was carried out with Ir(cod)2OTf (7.5 mol%), L-20c (7.5 mol%) 
and 1,4-dioxane (0.5 M with respect to substrate) and was run for 72 h. The title product was observed 
by 1H NMR analysis of the crude material. Characteristic 1H NMR peaks: 1H NMR (400 MHz, CDCl3): 











General Procedure U: The reaction was carried out with Ir(cod)2OTf (7.5 mol%), L-20c (7.5 mol%) 
and 1,4-dioxane (0.5 M with respect to substrate) and was run for 76 h. The crude material was purified 
by FCC (toluene/EtOAc 0−10%) to afford the title compound (25.3 mg, 51%) as a yellow oil. vmax/cm-
1: 3311 (m), 2952 (m), 1678 (s), 1513 (s); 1H NMR (400 MHz, CDCl3): δ 8.28 (1H, d, J = 8.0 Hz, C6-
H), 7.85 (1H, d, J = 8.5 Hz, C17-H), 7.68 (1H, d, J = 1.5 Hz, C14-H), 7.48 – 7.43 (1H, m, C18-H), 7.44 
– 7.36 (2H, m, C7-H, C19-H), 7.33 – 7.27 (2H, m, C9-H, C20-H), 7.16 (1H, dd, J = 8.0, 1.5 Hz, C8-H), 
7.09 (1H, s, N-H), 5.96 (1H, d, J = 1.0 Hz, C12-H2), 5.41 (1H, d, J = 1.0 Hz, C12-H2), 2.25 (1H, p, J = 
7.5 Hz, C1-H), 1.57 – 1.31 (8H, m, C2-H2, C3-H2); 13C NMR (101 MHz, CDCl3): δ 174.2 (C4), 146.5 
(C11), 140.2 (C15), 140.0 (C16), 135.7 (C13), 135.7 (C5), 131.7 (C10), 130.5 (C9), 129.0 (C7), 127.6 
(C18), 124.2 (C20), 124.1 (C8), 122.9 (C17), 122.7 (C19), 122.0 (C14), 121.5 (C6), 117.2 (C12), 47.0 




General Procedure U: The reaction was carried out with Ir(cod)2OTf (7.5 mol%), L-20c (7.5 mol%) 
and 1,4-dioxane (0.5 M with respect to substrate) and was run for 72 h. The title product was observed 
by 1H NMR analysis of the crude material. Characteristic 1H NMR peaks: 1H NMR (400 MHz, CDCl3): δ 
8.23 (1H, d, J = 8.0 Hz), 5.58 (1H, d, J = 1.5 Hz), 5.54 (1H, d, J = 1.5 Hz,). 
N-(2-(1-(Naphthalen-2-yl)vinyl)phenyl)cyclopentanecarboxamide (104ow’) 
 
General Procedure U: The reaction was carried out with Ir(cod)2OTf (7.5 mol%), L-20c (7.5 mol%) 
and 1,4-dioxane (0.5 M with respect to substrate) and was run for 72 h. The title product was observed 
by 1H NMR analysis of the crude material. Characteristic 1H NMR peaks: 1H NMR (400 MHz, CDCl3): δ 
8.31 (1H, d, J = 8.0 Hz), 6.02 (1H, s), 5.44 (1H, s). 
 




Ethyl 2-(2-(cyclopentanecarboxamido)phenyl)acrylate (104ox’) 
 
General Procedure U: The reaction was carried out with Ir(cod)2OTf (7.5 mol%), L-20c (7.5 mol%) 
and 1,4-dioxane (0.5 M with respect to substrate) and was run for 72 h. The title product was observed 
by 1H NMR analysis of the crude material. Characteristic 1H NMR peaks: 1H NMR (400 MHz, CDCl3): δ 
8.73 (1H, s), 5.88 (1H, s), 5.84 (1H, s). 
N-(2-(Prop-1-en-2-yl)phenyl)cyclopentanecarboxamide (198) 
 
General Procedure U: The reaction was carried out with Ir(cod)2OTf (7.5 mol%), L-20c (7.5 mol%) 
and 1,4-dioxane (0.5 M with respect to substrate) and was run for 72 h. Purification of the residue by 
FCC (hexane/EtOAc 5−10%) afforded the title compound (2.60 mg, 11%) as a colourless oil. vmax/cm-
1: 3228 (m), 2960 (m), 1644 (s), 1530 (s); 1H NMR (500 MHz, CDCl3): δ 8.31 (1H, d, J = 8.0 Hz, C6-
H), 7.61 (1H, s, N-H), 7.37 – 7.19 (1H, m, C7-H), 7.13 (1H, dd, J = 8.0, 1.5 Hz, C9-H), 7.10 – 6.95 
(1H, m, C8-H), 5.40 (1H, s, C12-H2), 5.03 (1H, d, J = 1.0 Hz, C12-H2), 2.74 – 2.59 (1H, m, C1-H), 2.07 
(3H, s, C13-H3), 1.97 – 1.81 (4H, m, C2-H2), 1.81 – 1.73 (2H, m, C3-H2), 1.68 – 1.59 (2H, m, C3-H2); 
13C NMR (126 MHz, CDCl3): δ 174.3 (C4), 143.3 (C11), 134.3 (C5), 133.2 (C10), 128.1 (C7), 127.7 
(C9), 123.6 (C8), 120.8 (C6), 116.9 (C12), 47.3 (C1), 30.5 (C2), 26.0 (C3), 24.6 (C13); HRMS: (ESI+) 
calculated for C15H19NO 230.1539 Found [M+H]+ 230.1530. 
N-(2-(3-(Trimethylsilyl)prop-1-en-2-yl)phenyl)cyclopentanecarboxamide (1004oad’) 
 
General Procedure U: The reaction was carried out with Ir(cod)2OTf (7.5 mol%), L-20c (7.5 mol%) 
and 1,4-dioxane (0.5 M with respect to substrate) and was run for 72 h. Purification of the residue by 
FCC (hexane/EtOAc 5−10%) afforded the title compound (1.05 mg, 4%) as a colourless oil. vmax/cm-1 : 
2956 (m), 2926 (m), 2925 (s), 1701 (s), 1279 (s); 1H NMR (500 MHz, CDCl3): δ 8.38 (1H, d, J = 8.0 
Hz, C6-H), 7.27 – 7.23 (1H, m, C9-H), 7.21 (1H, s, N-H), 7.16 (1H, dd, J = 8.0, 1.5 Hz, C7-H), 7.08 – 
7.01 (1H, m, C8-H), 5.22 (1H, d, J = 2.0 Hz, C12-H2), 4.95 (1H, d, J = 2.0 Hz, C12-H2), 2.74 – 2.60 
(2H, m, C1-H), 1.90 (4H, ddd, J = 9.0, 7.0, 3.5 Hz, C2/3-H2), 1.82 – 1.74 (2H, m, C2/3-H2), 1.64 (2H, 
ddd, J = 14.0, 7.0, 5.5 Hz, C2/3-H2), 1.34 – 1.26 (2H, m, C13-H2), -0.05 (9H, s, C14-H3); 13C NMR 




(126 MHz, CDCl3) δ 174.2 (C4), 145.4 (C5), 135.2 (C11), 133.5 (C10), 128.2 (C7), 128.1 (C9), 123.4 
(C8), 120.5 (C6), 114.0 (C12), 47.5 (C1), 29.5 (C13), 26.2 (C2/3), 26.1 (C2/3), -1.3 (C14); HRMS: 




General Procedure U: The reaction was carried out with Ir(cod)2OTf (7.5 mol%), L-20c (7.5 mol%) 
and 1,4-dioxane (0.5 M with respect to substrate) and was run for 72 h. Purification of the residue by 
FCC (hexane/EtOAc 5−10%) afforded the title compound (23.1 mg, 56%) as an orange oil. vmax/cm-1: 
3313 (m), 2929 (m), 1735 (s), 1679 (s), 1514 (s); 1H NMR (500 MHz, CDCl3): δ 7.84 (1H, s, C4-H), 
7.38 – 7.28 (5H, m, C12-H, C13-H, C14-H), 7.18 (1H, s, C7-H), 6.84 (1H, s, N-H), 5.81 (1H, s, C10-
H2), 5.33 (1H, s, C10-H2), 3.02 – 2.89 (2H, m, C16-H2), 2.51 (1H, dd, J = 19.0, 8.5 Hz, C24-H2), 2.42 
– 2.25 (2H, m, C22-H2, C18-H2), 2.20 – 2.01 (3H, m, C15-H2, C23-H2, C24-H2), 1.94 (1H, dd, J = 12.0, 
4.0 Hz, C21-H2), 1.76 (3H, s, C1-H3), 1.70 – 1.58 (3H, m, C17-H, C23-H2), 1.56 – 1.41 (6H, m, C15-
H2, C17-H, C19-H, C21-H2, C22-H2, C23-H2), 0.92 (3H, s, C26-H3); 13C NMR (126 MHz, CDCl3): δ 
221.0 (C25), 168.2 (C2), 146.8 (C9), 139.8 (C11), 137.3 (C5), 136.1 (C6), 132.9 (C3), 129.9 (C8), 
128.9 (ArCH), 128.6 (C14), 127.3 (C7), 126.7 (ArCH), 122.4 (C4), 117.1 (C10), 50.6 (C19), 48.1 
(C20), 44.3 (C18), 38.3 (C17), 36.0 (C24), 31.7 (C21), 29.6 (C16), 26.6 (C15), 25.9 (C22), 24.3 (C1), 
21.7 (C23), 14.0 (C26); HRMS: (ESI+) calculated for C28H32NO2 414.2428. Found [M+H]+ 414.2427. 
 
7.7.3 − Product Derivatisations 
2-Methyl-4-phenylquinoline (199a) 
 
General Procedure V: The residue was purified by FCC (hexane/EtOAc 30%) to afford the title 
compound (91.6 mg, quantitative) as an off-white solid. 1H NMR (400 MHz, CDCl3): δ 8.09 (1H, d, J 
= 9.0 Hz), 7.86 (1H, dd, J = 9.0, 1.5 Hz,), 7.69 (1H, ddd, J = 8.5, 7.0, 1.5 Hz), 7.55 – 7.47 (5H, m), 7.44 
(1H, ddd, J = 8.5, 7.0, 1.5 Hz), 7.24 (1H, s), 2.78 (3H, s); 13C NMR (100 MHz, CDCl3): δ 158.6, 148.7, 
148.5, 138.3, 129.6, 129.5, 129.2, 128.7, 128.5, 125.9, 125.8, 125.2, 122.4, 25.5; m.p. 95−97 °C (CDCl3) 




(Lit.295 92−94 °C, recrystallisation solvent not specified ). The spectroscopic properties of this 
compound were consistent with the data available in the literature.295 
2-Methyl-3-phenyl-8,9-dihydro-7H-cyclopenta[h]quinoline (199b) 
 
General Procedure V: The crude material was purified by FCC (hexane/EtOAc 30%) to afford the 
title compound (11.2 mg, 60%) as a colourless oil. vmax/cm-1: 3030 (m), 2573 (s) 1590 (s), 1407 (m); 1H 
NMR (500 MHz, CDCl3): δ 7.66 (1H, d, J = 8.5 Hz, C5-H), 7.54 – 7.43 (5H, m, C12-H, C13-H, C14-
H), 7.33 (1H, d, J = 8.5 Hz, C6-H), 7.16 (1H, s, C3-H), 3.48 (2H, t, J = 7.5 Hz, C17-H2), 3.13 (2H, t, J 
= 7.5 Hz, C15-H2), 2.77 (3H, s, C10-H3), 2.27 (2H, app. p, J = 7.5 Hz, C16-H2); 13C NMR (126 MHz, 
CDCl3): δ 158.2 (C1), 148.8 (C2), 145.8 (C4), 145.3 (C7), 141.3 (C8), 139.0 (C11), 129.6 (C12/13), 
128.5 (C12/13), 128.2 (C14), 124.5 (C5), 124.0 (C9), 123.0 (C6), 121.3 (C3), 34.3 (C15), 31.3 (C17), 
25.8 (C10), 25.1 (C16); HRMS: (ESI+) calculated for C19H18N 260.1434. Found [M+H]+ 260.1437. 
2-Methyl-4-phenylbenzo[g]quinoline (199c) 
 
General Procedure V: The crude material was purified by FCC (hexane/EtOAc 20−30%) to afford the 
title compound (19.0 mg, 82%) as an orange oil. vmax/cm-1: 3057 (m), 2923 (m) 1596 (m), 1334 (m); 1H 
NMR (400 MHz, CDCl3): δ 8.67 (1H, s, C12-H), 8.40 (1H, s, C5-H), 8.07 (1H, d, J = 8.5 Hz, C10-H), 
7.89 (1H, d, J = 8.5 Hz, C7-H), 7.64 – 7.54 (5H, m, C16-H, C17-H, C18-H), 7.54 – 7.38 (2H, m, C9-
H, C8-H), 7.20 (1H, s, C2-H), 2.83 (3H, s, C14-H3); 13C NMR (101 MHz, CDCl3): δ 159.7 (C1), 148.7 
(C13), 145.0 (C3), 138.4 (C15), 133.9 (C11), 131.5 (C6), 129.7 (ArCH), 128.8 (ArCH), 128.6 (C18), 
128.6 (C7), 128.3 (C10), 126.6 (C12), 126.5 (C9), 125.7 (C8), 125.3 (C5), 124.3 (C4), 122.0 (C2), 25.9 
(C14); HRMS: (ESI+) calculated for C20H16N 270.1277. Found [M+H]+ 270.1290. 
2-Cyclobutyl-4-phenylquinoline (199d) 
 
General Procedure V: The crude material was purified by FCC (EtOAc 100%) to afford the title 
compound (21.5 mg, 98%) as an orange oil. vmax/cm-1: 3059 (m), 2935 (m) 1591 (m), 1443 (m); 1H 




NMR (400 MHz, CDCl3): δ 8.14 (1H, d, J = 8.5 Hz, C5-H), 7.86 (1H, d, J = 8.5 Hz, C8-H), 7.75 – 7.65 
(1H, m, C6-H), 7.56 – 7.48 (5H, m, C11-H, C12-H, C13-H), 7.46 – 7.40 (1H, m, C7-H), 7.35 – 7.26 
(1H, m, C2-H), 3.91 (1H, app. p, J = 9.0 Hz, C14-H), 2.55 – 2.40 (4H, m, C15-H2), 2.21 – 2.07 (1H, m, 
C16-H2), 2.03 – 1.89 (1H, m, C16-H2); 13C NMR (101 MHz, CDCl3): δ 164.7 (C3), 148.7 (C9), 148.4 
(C1), 138.6 (C10), 129.7 (ArCH), 129.5 (C5), 129.3 (C6), 128.7 (ArCH), 128.4 (C13), 125.9 (C7), 
125.7 (C8), 125.5 (C4), 120.0 (C2), 42.9 (C14), 28.5 (C15), 18.5 (C16); HRMS: (ESI+) calculated for 
C19H18N 260.1434. Found [M+H]+ 260.1437. 
2-Phenethyl-4-phenylquinoline (199e) 
 
General Procedure V: The crude material was purified by FCC (hexane/EtOAc 20%) to afford the 
title compound (22.3 mg, 86%) as a yellow oil; vmax/cm-1: 3059 (m), 2924 (m) 1592 (m), 1490 (m); 1H 
NMR (400 MHz, CDCl3): δ 8.16 (1H, d, J = 7.5 Hz, C8-H), 7.88 (f1H, dd, J = 8.5, 1.5 Hz, C5-H), 7.72 
(1H, ddd, J = 8.5, 7.0, 1.5 Hz, C7-H), 7.56 – 7.42 (6H, m, C6-H, ArCH), 7.34 – 7.24 (4H, m, ArCH), 
7.25 – 7.19 (1H m, ArCH), 7.17 (1H, s, C2-H), 3.37 – 3.30 (2H, m, C10-H2), 3.24 – 3.16 (2H, m, C11-
H2); 13C NMR (101 MHz, CDCl3): δ 161.4 (C1), 148.6 (C9), 148.6 (C3), 141.7 (C12), 138.3 (C16), 
129.6 (ArCH), 129.4 (C8), 129.4 (C7), 128.7 (ArCH), 128.6 (ArCH), 128.5 (ArCH), 128.4 (ArCH), 
126.1 (C6), 126.0 (C5), 125.8 (ArCH), 125.5 (C4), 122.0 (C2), 41.2 (C10), 36.2 (C11); HRMS: (ESI+) 




General Procedure V: The crude material was purified by FCC (EtOAc/MeOH 0−20%) to afford the 
title compound (13.6 mg, 61%) as a colourless solid. vmax/cm-1: 2928 (m), 2859 (m), 1738 (s), 1591 (s); 
1H NMR (400 MHz, CDCl3): δ 7.82 (1H, s, C9-H), 7.76 (1H, s, C6-H), 7.60 – 7.44 (5H, m, C22-H, 
C23-H, C24-H), 7.14 (1H, s, C2-H), 3.23 – 3.06 (2H, m, C13-H2), 2.74 (3H, s, C25-H3), 2.51 (1H, dd, 
J = 18.0, 8.5 Hz, C20-H2), 2.43 – 2.33 (1H, m, C10-H), 2.33 – 2.22 (1H, m, C14-H2), 2.21 – 2.02 (3H, 
m, C12-H2, C19-H2, C20-H2), 1.92 (1H, ddd, J = 13.0, 13.0, 3.0 Hz, C15-H2), 1.73 – 1.38 (5H, m, C11-
H, C12-H2, C14-H2, C15-H2, C17-H), 0.90 (3H, s, C26-H3); 13C NMR (126 MHz, CDCl3): δ 220.7 
(C18), 158.0 (C1), 148.2 (C3), 146.9 (C5), 139.3 (C8), 138.9 (C7), 138.4 (C21), 129.4 (ArCH), 128.6 
(ArCH), 128.3 (C24), 127.6 (C9), 123.3 (C4), 121.6 (C2), 121.3 (C6), 50.8 (C17), 47.9 (C16), 44.6 




(C10), 38.1 (C11), 35.9 (C20), 31.4 (C15), 29.5 (C13), 26.5 (C12), 25.6 (C14), 25.2 (C25), 21.7 (C19), 
13.8 (C26); HRMS: (ESI+) calculated for C28H30NO 396.2322. Found. [M+H]+ 396.2317. m.p. 
293−295 °C (hexane/EtOAc); [α]20D = + 134.7 (c = 0.20, CH2Cl2). 
The structure of compound 199f was confirmed by single crystal X-ray diffraction of crystals obtained 






The title compound was prepared following a literature procedure.228 An oven-dried Schlenk tube was 
charged with N-(2-(1-phenylvinyl)phenyl)acetamide 104aa’ (50.0 mg, 0.21 mmol) and SelectFluor 
(82.0 mg, 0.23 mmol) and purged with nitrogen. Dry MeCN (2 mL) was added and the tube was sealed 
with a Young’s tap and stirred at ambient temperature overnight. The solution was taken up in EtOAc 
before the solvent was removed in vacuo. Purification of the residue by FCC (hexane/EtOAc 10−20%) 
afforded the title compound (43.6 mg, 81% yield) as colourless cubes. 1H NMR (400 MHz, CDCl3): δ 
7.42 – 7.31 (6H, m), 7.31 – 7.21 (2H, m), 7.22 – 7.10 (1H, m), 4.92 (2H, d, J = 47.0 Hz), 2.24 (3H, s); 
13C NMR (101 MHz, CDCl3): δ 159.6, 139.5, 139.2, 139.2 (d, 3JC-F = 3.0 Hz), 129.7, 129.0, 128.7, 
126.6, 126.4, 125.1, 124.8, 123.5, 84.4 (d, 1JC-F = 186.5 Hz), 82.2 (d, 2J C-F = 18.5 Hz), 21.9; 19F NMR 
(377 MHz, CDCl3): δ -219.4 (t, 1JF-H = 47.5 Hz); m.p. 86−88 °C (CDCl3). The spectroscopic properties 
for this compound were consistent with the data available in the literature.228  
1-(8-(Iodomethyl)-8-phenyl-7-azabicyclo[4.2.0]octa-1,3,5-trien-7-yl)ethan-1-one (201) 
  
The title compound was prepared following a literature procedure.229 To a solution of N-(2-(1-
phenylvinyl)phenyl)acetamide 104aa’ (55.0 mg, 0.23 mmol) and NaHCO3 (58.0 mg, 0.69 mmol) in dry 
MeCN (3 mL) under nitrogen at 0 °C was added I2 (176 mg, 0.70 mmol) portion-wise over 15 minutes. 
The resulting solution was stirred overnight before being quenched with an aq. solution of Na2S2O3 
(10%) until the solution turned colourless. The solution was concentrated in vacuo before being 




extracted with diethyl ether (3 × 10 mL). The organic extracts were combined, dried and concentrated 
in vacuo to afford the title compound (36.8 mg, 44%) as an orange oil. vmax/cm-1: 3029 (m), 2925 (m) 
1645 (m), 1257 (m); 1H NMR (400 MHz, CDCl3): δ 7.39 – 7.29 (6H, m, C11-H, C12-H, 2 × ArCH), 
7.24 – 7.16 (2H, m, 2× ArCH), 7.05 – 6.99 (1H, m, C7-H), 3.90 (2H, s, C14-H2), 2.25 (3H, s, C1-H3); 
13C NMR (126 MHz, CDCl3): δ 159.6 (C2), 140.6 (C10), 138.9 (C3), 129.7 (C5), 128.7 (ArCH), 128.6 
(ArCH), 126.5 (C6), 126.2 (ArCH), 126.0 (C8), 124.9 (ArCH), 124.8 (C7), 81.6 (C9), 22.1 (C14), 13.5 
(C1); HRMS: (ESI+) calculated for C16H15INO 364.0193. Found [M+H]+ 364.0205. 
2-(1-Phenylvinyl)aniline (202) 
 
To a reaction tube was added 104aa’ (50 mg, 0.188 mmol), aq. HCl (3 M, 14 mL) and 1,4-dioxane (0.8 
mL). The reaction tube was sealed and heated at reflux for 3 h. The reaction was cooled to ambient 
temperature before being quenched by the addition of saturated aq. NaHCO3 (10 mL) and extracted 
with Et2O (3 × 10 mL). The organic extracts were combined, dried over Na2SO4 and concentrated in 
vacuo. The residue was purified by FCC (hexane/Et2O 50%) to afford the title compound (34.6 mg, 
99%) as a colourless solid. 1H NMR (400 MHz, CDCl3): δ 7.40 – 7.36 (2H, m), 7.36 – 7.29 (3H, m), 
7.17 (1H, ddd, J = 8.0, 7.5, 1.5 Hz), 7.12 (1H, dd, J = 8.0, 1.5 Hz), 6.80 (1H, td, J = 7.5, 1.0 Hz), 6.70 
(1H, dd, J = 8.0, 1.0 Hz), 5.81 (1H, d, J = 1.5 Hz), 5.37 (1H, d, J = 1.5 Hz), 3.56 (2H, s). 13C NMR (101 
MHz, CDCl3): δ 147.3, 144.1, 139.8, 131.0, 128.9, 128.7, 128.2, 127.5, 126.8, 118.5, 116.3, 115.7; m.p. 
= 74−75 °C (CDCl3) (Lit.296 80−82 °C, no recrystallisation solvent specified); The spectroscopic 
proprieties were consistent with the data available in literature.296  
Phenylcinnoline (203) 
 
The title compound was prepared following a literature procedure.297 To a Schlenk tube was added 
104aa’ (100 mg, 0.512 mmol) and aq. HCl (2 M, 1.4 mL) under nitrogen and the reaction was cooled 
to -5 °C. NaNO2 (88.3 mg, 1.28 mmol) was added and the solution was stirred for 15 mins. Aq. H3PO2 
(50%, 1 mL) was added and the resulting solution was stirred for 3 h at -5 °C before the reaction was 
warmed to ambient temperature and stirred for a further 3 h. The reaction was quenched by the addition 
of water (15 mL) and extracted with Et2O (3 × 15 mL). The organic extracts were combined, dried over 
Na2SO4 and concentrated in vacuo. The residue was purified by FCC (hexane/Et2O 50%) to afford the 
title compound (106 mg, quantitative) as a yellow oil. 1H NMR (400 MHz, CDCl3): δ 9.25 (1H, s), 8.59 
(1H, dd, J = 8.5, 1.5 Hz), 7.98 (1H, d, J = 8.5 Hz,), 7.84 (1H, ddd, J = 8.5, 7.0, 1.5 Hz), 7.71 (1H, ddd, 
J = 8.5, 7.0, 1.5 Hz), 7.60 – 7.49 (5H, m); 13C NMR (101 MHz, CDCl3): δ 150.6, 144.6, 135.2, 134.3, 




131.3, 130.5, 130.2, 129.9, 129.3, 129.1, 124.7, 124.5. The spectroscopic properties for this compound 
were consistent with the data available in the literature.298  
2-Methyl-2,4-diphenyl-1,2-dihydroquinoline (204) 
 
The title compound was prepared following a modified literature procedure.299 To a resealable Schlenk 
tube was added 104aa’ (100 mg, 0.512 mmol), TsOH (5.2 mg, 0.027 mmol), 2-acetophenone (78 μL, 
0.666 mmol), Na2SO4 (145 mg, 1.02 mmol) and toluene (0.8 mL) under nitrogen. The tube was sealed 
and heated to 110 °C for 24 h. The solution was cooled to ambient temperature and quenched by the 
addition of water (15 mL) and extracted with Et2O (3 × 15 mL). The organic extracts were combined, 
dried over Na2SO4 and concentrated in vacuo. Purification of the residue by FCC (toluene/hexane 10%) 
afforded the title compound (148 mg, 97%) as colourless plates. 1H NMR (400 MHz, CDCl3): δ 7.57 
(2H, dd, J = 8.0, 1.5 Hz), 7.46 – 7.31 (7H, m), 7.30 – 7.18 (1H, m), 7.04 (1H, ddd, J = 8.0, 1.5, 1.5 Hz), 
6.91 (1H, dd, J = 8.0, 1.5 Hz,), 6.61 – 6.52 (2H, m), 5.64 (1H, s), 4.21 (1H, br. s), 1.78 (3H, s); 13C 
NMR (101 MHz, CDCl3): δ 148.6, 142.9, 139.5, 135.9, 129.2, 129.1, 129.1, 128.5, 128.3, 127.5, 127.0, 
126.3, 125.5, 120.6, 117.6, 113.6, 57.3, 30.2; m.p. = 114−116 °C (CDCl3) (Lit.28 113−115 °C, no 
recrystallisation solvent specified). The spectroscopic properties for this compound were consistent 
with the data available in the literature.30  
 




General Procedure W: The reaction was carried out with 126b (0.143 mmol), [Ir(cod)2]OTf (7.5 mol%) 
and (S,S)-f-Binaphane (7.5 mol%) and was run for 48 h. The residue was purified by FCC 
(hexane/EtOAc 0−10%) to afford the title compound (11.0 mg, 29%) as a colourless oil. vmax/cm-1: 2974 
(m), 2934 (m), 1687 (s), 1425 (s); 1H NMR (500 MHz, CDCl3): δ 7.36 – 7.27 (5H, m, C11-H, C12-H, 
C13-H), 7.06 – 6.75 (1H, m, C4-H), 6.30 – 6.27 (1H, m, C6-H), 6.24 – 6.12 (1H, m, C5-H), 5.38 (1H, 
d, J = 1.0 Hz, C9-H2), 5.35 (1H, d, J = 1.0 Hz, C9-H2), 3.14 (4H, q, J = 7.0 Hz, C2-H2), 0.94 (6H, t, J 
= 7.0 Hz, C1-H3); 13C NMR (126 MHz, CDCl3): δ 153.7 (C3), 141.1 (C10), 140.9 (C8), 134.1 (C7), 
128.2 (ArCH), 128.1 (C13), 127.7 (ArCH), 121.6 (C4), 114.0 (C9), 112.6 (C6), 109.4 (C5), 42.1 (C2), 
12.9 (C1); HRMS: (ESI+) calculated for C17H21N2O 269.1648. Found [M+H]+ 269.1648.  
 






General Procedure W: The reaction was carried out with 126a (0.143 mmol), [Ir(cod)2]OTf (7.5 mol%) 
and (S,S)-f-Binaphane (7.5 mol%) and was run for 48 h. The crude material was purified by FCC 
(hexane/EtOAc 0−4%) to afford the title compound (31.2 mg, 74%) as a colourless oil. vmax/cm-1: 2969 
(m), 2933 (m), 1687 (s) 1432 (s), 1324 (s); 1H NMR (400 MHz, CDCl3): δ 7.43 – 7.35 (2H, m, C11-H), 
7.34 – 7.27 (3H, m, C12-H, C13-H), 6.84 – 6.77 (1H, m, C4-H), 6.22 – 6.17 (2H, m, C5-H, C6-H), 5.40 
(1H, d, J = 1.0 Hz, C9-H), 5.34 (d, J = 1.0 Hz, 1H, C9-H), 3.56 – 3.39 (2H, m, C2-H), 1.22 – 1.10 (12H, 
m, C1-H3); 13C NMR (101 MHz, CDCl3): δ 152.0 (C3), 141.3 (C10), 141.0 (C8), 134.1 (C7), 128.2 
(C12), 128.1 (C11), 127.9 (C13), 121.1 (C4), 113.9 (C9), 112.2 (ArCH), 109.2 ArCH), 48.4 (C2), 20.5 




General Procedure W: The reaction was carried out with 126c (0.143 mmol), [Ir(cod)2]OTf (7.5 mol%) 
and (S,S)-f-Binaphane (7.5 mol%) and was run for 48 h. The crude material was purified by FCC 
(hexane/Et20 5−10%) to afford the title compound (26.7 mg, 50%) as a red oil. vmax/cm-1: 2928 (m), 
2853 (m), 1682 (s) 1427 (s), 1308 (s); 1H NMR (400 MHz, CDCl3): δ 7.42 – 7.35 (2H, m, C13-H), 7.33 
– 7.27 (3H, m,C14-H, C15-H), 6.80 – 6.75 (1H, m, C6-H), 6.22 – 6.16 (2H, m, C7-H, C8-H), 5.41 (1H, 
s, C11-H2), 5.32 (1H, s, C11-H2), 3.05 – 2.87 (2H, m,C1-H), 1.84 – 1.00 (20H, m, Cy); 13C NMR (101 
MHz, CDCl3): δ 152.5 (C5), 141.4 (C12), 140.9 (C10), 133.9 (C9), 128.1 (ArCH), 128.1 (ArCH), 127.9 
(ArCH), 121.0 (C6), 113.7 (C11), 112.2 (C7/8), 109.2 (C7/8), 58.1 (C1), 30.3 (Cy), 26.1 (Cy), 25.3 
(Cy); HRMS: (ESI+) calculated for C25H33N2O 377.2587. Found [M+H]+ 377.2594. 
2-(1-(4-(tert-Butyl)phenyl)vinyl)-N,N-diisopropyl-1H-pyrrole-1-carboxamide (128ap’) 
 
General Procedure W: The reaction was carried out with 126a (0.1 mmol), [Ir(cod)2]OTf (7.5 mol%) 
and (S,S)-f-Binaphane (7.5 mol%) and was run for 72 h. The crude material was purified by FCC 




(hexane/EtOAc 0−3%) to afford the title compound (25.4 mg, 72%) as an orange oil. vmax/cm
-1: 2964 
(m), 2932 (m), 1689 (s), 1325 (s); 1H NMR (400 MHz, CDCl3): δ 7.36 – 7.28 (4H, m, C11-H, C12-H), 
6.80 (1H, dd, J = 3.0, 1.5 Hz, C4-H), 6.26 – 6.10 (2H, m, C5-H, C6-H), 5.37 (1H, d, J = 1.5 Hz, C9-
H2), 5.33 (1H, d, J = 1.5 Hz, C9-H2), 3.48 (2H, br. s, C2-H), 1.31 (9H, s, C15-H3), 1.17 – 1.05 (12H, m, 
C1-H3); 13C NMR (101 MHz, CDCl3): δ 152.0 (C3), 150.8 (C13), 140.9 (C8), 138.3 (C10), 134.4 (C7), 
127.7 (C11), 125.2 (C12), 120.9 (C4), 113.5 (C9), 112.1 (C5), 109.2 (C6), 48.2 (C2), 34.7 (C14), 31.5 
(C15), 20.5 (C1); HRMS: (ESI+) calculated for C23H32N2ONa 375.2407. Found [M+Na]+ 375.2398. 
2-(1-(4-Fluorophenyl)vinyl)-N,N-diisopropyl-1H-pyrrole-1-carboxamide (128an’) 
 
General Procedure W: The reaction was carried out with 126a (0.1 mmol), [Ir(cod)2]OTf (7.5 mol%) 
and (S,S)-f-Binaphane (7.5 mol%) and was run for 72 h. The crude material was purified by FCC 
(hexane/EtOAc 0−4%) to afford the title compound (19.6 mg, 62%) as an orange oil. vmax/cm-1: 2969 
(m), 2931 (m), 1688 (s), 1507 (s); 1H NMR (400 MHz, CDCl3): δ 7.39 – 7.32 (2H, m, C11-H), 6.99 
(2H, dd, J = 8.5, 1.5 Hz, C12-H), 6.84 – 6.77 (1H, m, C4-H), 6.21 – 6.18 (1H, m, C5-H), 6.18 – 6.13 
(1H, m, C6-H), 5.36 (1H, s, C9-H2), 5.29 (1H, s, C9-H2), 3.54 – 3.41 (2H, m, C2-H), 1.17 (12H, d, J = 
6.5 Hz, C1-H3); 13C NMR (101 MHz, CDCl3) δ 162.70 (d, 
1JC-F = 246.5 Hz, C13), 152.0 (C3), 140.0 
(C8), 137.4 (C10), 133.9 (C7), 129.70 (d, 3JC-F = 8.0 Hz, C11), 121.2 (C4), 115.05 (d, 2JC-F = 21.5 Hz, 
C12), 113.8 (C9), 112.3 (C6), 109.3 (C5), 48.6 (C2), 20.5 (C1); HRMS: (ESI+) calculated for 
C19H23N2OFNa 337.1687. Found [M+Na]+ 337.1702. 
2-(1-([1,1'-Biphenyl]-4-yl)vinyl)-N,N-diisopropyl-1H-pyrrole-1-carboxamide (128ak’) 
 
General Procedure W: The reaction was carried out with 126a (0.1 mmol), [Ir(cod)2]OTf (7.5 mol%) 
and (S,S)-f-Binaphane (7.5 mol%) and was run for 72 h. The crude material was purified by FCC 
(hexane/EtOAc 0−4%) to afford the title compound (13.4 mg, 36%) as an orange oil. vmax/cm
-1: 2969 
(m), 2935 (m), 1688 (s), 1326 (s); 1H NMR (400 MHz, CDCl3): δ 7.65 – 7.50 (4H, m, C15-H, C16-H), 
7.49 – 7.40 (4H, m, C11-H, C12-H), 7.38 – 7.32 (1H, m, C17-H), 6.83 (1H, dd, J = 3.0, 1.5 Hz, C4-H), 
6.30 – 6.16 (2H, m, C5-H, C6-H), 5.43 (1H, d, J = 1.0 Hz, C9-H2), 5.41 (1H, d, J = 1.0 Hz, C9-H2), 
3.51 (2H, br. ap. s, C2-H), 1.17 (12H, d, J = 6.5 Hz, C1-H3); 13C NMR (101 MHz, CDCl3): δ 152.0 
(C3), 141.0 (C8), 140.8 (C14), 140.6 (C13), 140.3 (C10), 134.0 (C7), 128.9 (C11), 128.5 (C12), 127.4 




(C15), 127.2 (C16), 127.0 (C17), 121.1 (C4), 114.0 (C9), 112.3 (C5), 109.3 (C6), 49.0 (C2), 20.5 (C1); 
HRMS: (ESI+) calculated for C25H28N2ONa 395.2094. Found [M+Na]+ 395.2098. 
2-(1-(3-Chlorophenyl)vinyl)-N,N-diisopropyl-1H-pyrrole-1-carboxamide (128as’) 
 
General Procedure W: The reaction was carried out with 126a (0.1 mmol), [Ir(cod)2]OTf (7.5 mol%) 
and (S,S)-f-Binaphane (7.5 mol%) and was run for 72 h. The title product was observed by 1H NMR 
analysis of the crude material. Characteristic 1H NMR peaks: 1H NMR (400 MHz, CDCl3): δ 6.16 – 
6.13 (1H, m), 5.34 (1H, s), 5.25 (1H, s), 3.76 (2H, h, J = 6.5 Hz), 1.28 (6H, d, J = 6.5 Hz). 
2-(Hex-1-en-2-yl)-N,N-diisopropyl-1H-pyrrole-1-carboxamide (128ac’) 
 
General Procedure W: The reaction was carried out with 126a (0.1 mmol), [Ir(cod)2]OTf (7.5 mol%) 
and (S,S)-f-Binaphane (7.5 mol%) and was run for 72 h. The title product was observed by 1H NMR 
analysis of the crude material. Characteristic 1H NMR peaks: 1H NMR (400 MHz, CDCl3): δ 6.69 (1H, 
dd, J = 3.0, 1.0 Hz), 6.18 – 6.14 (1H, m), 5.11 (1H, s), 4.96 (1H, d, J = 1.0 Hz), 3.40 (2H, p, J = 6.5 
Hz), 2.41 – 2.30 (2H, m), 0.91 (3H, t, J = 7.0 Hz). 
N,N-Diisopropyl-3-phenyl-2-(1-phenylvinyl)-1H-pyrrole-1-carboxamide (128ea’) 
 
General Procedure W: The reaction was carried out with 126e (0.1 mmol), [Ir(cod)2]OTf (10 mol%) 
and (S,S)-f-Binaphane (10 mol%) and was run for 72 h. The crude material was purified by FCC (1st 
column, AgNO3 treated silica300: toluene/CH2Cl2/Et2O 75:25:1; 2nd column: hexane/Et2O 10%) to afford 
the title compound (18.5 mg, 50%) as an orange oil. vmax/cm-1: 2956 (m), 2928 (m), 1687 (s), 1432 (s); 
1H NMR (400 MHz, CDCl3): δ 7.53 – 7.48 (2H, m, C9-H), 7.45 – 7.40 (2H, m, C10-H), 7.37 – 7.30 
(5H, m, C15-H, C16-H, C17-H), 7.20 (1H, t, J = 7.5 Hz, C11-H), 7.10 (1H, d, J = 2.0 Hz, C4-H), 6.52 
(1H, d, J = 2.0 Hz, C6-H), 5.46 (1H, s, C13-H2), 5.40 (1H, s, C13-H2), 3.60 – 3.51 (2H, m, C2-H), 1.19 
(12H, d, J = 6.5 Hz, C1-H3); 13C NMR (101 MHz, CDCl3): δ 151.6 (C3), 140.9 (C14), 140.7 (C8), 134.8 
(C7), 134.6 (C12), 128.7 (C15/16), 128.2 (C15/16), 128.0 (C10), 127.9 (C17), 126.1 (C11), 125.3 (C5), 




125.3 (C9), 117.2 (C4), 114.2 (C13), 110.2 (C6), 30.3 (C2), 29.7 (C2), 20.4 (C1); HRMS: (ESI+) 
calculated for C25H29N2O 373.2274. Found [M+H]+ 373.2293. 
N,N-Diisopropyl-1-methyl-2-(1-phenylvinyl)-1H-pyrrole-3-carboxamide (205a’, C2) 
  
General Procedure W: The reaction was carried out with 150 (0.143 mmol), [Ir(cod)2]OTf (7.5 mol%) 
and (S,S)-f-Binaphane (7.5 mol%) and was run for 48 h. The crude material was purified by FCC 
(hexane/EtOAc 20−30%) to afford the title compound (6.7 mg, 22%) as a yellow oil. vmax/cm-1: 2954 
(m), 2927 (m), 1621 (s), 1498 (s); 1H NMR (400 MHz, CDCl3): δ 7.33 – 7.27 (5H, m, C12-H, C13-H, 
C14-H), 6.56 (1H, d, J = 3.0 Hz, C6-H), 6.14 (1H, d, J = 3.0 Hz, C5-H), 5.71 (1H, d, J = 1.5 Hz, C10-
H2), 5.42 (1H, d, J = 1.5 Hz, C10-H2), 4.38 – 4.18 (1H, m, C2-H), 3.57 – 3.25 (1H, m, C2-H), 3.22 (3H, 
s, C8-H3), 1.50 – 0.77 (12H, m, C1-H3); 13C NMR (101 MHz, CDCl3): δ 168.0 (C3), 140.7 (C11), 139.5 
(C9), 131.4 (C7), 128.6 (C12/13), 127.9 (C14), 127.0 (C12/13), 122.3 (C4), 122.2 (C6), 118.5 (C10), 
106.6 (C5), 35.0 (C8), 20.9 (C1); HRMS: (ESI+) calculated for C20H27N2O 311.2118. Found [M+H]+ 
311.2131. 
Note: C2 was not observed by 13C NMR analysis. 
N,N-Diisopropyl-1-methyl-4-(1-phenylvinyl)-1H-pyrrole-3-carboxamide (205a’, C4) 
 
General Procedure W: The reaction was carried out with 150 (0.143 mmol), [Ir(cod)2]OTf (7.5 mol%) 
and (S,S)-f-Binaphane (7.5 mol%) and was run for 48 h. The crude material was purified by FCC 
(hexane/EtOAc 20−30%) to afford the title compound (11.6 mg, 37%) as a yellow oil. vmax/cm-1: 2957 
(m), 2929 (m), 1616 (s), 1443 (s); 1H NMR (400 MHz, CDCl3): δ 7.45 – 7.39 (2H, m, C12-H), 7.32 – 
7.25 (3H, m, C13-H, C14-H), 6.62 (1H, d, J = 2.5 Hz, C7-H), 6.37 (1H, d, J = 2.5 Hz, C6-H), 5.31 (1H, 
d, J = 1.5 Hz, C10-H2), 5.20 (1H, d, J = 1.5 Hz, C10-H2), 4.32 – 4.05 (1H, m, C2-H), 3.58 (3H, s, C8-
H3), 3.47 – 3.15 (1H, m, C2-H), 1.38 – 0.79 (12H, m, C1-H3); 13C NMR (101 MHz, CDCl3): δ 167.6 
(C3), 142.7 (C9), 142.5 (C11), 128.1 (C12/13), 128.1 (C12/13) 127.5 (C14), 123.2 (C5), 122.0 (C6), 
121.3 (C4), 120.7 (C7), 112.3 (C10), 51.0 (C2), 45.6 (C2), 36.3 (C8), 20.8 (C1); HRMS: (ESI+) 
calculated for C20H27N2O 311.2118. Found [M+H]+ 311.2127. 
 
 




7.7.5 − Deuterium Labelling Experiments 
 [4-(vinyl-β,β-d2)-1,1'-biphenyl] (deuterio-91k’) 
 
To a suspension of methyl-d3-triphenylphosphonium iodide (2.69 g, 6.60 mmol) and biphenyl-4-
carboxaldehyde (1.00 g, 5.50 mmol) in anhydrous THF (25 mL) was added portion-wise NaH (581 mg, 
24.2 mmol, 60% in mineral oil) at 0 ˚C. The reaction was slowly warmed to ambient temperature and 
stirred for 16 h. The mixture was diluted with CH2Cl2 (50 mL), washed with brine (3 × 10 mL), dried 
over Na2SO4, filtered and concentrated in vacuo. The crude material was purified by FCC 
(hexane/EtOAc 0−10%) to provide the title compound (1.00 g, quantitative yield, 89% deuteration) as 
a colourless solid. 1H NMR (CDCl3, 400 MHz): δ 7.74 – 7.56 (4H, m), 7.56 – 7.41 (4H, m), 7.42 – 7.31 
(1H, m), 6.78 (1H, br. s); 2H NMR (CH2Cl2, 77 MHz): δ 5.81 (1D, br. s), 5.27 (1D, s); m.p. 121−123 
˚C (hexane/CH2Cl2) (Lit.301 122−125 °C, no recrystallisation solvent specified). The spectroscopic 
properties of this compound were consistent with the data available in the literature.301 
Deuterium labelling experiment of 60aa 
 
An oven-dried re-sealable tube, fitted with a magnetic stirrer, was charged with substrate 60aa (21.3 
mg, 0.143 mmol), [Ir(cod)2]OTf (7.5 mol%) and L-20c (7.5 mol%). The tube was fitted with a rubber 
septum and purged with nitrogen. Deuterio-91k’ (0.644 mmol) and t-butylethylene (200 mol%) in 
anhydrous 1,4-dioxane (0.5 M concentration with respect to substrate) was added and the tube was fitted 
with a Young’s tap. The reaction mixture was then heated to 130 °C for 72 h, before being cooled to 
ambient temperature and concentrated in vacuo. Purification of the residues by FCC (toluene/EtOAc 
0−10%) afforded the deuterio-products. 
 






For comparison, the non-deuterated product was synthesised by General Procedure U. The reaction 
was carried out with Ir(cod)2]OTf (7.5 mol%), L-20c (7.5 mol%) and 1,4-dioxane (0.5 M with respect 
to substrate) and was run for 96 h. The crude material was purified by FCC (toluene/EtOAc 0−10%) to 
afford the title compound (23.1 mg, 49%) as colourless cubes. vmax/cm-1: 3283 (m), 3029 (m), 2923 (s), 
1656 (s), 1513 (s); 1H NMR (400 MHz, CDCl3): δ 8.02 (1H, d, J = 8.5 Hz, C4-H), 7.50 – 7.45 (4H, m, 
C13-H, C16-H), 7.45 (2H, dd J = 7.5, 7.5 Hz, C17-H), 7.42 – 7.33 (3H, m, C12-H, C18-H), 7.20 (1H, 
dd, J = 8.5, 2.0 Hz, C5-H), 7.10 (1H, d, J = 2.0 Hz, C7-H), 6.95 (1H, s, N-H), 5.91 (1H, s, C10-H2), 
5.37 (1H, s, C10-H2), 2.35 (3H, s, C19-H3), 1.81 (3H, s, C1-H3); 13C NMR (101 MHz, CDCl3): δ 168.2 
(C2), 146.1 (C9), 141.3 (C14), 140.4 (C15), 138.5 (C11), 134.2 (C6), 132.8 (C3), 132.1 (C8), 130.8 
(C7), 129.5 (C5), 129.0 (C17), 127.7 (C18), 127.5 (C13), 127.1 (C12, C16), 122.2 (C4), 117.0 (C10), 
24.4 (C1), 21.0 (C19); HRMS: (ESI+) calculated for C23H22NO 328.1696. Found [M+H]+ 328.1689; 
m.p. 152−154 °C (CDCl3).  
The data for the deuterated products is presented below: 
deuterio-104aak’ 
 
1H NMR (400 MHz, CDCl3): δ 8.02 (0.7H, d, J = 8.5 Hz), 7.62 – 7.53 (4H, m), 7.49 – 7.33 (5H, m), 
7.24 – 7.16 (1H, m), 7.10 (1H, d, J = 2.0 Hz), 6.95 (1H, s), 5.91 (0.56H, d, J = 6.0 Hz), 5.37 (0.56H, d, 
J = 6.0 Hz), 2.36 (3H, s), 1.82 (2.43H, s); 2H NMR (77 MHz, CHCl3): δ 8.07 (0.3D, s), 5.94 (0.44D, s), 
5.40 (0.44D, s), 1.81 (0.57D, d, J = 2.5 Hz). Deuterium incorporation was calculated by integration of 










1H NMR (400 MHz, CDCl3): δ 7.36 (1.48H, dd, J = 8.5, 6.0 Hz), 7.22 – 7.16 (1H, m), 7.16 – 7.06 (2H, 
m), 2.31 (3H, s), 2.15 (3H, s); 2H NMR (77 MHz, CHCl3): δ 7.43 (0.52D, s). Deuterium incorporation 
was calculated by integration of both 1H NMR and 2H NMR signals. 
deuterio-91k’ 
 
1H NMR (400 MHz, CDCl3): δ 7.79 – 7.31 (9H, m), 6.86 – 6.74 (0.57H, m), 5.86 – 5.76 (0.57H, m), 
5.35 – 5.24 (0.57H, m); 2H NMR (77 MHz, CHCl3): δ 6.83 (0.43D, s), 5.86 (0.43D, s), 5.34 (0.43D, s). 
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